<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> Moleculin Biotech, Inc. (Form: S-1/A, Received: 02/07/2017 10:31:42) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_REGISTRATION_FEE **FIS_SUBJECT_STOCK_INFO **FIS_TABLE_OF_CONTENTS **FIS_BALANCE_SHEET **FIS_PROSPECTUS_SUMMARY **FIS_THE_OFFERING **FIS_FINANCIAL_DATA **FIS_RISK_FACTORS **FIS_FORWARD_LOOK **FIS_PROCEED_USE **FIS_DIVIDEND_POLICY **FIS_CAPITALIZATION **FIS_DILUTION **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_MANAGEMENTS_DISCUSSION **FIS_BUSINESS **FIS_LIQUIDITY **FIS_COMPETITION **FIS_EMPLOYEES **FIS_LEGAL_PROCEEDINGS **FIS_PROPERTIES **FIS_MANAGEMENT **FIS_NAME_AND_TITLE **FIS_EXECUTIVE_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_DIRECTOR_COMPENSATION **FIS_STOCK_PLANS **FIS_CERTAIN_TRANSACTIONS **FIS_CERTAIN_TRANSACTIONS_2 **FIS_STOCKHOLDERS **FIS_BENEFICIAL_OWNERS **FIS_SECURITIES_DESCRIPTION **FIS_TRANSFER_AGENT **FIS_SECURITIES_DESCRIPTION_2 **FIS_UNDERWRITING **FIS_INDEMNIFICATION **FIS_VALIDITY **FIS_EXPERTS **FIS_MORE_INFORMATION **FIS_FINANCIAL_STATEMENTS **FIS_BALANCE_SHEET_2 **FIS_INCOME_STATEMENT **FIS_CASH_FLOW **FIS_SECURITIES_DESCRIPTION_3 **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET_3 **FIS_INCOME_STATEMENT_2 **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW_2 **FIS_SECURITIES_DESCRIPTION_4 **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET_4 **FIS_INCOME_STATEMENT_3 **FIS_STOCKHOLDERS_EQUITY_2 **FIS_CASH_FLOW_3 **FIS_SECURITIES_DESCRIPTION_5 **FIS_PART_II **FIS_OFFERING_EXPENSE **FIS_INDEMNIFICATION_2 **FIS_SALE_OF_UNREGISTERED_SECURITIES **FIS_EXHIBITS **FIS_UNDERTAKINGS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_1 FIS_EXHIBIT_4 FIS_EXHIBIT_5 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT ">
<META NAME="DETECTED PAGES" CONTENT="192">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V458551_S1A_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	As filed with the Securities and
	Exchange Commission on February 7, 2017.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Registration No.&nbsp;333-214898
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	AMENDMENT NO. 2 TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	FORM S-1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	REGISTRATION STATEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<I>
	UNDER
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<I>
	THE SECURITIES ACT OF 1933
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Exact Name of Registrant as Specified in
	Its Charter)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2834
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	47-4671997
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(State or Other Jurisdiction of
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Primary Standard Industrial
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(I.R.S. Employer
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Incorporation or Organization)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Classification Code Number)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Identification Number)
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	2575 West Bellfort, Suite 333
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Houston, Texas 77054
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(713) 300-5160
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Address, Including Zip Code, and Telephone
	Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Mr.&nbsp;Walter Klemp, Chief Executive Officer
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	2575 West Bellfort, Suite 333
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Houston, Texas 77054
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(713) 300-5160
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Name, Address, Including Zip Code, and Telephone
	Number, Including Area Code, of Agent For Service)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Copies to:
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Cavas S. Pavri
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Robert F. Charron, Esq.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Schiff Hardin LLP
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Ellenoff Grossman &amp; Schole LLP
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	100 N. 18th, Suite 300
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1345 Avenue of the Americas
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Philadelphia, PA 19103
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	New York, NY 10105-0302
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Telephone:
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	(202)&nbsp;724-6847
</FONT>
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Telephone: (212) 370-1300
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Fax: (202) 778-6460
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN">
<B>
	Approximate date of commencement of proposed sale
	to the public:
</B>
	As soon as practicable after the effective date of this Registration Statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 18.35PT">
	If any of the securities being registered
	on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
	following box.&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 18.35PT">
	If this form is filed to register additional
	securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act
	registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 18.35PT">
	If this form is a post-effective amendment
	filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
	number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 18.35PT">
	If this form is a post-effective amendment
	filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
	number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 18.35PT">
	Indicate by check mark whether the registrant
	is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
	of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
	of the Securities Exchange Act of 1934. (Check one):&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 10PT">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 10PT">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Non-accelerated filer
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	&uml;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;(Do not check if a smaller reporting company)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Smaller&nbsp;reporting&nbsp;company
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	x
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_REGISTRATION_FEE>
<A NAME="FIS_REGISTRATION_FEE"></A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	CALCULATION OF REGISTRATION FEE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	Title
	of each class of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	securities
	to be registered
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	Proposed
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	maximum
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	aggregate
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	offering
	price (1)
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	Amount
	of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	registration
	fee
</B>
</P>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT; TEXT-INDENT: -9PT; PADDING-LEFT: 9PT">
	Units, each consisting of one share of Common
	stock, par value $0.001 per share, and Series A, Series B and Series C Warrants, to purchase shares of Common stock
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	5,750,000.00
</P>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	666.43
</P>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common stock included in the Units (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="MARGIN: 0PT 0">
	Series A Warrants included in the Units (3)
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common Stock underlying the Series A Warrants included in the Units (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	2,875,000.00
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	333.21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series B Warrants included in the Units (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common Stock underlying the Series B Warrants included in the Units (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	$
</P>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	5,750,000.00
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	666.43
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Series C Warrants included in the Units (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	&nbsp;-
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common Stock underlying the Series C Warrants included in the Units (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	2,875,000.00
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: RIGHT; MARGIN-BOTTOM: 0PT">
	333.21
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Representatives&rsquo; warrant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common stock issuable upon exercise of the Representatives&rsquo; warrant (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	402,500.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,652,500.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,045.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	(4)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated
	solely for purposes of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933.
	The fee table assumes offering price of $2.00 per Unit, which is based on the closing price of the registrant&rsquo;s common stock
	on February 6, 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional
	shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	fee is required pursuant to Rule 457(i) under the Securities Act of 1933, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
	this amount, $2,032.06 was previously paid.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
<B>
	The Registrant hereby amends this Registration
	Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment
	which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)
	of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting
	pursuant to said Section&nbsp;8(a), may determine.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; COLOR: #CC062A">
<B>
	The information in this
	preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement is
	filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, nor does it
	seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
</B>
</P>
</EFX_REGISTRATION_FEE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; COLOR: #CC062A; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; COLOR: #CC062A">
</P>
<EFX_SUBJECT_STOCK_INFO>
<A NAME="FIS_SUBJECT_STOCK_INFO"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #CC062A">
<B>
	Subject to Completion
	Dated February 7, 2017
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	2,500,000 Units
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Each Consisting of One Share of Common
	Stock and
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series A Warrant to Purchase 0.50
	Shares of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series B Warrant to Purchase One
	Share of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series C Warrant to Purchase 0.50
	Shares of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; COLOR: #CC062A">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 24PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	We are offering 2,500,000 units, with
	each unit consisting of: (i) one share of our common stock, (ii) a Series A warrant to purchase 0.50 of a share of our common
	stock (and the 1,250,000 shares of our common stock issuable from time to time upon exercise of the Series A warrants), (iii)
	a Series B warrant to purchase one share of our common stock (and the 2,500,000 shares of our common stock issuable from time
	to time upon exercise of the Series B warrants), and (iv) a Series C warrant to purchase 0.50 of a share of our common stock (and
	the 1,250,000 shares of our common stock issuable from time to time upon exercise of the Series C warrants). The Series C warrants
	in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its corresponding
	Series B warrants included in the unit. The purchase price for each unit is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	. Each warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (100%
	of the unit purchase price). The Series A and C warrants will expire five years from the closing date of this offering. The Series
	B warrants will expire 90 days from the closing date of this offering. The units will not be issued or certificated. The shares
	of common stock and the warrants are immediately separable and will be issued separately, but will be purchased together in this
	offering. The shares of common stock, warrants and shares of common stock underlying the warrants are sometimes collectively referred
	to herein as the &ldquo;securities.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	Our common stock is listed on the NASDAQ
	Capital Market under the symbol &ldquo;MBRX.&rdquo; On February 6, 2017, the last sale price for our common stock as reported
	on the NASDAQ Capital Market was $2.00 per share. There is no established public trading market for the warrants, and we do not
	expect a market to develop. In addition, we do not intend to apply for a listing of the warrants on any national securities exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	The offering is being underwritten
	on a firm commitment basis. We have granted the underwriters an option to buy up to an additional 375,000 shares and/or an additional
	375,000 warrants combinations (comprised of 187,500 Series A warrants, 375,000 Series B warrants and 187,500 Series C warrants),
	in any combinations thereof, from us to cover over-allotments at the public offering price per share and public offering price
	per warrant combination, respectively, less the underwriting discounts and commissions. The underwriters may exercise this option
	at any time and from time to time during the 45-day period from the date of this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	We are an &ldquo;emerging growth company&rdquo;
	as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, and we have elected to comply with certain reduced public
	company reporting requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.1IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Per Unit(1)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Total
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Public offering price
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Underwriting discounts and commissions (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Proceeds, before expenses, to us
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The public
	offering price and underwriting discount correspond to an assumed public offering price
	per share of common stock of $____ and an assumed public offering price per combination
	of a Series A warrant, a Series B warrant and a Series C warrant of $____.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	We have also agreed to issue to the representative warrants to purchase shares of common stock in an amount equal to 7% of
	the aggregate number of shares sold in this offering, and to reimburse the representative for certain of its expenses. See &ldquo;Underwriting&rdquo;
	for a description of compensation payable to the underwriters.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Investing in our securities involves a high degree of risk.
	See the section entitled &ldquo;Risk Factors&rdquo; appearing on page 12 of this prospectus for a discussion of information that
	should be considered in connection with an investment in our securities.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Neither the Securities and Exchange Commission nor any other
	regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any
	representation to the contrary is a criminal offense.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The underwriters expect to deliver the common stock and
	warrants representing the units to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
	2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
	2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Roth Capital Partners
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	National Securities Corporation
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SUBJECT_STOCK_INFO>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_TABLE_OF_CONTENTS>
<A NAME="FIS_TABLE_OF_CONTENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Table
	of Contents
</B>
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 92%">
<A HREF="#V458551_S1A_HTM_A_017">
	PROSPECTUS SUMMARY
</A>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_018">
	RISK FACTORS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_019">
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_020">
	USE OF PROCEEDS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_021">
	DIVIDEND POLICY
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_022">
	CAPITALIZATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_023">
	DILUTION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_024">
	UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_025">
	MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_026">
	BUSINESS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_027">
	MANAGEMENT
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_028">
	RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	78
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_029">
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_030">
	DESCRIPTION OF CAPITAL STOCK
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	81
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_031">
	DESCRIPTION OF UNITS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	85
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_032">
	UNDERWRITING
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	86
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_033">
	VALIDITY OF SECURITIES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#V458551_S1A_HTM_A_034">
	EXPERTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<A HREF="#V458551_S1A_HTM_A_035">
	WHERE YOU CAN FIND MORE INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	No dealer, salesperson or other person is authorized
	to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information
	or representations. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions
	where it is lawful to do so. The information contained in this prospectus is current only as of its date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	Market data and certain industry data and forecasts
	used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available
	information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant
	surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable,
	but that the accuracy and completeness of such information is not guaranteed. While we are not aware of any misstatements regarding
	the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on
	various factors, including those discussed under the heading &ldquo;Risk Factors&rdquo; in this prospectus.
</P>
</EFX_TABLE_OF_CONTENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_PROSPECTUS_SUMMARY>
<A NAME="FIS_PROSPECTUS_SUMMARY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<B>
<A NAME="V458551_S1A_HTM_A_017" TITLE="PROSPECTUS SUMMARY">
</A>
	PROSPECTUS SUMMARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
<I>
	This summary highlights information contained
	elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to
	invest in our securities. You should read this entire prospectus carefully, including the &ldquo;Risk Factors&rdquo; section, our
	historical financial statements and the notes thereto, and unaudited pro forma financial information, each included elsewhere in
	this prospectus. The terms &ldquo;MBI&rdquo;, the &ldquo;Company&rdquo;, &ldquo;our&rdquo;, or &ldquo;we&rdquo; refer to Moleculin
	Biotech, Inc. and, unless the context otherwise requires, its predecessors.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are a preclinical-stage pharmaceutical
	company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University
	of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. Our lead drug candidate is liposomal
	Annamycin, which we refer to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid
	leukemia, or AML. Annamycin has been in clinical trials pursuant to an Investigational New Drug application, or IND, that had
	been filed with the U.S. Food and Drug Administration, or FDA. Due to a lack of development activity by a prior drug developer,
	this IND was terminated. However, we intend to apply for a new IND based on the same data that supported the original IND, updated
	for subsequent clinical data, and to resume clinical trials for Annamycin. We have two other drug development projects in progress,
	one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation of key regulatory
	transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic
	processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have been granted royalty-bearing, worldwide,
	exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122 Portfolio drug technologies,
	as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection.
	We intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product
	candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential
	patent protection, we believe Annamycin will qualify for Orphan Drug status and have submitted our application to the FDA, which
	could entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (&ldquo;NDA&rdquo;)
	and Marketing Authorization (&ldquo;MA&rdquo;), in the US and the European Union (&ldquo;EU&rdquo;), respectively. However, there
	can be no assurance that such status will be granted. Separately, the FDA may also grant market exclusivity of up to five years
	for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity
	will be granted or, if granted, for how long.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Drug Candidates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Annamycin
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our lead product candidate is Annamycin, an
	anthracycline intended to target the treatment of relapsed or refractory AML. Anthracyclines are a class of chemotherapy drugs
	designed to disrupt the DNA of, and eventually destroy, targeted cancer cells. They are considered to be among the most effective
	anticancer drugs developed and are used to treat a range of cancers, including leukemias, lymphomas, and breast, stomach, uterine,
	ovarian, bladder, and lung cancers. The effectiveness of currently approved anthracyclines is limited, however, by their propensity
	to cause heart damage (cardiotoxicity) and for cancer cells to become resistant by natural cell defense (multidrug resistance)
	mechanisms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Leukemia is a cancer of the white blood cells
	and acute forms of leukemia can manifest quickly and leave patients with limited treatment options. AML is the most common type
	of acute leukemia in adults. It occurs when a clone of leukemic progenitor white blood cells proliferates in the bone marrow,
	suppressing the production of normal blood cells. Currently, the only viable option for acute leukemia patients is a bone marrow
	transplant, which is successful in a significant number of patients. However, in order to qualify for a bone marrow transplant,
	the patient&rsquo;s leukemia cells must be decreased to a sufficiently low level. This begins with a therapy of combining two
	chemotherapeutic drugs, which always includes an anthracycline, in inducing remission (a complete response, or CR), which therapy
	has not improved since it was first used in the 1970s and we estimate that this induction therapy has the same success rate of
	about 20% as at that time. Unfortunately, the current clinically approved anthracyclines are cardiotoxic, which can result in
	damage to the heart and limit the dosage amount that may be administered to patients. Additionally, the tumor cells often present
	de novo or develop resistance to the first line anthracycline, often through what is called &ldquo;multidrug resistance&rdquo;,
	enabling them to purge themselves of the available anthracyclines. Consequently, there remains no effective therapy for these
	patients and most will succumb quickly to their leukemia. If a patient&rsquo;s leukemia reappears before they can be prepared
	for a bone marrow transplant, they are considered to have &ldquo;relapsed&rdquo;. If a patient fails to achieve a sufficient response
	from the induction therapy to qualify for a bone marrow transplant, they are considered to be &ldquo;refractory&rdquo; (resistant
	to therapy). Together, this group of relapsed and refractory AML patients constitutes our primary focus for treatment with Annamycin
	and our intent is to pursue FDA approval for Annamycin as a second-line induction therapy for adult relapsed and refractory AML
	patients.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe that pursuing approval as a second
	line induction therapy for adult relapsed or refractory AML patients is the shortest path to regulatory approval, but we also believe
	that one of the most important potential uses of Annamycin is in the treatment of children with either AML or ALL (acute lymphoblastic
	leukemia, which is more common in children). Accordingly, we also intend to pursue approval for pediatric use when practicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Annamycin is a liposome formulated anthracycline
	(also referred to in literature as &ldquo;L-Annamycin&rdquo;). It has been tested in 6 clinical trials and 114 patients without
	any reporting of cardiotoxicity and, in the two of those clinical trials focused on leukemia, with fewer dose-limiting toxicities
	than are normally experienced with doxorubicin (one of the leading first-line anthracyclines used for induction therapy). Each
	of these trials was conducted by previous holders of the intellectual property surrounding Annamycin and not by our company. Annamycin
	demonstrated significant activity in 8 of 16 patients in a Phase I study in adult relapsed or refractory AML patients, with 6 of
	14 patients completely clearing leukemic blasts. A 30 patient dose-ranging Phase I/II study in ALL demonstrated a similar level
	of activity, with 3 of 10 patients treated with the maximum tolerable dose clearing their leukemic blasts to a level sufficient
	to qualify for a bone marrow transplant. One of these patients went on to receive a successful curative bone marrow transplant.
	The other two of these three patients died of tumor lysis syndrome, a condition resulting from the overloading of their system
	with the debris from leukemic blast cells destroyed by the induction therapy. Armed with the knowledge of this potential, prophylactic
	pretreatment known to protect patients from the effects of tumor lysis syndrome will be deployed where appropriate in future trials.
	Based on the results of the above clinical trials, we believe Annamycin is different from currently approved induction therapy
	drugs in four key ways: (i) it has demonstrated clinical activity in a patient population for whom there are currently no effective
	therapies, (ii) it appears to be capable of avoiding the &ldquo;multi-drug resistance&rdquo; mechanisms that often limit the effectiveness
	of currently approved anthracyclines; (iii) it has been shown to be non-cardiotoxic in animal models and no events of cardiotoxicity
	have been reported from the use of Annamycin in 114 patients; and (iv) in AML cell lines, it has been shown to be more potent than
	one of the leading approved drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Because the prior developer of Annamycin allowed
	their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. Toward this end, we recently
	submitted a request for a Pre-IND meeting with the FDA. Based on subsequent conversations with the FDA, we will be allowed to incorporate
	by reference the prior developer&rsquo;s IND in submitting our new request for IND. We believe this will not only save time and
	expense with regard to our IND submission, but it should also reduce the risk that our IND submission is delayed due to a review
	of any of this prior data. Written communication from the FDA indicates they do not see a need for a Pre-IND meeting and plan to
	respond to questions in our Pre-IND briefing document in writing on December 6, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Based on initial conversations with the FDA,
	because of the serious unmet medical need, we believe Annamycin may qualify for accelerated approval based on our planned clinical
	trials. In order to facilitate our communication with the FDA, we requested access to and reviewed in detail the available data
	supporting the dose-ranging Phase I/II clinical trial discussed above, which was conducted by a previous developer of Annamycin.
	In October 2016, we announced that we had identified some positive findings from this review, which gave rise to a modification
	of our own clinical development plan. We had indicated that our plan was to conduct a detailed review of the clinical results generated
	by that prior developer, and then to use those results to reestablish an IND in order to continue clinical trials of Annamycin.
	However, in the course of our review, we identified that Annamycin may have greater potential for efficacy than we originally believed,
	based on an unexpected opportunity to increase the drug&rsquo;s Maximum Tolerable Dose (&ldquo;MTD&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In particular, the Dose Limiting Toxicities
	(&ldquo;DLTs&rdquo;) reported in the previous trial that led to the establishment of the current MTD of 150 mg/m
<SUP>
	2
</SUP>
	were
	all from patients who had an unusually high number of first-line induction therapy failures prior to being treated with Annamycin.
	Specifically, of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior
	induction therapy attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. We
	concluded from our review of this data that, if the heavily treated patients are excluded from the data set, the MTD could have
	been closer to 250 mg/m
<SUP>
	2
</SUP>
	, substantially higher than the level that was actually set by this previous trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We view this as an encouraging development because
	it means we may have an opportunity to increase the MTD for our next trial from 150 mg/m
<SUP>
	2
</SUP>
	to 200 or even 250 mg/m
<SUP>
	2
</SUP>
	.
	If that turns out to be the case, we believe it could increase the chance for positive outcomes in our next trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With the discovery that we may be able to increase
	our MTD, we determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial, which will add expense
	to our development effort. We believe this change in strategy will add several months to the eventual final approval of the drug,
	if the drug is approved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have also applied for Orphan Drug
	status with the FDA for Annamycin. The FDA has responded to our request for Orphan Drug status by requesting additional information,
	which we have now provided. We expect a response to our revised application in the near future, but can provide no assurance as
	to when any response will be received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The prevalence ceiling for qualifying rare diseases
	under the US Orphan Drug Act is 200,000 patients and proportionally similar guidelines exist in the EU. The most recently published
	prevalence statistics from the National Cancer Institute reported that an estimated 37,726 patients had acute myeloid leukemia
	in the United States as of January 1, 2011, and trend data since that publication would indicate that the prevalence today should
	still be well below the 200,000 patient limitation for Orphan Drugs, which would permit Annamycin for the treatment of acute myeloid
	leukemia to qualify for Orphan Drug status. Annamycin already qualified for Orphan Drug status with its prior developer and we
	intend to repeat that process. However, we can provide no assurance that we will be successful in obtaining Orphan Drug status
	for Annamycin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	The WP1066 Portfolio
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have a license agreement with MD Anderson
	pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
	to WP1066 and its close analogs, molecules targeting the modulation of key oncogenic transcription factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	In vitro
</I>
	testing has shown a high level
	of activity for WP1066 against a wide range of solid tumors, and
<I>
	in vitro
</I>
	testing has shown significant activity against
	head and neck, pancreatic, stomach, and ovarian cancers, as well as metastatic melanoma and glioblastoma, among others.
<I>
	In vitro
</I>
	testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that provides necessary
	blood supply to tumors) and increases survival.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With respect to our WP1066 Portfolio, we must
	complete pre-clinical toxicology testing, along with additional chemistry, manufacturing and control work to fully characterize
	the drug, establish the desired formulation and develop reference standards for future drug release, among others, prior to submitting
	an application for an IND. A clinician at MD Anderson has advised us that she is proceeding with a physician-sponsored IND for
	WP1066 treatment of brain tumors. We are not participating in this IND process. The clinician has submitted an IND to the FDA and
	has indicated that this IND is on hold until documentation of Good Manufacturing Process or GMP production of WP1066 can be presented
	to the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	An analog of WP1066, referred to as WP1220,
	was previously the subject of an IND (WP1220 was referred to as MOL4239 for purposes of this IND) related to use of the molecule
	in the topical treatment of psoriasis. Clinical trials were commenced on WP1220 in the US, but were terminated early due to limited
	efficacy in the topical treatment of psoriatic plaques. Notwithstanding its limitations in treating psoriasis, our pre-clinical
	research has shown WP1220 to be effective in inhibiting cutaneous T-cell lymphoma (&ldquo;CTCL&rdquo;) in multiple CTCL cell lines.
	Based on this encouraging data, we are collaborating with a Polish drug development company, Dermin Sp. Zo. O. (&ldquo;Dermin&rdquo;),
	which has received a Polish government grant to begin a clinical trial in Poland for the topical treatment of early stage CTCL
	patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We also conducted a Phase II clinical trial
	for WP1066 for the topical treatment of psoriasis, however this trial was terminated early as a significant number of patients
	experienced a non-permanent worsening of their psoriatic plaques after extended use of the drug, suggesting that its use as a topical
	agent for non-life threatening diseases such as psoriasis will require further study to optimize dosing and scheduling regimens.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	The WP1122 Portfolio
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have a license agreement with MD Anderson
	pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
	to our WP1122 Portfolio and similar molecules targeting the treatment of glioblastoma multiform, or GBM, and related central nervous
	system, or CNS, malignancies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe this technology has the potential
	to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and
	important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system
	malignancies and especially GBM. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous
	system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the
	treatment options available to their physicians are among the most limited of any cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The American Cancer Society has estimated 23,770
	new cases of brain and other nervous system cancers will occur in the United States in 2016, resulting in 16,050 deaths. Despite
	the severity and poor prognosis of these tumors, there are few FDA-approved drugs on the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have proof of concept data for our WP1122
	Portfolio, including data on survival of animals subjected to xenografts of human brain tumors, as well as biodistribution and
	pharmacokinetics. In non-optimal doses and treatment regimes, our WP1122 Portfolio performed equal to or better than the current
	market leader, temozolomide and provided for superior survival for animals treated in combination with temozolomide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Relating to Our Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As a preclinical-stage, pharmaceutical company,
	our business and ability to execute our business strategy are subject to a number of risks of which you should be aware before
	you decide to buy our securities. In particular, you should consider the following risks, which are discussed more fully in the
	section entitled &ldquo;Risk Factors&rdquo;:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;&bull;
</TD>
<TD>
	we currently do not have regulatory approval for our lead drug candidate, Annamycin, or any other product candidates, in the
	United States or elsewhere, although we plan to conduct clinical trials in the United States for Annamycin and other drug candidates
	in the future, there is no assurance that we will be successful in our clinical trials or receive regulatory approval in a timely
	manner, or at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	a portion of our business is dependent upon the intellectual property rights that we license from MD Anderson, and in the past
	we have been in breach of these license agreements. Although we are currently in compliance with our obligations under our license
	agreements, there is no assurance that in the future we will not again be in breach of these agreements. Additionally, the intellectual
	property that we have licensed from MD Anderson may have been developed under a funding agreement with the United States government.
	To the extent that is the case, our license agreements with and the intellectual property rights we have licensed from MD Anderson
	are subject to such a funding agreement and any superior rights that the U.S. government may have with respect to the licensed
	intellectual property;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	our lead drug candidate, Annamycin, is not the subject of any patent protection, and, although we intend to apply for formulation
	and method-of-use patents for Annamycin, there is no assurance that we will be successful in obtaining such patents and, even if
	we are successful, such patents generally offer less protection than original composition of matter patents;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	unforeseen side effects from any of our product candidates could arise during clinical development. For example, in the most
	recent Phase I/II dose-ranging clinical trial of Annamycin, two patients succumbed to tumor lysis syndrome (&ldquo;TLS&rdquo;)
	resulting from the debris created by Annamycin killing the targeted leukemic blasts more rapidly than anticipated. As another example,
	we intend to attempt to increase the maximum tolerable dose (&ldquo;MTD&rdquo;) for Annamycin by conducting another Phase I dose-ranging
	trial, however, unforeseen side effects could prevent us from increasing the MTD from the one established in the prior Phase I/II
	trial;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we do not currently carry product liability insurance covering any of our drug candidates and, although we intend to obtain
	product liability insurance for future clinical trial liability that we may incur, there can be no assurance that we will secure
	adequate coverage or that, even if we do so, any such coverage will be sufficient to prevent the exposure of our operations to
	significant potential liability in the future;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the patents we have licensed from MD Anderson may not be valid or enforceable and may not protect us against competitors who
	challenge those licensed patents, obtain their own patents that may have an adverse effect on our ability to conduct business,
	or are able to otherwise circumvent our patents. Additionally, our products and technologies are complex and one patent may not
	be sufficient to protect our products where a series of patents may be needed. Further, we may not have the necessary financial
	resources to enforce or defend our patents or patent applications. In addition, any patent applications we may have made or may
	make relating to inventions for our actual or potential products and technologies may not result in patents being issued or may
	result in patents that provide insufficient or incomplete coverage for our inventions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	third parties may claim that the manufacture, use or sale of our technologies infringe their intellectual property rights.
	As with any litigation where such claims may be asserted, we may have to seek licenses, defend infringement actions or challenge
	the validity of those patents in the patent office or the courts. If these are not resolved favorably, we may not be able to continue
	to develop and commercialize our product candidates. Even if we were able to obtain rights to a third party&rsquo;s intellectual
	property, these rights may be non-exclusive, thereby giving our competitors potential access to the same intellectual property.
	If we are found liable for infringement or are not able to have these patents declared invalid or unenforceable, we may be liable
	for significant monetary damages, encounter significant delays in bringing products to market or be precluded from participating
	in the manufacture, use or sale of products or technologies by patents of others. We may not have identified, or be able to identify
	in the future, U.S. or foreign patents that pose a risk of potential infringement claims;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we have completed related party transactions that were not conducted on an arm&rsquo;s length basis. We acquired the rights
	to the license agreement with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation, a company affiliated
	with certain members of our management and board of directors. We acquired the rights to all data related to the development of
	Annamycin held by AnnaMed, Inc., a company affiliated with certain members of our management and board of directors. Prior to our
	IPO, Moleculin, LLC was merged with and into our company. Moleculin, LLC is affiliated with certain members of our management and
	board of directors. In addition, prior to our IPO, we entered into an agreement with Houston Pharmaceuticals, Inc., or HPI, whereby
	HPI agreed to terminate its option to sublicense certain rights to the WP1066 Portfolio and to enter into a co-development agreement
	with us. Our largest shareholder and a member of our management are shareholders of HPI. Since these transactions were not conducted
	on an arm&rsquo;s length basis, it is possible that the terms were less favorable to us than in an arm&rsquo;s length transaction.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we have never been profitable, have not generated significant revenue to date and we expect to incur significant additional
	losses to fund our clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we will require substantial additional funding beyond the proceeds of the offering to which this prospectus relates to complete
	the development and commercialization of our drug candidates, and such funding may not be available on acceptable terms or at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	our development work is dependent in part on collaborations with other drug development companies and funding from government
	and philanthropic funding sources and there can be no assurance that such collaborations and funding will continue in the future;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	our short-to-medium term prospects depend largely on our ability to develop and commercialize one drug candidate, Annamycin,
	and our ability to generate revenues in the future will depend heavily on the successful development and commercialization of Annamycin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we may be subject to delays in our clinical trials, which could result in increased costs and delays or limit our ability to
	obtain regulatory approval for Annamycin and/or any other potential drug candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we have never commercialized any of our drug candidates, including Annamycin, and, even if approved, our drug candidates may
	not be accepted by healthcare providers or healthcare payors; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	we may be unable to maintain and protect our intellectual property assets, which could impair the advancement of our pipeline
	and commercial opportunities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Implications of Being an Emerging Growth Company
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We qualify as an &ldquo;emerging growth company&rdquo;
	as the term is used in The Jumpstart Our Business Startups Act of 2012 (&ldquo;JOBS Act&rdquo;), and therefore, we may take advantage
	of certain exemptions from various public company reporting requirements, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	a requirement to only have two years of audited financial statements and only two years of related selected financial data
	and management&rsquo;s discussion and analysis;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	exemption from the auditor attestation requirement on the effectiveness of our internal controls over financial reporting;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	reduced disclosure obligations regarding executive compensation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden
	parachute payments.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We may take advantage of these provisions until
	December 31, 2021 or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth
	company if we have more than $1.0 billion in annual revenues, have more than $700 million in market value of our capital stock
	held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period. We may choose to take
	advantage of some, but not all, of the available benefits of the JOBS Act. We have taken advantage of some of the reduced reporting
	requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive
	from other public companies in which you hold stock. In addition, the JOBS Act provides that an emerging growth company can delay
	adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably
	elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to
	the same new or revised accounting standards as other public companies that are not emerging growth companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our principal executive offices are located
	at 2575 West Bellfort, Suite 333, Houston, Texas 77054. Our telephone number is (713) 300-5160. Our website address is www.moleculin.com.
	The information on or accessible through our website is not part of this prospectus.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_PROSPECTUS_SUMMARY>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_THE_OFFERING>
<A NAME="FIS_THE_OFFERING"></A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	The Offering
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42%; BORDER: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Public
	offering price
</FONT>
</TD>
<TD STYLE="WIDTH: 58%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
	unit
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Common
	stock we are offering
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2,500,000
	shares, plus: (i) 1,250,000 shares of our common stock underlying the Series A warrants offered in this offering; (ii) 2,500,000
	shares of our common stock underlying the Series B warrants offered in this offering; and (iii) 1,250,000 shares of our common
	stock underlying the Series C warrants offered in this offering.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Common
	stock outstanding immediately before this offering
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	12,164,851
	shares
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Common
	stock outstanding immediately after this offering
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	14,664,851
	shares (assuming none of the warrants issued in this offering are exercised).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Warrants
	we are offering
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<P STYLE="MARGIN: 0PT 0">
	Each
	share of common stock purchased in this offering will include: (i) a Series A warrant
	to purchase 0.50 of a share of our common stock, (ii) a Series B warrant to purchase
	one share of our common stock, and (iii) a Series C warrant to purchase 0.50 of a share
	of our common stock. The Series C warrants in a unit may only be exercised to the extent
	and in proportion to a holder of the Series C warrants exercising its corresponding Series
	B warrants included in the unit. The Series A and C warrants will expire five years from
	the date of issuance. The Series B warrants will expire 90 days from the date of issuance.
	Each warrant will have an initial exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
	share of common stock (100% of the unit purchase price). This prospectus also relates
	to the offering of shares of our common stock issuable upon exercise of the warrants.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Use
	of proceeds
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	We
	intend to use the proceeds from this offering for working capital and general corporate purposes. See &ldquo;Use of Proceeds&rdquo;
	for more information.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	NASDAQ
	symbol
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Our
	common stock is listed on the NASDAQ Capital Market under the symbol &ldquo;MBRX&rdquo;. There is no established public trading
	market for the warrants, and we do not expect a market to develop. The warrants are not and will not be listed for trading
	on the NASDAQ Capital Market, any other national securities exchange or other nationally recognized trading system.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Risk
	Factors
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; PADDING-RIGHT: 0.1IN; PADDING-BOTTOM: 5.4PT; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	See
	&ldquo;Risk Factors&rdquo; and other information appearing elsewhere in this prospectus for a discussion of factors you should
	carefully consider before deciding whether to invest in our common stock.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The number of shares
	of common stock to be outstanding after this offering is based on 12,164,851 shares of common stock outstanding as of January
	17, 2017 and does not take into account, as of January 17, 2017:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;510,000
	shares of our common stock issuable upon exercise of outstanding stock options to purchase shares of our common stock at a weighted
	average exercise price of $5.28 per share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107,802
	shares of our common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price of $7.50 per
	share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,990,000
	shares of our common stock reserved for issuance under our 2015 Stock Plan;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,818,861
	shares upon the conversion of outstanding bridge notes. These notes were to be automatically converted according to their terms
	into our common stock upon the closing of our IPO to the extent and provided that no holder of these notes was or will be permitted
	to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of our
	common stock after such conversion. Due to this 4.99% limitation, certain of these notes remained outstanding and will be converted
	into shares of our common stock at such time as the 4.99% limitation continues to be met;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79,167
	shares of our common stock issuable to a third-party in settlement of $237,500 in past due amounts;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,000,000
	shares of common stock issuable upon the exercise of the warrants included in the units being sold in this offering; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175,000
	shares of common stock issuable upon the exercise of the warrants issued to the representatives of the underwriters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Unless otherwise indicated, all information in this prospectus assumes
	that no exercise of the outstanding options and warrants described above or the warrants offered hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_THE_OFFERING>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Summary Financial Data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth data derived from our balance sheet
	at December 31, 2015 and our statement of operations for the period from July 28, 2015 (Inception) to December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	From July 28, 2015
<BR>
	(Inception) to
<BR>
	December 31, 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statement of Operations Data - MBI
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT">
	Research and development expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	260,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	477,810
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Net loss per common share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	December
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	31,
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Balance Sheet Data - MBI
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(744,699
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total stockholders' deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(744,699
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth data derived from Moleculin, LLC&rsquo;s
	balance sheets at December 31, 2015 and 2014 and the related statements of operations for each of the years then ended:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Year Ended December 31,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statements of Operations Data
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Research and development expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	125,442
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	798,785
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	328,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	839,556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,005
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other (income)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	expense
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(99,537
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	159,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statements of Financial Position Data
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	31,867
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	524,477
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,844,589
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,095,276
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,480
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	781,448
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,203,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,837,705
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total members' deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,833,330
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,467,519
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth data derived from our balance sheet
	at September 30, 2016 and the related statement of operations for the nine months ended September 30, 2016 and the period from
	July 29, 2015 (Inception) to September&nbsp;30, 2015. Moleculin, LLC was acquired by MBI on May 2, 2016 and ceased to exist after
	such acquisition by MBI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Nine Months
<BR>
	Ended September 30,
<BR>
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	From July 29, 2015
<BR>
	(Inception) to
<BR>
	September 30, 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statement of Operations Data - MBI
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Research and development expense
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	616,498
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	38,409
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,849,242
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,344
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	37,307
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,562
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,503,047
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Net loss per common share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30, 2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Balance Sheet Data - MBI
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6,183,783
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Working capital deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,148,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,573,788
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,251,407
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total stockholders' equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,243,635
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<A NAME="V458551_S1A_HTM_A_018" TITLE="RISK FACTORS">
</A>
<B>
	Risk
	Factors
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
<I>
	Investing in our securities involves a high
	degree of risk. You should carefully consider each of the following risks, together with all other information set forth in this
	prospectus, including the financial statements and the related notes, before making a decision to buy our securities. If any of
	the following risks actually occurs, our business could be harmed. In that case, the trading price of our securities could decline,
	and you may lose all or part of your investment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Relating to Our Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We will require substantial additional funding, which may
	not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease
	our operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We intend to use the proceeds from our previous
	offering, as well as the proceeds from this offering, to, among other uses, advance Annamycin through clinical development. Developing
	pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial
	additional future capital in order to complete clinical development and commercialize Annamycin. If the FDA requires that we perform
	additional nonclinical studies or clinical trials, or if we determine, as we did in October 2016, that additional clinical trials
	are required for Annamycin, our expenses would further increase beyond what we currently expect and the anticipated timing of any
	potential approval of Annamycin would likely be delayed. Further, there can be no assurance that the costs we will need to incur
	to obtain regulatory approval of Annamycin will not increase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We will continue to require substantial additional
	capital to continue our clinical development and commercialization activities. Because successful development of our product candidates
	is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize
	our products under development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The amount and timing of our future funding
	requirements will depend on many factors, including but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	whether our updated plan for clinical trials will be completed on a timely basis and, if completed, will be successful in producing
	useful clinical data in 2017;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	whether we are successful in obtaining an accelerated approval pathway with the FDA related to Annamycin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the progress, costs, results of and timing of our clinical trials for Annamycin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the continued progress of our collaborative drug development partner, which is dependent upon their continued access to grant
	funding;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the costs associated with securing and establishing commercialization and manufacturing capabilities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	market acceptance of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	our ability to maintain, expand and enforce the scope of our intellectual property portfolio, including the amount and timing
	of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense
	and enforcement of any patents or other intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	our need and ability to rely on data to be generated by our sublicensee partner, Dermin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	our need and ability to hire additional management and scientific and medical personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the effect of competing drug candidates and new product approvals;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	our need to implement additional internal systems and infrastructure, including financial and reporting systems; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD>
	the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing
	or other arrangements into which we may enter in the future.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Some of these factors are outside of our control.
	Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operational plan
	through the third quarter of 2017. This period could be shortened if there are any significant increases in planned spending on
	development programs or more rapid progress of development programs than anticipated. We do not believe that our existing capital
	resources are sufficient to enable us to complete the development and commercialization of Annamycin, if approved, or to initiate
	any clinical trials or additional development work needed for any other drug candidates, other than as described above. Accordingly,
	we expect that we will need to raise additional funds in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We may seek additional funding through a combination
	of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements
	and other collaborations, strategic alliances and licensing arrangements. Additional funding may not be available to us on acceptable
	terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. In
	addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares
	to decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If we are unable to obtain funding on a timely
	basis, we may be required to significantly curtail one or more of our research or development programs. We also could be required
	to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of
	our technologies or product candidates or otherwise agree to terms unfavorable to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have in the past completed related party transactions that
	were not conducted on an arm&rsquo;s length basis.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We acquired the rights to the license agreement
	with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation, a company affiliated with certain members of our
	management and board of directors. We acquired the rights to all data related to the development of Annamycin held by AnnaMed,
	Inc., a company affiliated with certain members of our management and board of directors. Prior to our IPO, Moleculin, LLC merged
	with and into our company. Moleculin, LLC was affiliated with certain members of our management and board of directors. Prior to
	our IPO, we, on Moleculin, LLC&rsquo;s behalf, entered into an agreement with HPI whereby HPI agreed to terminate its option to
	sublicense certain rights to the WP1066 Portfolio and entered into a co-development agreement with us. Our largest shareholder
	and a member of our management are shareholders of HPI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	None of the foregoing transactions were conducted
	on an arm&rsquo;s length basis. As such, it is possible that the terms were less favorable to us than in an arm&rsquo;s length
	transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our ability to retain the development rights to the WP1066
	Portfolio will require us to make up to $1.75 million in future payments to HPI, in addition to payments of shares of our common
	stock and cash made in connection with our IPO, pursuant to the development agreement we entered into with HPI.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our acquisition of Moleculin, LLC prior to our
	IPO provided us with the rights to the license agreement Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However,
	Moleculin, LLC previously granted HPI an option to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological
	fields. Prior to our IPO, we, on Moleculin, LLC&rsquo;s behalf, entered into two agreements with HPI. The first agreement terminated
	HPI&rsquo;s option to obtain the aforementioned exclusive sublicense in exchange for a payment of $100,000 and the issuance of
	629,000 shares of our common stock. The second agreement, the HPI Out-Licensing Agreement is a technology rights and development
	license agreement that provided HPI with a non-exclusive sublicense to develop the WP1066 Portfolio. Pursuant to this HPI Out-Licensing
	Agreement, we agreed to make payments to HPI of $750,000 over a three-year period commencing after our IPO in exchange for HPI
	allowing us to access any data, information or know-how resulting from the research and development conducted by HPI, which payments
	will be expensed when incurred. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement
	does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement,
	we have the right within three years of the date we entered into the agreement to buy-out from HPI all rights granted to HPI under
	the agreement for a payment of $1.0 million. If we do not exercise the foregoing buy-out right within three years, the license
	granted to HPI shall convert into an exclusive license even as to our company. As such, if we do not exercise the buy-out right
	for any reason, we will no longer have access to the non-dermatology uses of the WP1066 Portfolio and all amounts paid to HPI prior
	to such date will have value only to the extent that the data, information and know-how may be applicable to dermatology applications
	of the WP1066 Portfolio. We do not expect to maintain a reserve of $1.0 million to exercise the buy-out payment and, as such, we
	will need to raise additional funds to make the buy-out payment. We cannot assure you that such additional funding, if required,
	will be available on satisfactory terms, or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have never been profitable, we have no products approved
	for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses
	and reach profitability is unproven, and we may never achieve or sustain profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have never been profitable and do not expect
	to be profitable in the foreseeable future. We have not yet submitted any drug candidates for approval by regulatory authorities
	in the United States or elsewhere. For the nine-month period ended September 30, 2016, we incurred a net loss of $2,503,047. We
	had an accumulated deficit of $3,251,407 as of September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	To date, we have devoted most of our financial
	resources to research and development, including our drug discovery research, preclinical development activities and clinical
	trial preparation, as well as corporate overhead. We have not generated any revenues from product sales. We expect to continue
	to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek
	regulatory approvals for Annamycin, prepare for and begin the commercialization of any approved products, and add infrastructure
	and personnel to support our continuing product development efforts. We anticipate that any such losses could be significant for
	the next several years. If Annamycin or any of our other drug candidates fail in clinical trials or does not gain regulatory approval,
	or if our drug candidates do not achieve market acceptance, we may never become profitable. As a result of the foregoing, we expect
	to continue to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows
	have had, and will continue to have, an adverse effect on our stockholders' equity and working capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Because of the numerous risks and uncertainties
	associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses
	or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA
	to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials
	or the development of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of future growth
	of our expenses and our ability to generate revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our financial condition would be adversely impacted if our
	intangible assets become impaired.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As a result of the accounting for our acquisition
	of Moleculin, LLC and the agreement we, on Moleculin, LLC&rsquo;s behalf, entered into with Houston Pharmaceuticals, Inc., we have
	carried on our balance sheet within intangible assets in-process research and development (&ldquo;IPR&amp;D&rdquo;) of $11,128,790
	as of September 30, 2016. Intangibles are evaluated quarterly and are tested for impairment at least annually or when events or
	changes in circumstances indicate the carrying value of each segment, and collectively our company taken as a whole, might exceed
	its fair value. We have retained a third party valuation firm to provide us with an initial valuation of these intangible assets;
	and we expect to receive their final report prior to the filing of our Form 10-K for the year ended December 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Intangible assets related to IPR&amp;D are considered
	indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist.
	If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record
	a noncash impairment loss on its statement of operations. For those compounds that reach commercialization, if any, the IPR&amp;D
	assets will be amortized over their estimated useful lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If after receipt of the foregoing valuation
	report we determine that the value of our intangible assets is less than the amounts reflected on our balance sheet, we will be
	required to reflect an impairment of our intangible assets in the period in which such determination is made. An impairment of
	our intangible assets would result in our recognizing an expense in the amount of the impairment in the relevant period, which
	would also result in the reduction of our intangible assets and a corresponding reduction in our stockholders&rsquo; equity in
	the relevant period. As the transactions discussed above were related party transactions and were not conducted on an arm&rsquo;s
	length basis, it is possible that the terms were less favorable to us than what we would have received in an arm&rsquo;s length
	transaction. We can provide no assurance that the final valuation of our intangible assets will not result in an impairment charge.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have a limited operating history and we expect a number
	of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are a preclinical pharmaceutical company
	with a limited operating history. Our operations to date have been limited to acquiring our technology portfolio. We have not yet
	commenced any clinical trials or obtained any regulatory approvals for any of our drug candidates. Consequently, any predictions
	made about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved
	products on the market. Our operating results are expected to significantly fluctuate from quarter-to-quarter or year-to-year due
	to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	any delays in regulatory review and approval of our product candidates in clinical development, including our ability to receive
	approval from the FDA for Annamycin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays in the commencement, enrollment and timing of clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	difficulties in identifying patients suffering from our target indications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the success of our clinical trials through all phases of clinical development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential side effects of our product candidate that could delay or prevent approval or cause an approved drug to be taken
	off the market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to obtain additional funding to develop drug candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to identify and develop additional drug candidates beyond Annamycin and our WP1066 and WP1122 Portfolios;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	competition from existing products or new products that continue to emerge;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to adhere to clinical trial requirements directly or with third parties such as contract research organizations
	(CROs);
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our dependency on third-party manufacturers to manufacture our products and key ingredients;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to establish or maintain collaborations, licensing or other arrangements, particularly with MD Anderson;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to defend against any challenges to our intellectual property including, claims of patent infringement;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to enforce our intellectual property rights against potential competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to secure additional intellectual property protection for our developing drug candidates and associated technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to attract and retain key personnel to manage our business effectively; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential product liability claims.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Accordingly, the results of any historical quarterly
	or annual periods should not be relied upon as indications of future operating performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We cannot be certain that Annamycin will receive regulatory
	approval, and without regulatory approval we will not be able to market Annamycin.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our business currently depends largely on the
	successful development and commercialization of Annamycin. Our ability to generate revenue related to product sales, if ever, will
	depend on the successful development and regulatory approval of Annamycin for the treatment of relapsed or refractory acute myeloid
	leukemia, or AML.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We currently have no products approved for sale
	and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating
	to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in
	other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the
	United States until we receive approval of a NDA from the FDA. We have not submitted any marketing applications for any of our
	product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	NDAs must include extensive preclinical and
	clinical data and supporting information to establish the product candidate&rsquo;s safety and effectiveness for each desired indication.
	NDAs must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval
	of a NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review processes
	can take years to complete and approval is never guaranteed. If we submit a NDA to the FDA, the FDA must decide whether to accept
	or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA.
	Regulators in other jurisdictions have their own procedures for approval of product candidates. Even if a product is approved,
	the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or
	require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries
	outside of the United States and Europe also have requirements for approval of drug candidates with which we must comply with prior
	to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure
	that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing
	applications in the United States, Europe or other countries may be based upon many factors, including regulatory requests for
	additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations
	of data and results, changes in regulatory policy during the period of product development and the emergence of new information
	regarding our product candidates or other products. Also, regulatory approval for any of our product candidates may be withdrawn.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If we are unable to obtain approval from the
	FDA, or other regulatory agencies, for Annamycin and our other product candidates, or if, subsequent to approval, we are unable
	to successfully commercialize Annamycin or our other product candidates, we will not be able to generate sufficient revenue to
	become profitable or to continue our operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Any statements in this prospectus indicating
	that Annamycin has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA&rsquo;s or any other
	comparable governmental agency&rsquo;s assessment of Annamycin and do not indicate that Annamycin will achieve favorable efficacy
	results in any later stage trials or that the FDA or any comparable agency will ultimately determine that Annamycin is effective
	for purposes of granting marketing approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Delays in the commencement, enrollment and completion of clinical
	trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for Annamycin
</I>
</B>
<B>
<I>
	and our other product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Delays in the commencement, enrollment and completion
	of clinical trials could increase our product development costs or limit the regulatory approval of our product candidates. We
	do not know whether any future trials or studies of our other product candidates will begin on time or will be completed on schedule,
	if at all. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing
	challenges, including delays or shortages in available drug product, required clinical trial administrative actions, slower than
	anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative drug or required
	prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties
	in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical
	trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering
	from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment
	are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, that
	include the age and condition of the patients and the stage and severity of disease, the nature of the protocol, the proximity
	of patients to clinical sites and the availability of effective treatments and/or availability of investigational treatment options
	for the relevant disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	A product candidate can unexpectedly fail at
	any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific
	feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or
	early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of
	the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate
	at any time for various reasons, including, but not limited to, a belief that subjects participating in such trials are being exposed
	to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. We may not have the financial
	resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or
	other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	inability to obtain sufficient funds required for a clinical trial;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject
	to extensive negotiation and may vary significantly among different CROs and trial sites;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to
	ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	serious and unexpected drug-related side effects experienced by subjects in our clinical trials or by individuals using drugs
	similar to our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays in enrolling research subjects in clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	high drop-out rates and high fail rates of research subjects;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our
	clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	greater than anticipated clinical trial costs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	poor effectiveness of our product candidates during clinical trials; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or vendor.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have never conducted a clinical
	trial or submitted an NDA before, and any product candidate we advance through clinical trials may not have favorable results in
	later clinical trials or receive regulatory approval.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Clinical failure can occur at any stage of our
	clinical development. Clinical trials may produce negative or inconclusive results, and our collaborators or we may decide, or
	regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials
	and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which
	may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure that
	subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy
	and safety of a product candidate. A number of companies in the pharmaceutical industry, including those with greater resources
	and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier clinical
	trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In addition, the design of a clinical trial
	can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become
	apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory
	approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development
	efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If Annamycin is found to be unsafe or lack efficacy,
	we will not be able to obtain regulatory approval for it and our business would be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In some instances, there can be significant
	variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including
	changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial
	protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we or any of our
	potential future collaborators may conduct will demonstrate the consistent or adequate efficacy and safety that would be required
	to obtain regulatory approval and market any products. If we are unable to bring Annamycin to market, or to acquire other products
	that are on the market or can be developed, our ability to create long-term stockholder value will be limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our product candidates may have undesirable side effects that
	may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to
	include safety warnings or otherwise limit their sales.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Unforeseen side effects from any of our product
	candidates could arise either during clinical development or, if Annamycin is approved, after the approved product has been marketed.
	For example, in the most recent Phase I/II dose-ranging clinical trial of Annamycin, two patients succumbed to tumor lysis syndrome
	(TLS) resulting from the debris created by Annamycin killing the targeted leukemic blasts more rapidly than anticipated. Now that
	this potential has been identified, prophylactic measures known to protect patients from TLS will be deployed in future clinical
	trials, but there can be no assurance that such measures will be effective or that other adverse events may not emerge related
	to our drug. As another example, we intend to attempt to increase the maximum tolerable dose (MTD) for Annamycin by conducting
	another Phase I dose-ranging trial, however, unforeseen side effects could prevent us from increasing the MTD from the one established
	in the prior Phase I/II trial. Additional or unforeseen side effects from Annamycin or any of our other product candidates could
	arise either during clinical development or, if approved, after the approved product has been marketed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The range and potential severity of possible
	side effects from therapies such as Annamycin are significant. If Annamycin causes undesirable or unacceptable side effects in
	the future, this could interrupt, delay or halt clinical trials and result in the failure to obtain or suspension or termination
	of marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory
	authorities only with restrictive label warnings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If any of our product candidates receives marketing
	approval and we or others later identify undesirable or unacceptable side effects caused by such products:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts
	to physicians and pharmacies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we may be required to change instructions regarding the way the product is administered, conduct additional clinical trials
	or change the labeling of the product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we may be subject to limitations on how we may promote the product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	sales of the product may decrease significantly;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	regulatory authorities may require us to take our approved product off the market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we may be subject to litigation or product liability claims; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our reputation may suffer.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;Any of these events could prevent us or
	our potential future collaborators from achieving or maintaining market acceptance of the affected product or could substantially
	increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from
	the sale of our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If the FDA does not find the manufacturing facilities of our
	future contract manufacturers acceptable for commercial production, we may not be able to commercialize any of our product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We do not intend to manufacture the pharmaceutical
	products that we plan to sell. We are currently utilizing contract manufacturers for the production of the active pharmaceutical
	ingredients and the formulation of drug product for our trials of Annamycin that we will need to conduct prior to seeking regulatory
	approval.
<B>
<I>
</I>
</B>
	However, we do not have agreements for supplies of Annamycin or any of our other product candidates and
	we may not be able to reach agreements with these or other contract manufacturers for sufficient supplies to commercialize Annamycin
	if it is approved. Additionally, the facilities used by any contract manufacturer to manufacture Annamycin or any of our other
	product candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate manufactured
	at that facility. We are completely dependent on these third-party manufacturers for compliance with the requirements of U.S. and
	non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material
	that conform to our specifications and the FDA&rsquo;s current good manufacturing practice standards, or cGMP, and other requirements
	of any governmental agency whose jurisdiction to which we are subject, our product candidates will not be approved or, if already
	approved, may be subject to recalls. Reliance on third-party manufacturers entails risks to which we would not be subject if we
	manufactured our product candidates, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the possibility that we are unable to enter into a manufacturing agreement with a third party to manufacture our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified
	replacement third-party manufacturer.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Any of these factors could cause the delay of
	approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our
	product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to
	deliver the required commercial quantities of finished product on a timely basis at commercially reasonable prices and we are unable
	to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
	volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue.
	It may take several years to establish an alternative source of supply for our product candidates and to have any such new source
	approved by the government agencies that regulate our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have no sales, marketing or distribution experience and
	we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing
	arrangements.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have no sales, marketing or distribution
	experience. To develop sales, distribution and marketing capabilities, we will have to invest significant amounts of financial
	and management resources, some of which will need to be committed prior to any confirmation that Annamycin or any of our other
	product candidates will be approved by the FDA. For product candidates where we decide to perform sales, marketing and distribution
	functions ourselves or through third parties, we could face a number of additional risks, including that we or our third-party
	sales collaborators may not be able to build and maintain an effective marketing or sales force. If we use third parties to market
	and sell our products, we may have limited or no control over their sales, marketing and distribution activities on which our future
	revenues may depend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may not be successful in establishing and maintaining development
	and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and
	our financial condition and operating results.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Because developing pharmaceutical products,
	conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products
	are expensive, we may seek to enter into collaborations with companies that have more experience. Additionally, if any of our product
	candidates receives marketing approval, we may enter into sales and marketing arrangements with third parties with respect to our
	unlicensed territories. If we are unable to enter into arrangements on acceptable terms, if at all, we may be unable to effectively
	market and sell our products in our target markets. We expect to face competition in seeking appropriate collaborators. Moreover,
	collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial
	resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements
	for the development of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	When we collaborate with a third party for development
	and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of
	that product candidate to the third party. For example, we have formed a collaboration with a Polish drug development company called
	Dermin, where we have provided them with sub-license rights to our technologies for use in limited territories in exchange for
	their use of Polish government grant funding to pay for development costs we would otherwise have to fund ourselves. With the exception
	of Annamycin, Dermin&rsquo;s territories are primarily Poland and lesser surrounding countries, but not including any of the major
	European markets (UK, Germany, France, Spain and Italy). In the case of Annamycin, Dermin&rsquo;s territories also include Germany,
	but we retain the right to repurchase that territory for $500,000 at any time in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We announced in October 2016 that we had secured
	an agreement with Dermin to utilize Dermin&rsquo;s supply of Annamycin for our upcoming clinical trial. If Dermin is unable to
	provide us with sufficient supply for clinical trials, or if the drug product supplied is unacceptable for use in our clinical
	trials, our clinical trials may be delayed or the outcomes may be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	One or more of our collaboration partners may
	not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization.
	The terms of any collaboration or other arrangement that we establish may contain provisions that are not favorable to us. In addition,
	any collaboration that we enter into may be unsuccessful in the development and commercialization of our product candidates. In
	some cases, we may be responsible for continuing preclinical and initial clinical development of a product candidate or research
	program under a collaboration arrangement, and the payment we receive from our collaboration partner may be insufficient to cover
	the cost of this development. If we are unable to reach agreements with suitable collaborators for our product candidates, we would
	face increased costs, we may be forced to limit the number of our product candidates we can commercially develop or the territories
	in which we commercialize them. As a result, we might fail to commercialize products or programs for which a suitable collaborator
	cannot be found. If we fail to achieve successful collaborations, our operating results and financial condition could be materially
	and adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our success depends greatly on the success of Annamycin&rsquo;s
	development for the treatment of relapsed or refractory AML, and our pipeline of product candidates beyond this lead indication
	is extremely early stage and limited.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Other than Annamycin, our other two drug candidates,
	our WP1066 Portfolio and our WP1122 Portfolio, are each in the early stages of development. As such, we are dependent on the success
	of Annamycin in the near term. We cannot provide you any assurance that we will be able to successfully advance any of these indications
	through the development process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We face competition from other biotechnology and pharmaceutical
	companies and our operating results will suffer if we fail to compete effectively.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The biotechnology and pharmaceutical industries
	are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States,
	Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty
	pharmaceutical and generic drug companies and universities and other research institutions. Many of our competitors have greater
	financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations
	than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory
	approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research,
	sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions.
	Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license
	novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors
	may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing drugs for the diseases
	that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance
	than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
	with large, established companies. In addition, many universities and private and public research institutes may become active
	in our target disease areas. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies
	and drug products that are more effective or less costly than any of our product candidates that we are currently developing or
	that we may develop, which could render our products obsolete or noncompetitive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	A number of attempts have been made or are under
	way to provide an improved treatment for AML. Drugs attempting to target a subset of AML patients who present with particular anomalies
	involving a gene referred to as FLT3 are currently in clinical trials. Other approaches to improve the effectiveness of induction
	therapy are in early stage clinical trials and, although they do not appear to address the underlying problems with anthracyclines,
	we can provide no assurance that such improvements, if achieved, would not adversely impact the need for improved anthracyclines.
	A modified version of doxorubicin designed to reduce cardiotoxicity is in clinical trials for the treatment of sarcoma and, although
	this drug does not appear to address multidrug resistance and is not currently intended for the treatment of acute leukemia, we
	can provide no assurance that it will not become a competitive alternative to Annamycin. Although we are not aware of any other
	single agent therapies in clinical trials that would directly compete against Annamycin in the treatment of relapsed and refractory
	AML, we can provide no assurance that such therapies are not in development, will not receive regulatory approval and will reach
	market before our drug candidate Annamycin. In addition, any such competing therapy may be more effective and / or cost-effective
	than ours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	If our competitors market products that are
	more effective, safer or less expensive or that reach the market sooner than our future products, if any, we may not achieve commercial
	success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each
	technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological
	advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive
	or not economical.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Annamycin does not have any patent protections, including
	composition of matter patent protection.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We intend to pursue patents with claims directed
	to Annamycin drug product formulations and the methods of use of Annamycin to treat relapsed or refractory AML and other conditions,
	and methods for its synthesis, as the composition of matter patent protection for Annamycin has expired. As a result, competitors
	may be able to offer and sell products so long as these competitors do not infringe any other patents that third parties or we
	hold, including formulation, synthesis and method of use patents. However, method of use patents, in particular, are more difficult
	to enforce than composition of matter patents because of the risk of off-label sale or use of the subject compounds. Physicians
	are permitted to prescribe an approved product for uses that are not described in the product's labeling. Although off-label prescriptions
	may infringe our method of use patents, the practice is common across medical specialties and such infringement is difficult to
	prevent or prosecute. Off-label sales would limit our ability to generate revenue from the sale of Annamycin, if approved for commercial
	sale.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The intellectual property rights we have licensed from MD
	Anderson are subject to the rights of the U.S. government.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have obtained a royalty-bearing, worldwide,
	exclusive license to intellectual property rights, including patent rights related to our WP1066 Portfolio and WP1122 Portfolio
	drug product candidates from MD Anderson. Some of our licensed intellectual property rights from MD Anderson have been developed
	in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual
	property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions
	developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions
	for any governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee
	to such inventions, to grant licenses to any of these inventions to a third party if they determine that: (i) adequate steps have
	not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; (iii)
	government action is necessary to meet requirements for public use under federal regulations; or (iv) the right to use or sell
	such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the
	U.S. government&rsquo;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use
	or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing
	substantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if we
	fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified
	time limits. In addition, the U.S. government may acquire title in any country in which a patent application is not filed within
	specified time limits. Additionally, certain inventions are subject to transfer restrictions during the term of these agreements
	and for a period thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the
	relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any
	of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair
	the value of our intellectual property and could adversely affect our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may incur substantial costs as a result of litigation or
	other proceedings relating to patent and other intellectual property rights.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We may from time to time seek to enforce our
	intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase
	in the value of the intellectual property. If we choose to enforce our patent rights against a party, then that individual or company
	has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our
	patents and the patents we have licensed may be challenged if a petition for post grant proceedings such as inter-partes review
	and post grant review is filed within the statutorily applicable time with the U.S. Patent and Trademark Office (USPTO). These
	lawsuits and proceedings are expensive and would consume time and resources and divert the attention of managerial and scientific
	personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court
	will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions.
	There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the
	ground that such other party's activities do not infringe our intellectual property rights. In addition, in recent years the U.S.
	Supreme Court modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood
	that we will be able to obtain patents and increase the likelihood of a challenge of any patents we obtain or license.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may be subject to claims that our employees have wrongfully
	used or disclosed alleged trade secrets of their former employers.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As is common in the biotechnology and pharmaceutical
	industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
	competitors or potential competitors. We may be subject to claims that these employees, or we, have used or disclosed trade secrets
	or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if
	we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If we are not able to adequately prevent disclosure of trade
	secrets and other proprietary information, the value of our technology and products could be significantly diminished.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We rely on trade secrets to protect our proprietary
	technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
	to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
	researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively
	prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of
	confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly
	and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain
	or maintain trade secret protection could adversely affect our competitive business position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We will need to expand our operations and increase the size
	of our company, and we may experience difficulties in managing growth.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As of September 30, 2016, we had two full-time
	and four part-time employees. As we advance our product candidates through preclinical studies and clinical trials, we will need
	to increase our product development, scientific and administrative headcount to manage these programs. In addition, to meet our
	obligations as a public company, we may need to increase our general and administrative capabilities. Our management, personnel
	and systems currently in place may not be adequate to support this future growth. If we are unable to successfully manage this
	growth and increased complexity of operations, our business may be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may not be able to manage our business effectively if we
	are unable to attract and retain key personnel and consultants.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We may not be able to attract or retain qualified
	management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel and
	consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel
	and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement
	of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are highly dependent on the development,
	regulatory, commercialization and business development expertise of our management team, key employees and consultants. If we lose
	one or more of our executive officers or key employees or consultants, our ability to implement our business strategy successfully
	could be seriously harmed. Any of our executive officers or key employees or consultants may terminate their employment at any
	time. Replacing executive officers, key employees and consultants may be difficult and may take an extended period of time because
	of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory
	approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited
	pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure
	to retain key personnel or consultants could materially harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In addition, we have scientific and clinical
	advisors and consultants who assist us in formulating our research, development and clinical strategies. These advisors are not
	our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
	to us and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work
	for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other
	companies to assist those companies in developing products or technologies that may compete with ours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our chief executive officer and our chief operating officer
	are currently working for us on a part-time basis.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Two of our key employees are currently part-time
	and provide services for other biotechnology development efforts. Specifically, Walter Klemp, our chairman and chief executive
	officer is also the chief executive officer of Soliton, Inc., a medical device development company whose business operations we
	do not believe conflict with those of our company, and Donald Picker, our president and chief operating officer, is currently also
	serving as chief operating officer of two other biotechnology companies, whose business operations we do not believe conflict with
	those of our company. As we progress, if the full-time services of a CEO or COO are required and the current officers cannot provide
	that level of commitment, we will need to identify a suitable CEO or COO who can dedicate such time to our company. We can provide
	no assurance that we will be able to successfully identify and retain a qualified candidate for this position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We do not expect that our insurance policies will cover all
	of our business exposures thus leaving us exposed to significant uninsured liabilities.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We do not carry insurance for all categories
	of risk that our business may encounter. In particular, we do not carry product liability insurance covering any clinical trials
	liability that we may incur. Although we intend to obtain such insurance before we commence any clinical trials, there can be no
	assurance that we will secure adequate insurance coverage or that any such insurance coverage will be sufficient to protect our
	operations to significant potential liability in the future. Any significant uninsured liability may require us to pay substantial
	amounts, which would adversely affect our financial position and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Relating to this Offering of Our Units
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Purchasers in this offering will experience immediate and
	substantial dilution in net tangible book value.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The public offering price in this offering is
	substantially higher than the net tangible book value of each outstanding share of our common stock. Purchasers of units in this
	offering will experience immediate and substantial dilution on a book value basis. The dilution per share in the net tangible book
	value per share of common stock (attributing no value to the warrants included in the units) will be $ per share. See &ldquo;Dilution.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Your ownership may be diluted if additional capital stock
	is issued to raise capital, to finance acquisitions or in connection with strategic transactions.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We intend to seek to raise additional funds,
	finance acquisitions or develop strategic relationships by issuing equity or convertible debt securities in addition to the shares
	issued in this offering, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the
	authority, without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common
	or preferred stock. Our certificate of incorporation authorizes us to issue up to 75,000,000 shares of common stock and 5,000,000
	shares of preferred stock. Future issuances of common or preferred stock would reduce your influence over matters on which stockholders
	vote and would be dilutive to earnings per share. In addition, any newly issued preferred stock could have rights, preferences
	and privileges senior to those of the common stock. Those rights, preferences and privileges could include, among other things,
	the establishment of dividends that must be paid prior to declaring or paying dividends or other distributions to holders of our
	common stock or providing for preferential liquidation rights. These rights, preferences and privileges could negatively affect
	the rights of holders of our common stock, and the right to convert such preferred stock into shares of our common stock at a rate
	or price that would have a dilutive effect on the outstanding shares of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The concentration of our common stock ownership by our current
	management will limit your ability to influence corporate matters.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Upon completion of this offering, our
	founders, directors and executive officers will beneficially own and will be able to vote in the aggregate approximately&nbsp;48.3%
	of our outstanding common stock. As such, our founders, directors and executive officers, as stockholders, will continue to have
	the ability to exert significant influence over all corporate activities, including the election or removal of directors and the
	outcome of tender offers, mergers, proxy contests or other purchases of common stock that could give our stockholders the opportunity
	to realize a premium over the then-prevailing market price for their shares of common stock. This concentrated control will limit
	your ability to influence corporate matters and, as a result, we may take actions that purchasers in this offering do not view
	as beneficial. In addition, such concentrated control could discourage others from initiating changes of control. In such cases,
	the perception of our prospects in the market may be adversely affected and the market price of our common stock may decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Our stock price has been and may continue to be volatile,
	which could result in substantial losses for investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Since our IPO in June 2016, our stock
	price has ranged from a high of $9.58 to a low of $1.41, and the market price of our common stock is likely to continue to be
	highly volatile and could fluctuate widely in response to various factors, many of which are beyond our control. In addition,
	the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the
	operating performance of particular companies. These market fluctuations may also significantly affect the market price of our
	common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	There is no public market for the warrants to purchase shares
	of our common stock being offered by us in this offering.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	There is no established public trading market
	for the warrants being offered in this offering, and a public market may never develop. In addition, we do not intend to apply
	to list the warrants on any national securities exchange or other nationally recognized trading system, including the NASDAQ Capital
	Market. Without an active market, the liquidity of the warrants will be limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Holders of our warrants will have no rights as a common stockholder
	until such holders exercise their warrants and acquire our common stock.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Until holders of warrants acquire shares of
	our common stock upon exercise of the warrants, holders of warrants will have no rights with respect to the shares of our common
	stock underlying such warrants. Upon exercise of the warrants, the holders thereof will be entitled to exercise the rights of a
	common stockholder only as to matters for which the record date occurs after the exercise date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The warrants included in this offering may not have any value.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Each warrant has an initial exercise
	price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock,
	the Series A and C warrants will expire five years from the closing date of this offering, and the Series B warrants will expire
	90 days from the closing date of this offering. In the event our common stock price does not exceed the exercise price of the
	warrants during the period when the warrants are exercisable, the warrants may not have any value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Significant holders or beneficial holders of our common stock
	may not be permitted to exercise warrants that they hold.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The warrants being offered hereby will
	prohibit a holder from exercising its warrants if doing so would result in such holder (together with such holder&rsquo;s affiliates
	and any other persons acting as a group together with such holder or any of such holder&rsquo;s affiliates) beneficially owning
	more than 4.99% (or upon election of the holder, 9.99%)of our common stock. Furthermore, during any period in which a holder beneficially
	owns less than 5% of our common stock, the warrants will limit the ability of such holder to exercise its warrants if doing so
	would result in such holder (together with such holder&rsquo;s affiliates and any other persons acting as a group together with
	such holder or any of such holder&rsquo;s affiliates) beneficially owning more than 4.99% of our common stock. As a result, you
	may not be able to exercise your warrants for shares of our common stock at a time when it would be financially beneficial for
	you to do so. In such circumstance you could seek to sell your warrants to realize value, but you may be unable to do so.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Certain provisions in our organizational documents could enable
	our board of directors to prevent or delay a change of control.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our organizational documents contain provisions
	that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals,
	that a stockholder might consider favorable. These include provisions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	prohibiting the stockholders from acting by written consent;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	requiring advance notice of director nominations and of business to be brought before a meeting of stockholders;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	requiring a majority vote of the outstanding shares of common stock to amend the bylaws; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	limiting the persons who may call special stockholders&rsquo; meetings.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Furthermore, our board of directors has the
	authority to issue shares of preferred stock in one or more series and to fix the rights and preferences of these shares without
	stockholder approval. Any series of preferred stock is likely to be senior to our common stock with respect to dividends, liquidation
	rights and, possibly, voting rights. The ability of our board of directors to issue preferred stock also could have the effect
	of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In addition, Delaware law makes it difficult
	for stockholders that recently have acquired a large interest in a corporation to cause the merger or acquisition of the corporation
	against the directors&rsquo; wishes. Under Section&nbsp;203 of the Delaware General Corporation Law, a Delaware corporation may
	not engage in any merger or other business combination with an interested stockholder for a period of three years following the
	date that the stockholder became an interested stockholder except in limited circumstances, including by approval of the corporation&rsquo;s
	board of directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have no intention of declaring dividends in the foreseeable
	future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The decision to pay cash dividends on our common
	stock rests with our board of directors and will depend on our earnings, unencumbered cash, capital requirements and financial
	condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund
	our operations. Investors in our common stock should not expect to receive dividend income on their investment, and investors will
	be dependent on the appreciation of our common stock to earn a return on their investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Failure to maintain effective internal control over our financial
	reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are required pursuant to Section 404 of the
	Sarbanes-Oxley Act of 2002, or Section 404, to maintain internal control over financial reporting and to assess and report on the
	effectiveness of those controls. This assessment includes disclosure of any material weaknesses identified by our management in
	our internal control over financial reporting. Our management concluded that our disclosure controls and procedures were, and continue
	to be ineffective, and as of June 30, 2016, identified a material weakness in our internal controls over the accounting and reporting
	for acquisitions. While management is working to remediate the material weakness, there is no assurance that the changes will remediate
	the identified material weakness or that the controls will prevent or detect future material weaknesses. If we are not able to
	maintain effective internal control over financial reporting, our financial statements, including related disclosures, may be inaccurate,
	which could have a material adverse effect on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Failure to continue improving our accounting systems and controls
	could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As a public company, we operate in an increasingly
	demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations
	of the SEC. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal
	control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce
	reliable financial reports and are important to help prevent financial fraud.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our management concluded that our disclosure
	controls and procedures were, and continue to be, ineffective and, as of June 30, 2016 identified a material weakness in our internal
	controls over the accounting and reporting for acquisitions. Section 404(a) of the Sarbanes-Oxley Act requires annual management
	assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that
	we would expect to file with the SEC. However, for as long as we remain an &ldquo;emerging growth company&rdquo; as defined in
	the JOBS Act, we have and intend to continue to take advantage of certain exemptions from various reporting requirements that are
	applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being
	required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We may continue to take
	advantage of these reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; If we cannot provide reliable
	financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence
	in our reported financial information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	On November 14, 2016, our Audit Committee,
	after discussion with management and our independent registered public accountants, determined that our unaudited consolidated
	financial statements for the quarter ended June 30, 2016, as reported in our Quarterly Report on Form 10-Q filed on August 15,
	2016 should no longer be relied upon due to an error identified therein, and that a restatement of these financial statements
	is required. We identified certain non-cash errors due to an error in the accounting for the business combination of Moleculin,
	LLC. We filed a Form 10-Q/A for the quarter ended June 30, 2016 on November 21, 2016 reflecting such corrections in errors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	As an &ldquo;emerging growth company&rdquo; under the Jumpstart
	Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As an &ldquo;emerging growth company&rdquo;
	under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. We are an emerging
	growth company until the earliest of:&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the last day of the fiscal year during which we have total annual gross revenues of $1 billion or more;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the last day of the fiscal year following the fifth anniversary of our IPO, or December 31, 2021;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the date on which we are deemed a &ldquo;large accelerated issuer&rdquo; as defined under the federal securities laws.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	For so long as we remain an emerging growth
	company, we will not be required to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	have an auditor report on our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit
	firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
	statements (auditor discussion and analysis);
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submit certain executive compensation matters to shareholders advisory votes pursuant to the &ldquo;say on frequency&rdquo;
	and &ldquo;say on pay&rdquo; provisions (requiring a non-binding shareholder vote to approve compensation of certain executive
	officers) and the &ldquo;say on golden parachute&rdquo; provisions (requiring a non-binding shareholder vote to approve golden
	parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the
	Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	include detailed compensation discussion and analysis in our filings under the Securities Exchange Act
	of 1934, as amended, and instead may provide a reduced level of disclosure concerning executive compensation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	may present only two years of audited financial statements and only two years of related Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We intend to take advantage of all of these
	reduced reporting requirements and exemptions. Certain of these reduced reporting requirements and exemptions were already available
	to us due to the fact that we also qualify as a &ldquo;smaller reporting company&rdquo; under SEC rules. For instance, smaller
	reporting companies are not required to obtain an auditor attestation and report regarding management&rsquo;s assessment of internal
	control over financial reporting; are not required to provide a compensation discussion and analysis; are not required to provide
	a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related
	MD&amp;A disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Under the JOBS Act, we may take advantage of
	the above-described reduced reporting requirements and exemptions until December 31, 2021, or such earlier time that we no longer
	meet the definition of an emerging growth company.&nbsp;In this regard, the JOBS Act provides that we would cease to be an &ldquo;emerging
	growth company&rdquo; if we have more than $1.0 billion in annual revenues, have more than $700 million in market value of our
	common stock held by non-affiliates, or issue more than $1.0 billion in principal amount of non-convertible debt over a three-year
	period.&nbsp;Further, under current SEC rules, we will continue to qualify as a &ldquo;smaller reporting company&rdquo; for so
	long as we have a public float (i.e., the market value of common equity held by non-affiliates) of less than $75 million as of
	the last business day of our most recently completed second fiscal quarter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We cannot predict if investors will find our
	securities less attractive due to our reliance on these exemptions.&nbsp;If investors were to find our common stock less attractive
	as a result of our election, we may have difficulty raising capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_FORWARD_LOOK>
<A NAME="FIS_FORWARD_LOOK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_019" TITLE="CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS">
</A>
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING
	STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We make forward-looking statements under the
	&ldquo;Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of
	Financial Condition and Results of Operations&rdquo; and in other sections of this prospectus. In some cases, you can identify
	these statements by forward-looking words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo;
	&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
	&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo; and the negative of these terms
	and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties
	and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated
	trends in our business. These statements are only predictions based on our current expectations and projections about future events.
	There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially
	from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular,
	you should consider the numerous risks and uncertainties described under &ldquo;Risk Factors.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	While we believe we have identified material
	risks, these risks and uncertainties are not exhaustive. Other sections of this prospectus describe additional factors that could
	adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment.
	New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we
	assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
	results to differ materially from those contained in any forward-looking statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Although we believe the expectations reflected
	in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.
	Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking
	statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update
	any of these forward-looking statements after the date of this prospectus to conform our prior statements to actual results or
	revised expectations, and we do not intend to do so.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Forward-looking statements include, but are
	not limited to, statements about:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to obtain additional funding to develop our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the need to obtain regulatory approval of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the success of our clinical trials through all phases of clinical development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	compliance with obligations under intellectual property licenses with third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	any delays in regulatory review and approval of product candidates in clinical development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to commercialize our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	market acceptance of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	competition from existing products or new products that may emerge;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential product liability claims;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our dependency on third-party manufacturers to supply or manufacture our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to establish or maintain collaborations, licensing or other arrangements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability and third parties&rsquo; abilities to protect intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to adequately support future growth; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to attract and retain key personnel to manage our business effectively.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We caution you not to place undue reliance on
	the forward-looking statements, which speak only as of the date of this prospectus in the case of forward-looking statements contained
	in this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_FORWARD_LOOK>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_PROCEED_USE>
<A NAME="FIS_PROCEED_USE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_020" TITLE="USE OF PROCEEDS">
</A>
	USE OF PROCEEDS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The net proceeds from the sale of the units
	in this offering are estimated to be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
	if the underwriters exercise in full their option to purchase additional units in this offering, after deducting the underwriting
	discounts and commissions and estimated offering expenses payable by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We currently intend to use the net proceeds
	from this offering for working capital and general corporate purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The amounts and timing of our use of the net
	proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development
	efforts, the timing and progress of any partnering and commercialization efforts, and technological advances. As of the date of
	this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly,
	our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds
	as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments. We reserve the right,
	at the sole discretion of our Board of Directors, to reallocate the proceeds of this offering in response to developments in our
	business and any other factors.&nbsp;
</P>
</EFX_PROCEED_USE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_DIVIDEND_POLICY>
<A NAME="FIS_DIVIDEND_POLICY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_021" TITLE="DIVIDEND POLICY">
</A>
<B>
	DIVIDEND POLICY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have never declared or paid any cash dividends
	on our capital stock. We currently intend to retain earnings, if any, to finance the growth and development of our business. We
	do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, will
	be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements,
	restrictions contained in any financing instruments, provisions of applicable law and other factors the board deems relevant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_DIVIDEND_POLICY>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CAPITALIZATION>
<A NAME="FIS_CAPITALIZATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_022" TITLE="CAPITALIZATION">
</A>
	CAPITALIZATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth our cash and
	cash equivalents and capitalization as of September 30, 2016 on:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	an actual basis; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="MARGIN: 0PT 0">
	a
	pro forma as adjusted basis after giving effect to the sale of 2,500,000 shares of our
	common stock underlying the units in this offering at an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
	share, and our receipt of the estimated $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
	in net proceeds from this offering, after deducting underwriting commissions and estimated
	offering expenses payable by us.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	You should read this capitalization table together
	with &ldquo;Use of Proceeds,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
	and our financial statements and the related notes appearing elsewhere in this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	At September 30, 2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Actual
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma - As adjusted
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6,183,783
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT; WIDTH: 10%">
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Notes payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	297,656
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stockholders' equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Preferred stock, $0.001 par value: 5,000,000 shares authorized, no shares issued and outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<P STYLE="MARGIN: 0PT 0">
	Common stock, $0.001 par value: 75,000,000 shares authorized; 12,054,813
	shares issued and outstanding, actual;&nbsp;and 14,554,813 shares issued and outstanding, pro
	forma as adjusted, respectively (1)
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,055
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,485,987
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Subscription receivable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total stockholders' equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,243,635
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total capitalization
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,541,291
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The number of shares
	of common stock to be outstanding after this offering is based on 12,164,851 shares of common stock outstanding as of January
	17, 2017 and does not take into account, as of January 17, 2017:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;510,000
	shares of our common stock issuable upon exercise of outstanding stock options to purchase shares of our common stock at a weighted
	average exercise price of $5.28 per share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107,802
	shares of our common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price of $7.50 per
	share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,990,000
	shares of our common stock reserved for issuance under our 2015 Stock Plan;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,818,861
	shares upon the conversion of outstanding bridge notes. These notes were to be automatically converted according to their terms
	into our common stock upon the closing of our IPO to the extent and provided that no holder of these notes was or will be permitted
	to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of our
	common stock after such conversion. Due to this 4.99% limitation, certain of these notes remained outstanding and will be converted
	into shares of our common stock at such time as the 4.99% limitation continues to be met;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79,167
	shares of our common stock issuable to a third-party in settlement of $237,500 in past due amounts;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,000,000
	shares of common stock issuable upon the exercise of the warrants included in the units being sold in this offering; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175,000
	shares of common stock issuable upon the exercise of the warrants issued to the representatives of the underwriters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_CAPITALIZATION>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_DILUTION>
<A NAME="FIS_DILUTION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_023" TITLE="DILUTION">
</A>
<B>
	DILUTION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Purchasers of our units in this offering will
	experience an immediate dilution of net tangible book value per share from the public offering price. Dilution in net tangible
	book value per share represents the difference between the amount per share paid by the purchasers of shares of common stock (attributing
	no value to the warrants included in the units) and the net tangible book value per share immediately after this offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As of September 30, 2016, our net tangible book
	value was $5,114,845, or $0.42 per share of common stock. Net tangible book value per share represents our total tangible assets,
	less our total liabilities, divided by the number of outstanding shares of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	After giving effect to the issuance
	and sale by us of 2,500,000 units in this offering at an offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per unit, and
	after deducting underwriting discounts and commissions and estimated offering expense payable by us, our as adjusted net tangible
	book value as of September 30, 2016 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in as adjusted net tangible book
	value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution in the as adjusted
	net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors purchasing shares of
	common stock in this offering at the offering price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Assumed public offering price per unit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 87%; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Net tangible book value per share at September 30, 2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Increase in net tangible book value per share to the existing stockholders attributable to this offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Adjusted net tangible book value per share after this offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Dilution in net tangible book value per share to new investors
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The above discussion
	and table are based on 12,164,851 shares of common stock outstanding as of January 17, 2017, which does not include, as of January
	17, 2017:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;510,000
	shares of our common stock issuable upon exercise of outstanding stock options to purchase shares of our common stock at a weighted
	average exercise price of $5.28 per share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107,802
	shares of our common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price of $7.50
	per share;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,990,000
	shares of our common stock reserved for issuance under our 2015 Stock Plan;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,818,861
	shares upon the conversion of outstanding bridge notes. These notes were to be automatically converted according to their terms
	into our common stock upon the closing of our IPO to the extent and provided that no holder of these notes was or will be permitted
	to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of our
	common stock after such conversion. Due to this 4.99% limitation, certain of these notes remained outstanding and will be converted
	into shares of our common stock at such time as the 4.99% limitation continues to be met;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79,167
	shares of our common stock issuable to a third-party in settlement of $237,500 in past due amounts;
</P>
<P STYLE="FONT: 10PT SYMBOL; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,000,000
	shares of common stock issuable upon the exercise of the warrants included in the units being sold in this offering; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175,000
	shares of common stock issuable upon the exercise of the warrants issued to the representatives of the underwriters.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_024" TITLE="UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION">
</A>
	UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	The following unaudited pro forma combined financial
	information is based on the historical financial statements of Moleculin Biotech, Inc. after giving effect to our acquisition of
	Moleculin, LLC described in Note 2 to our unaudited financial statements for the nine months ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	The unaudited pro forma combined statement of
	operations for the year ended December 31, 2015 and the nine months ended September 30, 2016 are presented as if our acquisition
	of Moleculin, LLC occurred on January 1, 2015 and were carried forward through to September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	We have based the pro forma adjustments upon available
	information and certain assumptions that we believe are reasonable under the circumstances. We describe in greater detail the assumptions
	underlying the pro forma combined financial statements in the notes to the unaudited pro forma combined financial statements. In
	many cases, we based these assumptions on preliminary information and estimates. The actual adjustments to our pro forma combined
	financial statements will depend upon a number of factors and additional information that will be available when we complete the
	valuation of Moleculin, LLC&rsquo;s assets. Accordingly, the actual adjustments that will appear in our financial statements will
	differ from these pro forma adjustments, and those differences may be material.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	We acquired Moleculin, LLC on May 2, 2016, and,
	going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition
	method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their
	estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&ldquo;IPR&amp;D&rdquo;)
	be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over
	the assigned values of the net assets acquired will be recorded as goodwill. The estimated fair values of assets acquired and liabilities
	assumed were determined based on management&rsquo;s best estimates. Preliminary estimated fair values have been made by management
	and are subject to measurement period adjustments which represent updates made to the preliminary purchase price allocation based
	on revisions to valuation estimates in the interim period subsequent to the acquisition and initial accounting date up until the
	purchase price allocation is finalized which cannot be any later than one year from the acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	The unaudited pro forma combined financial information
	is not intended to represent or be indicative of our consolidated results of operations or financial position that we would have
	reported had the Moleculin, LLC acquisition been completed as of the date presented, and should not be taken as a representation
	of our future consolidated results of operations or financial position. The unaudited pro forma combined financial information
	does not reflect any operating efficiencies and/or cost savings that we may achieve with respect to combining the companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	The following unaudited financial information
	should be read with the accompanying notes, the financial statements of Moleculin, LLC and the notes thereto included elsewhere
	in this prospectus and the financial statements of MBI and the notes thereto included elsewhere in this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Unaudited Pro Forma Combined Statement of
	Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the Year Ended December 31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Pro Forma
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Pro Forma
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Moleculin, LLC
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	MBI
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Adjustments
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Combined
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Revenue
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	125,442
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	260,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	385,860
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	328,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	477,810
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	806,380
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Depreciation and amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	11,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	(a)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	11,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	465,348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	738,228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,203,576
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(465,348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(738,228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,203,576
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	549,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	549,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(449,643
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(10,132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	422,874
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	(b)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(36,901
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total other income (expense)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	99,537
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(10,132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	422,874
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	512,279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(365,811
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(748,360
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	422,874
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	(c)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(691,297
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss per common share - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted average number of common shares outstanding - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,691,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	999,931
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	(d)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,691,734
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Unaudited Pro Forma Combined Statement of
	Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the Nine Months Ended September 30, 2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Moleculin,
<BR>
	LLC
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	(e)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	MBI
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma
<BR>
	Adjustments
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma
<BR>
	Combined
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Revenue
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	47,964
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	616,498
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	664,462
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44,766
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,847,613
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,892,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Depreciation and amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	3,438
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,629
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	(a)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	96,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,465,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,561,908
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(96,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,465,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,561,908
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(155,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(37,307
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	145,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	(b)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(47,338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total other income (expense)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(85,540
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(37,307
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	145,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	22,231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(181,708
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(2,503,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	145,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	(c)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(2,539,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss per common share - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted average number of common shares outstanding - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,066,804
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	446,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	(d)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,513,660
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Notes to Unaudited Pro Forma Combined Financial
	Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 1 &ndash; Basis of presentation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	The unaudited pro forma combined statements
	of operations for the nine months ended September 30, 2016 and the year ended December 31, 2015 are based on the historical financial
	statements of Moleculin Biotech, Inc. and Moleculin, LLC after giving effect to our acquisition of Moleculin, LLC described in
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Note 2 to our financial statements for the nine months ended September 30, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	We account for business combinations pursuant to Financial Accounting
	Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (ASC) 805,
<I>
	Business Combinations
</I>
	. In accordance with
	ASC 805, MBI uses its best estimates and assumptions to assign fair value to the tangible and intangible assets acquired and liabilities
	assumed at the acquisition date. Goodwill as of the acquisition date is measured as the excess of purchase consideration over the
	fair value of net tangible and identifiable intangible assets acquired.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The fair values assigned to Moleculin, LLC&rsquo;s tangible assets
	acquired and liabilities assumed are based on management&rsquo;s estimates and assumptions. The estimated fair values of these
	assets acquired and liabilities assumed are considered preliminary and are based on the information and the account balances that
	were available. We believe that the information provides a reasonable basis for estimating the fair values of assets acquired and
	liabilities assumed. We expect to finalize the valuation of the net tangible and intangible assets prior to the filing of our Form
	10-K for the year ended December 31, 2016, but not later than one year from the acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The unaudited pro forma combined financial information is not intended
	to represent or be indicative of our results of operations or financial position that would have been reported had the acquisition
	been completed as of the date presented, and should not be taken as a representation of our future consolidated results of operations
	or financial position. The unaudited pro forma combined financial information does not reflect any operating efficiencies and/or
	cost savings that we may achieve with respect to the combined companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For purposes of these unaudited combined pro forma statements of
	operations, the acquisition of Moleculin, LLC is assumed to have occurred on January 1, 2015. The pro forma statement of operations
	for the year ended December&nbsp;31, 2015 combined the results of Moleculin, LLC for the year ended December 31, 2015 and our results
	for the period from inception (July 28, 2015) through December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 2 &mdash; Pro forma adjustments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The pro forma adjustments are based on our preliminary estimates
	and assumptions that are subject to change. The following adjustments have been reflected in the unaudited pro forma condensed
	combined financial information:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	The amount of the amortization expense related to the intangibles is uncertain at this time as the
	Company is still in the process of valuing the intangibles acquired, including IPR&amp;D, as discussed in Note 1 above.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(b)
</TD>
<TD>
	Reflects the removal of interest expense accrued and the amortization of deferred financing cost and debt discount related
	to Moleculin, LLC&rsquo;s convertible notes payable to third parties and related parties. For the year ended December 31, 2015
	and the nine months ended September 30, 2016, interest expense related to convertible notes payable to third parties and related
	parties was $422,874 and $145,078, respectively.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(c)
</TD>
<TD>
	We have not reflected any pro forma adjustments to reflect the tax impact of the pro forma adjustments, as we believe that
	the tax impact would not be material.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(d)
</TD>
<TD>
	Reflects the issuance of 999,931 common shares of our common stock to the holders of Moleculin, LLC equity interests and convertible
	notes and assumed these shares were issued on January 1, 2015.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(e)
</TD>
<TD>
	Represents Moleculin, LLC&rsquo;s results of operations for the period from January 1, 2016 to May 1, 2016 (prior to our acquisition
	on May 2, 2016). Moleculin, LLC ceased to exist after MBI&rsquo;s acquisition on May 2, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_DILUTION>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_025" TITLE="MANAGEMENT'S DISCUSSION AND ANALYSIS">
</A>
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	MANAGEMENT&rsquo;S
	DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	This Management&rsquo;s Discussion and Analysis
	of Financial Condition and Results of Operations (&ldquo;MD&amp;A&rdquo;) contains certain forward-looking statements. Historical
	results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are
	based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially
	from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated by
	forward-looking statements include, but are not limited to, those discussed in &ldquo;Risk Factors.&rdquo; We undertake no obligation
	to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or
	circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results,
	events, levels of activity, performance, or achievements.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Highlights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are a preclinical-stage pharmaceutical
	development company organized as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates.
	We have three drug development projects. Our lead drug candidate is liposomal Annamycin, which is referred to as Annamycin, an
	anthracyline intended for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin has been in clinical
	trials pursuant to an investigational new drug application, or IND, that had been filed with the U.S. Food and Drug Administration,
	or FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated, however we intend to apply for
	a new IND based on the same data that supported the original IND, updated for subsequent clinical data, and to commence a clinical
	trial for Annamycin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have two other drug development projects
	in progress. One of them involves a collection of small molecules we refer to as the WP1066 Portfolio that was obtained via our
	acquisition of Moleculin, LLC and is focused on the modulation of key regulatory transcription factors involved in the progression
	of cancer. The other, which we call the WP1122 Portfolio, is a suite of molecules targeting the metabolic processes involved in
	cancer in general, and glioblastoma in particular that we acquired from IntertechBio Corporation. Both of these technologies are
	licensed on a worldwide exclusive basis from The University of Texas M.D. Anderson Cancer Center, or MD Anderson.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	MBI was founded in 2015 in order to combine
	and consolidate the development efforts involving several anti-cancer technologies, some of which are based on license agreements
	with MD Anderson. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed
	by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, we, on
	Moleculin, LLC&rsquo;s behalf, entered into a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, which culminated
	with the acquisition of Moleculin, LLC and MBI coincident with our initial public offering allowing us to gain control of the WP1066
	Portfolio.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	AnnaMed was formed in 2012 to take over the
	development of Annamycin from a prior drug development company, Callisto Pharmaceuticals, Inc., or Callisto. Callisto ceased development
	work on Annamycin leading to the termination of its IND by the FDA. In order to satisfy unmet license obligations, Callisto agreed
	to transfer all available Annamycin data to AnnaMed, which data we intend to now use to apply for a new IND.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	IntertechBio was formed in 2009 to license and
	begin development on the WP1122 Portfolio. In August 2015, IntertechBio agreed to assign all license rights to us in exchange for
	630,000 shares of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Moleculin, LLC was formed in 2006 and has been
	working to develop the WP1066 Portfolio it licensed from MD Anderson. On May&nbsp;2, 2016, Moleculin, LLC was merged with and into
	MBI. As a result of the merger, we issued the holders of Moleculin, LLC equity interests and convertible notes an aggregate of
	approximately 999,931 shares of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Since Moleculin, LLC commenced operations in 2006, substantially all of its efforts have been focused
	on research, development and the advancement of the WP1066 Portfolio. Moleculin, LLC did not generate any revenue from product
	sales and, as a result, incurred significant losses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Neither Moleculin, LLC nor MBI has manufacturing
	facilities and all manufacturing activities are contracted out to third parties. Additionally, Moleculin, LLC utilized third-party
	clinical research organizations to carry out clinical trials. Neither Moleculin, LLC nor MBI have a sales organization.
</P>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Recent Business Developments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Accelerated Plan for Clinical Drug Production
</I>
	&ndash; The Company announced on October 7, 2016, that it had secured an agreement with Dermin Sp. Zo. O. (&ldquo;Dermin&rdquo;)
	to utilize Dermin&rsquo;s supply of Annamycin for its upcoming clinical trial, substantially reducing the expenditures required
	for drug product and shortening the time required to produce clinical supplies. The Company believes that this is an important
	agreement and key milestone to be reached and that it reduces the potential for drug production to negatively impact its clinical
	timeline. With this agreement in place, the Company&rsquo;s drug product expense for upcoming clinical trials should be below
	previous estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Moleculin, LLC previously licensed Annamycin
	to Dermin within a limited region in Europe, enabling Dermin to deploy Polish grant funds toward producing Annamycin. The agreement
	reached between the two companies allows us to utilize this Annamycin in our upcoming clinical trials rather than having to produce
	new Annamycin for its own use. The Company believes Dermin benefits from a data sharing arrangement giving it access to our clinical
	data on a faster timeline than it would be able develop on its own.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Updated Plan for Clinical Trials for Annamycin
</I>
	&ndash; On October 20, 2016, the Company announced in a conference call that it had identified some significantly positive
	findings from its detailed review of the last clinical trial for Annamycin by a prior developer, which has given rise to a modification
	of its own clinical development plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As the Company previously disclosed, a prior
	developer had conducted a clinical trial with Annamycin, but then subsequently failed to maintain their IND with the FDA. The Company
	had previously indicated that its plan was to conduct a detailed review of the clinical results generated by that prior developer.
	The Company would then use those results to reestablish an IND in order to continue clinical trials of Annamycin. However, the
	Company announced recently that, in the course of its review, it identified that Annamycin may have greater potential for efficacy
	than the Company originally believed, based on an unexpected potential opportunity to increase the drug&rsquo;s Maximum Tolerable
	Dose (&ldquo;MTD&rdquo;).&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In particular, the Dose Limiting Toxicities
	(&ldquo;DLTs&rdquo;) reported in that previous trial that led to the establishment of the current MTD of 150 mg/m2 were all from
	patients who had an unusually high number of first-line induction therapy failures prior to being treated with Annamycin. Specifically,
	of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior induction therapy
	attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. The Company has concluded
	from its review of this data that, if the heavily treated patients are excluded from the data set, the MTD could have been closer
	to 250 mg/m2, substantially higher than the level that was actually set by this previous trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Company views this as an encouraging development
	because it means it may have an opportunity to increase the MTD for its next trial from 150 mg/m2 to 200 or even 250 mg/m2. If
	that turns out to be the case, the Company believes it could increase the chance for positive outcomes in its next trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With the discovery that the Company may be able
	to increase its MTD, the Company determined to adjust its clinical strategy by adding in a Phase I arm to its next Phase II trial,
	which will add some expense to its development effort. However, the Company believes the money saved by utilizing the Dermin drug
	inventory (discussed above) will offset this added expense. The Company believes this change in strategy will add several months
	to the eventual final approval of the drug, however, the Company believes that it remains on track to generate useful Phase II
	data by the second half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	FDA Guidance Regarding Annamycin IND
</I>
	&ndash; On November 17, 2016, the Company announced it had received verbal positive guidance from the FDA regarding its planned
	IND submission indicating that the Company may incorporate by reference the IND established by a prior developer. The Company has
	indicated in previous disclosures that it expected to begin its next clinical trial by the first half of 2017, however this development
	may reduce that time frame by several months. The Company has submitted a pre-IND briefing document to the FDA along with key questions
	regarding its clinical development plan and a request for a meeting, if the FDA deems it necessary. The FDA recently indicated
	in writing that it intends to provide written responses to the Company by December 6, 2016 and that it does not believe a live
	meeting is necessary. Once those written responses are received, the Company will adjust its final IND submission document accordingly
	and submit for final FDA review. IND submissions are normally reviewed within 30 days of filing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Update on WP1066
</I>
	- A clinician at MD
	Anderson has advised the Company that she is proceeding with a physician-sponsored IND for WP1066 treatment of brain tumors. The
	Company is not participating nor has influence on this IND process. The clinician has submitted an IND to the FDA and has indicated
	that this IND is on hold until documentation of Good Manufacturing Process or GMP production of WP1066 can be presented to the
	FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Advancement of Preclinical Testing for Brain
	Tumors with WP1122
</I>
	&ndash; On October 25, 2016, the Company announced promising initial results of the preclinical toxicology
	work on WP1122, the Company&rsquo;s unique inhibitor of glucose metabolism, which is an important driver of glycolytic brain tumor
	progression and survival. The Company views this as an important step toward future clinical trials for WP1122. A similar chemical
	structure to that which turns morphine into heroine has been used to allow WP1122 to successfully enter the brain and increase
	circulation time. The Company indicated that preliminary escalating single dose toxicity testing in mice (oral administration)
	was successfully completed and even at the highest possible dose, no toxic death was observed. In multiple therapeutic doses,
	WP1122 was well tolerated during intense twice-daily oral dosing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Company believes moving forward with preclinical
	toxicology is the key to its ability to generate proof of concept in humans. The Company had previously announced the presentation
	of promising preclinical data in July 2016, supporting the potential for using WP1122 as a treatment for glioblastoma.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Appointment of New Chief Financial Officer
</I>
	- On August 22, 2016, the Company announced the appointment, effective August 19, 2016, of Jonathan P. Foster as Executive
	Vice President and Chief Financial Officer. Effective on August 19, 2016, Mr. Foster assumed the duties of CFO from Louis Ploth,
	Jr., who had come out of retirement in 2015 to help guide the new company through its initial public offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Mr. Foster joined us from InfuSystem Holdings,
	Inc., an NYSE MKT listed company and a leading national provider of infusion pumps and related services to the healthcare industry
	in the United States and Canada, primarily related to the treatment of cancer, where he served as Executive Vice President and
	Chief Financial Officer, since 2012. He brings more than 30 years of financial experience holding a variety of executive and senior
	financial positions with public, private, and start-up to large corporate and international companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Settlement of Outstanding Amounts
	Due
</I>
	. In January 2017, we agreed to issue 79,167 shares of our common stock at a value of $3.00 per share to a third-party
	in settlement of $237,500 in past due amounts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations &ndash; MBI
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Company was formed on July 28, 2015; therefore,
	the financial information for 2015 is not comparable to the financial results of the three and nine months ended September 30,
	2016. The following table sets forth, for the periods indicated, data derived from our statement of operations:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Three Months
<BR>
	Ended
<BR>
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	From
<BR>
	Inception
<BR>
	through
<BR>
	September&nbsp;30
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Nine Months
<BR>
	Ended
<BR>
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	From
<BR>
	Inception
<BR>
	through
<BR>
	September&nbsp;30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	496,659
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	38,409
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	616,498
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	38,409
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	924,041
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,344
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,847,613
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,344
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	977
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,629
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 18.7PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Total operating expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,421,677
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	222,753
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,465,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	222,753
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 18.7PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,421,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(222,753
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,465,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(222,753
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 18.7PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other expense:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	&nbsp;Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,402
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,562
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(37,307
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,562
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,432,079
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,503,047
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Three Months Ended September 30, 2016 compared to the period
	from July 28, 2015 (Inception) to September 30, 2015
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development Expense.
</B>
	Research and development
	expense was $496,659 and $38,409 for the three months ended September&nbsp;30, 2016 and for the period from July 28, 2015 (inception)
	to September 30, 2015, respectively. The increase of approximately $458,000 mainly represents accrued license fees to MD Anderson
	for approximately $40,000, $37,500 for research performed by HPI, and approximately $228,000 related to MD Anderson sponsored research.
	We expect to incur increased research and development costs in the future as our product development activities expand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General and Administrative Expense.
</B>
	General and administrative
	expense was $924,041 and $184,344 for the three months ended September&nbsp;30, 2016 and for the period from July 28, 2015 (inception)
	to September 30, 2015, respectively. The expense increase of approximately $740,000 was mainly attributable to additional payroll
	and related expenses of approximately $459,000 related to a full three months of our Chief Financial Officer&rsquo;s, Chief Operating
	Officer&rsquo;s and Chief Executive Officer&rsquo;s salaries and compensation for our Board of Directors. Also, included in this
	quarter&rsquo;s expense was $118,000 related to the severance of the former Chief Financial Officer. The Company also incurred
	approximately $289,000 of expenses related to investor relations, audit and accounting, and insurance costs. &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Interest Expense.
</B>
	Interest expense included expense accrued
	on our convertible promissory notes issued in 2015 and 2016 bearing interest at the rate of 8% per annum.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Net Loss.
</B>
	The net loss for the three months ended September
	30, 2016 was $1,432,079 which included non-cash expenses of $48,420 ($977 for depreciation and $47,443 for stock based compensation)
	and a one-time expense of $118,000 related to the severance of the former Chief Financial Officer. This loss for the period is
	a significant increase from the loss for the period from July 28, 2015 (inception) to September 30, 2015 of $224,315 as the Company
	had, at that time, just begun operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Nine Months Ended September 30, 2016 compared
	to the period from July 28, 2015 (inception) through September 30, 2015
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development Expense.
</B>
	Research and development
	expense was $616,498 and $38,409 for the nine months ended September&nbsp;30, 2016 and for the period from July 28, 2015 (inception)
	to September 30, 2015, respectively. The increase of approximately $578,000 mainly represents accrued license fees to MD Anderson
	for approximately $92,000, $37,500 for research performed by HPI, and approximately $228,000 related to MD Anderson sponsored research.
	We expect to incur increased research and development costs in the future as our product development activities expand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General and Administrative Expense.
</B>
	General and administrative
	expense was $1,847,613 and $184,344 for the nine months ended September 30, 2016 and for the period from July 28, 2015 (inception)
	to September 30, 2015, respectively. The expense increase of approximately $1,663,000 was mainly attributable to additional payroll
	and related expenses of approximately $551,000 related to compensation of our Chief Financial Officer&rsquo;s, Chief Operating
	Officer&rsquo;s and Chief Executive Officer&rsquo;s salaries and compensation for our Board of Directors during the third quarter
	of 2016. The Company also incurred approximately $951,000 of expenses related to investor relations, legal, audit and accounting,
	and insurance costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Interest Expense.
</B>
	Interest expense included expense accrued
	on our convertible promissory notes issued in 2015 and 2016 bearing interest at the rate of 8% per annum.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Net Loss.
</B>
	The net loss for the nine months ended September
	30, 2016 was $2,503,047 which included non-cash expenses of $210,568 ($1,629 for depreciation and $208,939 for stock based compensation
	and other stock based expenses) and a one-time expense of $118,000 related to the severance of the former Chief Financial Officer.
	This loss for the period is a significant increase from the loss for the period from July 28, 2015 (inception) to September 30,
	2015 of $224,315 as the Company had, at that time, just begun operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	The following table sets forth the components of MBI&rsquo;s
	statement of operations for the period from July 28, 2015 (Inception) to December 31, 2015:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	From July 28, 2015
<BR>
	(Inception)
<BR>
	to
<BR>
	December&nbsp;31, 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	260,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	477,810
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Total operating expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	738,228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 18.7PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development Expense.
</B>
	Research and development
	expense was $260,418 for the period from July&nbsp;28, 2015 (Inception) to December 31, 2015. The expense is mainly related to
	patent acquisition cost and travel expense of our research and development personnel.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General and Administrative Expense.
</B>
	General and administrative
	expense was $477,810 for the period from July&nbsp;28, 2015 (Inception) to December 31, 2015. The expense mainly included professional
	fees to our consultants, attorney, accountants and our previous investment banker and financial advisor for services related to
	our initial public offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Interest Expense.
</B>
	Interest expense included expense accrued
	on our convertible promissory notes issued in August, September and October 2015 bearing interest at the rate of 8% per annum.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations &ndash; Moleculin
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth the components of Moleculin, LLC&rsquo;s
	audited statements of operations for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	125,442
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	798,785
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	328,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	839,556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,336
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,005
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Total operating expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	465,348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,649,346
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 18.7PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Other income (expense)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	99,537
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(159,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development Expense.
</B>
	Research and development
	expense was approximately $125,000 for the year ended December 31, 2015 as compared to $799,000 for the prior year. This decrease
	of $673,000 was driven primarily by clinical trial costs reductions incurred during 2015 of approximately $250,000; a decrease
	of approximately $121,000 in manufacturing costs for clinical supplies; and a decrease in intellectual property costs of approximately
	$303,000 as compared to 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General and Administrative Expense.
</B>
	General and administrative
	expense for the year ended December 31, 2015 was $329,000 as compared to $840,000 for the prior year. This $511,000 decrease in
	general and administrative expense related primarily to a reduction in payroll and related personnel costs of approximately $350,000,
	a reduction in professional services fees of $96,000, and a reduction of travel expenses of $35,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Depreciation Expense.
</B>
	Depreciation expense was $11,000 for
	each of the years ended December 31, 2015 and 2014. Depreciation is generated from our fixed assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Other Income (Expense).
</B>
	Other income for the year ended December
	31, 2015 was approximately $100,000 as compared to other expense of $160,000 for the prior year. This decrease of $260,000 in expense
	related primarily to an increase of $289,000 in interest expense accrued on our convertible promissory notes issued late in 2014
	and amortization of debt discount and deferred financing cost associated with those notes, offset by a gain on debt extinguishment
	of $549,000 recorded in fourth quarter of 2015 related to the forfeiture of units by MD Anderson Cancer Center in conjunction with
	the amendment of a license agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LIQUIDITY>
<A NAME="FIS_LIQUIDITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	As of September 30, 2016, we had $6,183,783
	in cash. During the period from January 1, 2016 through May&nbsp;2, 2016, we sold 234,296 of common stock for $702,888. On May
	31, 2016, we completed our initial public offering, pursuant to which we sold 1,540,026 shares of our common stock at $6.00 per
	share for net proceeds of $8,464,183 after deducting underwriting discounts and commissions and direct offering expenses payable
	by us. We believe that our existing cash and cash equivalents as of September 30, 2016 will be sufficient to fund our planned operations
	to the end of the third quarter of 2017, which includes our revised clinical trial plan for Annamycin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We will not generate revenue from product sales
	unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more
	of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly,
	we anticipate that we will need to raise additional capital to fund our future operations. Until such time that we can generate
	substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity
	offerings and debt financings and we may seek to raise additional capital through strategic collaborations. However, we may be
	unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a
	negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or
	commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop
	and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore,
	even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable
	market conditions or strategic considerations, which may cause dilution to our existing stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth the primary sources
	and uses of cash of MBI for the period indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the Nine Months
<BR>
	Ended September 30,
<BR>
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT">
	Net cash used in operating activities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	(2,596,647
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash used in investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(109,793
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,862,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net increase in cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6,155,692
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash used in operating activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash used in operating activities was $2,596,647
	for the nine months ended September 30, 2016 and mainly included payments made for payroll, travel, insurance and professional
	fees to our consultants, attorneys and accountants for services related to our becoming a publicly traded company and related filing
	fees, along with payments made to MD Anderson for license and maintenance fees. Additionally, prepayments were made for insurance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash used in investing activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash used in investing activities was $109,793
	for the nine months ended September 30, 2016 and primarily represents the cash paid to acquire Moleculin, LLC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash provided by financing activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash provided by financing activities was
	$8,862,132 for the nine months ended September 30, 2016. We received $8,464,183 net proceeds from our IPO stock issuance, $702,888
	from issuance of common shares at $3 per share, and $165,000 from issuance of convertible notes. Net cash used in financing activities
	included approximately $470,000 for payments of notes payable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Since Moleculin, LLC&rsquo;s inception and through
	December 31, 2015, Moleculin, LLC funded its operations primarily through the sale and issuance of convertible preferred units
	and convertible and non-convertible promissory notes. From May to November 2014, Moleculin, LLC issued various convertible notes
	to its creditors. The note proceeds were $1.5 million. These notes bear interest at 8% per annum and were due on the earlier of
	June 30, 2016 or the consummation of a liquidation event (which event includes the merger between MBI and Moleculin, LLC occurred
	on May 2, 2016), unless these notes are converted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth the primary sources
	and uses of cash for the periods indicated for Moleculin, LLC:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Net cash used in operating activities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(724,910
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(1,354,145
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -9.35PT; PADDING-LEFT: 9.35PT">
	Net cash provided by investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	232,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,525,256
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net increase (decrease) in cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(492,610
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	171,111
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash used in operating activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash used in operating activities was approximately
	$725,000 and $1,354,000 for the years ended December 31, 2015 and 2014, respectively. The $629,000 decrease in net cash used in
	operating activities was primarily due to a decrease in spending in research and development, specifically in sponsored research
	performed by MD Anderson, as well as decrease in payments made to professionals and employees.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Cash used in investing activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash provided by investing activities was
	approximately $232,000 and $0 for the years ended December 31, 2015 and 2014, respectively. The increase was due to a collection
	of long-term receivable from Dermin, Sp. Zo. O. to whom the Company had provided funding assistance for Dermin&rsquo;s efforts
	in developing and commercializing certain pharmaceutical products.
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash provided by financing activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Net cash provided by financing activities was
	approximately $0 and $1,525,000 for the years ended December 31, 2015 and 2014, respectively. Cash was provided by issuance of
	convertible notes payable in 2014 of approximately $1,525,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	JOBS Act and Recent Accounting Pronouncements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The recently enacted JOBS Act provides that
	an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B)
	of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an &ldquo;emerging
	growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
	companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt
	new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have implemented all new accounting pronouncements
	that are in effect and may impact our financial statements and we do not believe that there are any other new accounting pronouncements
	that have been issued that might have a material impact on our financial position or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Critical Accounting Policies and Significant Judgments and Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The financial statements have been prepared
	in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements
	requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
	contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the
	reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable
	under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
	that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
	conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe that the following accounting policies
	are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult,
	subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain
<B>
	.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
<B>
<I>
	Acquisition
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We acquired Moleculin,
	LLC on May 2, 2016, and, going forward our financial statements will include the operations of Moleculin, LLC. We account for acquired
	businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities
	assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process
	research and development (&ldquo;IPR&amp;D&rdquo;) be recorded on the balance sheet. Transaction costs are expensed as incurred.
	Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The
	estimated fair values of assets acquired and liabilities assumed were determined based on management&rsquo;s best estimates. Preliminary
	estimated fair values are subject to measurement period adjustments which represent updates made to the preliminary purchase price
	allocation based on revisions to valuation estimates in the interim period subsequent to the acquisition and initial accounting
	date up until the purchase price allocation is finalized which cannot be any later than one year from the acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
<B>
<I>
	Beneficial Conversion Feature
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	From time to time, we may issue convertible
	notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion
	feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is
	convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion
	of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with
	the debt. We estimate the fair value of our common stock using the most recent selling price available. The intrinsic value of
	the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The
	debt discount is amortized to interest expense over the life of the note using the effective interest method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Research and Development Costs
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We record accrued expenses for estimated costs
	of our research and development activities conducted by third-party service providers, which include the conduct of pre-clinical
	studies and clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities
	based upon the estimated amount of services provided but not yet invoiced, and we include these costs in accrued liabilities in
	the balance sheets and within research and development expense in the statement of operations. These costs are a significant component
	of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed
	and in accordance with agreements established with these third parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We estimate the amount of work completed through
	discussions with internal personnel and external service providers as to the progress or stage of completion of the services and
	the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance
	in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates
	to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the
	number of patients enrolled and the rate of patient enrollment may vary from our estimates and could result in us reporting amounts
	that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely
	and accurate reporting from clinical research organizations and other third-party service providers. To date, there have been no
	material differences from our accrued expenses to actual expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Impairment of Long-Lived Assets &nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Management reviews long-lived assets for impairment
	whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during
	the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the
	asset are compared to the asset&rsquo;s carrying value to determine if an impairment of such asset is necessary. The effect of
	any impairment would be to expense the difference between the fair value of such asset and its carrying value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Components of our Results of Operations and Financial Condition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Operating expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We classify our operating expenses into three
	categories: research and development, general and administrative and depreciation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Research and development
</I>
	. Research and
	development expenses consist primarily of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	costs incurred to conduct
	research, such as the discovery and development of our product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0 0 0 0IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	costs related to production
	of clinical supplies, including fees paid to contract manufacturers;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	fees paid to clinical consultants,
	clinical trial sites and vendors, including clinical research organizations in conjunction with implementing and monitoring our
	clinical trials and acquiring and evaluating clinical trial data, including all related fees, such as patient screening fees,
	laboratory work and statistical compilation and analysis; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	costs related to compliance
	with drug development regulatory requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We recognize all research and development costs
	as they are incurred. Clinical trial costs, contract manufacturing and other development costs incurred by third parties are expensed
	as the contracted work is performed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 42.85PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We expect our research and development expenses
	to increase in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval
	of our product candidates in the United States and Europe. The process of conducting the necessary clinical research to obtain
	regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected
	by a variety of factors including: the quality of our product candidates, early clinical data, investment in our clinical program,
	competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of
	our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion
	costs of our research and development projects or when and to what extent, if any, we will generate revenue from the commercialization
	and sale of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<I>
	General and administrative.
</I>
	General and administrative expense consists of personnel related costs, which include salaries, as well as the costs of professional
	services, such as accounting and legal, facilities, information technology and other administrative expenses. We expect our general
	and administrative expense to increase following the completion of this offering due to the anticipated growth of our business
	and related infrastructure as well as accounting, insurance, investor relations and other costs associated with becoming a public
	company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Depreciation.
</I>
	Depreciation expense consists
	of depreciation on our property and equipment. We depreciate our assets over their estimated useful life. We estimate machinery
	and equipment to have a 5-year life and furniture and fixtures to have a 7-year life.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: 0.25IN">
<B>
<I>
	Other income (expense), net
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Other income (expense), net consists of interest
	expense associated with our notes payable and interest income earned on our cash and investment balances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<A NAME="V458551_S1A_HTM_A_026" TITLE="BUSINESS">
</A>
<B>
	BUSINESS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We are a preclinical-stage, pharmaceutical
	company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University
	of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. Our lead drug candidate is liposomal
	Annamycin, which we refer to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid
	leukemia, or AML. Annamycin has been in clinical trials pursuant to an Investigational New Drug application, or IND, that had
	been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. However we
	intend to apply for a new IND based on the same data that supported the original IND, updated for subsequent clinical data and
	to resume clinical trials for Annamycin. We have two other drug development projects in process, one involving a collection of
	small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation of key regulatory transcription factors
	involved in the progression of cancer, and the WP1222 Portfolio, a suite of molecules targeting the metabolic processes involved
	in cancer in general and glioblastoma (the most common form of brain tumor) in particular. We also intend to sponsor ongoing research
	at MD Anderson in order to improve and expand our drug development pipeline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have been granted royalty-bearing, worldwide,
	exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122 Portfolio drug technologies,
	as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection.
	We intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product
	candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential
	patent protection, we believe Annamycin will qualify for Orphan Drug status and we have applied for such status with the FDA, which
	would entitle us to market exclusivity of 7 and 10 years from the date of approval of a New Drug Application (NDA) and Marketing
	Authorization (MA), in the United States and the European Union (EU), respectively. Separately, the FDA may also grant market exclusivity
	of up to 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that
	such exclusivity will be granted or, if granted, for how long.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Corporate History
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We were founded in 2015 by Walter Klemp (our
	chairman and CEO), Dr. Don Picker (our President and Chief Operating Officer) and Dr. Waldemar Priebe of MD Anderson (Chairman
	of our Scientific Advisory Board) in order to combine and consolidate development efforts that include several MD Anderson anti-cancer
	technologies. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed
	by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, we undertook
	an effort to gain control of the WP1066 Portfolio, which culminated with the merger of Moleculin, LLC and MBI and the establishment
	of a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, coincident with our IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	AnnaMed was formed in 2012 to take over the
	development of Annamycin from a prior drug development company, Callisto Pharmaceuticals, Inc., or Callisto. Callisto ceased development
	work on Annamycin, leading to the termination of its IND by the FDA. Callisto disclosed publicly in its Form 10-K filing for the
	year ended 2009 that the clinical data relating to acute leukemia patients &ldquo;did not support further clinical evaluation of
	L-Annamycin as a single agent to treat relapsed or refractory adult acute leukemia patients.&rdquo; In order to satisfy unmet license
	obligations, Callisto agreed to transfer all available Annamycin data to AnnaMed, which data we will use to apply for a new IND.
	As such, notwithstanding Callisto&rsquo;s determination to terminate its development of Annamycin, we will be utilizing the clinical
	data from Callisto&rsquo;s trials to apply for a new IND. The basis for our decision to proceed notwithstanding Callisto&rsquo;s
	determination is that we believe the actual clinical data as reported by Dr. Robert Shepard, our Chief Medical Officer and who
	was Callisto&rsquo;s Chief Medical Officer at the time of the clinical trials, to the 2009 Annual Meeting of the American Society
	of Clinical Oncology, and as further reported by the Principal Investigators of the clinical trials in a peer-reviewed journal
	article (Clin Lymphoma Myeloma Leuk. 2013 August; 13(4): 430&ndash;434. doi:10.1016/j.clml.2013.03.015.), makes clear that the
	data does support further clinical evaluation. In addition, the conclusion published in the 2013 Clinical Lymphoma, Myeloma &amp;
	Leukemia journal article was that &ldquo;Single agent nanomolecular liposomal annamycin appears to be well-tolerated and evidence
	of clinical activity as a single agent in refractory adult ALL.&rdquo; As reported in both the ASCO presentation and the 2013 journal
	article referenced, the definition of efficacy is based on the following Response Criteria: &ldquo;Response criteria were achievement
	of CR defined as &le;5% blasts, granulocyte count of &ge;1&times;109/L, and a platelet count of &ge;100&times;109/L. Partial remission
	was defined the same as CR, except for the presence of 6% to 25% blasts. Hematologic improvement was defined as for CR but platelet
	count &lt;100&times;109/L.&rdquo; The summary of patient response from the 2013 journal article reads: &ldquo;After determining
	the MTD, a 10-patient phase IIA was conducted. Eight of the patients completed one cycle of the three days of treatment at the
	MTD. Of these, five (62%) demonstrated encouraging anti-leukemic activity with complete clearing of circulating peripheral blasts.
	Three of these subjects also cleared bone marrow blasts with one subsequently proceeding onto successful stem cell transplantation.
	The other two developed tumor lysis syndrome and unfortunately expired prior to response assessment.&rdquo; In the Company&rsquo;s
	review of these trials, it confirmed that the activity demonstrated in this summary corresponds with a &ldquo;Partial remission&rdquo;
	as described in the Response Criteria and that the three subjects who &ldquo;cleared bone marrow blasts&rdquo; correspond with
	&ldquo;CR&rdquo; (Complete Response).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In 2012, AnnaMed out-licensed development rights
	in a limited territory to a Polish special purpose drug development company called Dermin in exchange for Dermin&rsquo;s development
	work based on its successful effort to obtain Polish government grant funding to assist in the development of Annamycin. Since
	that time, such grant funding has been used to produce Annamycin in preparation for future clinical trials. In August 2015, we
	entered into a rights transfer agreement with AnnaMed pursuant to which in exchange for 1,431,000 shares of our common stock AnnaMed
	agreed to transfer any and all data it had regarding the development of Annamycin and the Annamycin IND, including all trade secrets,
	know-how, confidential information and other intellectual property rights held by AnnaMed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	IntertechBio was formed in 2009 to license and
	begin development on the WP1122 Portfolio. The WP1122 Portfolio was also out-licensed to Dermin, which was awarded a Polish government
	grant to assist in drug development efforts. In August 2015, IntertechBio agreed to assign all license rights to us in exchange
	for our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Moleculin, LLC was formed in 2006 and has been
	working to develop the WP1066 Portfolio it licensed from MD Anderson. As a part of the formation of Moleculin, LLC, an agreement
	was reached with HPI to limit Moleculin, LLC&rsquo;s development efforts to uses in dermatology only, leaving non-dermatology indications
	to HPI. From 2006 to 2014, Moleculin, LLC funded its operations through the sale of equity and debt securities and through fees
	received from an out-licensing agreement with a Japanese dermatology drug development company, Maruho, Ltd., or Maruho. Since 2012,
	Moleculin, LLC conducted a series of clinical trials focused on the topical treatment of psoriasis. Although those trials have
	demonstrated drug activity, the results to date are not conclusive enough to warrant full commercialization as a topical dermatology
	drug. Additional study is required to determine optimal dosing and scheduling regimens for the topical treatment of psoriatic plaques.
	As a result of this additional complexity with regard to the potential treatment of psoriasis, Maruho did not elect to continue
	its funding of the psoriasis drug development effort and, therefore, forfeited their license rights to the WP1066 Portfolio that
	had been granted to it by Moleculin, LLC. Dermin is planning to clinically evaluate a candidate from the WP1066 Portfolio for the
	topical treatment of cutaneous T-cell lymphoma, or CTCL. We do not have control of the clinical plan or timeline for Dermin&rsquo;s
	development effort.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Prior to our IPO, Moleculin, LLC was merged
	with and into our company. The merger agreement contains mutual representations and warranties between the parties. Pursuant to
	the merger agreement, we agreed for a period of six years to indemnify and hold harmless each present and former director and/or
	officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or
	threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she
	was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions
	of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages
	reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on
	the date hereof and Moleculin, LLC made representations to this effect in the merger agreement. As additional consideration payable
	to the Moleculin, LLC unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully
	developed by us (or our successors) using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate,
	will be entitled to receive a 2.5% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction
	for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &ldquo;Existing
	IP Assets&rdquo; to mean all intellectual property, licensed by us and Moleculin, LLC as of the time of the merger, including,
	without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered
	into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License
	Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating
	to Annamycin. The right to receive the contingent royalty payments described herein are for drugs developed only for dermatology
	indications, and do not include drugs developed for any other indications. We have no obligation of any nature to pursue the development
	of any drugs for dermatology indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	From 2006 through 2015, HPI has been engaged
	in research related to the use of the WP1066 Portfolio for the treatment of non-dermatology cancers and has received grant awards
	totaling approximately $4.9 million toward this effort. Prior to our IPO, we entered into a co-development agreement with HPI whereby
	HPI is continuing its grant-funded research and making all resulting data available for our use in exchange for a development fee.
	We may buy HPI out of its co-development rights in the WP1066 Portfolio at our option. Please see the section &ldquo;Business &ndash;
	License Agreements&rdquo; for a description of our agreement with HPI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Neither our founders nor MBI have or will have
	any ownership stake in Dermin, our Polish grant-funded licensee. No Dermin-related grant money is expected to be paid directly
	to us, but rather the sublicense agreements require Dermin to share resulting data, which we believe will reduce costs we might
	otherwise have to incur directly. There can be no assurance, however, that Dermin will continue to receive the funds they have
	been awarded or that such funds will be spent by Dermin in a manner that will benefit MBI. The sublicensed territories granted
	to Dermin for the WP1066 Portfolio are Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia
	and Estonia. For the WP1122 Portfolio, the territory expanded to include Russia and Kazakhstan. For Annamycin, the territory is
	further expanded to include Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland,
	Finland, Luxembourg, Iceland, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany. However, in the case of Germany, this territory
	may be reclaimed by us for a payment of $500,000 to Dermin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following summarizes the transactional history
	and common relationships among HPI, IntertechBio, Moleculin, LLC, MBI, Callisto, AnnaMed, MD Anderson, and our officers and major
	shareholders:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Moleculin, LLC
</I>
	: Prior to our IPO, Moleculin, LLC was merged with and into our company. Moleculin, LLC was the holder
	of the license agreement with MD Anderson covering our WP 1066 Portfolio. As a result of the merger, we issued the equity interests
	holders of Moleculin, LLC an aggregate of 999,931 shares of our common stock. Waldemar Priebe, chairman of our Scientific Advisory
	Board, Walter Klemp, our chairman and chief executive officer, and Don Picker, our president and chief operating officer, were
	members of Moleculin, LLC and received 6,046 shares, 22,795 shares and 6,046 shares, respectively, of our common stock as a result
	of the merger. In addition, Walter Klemp and Don Picker were members of the board of Moleculin, LLC.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Houston Pharmaceuticals, Inc.
</I>
	: Prior to our IPO, MBI on Moleculin, LLC&rsquo;s behalf, entered into a co-development
	agreement with HPI whereby HPI is continuing its grant-funded research and making all resulting data available for our use in exchange
	for a development fee. Waldemar Priebe, chairman of our Scientific Advisory Board, and Don Picker, our president and chief operating
	officer, are shareholders of HPI, and Dr. Priebe has the voting and dispositive power over the shares held by HPI.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	IntertechBio Corporation
</I>
	: In August 2015, in exchange for the issuance of 630,000 shares of common stock, we acquired
	the rights to the license agreement with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation. Waldemar Priebe,
	chairman of our Scientific Advisory Board, and Don Picker, our president and chief operating officer, are shareholders of IntertechBio
	and control the voting and dispositive power over the shares held by IntertechBio.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	AnnaMed, Inc
</I>
	.: In August 2015, in exchange for 1,431,000 shares of our common stock, we acquired the rights to the Annamycin
	data related to the original Annamycin IND and the development of Annamycin held by AnnaMed, Inc., a company controlled by Walter
	Klemp, our chairman and chief executive officer.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Callisto Pharmaceuticals, Inc
</I>
	.: Our president and chief operating officer, Don Picker and our chief medical officer,
	Robert Shepard, were chief operating officer and chief medical officer, respectively, of Callisto. Since 2009, neither individual
	has had any relationship or ownership with Callisto.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	MD Anderson
</I>
	: Both Moleculin, LLC and IntertechBio entered into license agreements with MD Anderson. See &ldquo;Business
	&ndash; Our Licenses Agreements&rdquo; below. Waldemar Priebe, chairman of our Scientific Advisory Board, is a Professor of Medicinal
	Chemistry, Department of Experimental Therapeutics, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer
	Center.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Drug Candidates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Annamycin
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our lead product candidate is Annamycin. We
	intend to use a portion of the proceeds from this offering to conduct clinical trials for Annamycin as a monotherapy for the treatment
	of relapsed or refractory acute myeloid leukemia, or AML. If Annamycin is ultimately approved on this basis, it is possible, with
	the necessary subsequent testing and approval, that it could be used in the future in combination with other drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Market for Annamycin
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Leukemia is a cancer of the white blood cells
	and acute forms of leukemia can manifest quickly and leave patients with limited treatment options. AML is the most common type
	of acute leukemia in adults. It occurs when a clone of leukemic progenitor white blood cells proliferates in the bone marrow,
	suppressing the production of normal blood cells. Currently, the only viable option for acute leukemia patients is a bone marrow
	transplant, which is successful in a significant number of patients. However, in order to qualify for a bone marrow transplant,
	the patient&rsquo;s leukemia cells must be decreased to a sufficiently low level. This begins with a therapy of combining two
	chemotherapeutic drugs, which always includes an anthracycline, in inducing remission (a complete response, or CR), which therapy
	has not improved since it was first used in the 1970s and we estimate that this induction therapy has the same success rate of
	about 20% as at that time. Unfortunately, the current clinically approved anthracyclines are cardiotoxic, which can result in
	damage to the heart and limit the dosage amount that may be administered to patients. Additionally, the tumor cells often present
	de novo or develop resistance to the first line anthracycline, often through what is called &ldquo;multidrug resistance&rdquo;,
	enabling them to purge themselves of the available anthracyclines. Consequently, there remains no effective therapy for these
	patients and unfortunately most will succumb quickly to their leukemia. If a patient&rsquo;s leukemia reappears before they can
	be prepared for a bone marrow transplant, they are considered to have &ldquo;relapsed&rdquo;. If a patient fails to achieve a
	sufficient response from the induction therapy to qualify for a bone marrow transplant, they are considered to be &ldquo;refractory&rdquo;
	(resistant to therapy). Together, this group of relapsed and refractory AML patients constitutes our primary focus for treatment
	with Annamycin and our intent is to pursue FDA approval for Annamycin as a second-line induction therapy for adult relapsed and
	refractory AML patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe that pursuing approval as a second
	line induction therapy for adult relapsed or refractory AML patients is the shortest path to regulatory approval, but we also believe
	that one of the most important potential uses of Annamycin is in the treatment of children with either AML or ALL (acute lymphoblastic
	leukemia, which is more common in children). Accordingly, we also intend to pursue approval for pediatric use when practicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Of the estimated 18,860 U.S. cases of acute
	myeloid leukemia diagnosed in 2014, an estimated 97% were adult and although exact numbers are not available, we estimate that
	70% to 80% (approximately 13,000 to 14,000 patients) were expected to relapse or be resistant to first-line therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Prior Clinical Trials for Annamycin
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Annamycin is a liposome formulated anthracycline
	(also referred to in literature as &ldquo;L-Annamycin&rdquo;). It has been tested in 6 clinical trials and 114 patients without
	any reported cardiotoxicity and, in the two clinical trials focused on leukemia, with fewer dose-limiting toxicities than are normally
	expected with doxorubicin (one of the leading first-line anthracyclines used for induction therapy). Each of these trials was conducted
	by Callisto Pharmaceuticals, Inc., the previous holder of the intellectual property surrounding Annamycin, and not by our company.
	Annamycin demonstrated significant activity in 8 of 16 patients in a Phase I study in adult relapsed or refractory AML patients,
	with 6 of 14 patients completely clearing leukemic blasts. A 30 patient dose-ranging Phase I/II study in ALL demonstrated a similar
	level of activity, with 3 of 10 patients treated with the maximum tolerable dose clearing their leukemic blasts to a level sufficient
	to qualify for a bone marrow transplant. One of these patients went on to receive a successful curative bone marrow transplant.
	The other two of these three patients died of tumor lysis syndrome, a condition resulting from the overloading of their system
	with the debris from leukemic blast cells destroyed by the induction therapy. Armed with the knowledge of this potential, prophylactic
	pretreatment known to protect patients from the effects of tumor lysis syndrome will be deployed in future trials. Based on the
	results of the above clinical trials, we believe Annamycin is different from currently approved induction therapy drugs in four
	key ways: (i) it has demonstrated clinical activity in a patient population for whom there are currently no effective therapies,
	(ii) it appears to be capable of avoiding the &ldquo;multi-drug resistance&rdquo; mechanisms that often limit the effectiveness
	of currently approved anthracyclines; (iii) it has been shown to be non-cardiotoxic in animal models and no events of cardiotoxicity
	have been reported from the use of Annamycin in 114 patients; and (iv) in AML cell lines, it has been shown to be more potent than
	one of the leading approved drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Because the prior developer of Annamycin allowed
	their IND to lapse, we are required to submit a new IND for continued clinical trials with Annamycin. Toward this end, we recently
	submitted a request for a Pre-IND meeting with the FDA. Based on subsequent conversations with the FDA, we will be allowed to incorporate
	by reference the prior developer&rsquo;s IND in submitting our new request for IND. We believe this will not only save time and
	expense with regard to our IND submission, but it should also reduce the risk that our IND submission is delayed due to a review
	of any of this prior data. Written communication from the FDA indicates they do not see a need for a Pre-IND meeting and plan to
	respond to questions in our Pre-IND briefing document in writing by December 6, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Based on initial conversations with the FDA,
	because of the serious unmet medical need, we believe Annamycin may qualify for accelerated approval based on our planned clinical
	trials. In order to facilitate our communication with the FDA, we requested access to and reviewed in detail the available data
	supporting the dose-ranging Phase I/II clinical trial discussed above, which was conducted by a previous developer of Annamycin.
	In October 2016, we announced that we had identified some positive findings from this review, which gave rise to a modification
	of our own clinical development plan. We had indicated that our plan was to conduct a detailed review of the clinical results generated
	by that prior developer, and then to use those results to reestablish an IND in order to continue clinical trials of Annamycin.
	However, in the course of our review, we identified that Annamycin may have greater potential for efficacy than we originally believed,
	based on an unexpected potential opportunity to increase the drug&rsquo;s Maximum Tolerable Dose (&ldquo;MTD&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In particular, the Dose Limiting Toxicities
	(&ldquo;DLTs&rdquo;) reported in the previous trial that led to the establishment of the current MTD of 150 mg/m
<SUP>
	2
</SUP>
	were
	all from patients who had an unusually high number of first-line induction therapy failures prior to being treated with Annamycin.
	Specifically, of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior
	induction therapy attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. We
	concluded from our review of this data that, if the heavily treated patients are excluded from the data set, the MTD could have
	been closer to 250 mg/m
<SUP>
	2
</SUP>
	, substantially higher than the level that was actually set by this previous trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We view this as an encouraging development because
	it means we may have an opportunity to increase the MTD for our next trial from 150 mg/m
<SUP>
	2
</SUP>
	to 200 or even 250 mg/m
<SUP>
	2
</SUP>
	.
	If that turns out to be the case, we believe it could increase the chance for positive outcomes in our next trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With the discovery that we may be able to increase
	our MTD, we determined to adjust our clinical strategy by adding in a Phase I arm to our next Phase II trial, which will add expense
	to our development effort. We believe this change in strategy will add several months to the eventual final approval of the drug,
	if the drug is approved.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have also applied for Orphan Drug
	status with the FDA for Annamycin. The FDA has responded to our request for Orphan Drug status by requesting additional information,
	which we have now provided. We expect a response to our revised application in the near future, but can provide no assurance as
	to when any response will be received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The prevalence ceiling for qualifying rare diseases
	under the US Orphan Drug Act is 200,000 patients and proportionally similar guidelines exist in the EU. The most recently published
	prevalence statistics from the National Cancer Institute reported that an estimated 37,726 patients had acute myeloid leukemia
	in the United States as of January 1, 2011, and trend data since that publication would indicate that the prevalence today should
	still be well below the 200,000 patient limitation for Orphan Drugs, qualifying Annamycin for the treatment of acute myeloid leukemia
	to qualify for Orphan Drug status. Annamycin already qualified for Orphan Drug status with its prior developer and we intend to
	repeat that process. However, we can provide no assurance that we will be successful in obtaining Orphan Drug status for Annamycin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;Lack of Cardiotoxicity
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	One of the key dose-limiting toxicities associated
	with currently available anthracyclines like doxorubicin is their propensity to induce life-threatening heart damage. This is especially
	problematic for pediatric leukemia patients whose life spans can be severely shortened by the very induction therapy designed to
	cure them of acute leukemia. In the animal model relied upon by the FDA as an indicator of human cardiotoxicity, the non-liposomal
	(free) form of Annamycin has been shown to be significantly less likely than doxorubicin to create heart lesions in mice and the
	liposomal formulation (L-Annamycin) has been shown in animal models to have reduced cardiotoxicity to the point where it is unlikely
	to cause harm to human patients. This lack of cardiotoxicity means L-Annamycin may be able to be used more aggressively in helping
	patients achieve remission without the potentially deadly long-term side effects of cardiotoxicity. This would be especially valuable
	in the case of pediatric acute leukemia (both AML and ALL) where long-term survival can be greatly impacted by cardiotoxicity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Circumventing Multidrug Resistance
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In addition to cardiotoxicity, the effectiveness
	of currently approved anthracyclines is limited by their propensity for succumbing to &ldquo;multidrug resistance&rdquo;, whereby
	transporters (one type of which is referred to as a &ldquo;P-glycoprotein pump&rdquo;) develop on the outer surface of cells to
	expel drugs like doxorubicin as a natural defense mechanism. The dosing of current therapies cannot be increased in an attempt
	to overcome multidrug resistance because of the likelihood of cardiotoxicity and other serious side effects. This limitation prevents
	adequate dosing of current anthracyclines to produce lasting remission. Annamycin appears to resist being expelled by P-glycoprotein
	pumps and other similar tested multidrug resistance transporters and thereby would seem to circumvent multidrug resistance. This
	characteristic has been shown in pre-clinical testing to allow for higher drug uptake in diseased cells, which we believe should
	allow for more effective induction therapy with less risk to the patient.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	In order for anthracyclines to provide effective induction therapy, they must be allowed to accumulate
	in leukemic cells sufficiently to enter the cell&rsquo;s nucleus where they damage the cell&rsquo;s DNA and induce apoptosis (cell
	death). As induction therapy progresses, however, the targeted cells can develop a natural defense mechanism to prevent the anthracycline
	activity. The graphic below provides a simplified depiction of the formation of a P-glycoprotein pump on the outer surface (membrane)
	of a leukemic cell. As typical anthracyclines enter the cell, they are attracted to such pumps and are expelled (referred to as
	&ldquo;efflux&rdquo;) before they can accumulate sufficiently to serve their purpose. In contrast, Annamycin avoids such pumps
	and is allowed to accumulate sufficiently to destroy the leukemia cell despite the presence of the multidrug resistance mechanisms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/07/0001144204-17-006369_PG64IMG1_S1.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	The WP1066 Portfolio
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have a license agreement with MD Anderson
	pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
	to our WP1066 Portfolio and its close analogs, molecules targeting the modulation of key oncogenic transcription factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Clinical Testing of WP1066 Portfolio
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	In vitro
</I>
	testing has shown a high level
	of activity for WP1066 against a wide range of solid tumors, and
<I>
	in vivo
</I>
	testing has shown significant activity against
	head and neck, pancreatic, stomach, and ovarian cancers, as well as metastatic melanoma and glioblastoma, among others.
<I>
	In vivo
</I>
	testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that provides necessary
	blood supply to tumors) and increases survival.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	With respect to our WP1066 Portfolio, we must
	complete pre-clinical toxicology testing, along with additional chemistry, manufacturing and control work to fully characterize
	the drug, establish the desired formulation and develop reference standards for future drug release, among others prior to submitting
	and application for IND. A clinician at MD Anderson has advised us that she is proceeding with a physician-sponsored IND for WP1066
	treatment of brain tumors. We are not participating in this IND process. The clinician has submitted an IND to the FDA and has
	indicated that this IND is on hold until documentation of Good Manufacturing Process or GMP production of WP1066 can be presented
	to the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	An analog of WP1066, referred to as WP1220,
	was previously the subject of an IND (WP1220 was referred to as MOL4239 for purposes of this IND) related to use of the molecule
	in the topical treatment of psoriasis. Clinical trials were commenced on WP1220 in the US, but were terminated early due to limited
	efficacy in the topical treatment of psoriatic plaques. Notwithstanding its limitations in treating psoriasis, our pre-clinical
	research has shown WP1220 to be effective in inhibiting cutaneous T-cell lymphoma (CTCL) in multiple CTCL cell lines. Based on
	this encouraging data, we are collaborating with a Polish drug development company, Dermin, which has received Polish government
	grant money to begin a clinical trial in Poland for the topical treatment of early stage CTCL patients. CTCL is a potentially deadly
	form of skin cancer for which there are limited treatment options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We also conducted a Phase II clinical trial
	for WP1066 for the topical treatment of psoriasis, however this trial was terminated early as a significant number of patients
	experienced a non-permanent worsening of their psoriatic plaques after extended use of the drug, suggesting that its use as a topical
	agent for non-life threatening diseases such as psoriasis will require further study to optimize dosing and scheduling regimens.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Scientific Rationale for WP1066 Portfolio
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Cellular biology depends upon signaling mechanisms
	to regulate functions such as cell growth, death and adaptation. Signal &ldquo;transduction&rdquo; is such a mechanism that converts
	an upstream stimulus to a cell into a specific cellular response. Signal transduction starts with a signal to a receptor or via
	a compound capable of passing through the cell membrane and ends with a change in cell function. The end result of this signal
	is often the activation of &ldquo;transcription&rdquo;, whereby genetic information is expressed and, in the case of oncogenic
	transcription, disease processes are initiated or maintained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Receptors span the cell membrane, with part
	of the receptor outside and part inside the cell. When a chemical signal represented by a specific protein binds to the outer portion
	of the receptor, it conveys another signal inside the cell. Often there is a cascade of signals within the cell, wherein an upstream
	inducer starts a chain of events that resembles a domino effect. Collectively, this sequence is referred to as a &ldquo;signaling
	pathway.&rdquo; Eventually, the signal creates a change in the cell function by changing the expression of specific genes and production
	of specific proteins within the cell, and again, in the case of tumor development, such expression results in unwanted oncogenic
	processes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Importantly, while normal healthy cell function
	relies on signaling mechanisms, diseases are capable of co-opting these mechanisms with negative consequences. Oncogenic processes
	(including inflammation and proliferation) depend upon signaling pathways that are responsible for coordinating functions such
	as cell growth, survival and cell differentiation. A particular class of proteins referred to as Signal Transducers and Activators
	of Transcription (such proteins are &ldquo;STATs&rdquo;) regulates the process of disease cell survival and proliferation, angiogenesis
	and immune system function and is persistently activated in a large number of human inflammatory processes and in hyper-proliferating
	diseases. Because certain of these proteins are known to be co-opted by tumor cells, we refer to them as &ldquo;oncogenic transcription
	factors,&rdquo; of which certain STATs are a subset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Some STATs, such as STAT3, can be activated
	by any one of many different upstream inducers, making them very difficult to target by blocking just one or more of these upstream
	inducers. We believe that blocking a targeted STAT directly rather than via its multiple upstream inducers should result in greater
	efficacy with lower toxicity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	In the diagram shown below, any one of many
	different pathways (categorized as Growth Factor Receptors, Cytokine Receptors and Non-Receptor Tyrosine Kinases) triggers the
	activation of STAT3 proteins in a process called &ldquo;phosphorylation&rdquo;. In this process, phosphates attach to corresponding
	receptors on STAT3 and, eventually, two phosphorylated STAT3 proteins (&ldquo;p-STAT3&rdquo;) bind together in a pair referred
	to as a &ldquo;dimer&rdquo;. Once the dimer is formed, it enters the cell nucleus and triggers gene transcription. Conversely,
	if we reduce the presence of p-STAT3 before dimers can be formed, we can prevent the triggering of gene transcription and effectively
	inhibit the disease process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/07/0001144204-17-006369_PG66IMG1_S1.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The upstream effectors shown in the above diagram
	(SRC, JAK and ABL) are just some of those capable of activating STAT3 once they themselves are activated by a variety of signal
	compounds. The complexity and diversity of pathways capable of activating STAT3 make it very difficult to develop effective drugs
	that attempt to target the upstream effectors. Furthermore, many of these upstream pathways are necessary for normal healthy cell
	function, so blocking them indiscriminately can lead to unwanted toxicities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Published research has identified STAT3 as a
	master regulator of a wide range of tumors and clearly links STAT3 activation with the progression of these tumors. For this reason,
	it is believed that direct inhibition of p-STAT3 should be an effective way to reduce or eliminate the progression of these diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Many research efforts have
	been directed toward development of specific methods to control activation of STAT3, but most have focused on targeting the upstream
	effectors of these pathways like growth factors, cytokines, and specific kinases including Janus kinases (JAKs). However, we believe
	that the multifactorial nature of the activation of STAT3 limits the effectiveness of such upstream approaches. Since the activity
	of p-STAT3 is a final and determinative step in triggering unwanted transcription, we believe it is preferable to inhibit p-STAT3
	more directly and independently from upstream effectors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We believe the WP1066 Portfolio
	represents a novel class of agents capable of hitting multiple targets, including p-STAT3, regardless of their upstream method
	of activation. By inhibiting the presence of p-STAT3, WP1066 directly attacks tumor cells, as has been demonstrated in numerous
	preclinical tests involving a wide range of tumor cells. We believe the effectiveness of WP1066 is not only the result of attacking
	tumors directly, but also indirectly by stimulating the immune system, increasing the patient&rsquo;s natural ability to fight
	off tumor development. STAT1 is believed to stimulate T-cell activity and thereby the immune system responsible for fighting tumors.
	WP1066 has been shown to increase the activity of STAT1 at the same time it inhibits the activity of p-STAT3. We believe this dual
	activity makes WP1066 a uniquely promising anticancer drug candidate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	We believe the combination of the direct and indirect effects of WP1066 are to be credited with
	significant tumor suppression and increased survival in a number of
<I>
	in vitro
</I>
	cancer models. Below is one example showing
	a dramatic increase in survival by treating mice with metastatic melanoma with WP1066.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0.75IN">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/07/0001144204-17-006369_PG67IMG1_S1.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	The WP1122 Portfolio
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have a license agreement with MD Anderson
	pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related
	to our WP1122 Portfolio and similar molecules targeting the treatment of GBM and related CNS malignancies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe this technology has the potential
	to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and
	important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system
	malignancies and especially GBM. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous
	system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the
	treatment options available to their physicians are among the most limited of any cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The American Cancer Society has estimated 23,770
	new cases of brain and other nervous system cancers will occur in the United States in 2016, resulting in 16,050 deaths. Despite
	the severity and poor prognosis of these tumors, there are few FDA-approved drugs on the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We have proof of concept data for WP1122, including
<I>
	in vitro
</I>
	activity against cancer cell lines, as well as data on survival of animals subjected to xenografts of human brain
	tumors, including data regarding biodistribution and pharmacokinetics. In non-optimal doses and treatment regimes, WP1122 performed
	equal to or better than the current market leader, temozolomide and provided for superior survival for animals treated in combination
	with temozolomide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Scientific Rationale for WP1122
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Science has recognized that many cancer cells
	have a unique metabolism, distinct from that of normal cells. Dubbed the &ldquo;Warburg Effect&rdquo; by its discoverer, tumors
	rely preferentially on glycolysis for the metabolism of glucose, even in the presence of abundant oxygen, for energy (adenosine
	triphosphate (ATP)) production. This alternative form of energy production makes cancer cells as much as 17 times more dependent
	on glucose than normal cells.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The fundamental mechanism for imaging actively
	growing tumors using positron emission tomography (PET scans) is the Warburg Effect. A radiolabeled glucose decoy called F18DG
	accumulates disproportionately in tumors because of their dramatically increased rate of glucose uptake and accumulation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Researchers have theorized that if a tumor&rsquo;s
	access to glucose could be blocked the tumor could be starved out of existence. Previous attempts at targeting the metabolism of
	tumor cells have failed due to the rapid metabolism and short half-life (minutes) of the drugs being investigated. Efforts to target
	tumor metabolism in the brain were further thwarted by the inability to get glycolytic inhibitors into the brain in sufficient/therapeutic
	amounts due to the presence of what is called the &ldquo;blood brain barrier&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We believe WP1122 has the potential for developing
	a technology platform for enabling increased cellular uptake, increased drug half-life and, importantly, an increased ability to
	cross the blood brain barrier, enabling greater uptake in the brain. Our approach was inspired by the same principle that distinguishes
	morphine from heroin. Heroin is chemically the diacetyl ester of morphine. While morphine has a limited ability to cross the blood
	brain barrier (making it a good candidate for pain killing without impairing mental function), its diacetyl form, heroin, has the
	ability to accumulate in the brain by 10 to 100 times more than morphine. Once across the blood brain barrier, the acetyl groups
	are cleaved off by natural enzyme esterases, leaving pure morphine to accumulate in the brain. Similarly, we believe, based on
	pre-clinical testing, that WP1122, the diacetyl form of a glucose analog and decoy known as &ldquo;2-DG&rdquo;, crosses the blood
	brain barrier where its acetyl groups are cleaved off, allowing the resulting 2-DG to accumulate in the brain at a much higher
	rate than free 2-DG can do by itself.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Adding to the difficulty in getting free 2-DG
	across the blood brain barrier in therapeutic quantities is the relatively short half-life of 2-DG. The free form of 2-DG is rapidly
	metabolized and rendered ineffective within minutes of entering the body. In contrast, WP1122 has a half-life of approximately
	6 hours, making it much more feasible to deliver quantities adequate for a therapeutic effect. In addition, we believe WP1122 may
	represent an improvement to current PET scan diagnostics techniques because of its unique ability to cross the blood brain barrier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview of the market for our anti-cancer drugs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Cancer is the second leading cause of death
	in the United States behind heart disease. In 2014, an estimated 14.5 million people in the United States were living with a past
	or current diagnosis of cancer and, in 2016, the National Institutes of Health estimates that nearly 1.7 million new cases will
	be diagnosed and almost 600,000 Americans will die from cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<B>
	&nbsp;
</B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/07/0001144204-17-006369_PG60IMG1_S1.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Source: American Cancer Society - Cancer Facts &amp; Figures
	2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Digestive, reproductive, breast and respiratory
	cancers comprise 65% of expected cancer diagnoses in 2016, while cancers like leukemia and brain tumors are considered &ldquo;rare
	diseases&rdquo;. Leukemia in particular, can be divided into acute, chronic and other, with acute lymphoblastic leukemia (ALL)
	and acute myeloid leukemia (AML) comprising 26,540 of the estimated 60,140 new cases expected in the United States this year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The worldwide cancer drug business has been
	estimated to represent approximately $100 billion in annual sales. Our lead drug, Annamycin, is in a class of drugs referred to
	as anthracyclines, which are chemotherapy drugs designed to destroy the DNA of targeted cancer cells. The most common approved
	anthracyclines are daunorubicin and doxorubicin and, prior to the expansion of their generic equivalents, annual revenues generated
	from anthracyclines have been estimated in the range of $600 million. Acute leukemia is one of a number of cancers that are treated
	with anthracyclines. One industry report estimates that annual drug revenues generated from the demand for AML-related therapies
	in the United States, United Kingdom, France, Germany, Italy and Spain were in the range of $151 million in 2012, and we believe
	that this number may increase if and when improved AML treatments are available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Our other two active development projects have
	applications (among others) in the treatment of brain tumors, another rare disease for which there are few available treatments.
	The leading brain tumor drug is temozolomide, a drug introduced under the brand name Temodar. In 2012, one industry source reported
	annual revenues of approximately $882 million for Temodar before the expiration of its patent protection, at which point generic
	versions of the drug began to enter the market and reduce prices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The Orphan Drug Act of 1983 and other legislative
	initiatives provide incentives and in some cases, accelerated approval pathways for companies that pursue the development of treatments
	for rare diseases and diseases for which there are few or no acceptable available treatment alternatives. Over the last 10 years,
	an increasing number of companies have begun using these designations to obtain new drug approvals for drugs where patent coverage
	has expired and/or where accelerated approval appears possible. An IMS Health report estimated that, in 2013, the sale of drugs
	with full or partial Orphan Drug status represented approximately $29 billion in revenue. We consider obtaining Orphan Drug status
	and accelerated approval pathways to be an important part of our development strategy for our drug candidates. Notwithstanding
	these potential opportunities, we can provide no assurance that our drugs will receive Orphan Drug status or any other special
	designation that could, among other things, provide for accelerated approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our License Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	We acquired the rights and obligations under
	the Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson dated April 2, 2012 (the &ldquo;IntertechBio
	Agreement&rdquo;). Pursuant to that license agreement and an October 2015 amendment, IntertechBio obtained a royalty-bearing, worldwide,
	exclusive license to intellectual property including patent rights related to our WP1122 Portfolio and to our drug product candidate,
	WP1122. In consideration, IntertechBio agreed to make payments to MD Anderson, including an up-front payment, license documentation
	fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license
	agreement. Specifically, under the IntertechBio Agreement, IntertechBio agreed to pay a nonrefundable upfront documentation fee
	in the amount of $80,000; annual maintenance fee in the amount of $10,000 on the first anniversary of the effective date of the
	IntertechBio Agreement, $20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary
	of the effective date of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement, $80,000 on the
	fifth anniversary of the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of the agreement
	and every anniversary thereafter, except that such payments will no longer be due upon the first sale of a licensed product. Under
	the IntertechBio Agreement, IntertechBio also agreed to make a minimum annual royalty in the amount of $200,000 for the first anniversary
	following the first sale of a licensed product, $400,000 for the second anniversary following the first sale of a licensed product,
	and $600,000 for the third year following the first sale of a licensed product and every anniversary thereafter. IntertechBio also
	agreed to make one-time milestone payments in the amount of $200,000 upon commencement of a Phase II study for a licensed product,
	$250,000 upon commencement of a Phase III study for a licensed product, $400,000 upon filing of a New Drug Application (&ldquo;NDA&rdquo;)
	for a licensed product and $500,000 upon receipt of market approval for sale of a licensed product. MD Anderson has the right to
	terminate the agreement upon advance notice in the event of a default by IntertechBio. The agreement will also be terminated immediately
	upon IntertechBio&rsquo;s insolvency. Additionally, MD Anderson has the right to terminate the license agreement if (i) a preclinical
	toxicology program for a licensed product is not initiated within one year of the of effective date of the amendment, (ii) an investigational
	new drug application (IND) is not filed with the Food and Drug Administration (FDA) for a Phase I study for a licensed product
	within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within
	five years of the effective date of the amendment. The IntertechBio Agreement will expire upon the expiration of the licensed intellectual
	property. In August 2015, the IntertechBio Agreement and amendments thereto were assigned to MBI. Under the assignment, MBI has
	assumed the rights and obligations of IntertechBio including, without limitation, the right to manufacture, have manufactured,
	use, import, offer to sell and/or sell products worldwide for any indication under the licensed intellectual property with the
	right to sublicense. However, the rights obtained pursuant to the assignment of the IntertechBio Agreement are made subject to
	the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed
	under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing,
	prosecuting and maintaining the licensed patents have been and shall continue to be assumed by MBI. MBI is not required to issue
	MD Anderson any equity upon the completion of any milestones. On October 8, 2015, IntertechBio entered into a letter agreement
	with MD Anderson where MD Anderson agreed to receive past due maintenance fees and patent expenses of $98,108 owed by IntertechBio
	in four installments. The past due amount is related to certain metabolic inhibitor technology license that was assigned to MBI
	by IntertechBio and was owed by IntertechBio prior to MBI&rsquo;s acquisition of the license. Pursuant to the letter, IntertechBio
	Corporation also agreed to pay $65,504 patent fees to a law firm. In order to have the license in good standing, MBI agreed to
	pay MD Anderson the $98,108 and the $65,504 to a law firm on behalf of IntertechBio Corporation; all such payments have been made
	in full by MBI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Due to our acquisition of Moleculin, LLC, we
	obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to our
	WP1066 drug product candidate from MD Anderson. Moleculin, LLC entered into a June 2010 Patent and Technology License Agreement
	with MD Anderson (the &ldquo;Moleculin Agreement&rdquo;). Under the Moleculin Agreement and an October 2015 amendment, Moleculin,
	LLC obtained the right to manufacture, have manufactured, use, import, offer to sell and/or sell products worldwide for any indication
	under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed to make payments
	to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed
	under the license agreement. Specifically, under the Moleculin Agreement, Moleculin, LLC agreed to pay a nonrefundable upfront
	documentation fee in the amount of $223,585; annual maintenance fee in the amount of $20,000 on the first anniversary of the effective
	date of the Moleculin Agreement, which shall increase in $10,000 increments on an annual basis thereafter up to a maximum of $100,000,
	except that such payments will no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin
	Agreement, Moleculin, LLC also agreed to make a minimum annual royalty payment to MD Anderson in the amount of $200,000 after the
	first sale of a licensed product. Moleculin, LLC also agreed to make one-time milestone payments in the amount of $150,000 upon
	commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; $500,000 upon
	submission of the first NDA for a licensed product in the United States; and $600,000 upon receipt of the first marketing approval
	for sale of a licensed product in the United States. MD Anderson has the right to terminate the Moleculin Agreement upon advanced
	notice in the event of a default by Moleculin, LLC. Moleculin, LLC has the right to terminate the Moleculin Agreement for any reason
	upon advance written notice to MD Anderson. The Moleculin Agreement will also be terminated immediately upon Moleculin, LLC&rsquo;s
	insolvency. Per the October 2015 amendment to the Moleculin Agreement, MD Anderson relinquished any rights to any equity previously
	due MD Anderson in Moleculin, LLC. Upon completion of our acquisition of Moleculin, LLC, we assumed the rights and obligations
	of Moleculin, LLC including, without limitation, the right to manufacture, have manufactured, use, import, offer to sell and/or
	sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. However, the
	rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government
	to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between
	MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining
	the licensed patents have been and shall continue to be assumed by us. MBI is not required to issue MD Anderson any equity in our
	company upon the completion of any milestones.
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On October 8, 2015, Moleculin, LLC entered
	into a letter agreement with MD Anderson for Moleculin, LLC&rsquo;s past due fees to MD Anderson in the amount of $691,186 of which
	$300,000 had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining
	past due fee in three installments, which payments have been made in full.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Moleculin, LLC out-licensed certain intellectual
	property rights including rights covering the WP1066 drug product candidate to Dermin (&ldquo;Moleculin Out-License Agreement&rdquo;).
	The licensed intellectual property includes rights obtained by Moleculin, LLC pursuant to a license agreement with MD Anderson
	(&ldquo;Moleculin-MD Anderson Agreement&rdquo;). Under the Moleculin Out-License Agreement, Moleculin, LLC granted Dermin a royalty-bearing,
	exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics
	under the licensed intellectual property in the countries of Belarus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland,
	Romani, Slovakia and Ukraine (&ldquo;licensed territories&rdquo;). Additionally, Moleculin, LLC agreed to develop and provide a
	dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin agreed to make payments to Moleculin,
	LLC, including upfront development fees, annual royalty payments, sublicense fee, and milestone payments. Specifically, under the
	Moleculin Out-License Agreement, Dermin agreed to make a nonrefundable upfront dossier development payment in the amount of $100,000;
	a service fee in the amount of $100,000 for assistance provided to Dermin in securing additional funding; and royalty payments
	on sales of any licensed product at a rate of no less than the royalty rate due to MD Anderson under the Moleculin-MD Anderson
	Agreement plus 1%. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant to sublicense agreements
	in the amount of 25% prior to completion of a Phase IIb clinical study in a licensed territory and 10% on or after completion of
	a Phase IIb clinical study in a licensed territory, provided, however, if the sublicense fee is less than the sublicense fee due
	to MD Anderson under the Moleculin-MD Anderson Agreement, then Dermin shall be obligated to pay no less than the amount due to
	MD Anderson plus 5%. Also under the Moleculin Out-License Agreement, Dermin agreed to pay all out-of-pocket expenses incurred by
	Moleculin, LLC in filing, prosecuting and maintaining the licensed patents for which the license has been granted. The parties
	to the Moleculin Out-License Agreement each have the right to terminate the agreement upon advance notice in the event of a default
	by the other party. Dermin has the right to terminate the agreement if (i) Moleculin, LLC fails to timely provide the dossier to
	Dermin after Moleculin, LLC&rsquo;s filing of an NDA for a licensed product in the United States; or (ii) Moleculin, LLC does not
	cooperate in assisting Dermin to secure funds to develop the licensed subject matter. Upon completion of our acquisition of Moleculin,
	LLC, we assumed the rights and obligations of Moleculin, LLC under the Moleculin Out-License Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We acquired the rights and obligations to
	the Patent and Technology License Agreement entered into by and between IntertechBio and Dermin dated April 15, 2011 (the &ldquo;IntertechBio
	Out-License Agreement&rdquo;). Pursuant to that license agreement, IntertechBio exclusively out-licensed intellectual property
	rights to Dermin, including rights covering the WP1122 drug product candidate obtained from MD Anderson pursuant to the IntertechBio
	Agreement. Under the IntertechBio Out-License Agreement, IntertechBio granted Dermin a royalty-bearing, exclusive license to manufacture,
	have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual
	property in the countries of Belarus, Russia, Kazakhstan, Uzbekistan, Turkmenistan, Czech Republic, Estonia, Hungary, Latvia, Lithuania,
	Poland, Romania, Slovakia and Ukraine (&ldquo;licensed territories&rdquo;). Additionally, IntertechBio agreed to develop and provide
	a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin agreed to make payments to
	IntertechBio, including upfront development fees, annual royalty payments, sublicense fees, and milestone payments. Specifically,
	under the IntertechBio Out-licensing Agreement, Dermin agreed to make a nonrefundable upfront dossier development fee in the amount
	of $35,000; a service fee in the amount of $40,000 for assistance provided to Dermin in securing additional funding; and royalty
	payments on sales of any licensed product at a rate of no less than the royalty rate due to MD Anderson under the IntertechBio
	Agreement plus 2%. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant to sublicense agreements
	in the amount of 25% prior to completion of a Phase IIb clinical study in a licensed territory and 10% on or after completion of
	a Phase IIb clinical study in the licensed territories, provided, if the sublicense fee is less than the sublicense fee due to
	MD Anderson under the IntertechBio Agreement, then Dermin shall be obligated to pay not less than the amount due to MD Anderson
	plus 5%. Also under the IntertechBio Out-Licensing Agreement, Dermin agreed to pay all out-of-pocket expenses incurred by IntertechBio
	in filing, prosecution and maintaining the licensed patents for which the license has been granted. The parties to the IntertechBio
	Out-licensing Agreement each have the right to terminate the agreement upon advanced notice in the event of a default by the other
	party. Dermin has the right to terminate the agreement if (i) IntertechBio fails to timely provide the dossier to Dermin after
	IntertechBio&rsquo;s filing of an NDA for a licensed product in the United States; or (ii) IntertechBio does not cooperate in assisting
	Dermin to secure funds to develop the licensed subject matter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We entered into a May 2016 out-licensing
	agreement with HPI, pursuant to which we granted HPI certain intellectual property rights, including rights covering the potential
	drug candidate, WP1066 (&ldquo;HPI Out-Licensing Agreement&rdquo;). Under the HPI Out-Licensing Agreement we are required to make
	an upfront $100,000 payment and quarterly payments in the amount of $37,500 for the first four quarters following the effective
	date of the HPI Out-Licensing Agreement and $75,000 per quarter for the following eight quarters thereafter in consideration for
	the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing
	payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Upon
	payment in the amount of $1,000,000 to HPI within three years of the effective date of the HPI Out-Licensing Agreement we will
	regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including
	any IND, NDA or ANDA related to the licensed subject matter. In the event that we do not exercise our right to regain our rights
	to the licensed subject matter within three years of the effective date of the HPI Out-Licensing Agreement the license granted
	to HPI shall convert to an exclusive license upon HPI&rsquo;s written notice and we shall be obligated to transfer all existing
	data relating to licensed subject matter including any development data and any IND to HPI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Annamed out-licensed certain intellectual
	property rights including rights covering the potential drug product, Annamycin to Dermin pursuant to a Patent and Technology Development
	and License Agreement dated June 28, 2012 (the &ldquo;Annamed Agreement&rdquo;). The licensed intellectual property includes rights
	obtained by Annamed pursuant to a license agreement with MD Anderson (&ldquo;Annamed-MD Anderson Agreement&rdquo;). Under the Annamed
	Agreement, Annamed granted Dermin a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to
	sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland,
	Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland,
	Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazachstan, Russian Federation, Uzbekistan,
	Georgia, Armenia, Azerbaijan and Germany (&ldquo;Annamed licensed territories&rdquo;). Additionally, Annamed agreed to develop
	and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Annamed agreed to provide
	a running royalty at a rate of no less than the royalty due to MD Anderson under the Annamed-MD Anderson Agreement plus 2.5% for
	the sale of any licensed product in the Annamed licensed territories excluding Germany and at a rate of 15% for the sale of any
	licensed product in Germany. Dermin also agreed to provide a percentage of certain consideration Dermin receives pursuant to sublicense
	agreements in the amount of 25% prior to completion of a Phase IIb clinical study in an Annamed licensed territory and 10% on or
	after completion of a Phase IIb clinical study in an Annamed licensed territory, provided, however, if the sublicense fee is less
	than the sublicense fee due to MD Anderson under the Annamed-MD Anderson Agreement, then Dermin shall be obligated to pay no less
	than the amount due to MD Anderson plus 5%. Also under the Annamed Agreement, Dermin agreed to pay all out-of-pocket expenses incurred
	by Annamed in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Annamed has the
	right to terminate the Annamed Agreement as to any country within the Annamed licensed territories if Dermin fails to provide evidence
	of its use of commercially reasonable efforts to commercialize a licensed product in such country within ninety days of Annamed&rsquo;s
	written request. The Annamed Agreement may also be terminated by Annamed upon advanced written notice in the event that Dermin
	defaults. Dermin has the right to terminate the agreement if (i) Annamed fails to timely provide the documents and information
	required for Dermin to prepare a dossier within 30 days of Annamed&rsquo;s filing of an NDA for a licensed product in the United
	States; or (ii) Annamed does not cooperate in assisting Dermin to secure funds to develop the licensed subject matter. As of August
	2015, we have obtained the rights and obligations of Annamed under the Annamed Agreement.
</P>
</EFX_LIQUIDITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPETITION>
<A NAME="FIS_COMPETITION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We operate in a highly competitive segment
	of the pharmaceutical market, which market is highly competitive as a whole. We face competition from numerous sources including
	commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research
	institutions. Many of our competitors may have significantly greater financial, product development, manufacturing and marketing
	resources. Additionally, many universities and private and public research institutes are active in cancer research, and some may
	be in direct competition with us. We may also compete with these organizations to recruit scientists and clinical development personnel.
	Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
	with large and established companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The unmet medical need for more effective
	cancer therapies is such that anticancer drugs are, by far, the leading class of drugs in development. These include a wide array
	of products against cancer targeting many of the same indications as our drug candidates. While the introduction of newer targeted
	agents may result in extended overall survival, induction therapy regimens are likely to remain a cornerstone of cancer treatment
	in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	There are a number of established therapies
	that may be considered competitive for the cancer indications for which we intend to develop our lead product, Annamycin. A key
	consideration when treating AML patients is whether the patient is suitable for intensive therapy. The standard of care for the
	treatment of newly diagnosed AML patients who can tolerate intensive therapy is cytarabine in combination with an anthracycline
	(i.e., doxorubicin or daunorubicin) &ndash; for some patients, primarily those less than 60 years of age, a stem cell transplant
	could also be considered if the induction regimen is effective in attaining a CR (Complete Response). The regimen of cytarabine
	in combination with an anthracycline has been the standard of care for decades. A patient not suitable for intensive therapy may
	be offered the option for low-intensity therapy such as low-dose cytarabine, azacitidine or decitabine. It should be noted that,
	in the U.S., these are not approved by the FDA for the treatment of AML patients and there remains no effective therapy for these
	patients or for relapsed or refractory AML. The initial focus for Annamycin development is in patients for whom the standard induction
	regimen has failed. Also, several major pharmaceutical companies and biotechnology companies are aggressively pursuing new cancer
	development programs for the treatment of AML.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	A number of attempts have been made or are
	under way to provide an improved treatment for AML. Recently, Celator Pharmacetuicals, reported Phase III clinical trial results
	for a new combined formulation of cytarabine and daunorubicin (commonly used induction therapy drugs) they call Vyxeos. This new
	liposome formulation provides a 5:1 ratio of cytarabine and daunorubicin in each of three injections. When compared with patients
	receiving 7 injections of cytarabine and 3 injections of daunorubicin (traditional 7+3 induction therapy), patients receiving Vyxeos
	achieved an average increase in overall survival of approximately 3.5 months (9.5 months compared with 6 months). Despite this
	extension of overall survival, Vyxeos did not reduce the toxic side effects of daunorubicin (including cardiotoxicity) and it failed
	to qualify a significant majority of patients for curative bone marrow transplant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Drugs attempting to target a subset of AML
	patients who present with particular anomalies involving a gene referred to as FLT3 are currently in clinical trials. Other approaches
	to improve the effectiveness of induction therapy are in early stage clinical trials and, although they do not appear to address
	the underlying problems with anthracyclines, we can provide no assurance that such improvements, if achieved, would not adversely
	impact the need for improved anthracyclines. A modified version of doxorubicin designed to reduce cardiotoxicity is in clinical
	trials for the treatment of sarcoma and, although this drug does not appear to address multidrug resistance and is not currently
	intended for the treatment of acute leukemia, we can provide no assurance that it will not become a competitive alternative to
	Annamycin. Although we are not aware of any other single agent therapies in clinical trials that would directly compete against
	Annamycin in the treatment of relapsed and refractory AML, we can provide no assurance that such therapies are not in development,
	will not receive regulatory approval and will reach market before our drug candidate Annamycin. In addition, any such competing
	therapy may be more effective and / or cost-effective than ours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Government Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Government authorities in the U.S., at the
	federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing,
	manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval
	monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical drug
	product candidates that we develop must be approved by the FDA before they may be legally marketed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the United States, the FDA regulates
	pharmaceutical products under the Federal Food, Drug and Cosmetic Act, and implementing regulations. Pharmaceutical products are
	also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the
	subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
	time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
	process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could
	include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls,
	product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts,
	restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse
	effect on us. The process required by the FDA before a non-biological pharmaceutical product may be marketed in the U.S. generally
	involves the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or
	other applicable regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Submission to the FDA of an Investigational New Drug, or IND, which must become effective before human clinical studies may
	begin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Performance of adequate and well-controlled human clinical studies according to the FDA&rsquo;s current good clinical practices
	(&ldquo;GCP&rdquo;), to establish the safety and efficacy of the proposed pharmaceutical product for its intended use;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Submission to the FDA of an NDA for a new pharmaceutical product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical product is
	produced to assess compliance with the cGMP, to assure that the facilities, methods and controls are adequate to preserve the pharmaceutical
	product&rsquo;s identity, strength, quality and purity;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Potential FDA audit of the preclinical and clinical study sites that generated the data in support of the NDA; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	FDA review and approval of the NDA.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The lengthy process of seeking required
	approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial
	resources and approvals are inherently uncertain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Before testing any compounds with potential
	therapeutic value in humans, the pharmaceutical product candidate enters the preclinical testing stage. Preclinical tests include
	laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety
	and activity of the pharmaceutical product candidate. These early proof-of-principle studies are done using sound scientific procedures
	and thorough documentation. The conduct of the single and repeat dose toxicology and toxicokinetic studies in animals must comply
	with federal regulations and requirements including good laboratory practices. The sponsor must submit the results of the preclinical
	tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical
	protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA
	has concerns and notifies the sponsor. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before
	the clinical study can begin. If resolution cannot be reached within the 30-day review period, either the FDA places the IND on
	clinical hold or the sponsor withdraws the application. The FDA may also impose clinical holds on a pharmaceutical product candidate
	at any time before or during clinical studies due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission
	of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or
	terminate such clinical study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Clinical studies involve the administration
	of the pharmaceutical product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally
	physicians not employed by or under the clinical study sponsor&rsquo;s control. Clinical studies are conducted under protocols
	detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria,
	how the results will be analyzed and presented and the parameters to be used to monitor subject safety. Each protocol must be submitted
	to the FDA as part of the IND. Clinical studies must be conducted in accordance with GCP. Further, each clinical study must be
	reviewed and approved by an independent institutional review board (&ldquo;IRB&rdquo;) at, or servicing, each institution at which
	the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers
	such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation
	to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or
	his or her legal representative and must monitor the clinical study until completed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Human clinical studies are typically conducted
	in three sequential phases that may overlap or be combined:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 1: The pharmaceutical product is initially introduced into healthy human subjects and tested for safety, dosage tolerance,
	absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases such as
	cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human
	testing is often conducted in patients, with a goal of characterizing the safety profile of the drug and establishing a maximum
	tolerable dose (&ldquo;MTD&rdquo;). Our pharmaceutical products fall into this latter category because its products are intended
	to treat cancer and contain cytotoxic agents. Hence, our Phase 1 studies are conducted in late-stage cancer patients whose disease
	has progressed after treatment with other agents.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 2: With the maximum tolerable dose established in a Phase 1 trial, the pharmaceutical product is evaluated in a limited
	patient population at the MTD to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of
	the product for specific targeted diseases, to determine dosage tolerance, optimal dosage and dosing schedule and to identify patient
	populations with specific characteristics where the pharmaceutical product may be more effective.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 3: Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population
	at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio
	of the product and provide an adequate basis for product labeling. The studies must be well controlled and usually include a control
	arm for comparison. One or two Phase 3 studies are usually required by the FDA for an NDA approval, depending on the disease severity
	and other available treatment options. In some instances, where a Special Protocol Assessment is granted by the FDA, an NDA approval
	may be obtained based on Phase 2 clinical data with the understanding that the approved drug can be sold subject to a confirmatory
	Phase 3 trial to be conducted post-approval.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Post-approval studies, or Phase 4 clinical
	studies, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment
	of patients in the intended therapeutic indication. The FDA also may require post-marketing testing, known as Phase 4 testing,
	risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions on an approval
	that could restrict the distribution or use of the product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Progress reports detailing the results of
	the clinical studies must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA
	and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a
	significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical studies may not be completed successfully within any
	specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time
	on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.
	Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted
	in accordance with the IRB&rsquo;s requirements or if the pharmaceutical product has been associated with unexpected serious harm
	to patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Concurrent with clinical studies, companies
	usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
	of the pharmaceutical product as well as finalize a process for manufacturing the product in commercial quantities in accordance
	with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the pharmaceutical
	product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final
	pharmaceutical product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
	to demonstrate that the pharmaceutical product candidate does not undergo unacceptable deterioration over its shelf life.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The results of product development, preclinical
	studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry
	of the pharmaceutical product, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
	approval to market the product. The submission of an NDA is subject to the payment of substantial user fees. A waiver of such fees
	may be obtained under certain limited circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA reviews all NDAs submitted before
	it accepts them for filing and may request additional information rather than accepting an NDA for filing. Once the submission
	is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the
	Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), the FDA has 10 months after the 60-day filing date in which to complete its
	initial review of a standard NDA and respond to the applicant, and six months after the 60-day filing date for a priority NDA.
	The FDA does not always meet its PDUFA goal dates for standard and priority NDAs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	After the NDA submission is accepted for
	filing, the FDA reviews the NDA application to determine, among other things, whether the proposed product is safe and effective
	for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s
	identity, strength, quality and purity. The FDA may refer applications for novel pharmaceutical products or pharmaceutical products
	which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and
	other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions.
	The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making
	decisions. During the pharmaceutical product approval process, the FDA also will determine whether a risk evaluation and mitigation
	strategy (&ldquo;REMS&rdquo;) is necessary to assure the safe use of the pharmaceutical product. If the FDA concludes that a REMS
	is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Before approving an NDA, the FDA will inspect
	the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
	processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within
	required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites as well
	as the site where the pharmaceutical product is manufactured to assure compliance with GCP and cGMP. If the FDA determines the
	application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission
	and often will request additional testing or information. In addition, the FDA will require the review and approval of product
	labeling.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The NDA review and approval process is lengthy
	and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional
	clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that
	the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and the FDA may
	interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides
	not to approve the NDA. The complete response letter usually describes all of the specific deficiencies in the NDA identified by
	the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional
	clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place
	the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA,
	addressing all of the deficiencies identified in the letter, or withdraw the application.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	If a product receives regulatory approval,
	the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited,
	which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings
	or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical studies
	designed to further assess pharmaceutical product safety and effectiveness and may require testing and surveillance programs to
	monitor the safety of approved products that have been commercialized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Expedited Development and Review Programs
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The FDA has a Fast Track program that is
	intended to expedite or facilitate the process for reviewing new pharmaceutical products that meet certain criteria. Specifically,
	new pharmaceutical products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening
	condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the
	combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may
	consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides
	a schedule for the submission of the sections of the NDA, if the FDA determines that the schedule is acceptable and if the sponsor
	pays any required user fees upon submission of the first section of the NDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Any product submitted to the FDA for market,
	including a Fast Track program, may also be eligible for other FDA programs intended to expedite development and review, such as
	priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and
	effective therapy where no satisfactory alternative therapy exists or if it offers a significant improvement in the treatment,
	diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the
	evaluation of an application for a new pharmaceutical product designated for priority review in an effort to facilitate the review.
	Additionally, a product may be eligible for accelerated approval. Pharmaceutical products studied for their safety and effectiveness
	in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may
	receive accelerated approval, which means that the products may be approved on the basis of adequate and well-controlled clinical
	studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit,
	or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval,
	the FDA may require that a sponsor of a pharmaceutical product receiving accelerated approval perform adequate and well-controlled
	post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of
	promotional materials, which could impact the timing of the commercial launch of the product. Fast Track designation, priority
	review and accelerated approval do not change the standards for approval but may expedite the development or approval process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Post-Approval Requirements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Any pharmaceutical products for which the
	Company receives FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
	reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling
	and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion
	and advertising requirements, which include, among others, standards for direct-to-consumer advertising, prohibitions on promoting
	pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical product&rsquo;s approved
	labeling (known as &ldquo;off-label use&rdquo;), industry-sponsored scientific and educational activities and promotional activities
	involving the internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement
	letters from the FDA, actions by the U.S. Department of Justice and/or U.S. Department of Health and Human Services&rsquo; Office
	of Inspector General, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although
	physicians may prescribe legally available pharmaceutical products for off-label uses, manufacturers may not directly or indirectly
	market or promote such off-label uses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We rely, and expect to continue to rely,
	on third parties for the production of clinical and commercial quantities of our products. Manufacturers of our products are required
	to comply with applicable FDA manufacturing requirements contained in the FDA&rsquo;s cGMP regulations. cGMP regulations require,
	among other things, quality control and quality assurance, as well as the corresponding maintenance of records and documentation.
	Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical
	products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced
	inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue
	to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems
	with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal
	of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being
	implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims,
	are also subject to further FDA review and approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Patent Term Restoration and Marketing Exclusivity
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Depending upon the timing, duration and
	specifics of the FDA approval of the use of our pharmaceutical product candidates, some of our products covered by U.S. patents
	may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly
	referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
	compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
	cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term
	restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the
	time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved pharmaceutical
	product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent
	unless an extension is obtained. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and renders a decision
	on the application for any patent term extension or restoration. In the future, we may be able to apply for extension of patent
	term for one or more of our currently licensed patents or any future owned patents to add patent life beyond its current expiration
	date, depending upon the expected length of the clinical studies and other factors involved in the filing of the relevant NDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Market exclusivity provisions under the
	U.S. Food, Drug, and Cosmetic Act can also delay the submission or the approval of certain applications of other companies seeking
	to reference another company&rsquo;s NDA. Currently seven years of reference product exclusivity are available to pharmaceutical
	products designated as Orphan Drugs, during which the FDA may not approve generic products relying upon the reference product&rsquo;s
	data. Pediatric exclusivity is another type of regulatory market exclusivity in the U.S. Pediatric exclusivity, if granted, adds
	six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity
	protection or patent term, may be granted based on the voluntary completion of pediatric clinical studies in accordance with an
	FDA-issued &ldquo;Written Request&rdquo; for such a clinical study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Pharmaceutical Coverage, Pricing and
	Reimbursement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Significant uncertainty exists as to the
	coverage and reimbursement status of any pharmaceutical product candidates for which we may obtain regulatory approval. In the
	United States and in markets in other countries, sales of any products for which we receive regulatory approval for commercial
	sale will depend in part upon the availability of reimbursement from third-party payors. Third-party payors include government
	payors such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. The process for
	determining whether a payor will provide coverage for a pharmaceutical product may be separate from the process for setting the
	price or reimbursement rate that the payor will pay for the pharmaceutical product. Third-party payors may limit coverage to specific
	pharmaceutical products on an approved list, or formulary, which might not, and frequently does not, include all of the FDA-approved
	pharmaceutical products for a particular indication. Third-party payors are increasingly challenging the price and examining the
	medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. A payor&rsquo;s
	decision to provide coverage for a pharmaceutical product does not imply that an adequate reimbursement rate will be approved.
	Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate
	return on our investment in product development. In addition, in the United States there is a growing emphasis on comparative effectiveness
	research, both by private payors and by government agencies. We may need to conduct expensive pharmaco-economic studies in order
	to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA
	approvals. Our pharmaceutical product candidates may not be considered medically necessary or cost-effective. To the extent other
	drugs or therapies are found to be more effective than our products, payors may elect to cover such therapies in lieu of our products
	and/or reimburse our products at a lower rate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Different pricing and reimbursement schemes
	exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing
	and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers.
	Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price
	has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical
	studies that compare the cost-effectiveness of a particular pharmaceutical product candidate to currently available therapies.
	Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward
	pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high
	barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets
	exert a commercial pressure on pricing within a country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The marketability of any pharmaceutical
	product candidates for which we may receive regulatory approval for commercial sale may suffer if the government and third-party
	payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
	and we expect this will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement
	rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
	we may receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	International Regulation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition to regulations in the United
	States, there are a variety of foreign regulations governing clinical studies and commercial sales and distribution of our current
	and future product candidates. Whether or not FDA approval is obtained for a product, approval of a product must be obtained by
	the comparable regulatory authorities of foreign countries, or jurisdictions such as the EU, before clinical studies or marketing
	of the product can commence in those countries. The approval process varies from country to country, and the time may be longer
	or shorter than that required for FDA approval. The requirements governing the conduct of clinical studies, product licensing,
	pricing and reimbursement vary greatly from country to country. In addition, certain regulatory authorities may require us to repeat
	previously conducted preclinical and/or clinical studies under specific criteria for approval in their respective country or jurisdictions,
	which may delay and/or increase the cost of approval in certain markets targeted for approval by us.
</P>
</EFX_COMPETITION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_EMPLOYEES>
<A NAME="FIS_EMPLOYEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of September 30, 2016, we had two full-time
	employees and four part-time employees, and accordingly, a high percentage of the work performed for our development projects is
	outsourced to qualified independent contractors.
</P>
</EFX_EMPLOYEES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Legal Proceedings
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are not subject to any litigation.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Properties
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our corporate and executive offices are
	in located in a leased facility in Houston, Texas. The current lease is month-to-month but is expected to be renegotiated in the
	next six months. We believe our facilities are sufficient to meet our current needs and that suitable space will be available as
	and when needed. We do not own any real property.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_PROPERTIES>
</EFX_BUSINESS>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_MANAGEMENT>
<A NAME="FIS_MANAGEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_027" TITLE="MANAGEMENT">
</A>
<B>
	MANAGEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth certain information
	regarding our executive officers and directors as of November 28, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 5%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 0.1IN; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 53%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Walter V. Klemp
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	56
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Jonathan P. Foster
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	53
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer and Executive Vice President
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Donald Picker
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	70
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Operating Officer
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Robert Shepard
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	64
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Medical Officer
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Robert E. George
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	66
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Michael D. Cannon
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	71
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Jacqueline Northcut
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	54
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Set forth below is biographical information
	about each of the individuals named in the tables above:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Walter V. Klemp - Chairman of the
	Board and Chief Executive Officer
</I>
</B>
	. Mr. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive
	officer since July 2015. Since 2006, Mr. Klemp has served as the chairman, co-founder and part-time chief executive officer of
	Moleculin, LLC. Since November 2011, Mr. Klemp has also served as chief executive officer of Soliton, Inc., a medical device company
	focused on developing new technology for use in aesthetics. Mr. Klemp served as president and chief executive officer of Zeno Corporation
	from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market
	launch. From 1987 to 2000, Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational
	consumer products company that was listed as #1 on the INC 500 List of America&rsquo;s Fastest Growing Companies. We believe that
	Mr. Klemp&rsquo;s history with our company and background, coupled with his extensive experience in the medical field, provide
	him with the qualifications to serve as a Chairman of the Board and CEO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Jonathan P. Foster - Chief Financial
	Officer and Executive Vice President
</I>
</B>
	. Mr. Foster has served as our chief financial officer and executive vice president since August 2016. Mr.
	Foster brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public,
	private, start-up to large corporate and international companies. From February 2012 to August 2016, Mr. Foster served as Chief
	Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related
	services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer
	of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Mr. Foster served on the Board of Financial Institutions for
	the State of South Carolina from 2006 to 2012. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation
	of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting
	from Clemson University in 1985.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Donald Picker, PhD - President and
	Chief Operating Officer.
</I>
</B>
	Dr. Picker joined Moleculin, LLC in 2007 as its chief executive officer and has served as our chief operating
	officer since July 2015 and as our president since January 2016. In 2007, Dr. Picker became the chief executive officer of IntertechBio.
	From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy
	Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice present of research and development until 2006.
	Dr. Picker led the development of carboplatin and cisplatin from concept to FDA approval. Dr. Picker received his BS degree from
	Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only part of his work time
	to us, and provide services as needed by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Robert Shepard, MD, FACP, Chief Medical
	Officer.
</I>
</B>
	Dr. Shepard has served as our chief medical officer since June 2016. From 2013 until 2014, Dr. Shepard
	served as vice president of scientific and medical affairs for Accelovance. Shepard has extensive research credentials in hematology
	and oncology and is board certified in oncology, hematology and internal medicine. He has a wide array of experience in translational
	medicine and clinical research and has been actively involved in oncology research since 1970, responsible for the clinical development
	of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer
	for six companies. Dr. Shepard is a Magna Cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics
	and studied in the Harvard-M.I.T. Health Sciences program. He held fellowships in hematology and oncology at the Tufts-New England
	Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia, as well as fellowship in pharmacology
	and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School. Dr. Shepard holds academic appointments at
	Harvard University, Tufts University and the University of Virginia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Robert E. George
</I>
</B>
	-
<B>
<I>
	Director
</I>
</B>
	.
	Mr. George joined our board of directors upon our IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers
	(PWC) for 27 years until 2010, where his client service sectors included healthcare, among others. Mr. George currently serves
	as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, since June 2011, has been
	a member of The University of Texas at Austin, McCombs Graduate School of Business accounting faculty. Since January 2014, he also
	has been the Director of Energy Programs and Conferences for the Professional Development Institute. His past experience includes
	being an Editorial Advisor to the American Institute of Certified Public Accountants
<I>
	Journal of Accountancy
</I>
	and a contributing
	author for two accounting books. Mr. George graduated with accounting honors from the University of North Texas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Michael D. Cannon - Director
</I>
</B>
	.
	Mr. Cannon joined our board of directors upon our IPO. Between 1997 and 2004, Mr. Cannon was the Chief Science Officer, EVP and
	a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc.
	SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and generic biopharmaceuticals.
	While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international
	partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December
	2009, Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing
	in health care investments. From May 2005 until December 2011, Mr. Cannon was a partner in a private partnership formed to evaluate
	and perform preliminary development of intellectual property in the healthcare sector. Since 2005, Mr. Cannon has served as a board
	member for several private companies. Mr. Cannon currently serves on the board of directors of 4 privately held biotech companies,
	including 2 focused on cancer-related treatments, and has been a partner and advisor in several biotech venture firms. Mr. Cannon
	has a degree in chemistry from Fordham College.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Jacqueline Northcut - Director
</I>
</B>
	.
	Ms. Northcut joined our board of directors upon our IPO. Ms. Northcut served as President and CEO of BioHouston from 2002 until
	2015. BioHouston, Inc. is a non-profit organization founded by Houston, Texas area academic/research institutions to assist in
	the commercialization efforts of development stage life science and biotechnology companies. During this same period, Ms. Northcut
	became the founder and CEO of the Texas BioAlliance, an organization created to further assist with development efforts of biotechnology
	and medical device companies in the state of Texas. In these capacities she organized the Texas Life Science Forum and the Texas
	Life Science CEO Summit, helping connect biotech CEOs with funding, technical, regulatory and other resources. Ms. Northcut was
	previously a Partner in the international accounting firm of Arthur Andersen &amp; Co., where she worked from 1984 to 2002. Ms.
	Northcut received her BBS from Harding University in 1984.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Director Independence
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The rules of the Nasdaq Stock Market, or
	the Nasdaq Rules, require a majority of a listed company&rsquo;s board of directors to be composed of independent directors within
	one year of listing. In addition, the Nasdaq Rules require that, subject to specified exceptions, each member of a listed company&rsquo;s
	audit, compensation and nominating and governance committees be independent. Under the Nasdaq Rules, a director will only qualify
	as an independent director if, in the opinion of our board of directors, that person does not have a relationship that would interfere
	with the exercise of independent judgment in carrying out the responsibilities of a director. The Nasdaq Rules also require that
	audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended,
	or the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed
	company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board
	committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of
	its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In considering the independence
	of compensation committee members, the Nasdaq Rules require that our board of directors must consider additional factors relevant
	to the duties of a compensation committee member, including the source of any compensation we pay to the director and any affiliations
	with our company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our board of directors undertook a review
	of the composition of our board of directors and its committees and the independence of each director. Based upon information requested
	from and provided by each director concerning his background, employment and affiliations, including family relationships, our
	board of directors has determined that each of our directors, with the exception of Mr. Klemp are independent as defined under
	the Nasdaq Rules.
</P>
</EFX_MANAGEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<EFX_EXECUTIVE_COMPENSATION>
<A NAME="FIS_EXECUTIVE_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Compensation of Executive Officers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	Summary Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	MBI was formed in July 2015. To provide
	you with a complete picture of the compensation paid to our executive officers for the fiscal years ended December 31, 2016 and
	2015 when they acted in executive capacities for Moleculin, LLC and MBI, the following table and the related notes set forth information
	relating to the compensation paid to each of the named executive officers by Moleculin, LLC and us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Name and Principal Position
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Salary($)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option
<BR>
	awards
<BR>
	($) (1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All other
<BR>
	compensation
<BR>
	($) (2)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total ($)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Moleculin, LLC:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Walter V. Klemp, Chairman and Acting Chief Executive Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	40,650
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	40,650
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Don Picker, President and Chief Operating Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	47,425
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47,425
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	MBI:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Walter V. Klemp, Chairman and Chief Executive Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;175,000
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	175,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Don Picker, President and Chief Operating Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	131,250
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	131,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;----
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Jonathan P. Foster, Chief Financial Officer (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	97,717
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,506,909
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,199
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,611,825
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Louis Ploth, Jr., Former Chief Financial Officer (5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	111,009
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,485
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118,494
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;44,141
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(6)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,390
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71,531
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
	the full grant date fair value of the option grant calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily
	correspond to the actual value that may be realized by the named executive officer. For a summary of the assumptions made in the
	valuation of the awards made in 2015, please see Note 3 to our financial statements as of and for the period ended December 31,
	2015 included elsewhere in this prospectus. For a summary of the assumptions made in the valuation of the awards made in 2016,
	please see Note 4 to our financial statements as of and for the period ended September 30, 2016 included elsewhere in this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
	payments made for medical coverage.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
	Klemp&rsquo;s employment agreement provided that Mr. Klemp would defer 50% of his salary for 12 months, which deferred salary
	will be payable upon Mr. Klemp&rsquo;s termination or on June 1, 2019. Of the foregoing $175,000 amount, $87,500 was paid during
	the year and $87,500 represents the deferred portion of Mr. Klemp&rsquo;s salary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
	Foster became our chief financial officer in August 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.
	Ploth resigned as our chief financial officer in August 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes
	$7,000 of consulting fees paid during the year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employment Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Klemp Employment Agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On October 13, 2016, we entered into an
	employment agreement with Mr. Walter Klemp pursuant to which Mr. Klemp agreed to serve as our Chief Executive Officer commencing
	on such date. The agreement provides for an annual salary of $300,000, provided that Mr. Klemp has agreed to defer 50% of his salary
	for 12 months, which deferred salary will be payable upon Mr. Klemp&rsquo;s termination or on June 1, 2019. If Mr. Klemp&rsquo;s
	employment is terminated at our election without &ldquo;cause&rdquo; (as defined in the agreement), which requires 30 days advanced
	notice, or by Mr. Klemp for &ldquo;good reason&rdquo; (as defined in the agreement), Mr. Klemp shall be entitled to receive severance
	payments equal to the greater of 12 months of Mr. Klemp&rsquo;s base salary or the base salary Mr. Klemp would have received had
	he remained employed through the third anniversary of the date of the agreement. Mr. Klemp has agreed not to compete with us for
	12 months after the termination of his employment. If we determine to retain a new chief executive officer during the term of the
	agreement, we have the option, at our discretion, to convert Mr. Klemp into a consultant on the same terms as set forth above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Foster Employment Agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On August 19, 2016, we entered into an employment
	agreement with Mr. Jonathan P. Foster pursuant to which Mr. Foster agreed to serve as our Chief Financial Officer and Executive
	Vice President commencing on such date for an initial term of three years, which will be automatically renewed for additional one-year
	terms unless either party chooses not to renew the agreement. The agreement provides for an annual salary of $250,000. Mr. Foster
	is entitled to receive an annual bonus payable. The final determination on the amount of the annual bonus will be made by the Compensation
	Committee of the Board of Directors, based on criteria established by the Compensation Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Under the agreement, Mr. Foster was granted
	a ten-year option to purchase 400,000 shares at an exercise price per share equal to the closing price of our common stock on the
	date of execution of his employment agreement, which was $5.85. The option vests in four equal installments (or 100,000 shares
	each installment) on each of the succeeding four anniversary dates of the execution of the agreement, provided Mr. Foster is Chief
	Financial Officer on such vesting date. In the event of a &ldquo;change of control&rdquo; (as defined in the agreement) prior to
	the final vesting of all of the options, all of the unvested options shall immediately vest; provided, however, in the event the
	acquiring party desires to replace the unvested options with a substitute grant of equal or greater value, such proposed substitution
	shall be submitted to the Compensation Committee, and the Compensation Committee shall decide whether to allow the unvested options
	to vest or whether to cancel the unvested options and replace them with the substitute grant proposed by the acquiring party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	If Mr. Foster&rsquo;s employment is terminated
	at our election without &ldquo;cause&rdquo; (as defined in the agreement), which requires 90 days advance notice, or by Mr. Foster
	for &ldquo;good reason&rdquo; (as defined in the agreement), Mr. Foster shall be entitled to receive severance payments equal to
	nine months of Mr. Foster&rsquo;s base salary and a pro rata portion of the target bonus for the year in which such termination
	occurs. In addition, if Mr. Foster&rsquo;s employment is terminated prior to the end of the term of the agreement by us without
	cause or by Mr. Foster for good reason, and such termination occurs within three months prior to a change in control, in contemplation
	of a change in control or within six months after a change in control, Mr. Foster shall be entitled to receive, in addition to
	the severance discussed above, an acceleration of the vesting of the option grant described in the prior paragraph. Mr. Foster
	agreed not to compete with us until nine months after the termination of his employment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Equity Awards
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table
	sets forth certain information concerning our outstanding options for our named executive officers at December&nbsp;31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Outstanding Equity Awards At Fiscal
	Year-End&mdash;2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options
<BR>
	(#)
<BR>
	Exercisable
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options
<BR>
	(#)
<BR>
	Unexercisable
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option
<BR>
	Exercise&nbsp;Price
<BR>
	($)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option
<BR>
	Expiration&nbsp;Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: LEFT">
	Jonathan P. Foster
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	400,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	(1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	5.85
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	8/19/2026
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Louis Ploth (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12/10/2025
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	unvested shares underlying the option vest in equal annual installments over a four-year period commencing August 2017, provided
	Mr. Foster continues as our chief financial officer on each vesting date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	unvested shares underlying the option vested in equal annual installments over a four-year period commencing December 2017, provided
	Mr. Ploth was employed on each vesting date. Mr. Ploth resigned as our chief financial officer in August 2016. Pursuant to a separation
	agreement we entered into with Mr. Ploth, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock
	granted in December 2015, or 50,000 shares, until May 2020. The remaining options to purchase 150,000 shares were cancelled.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_EXECUTIVE_COMPENSATION>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_DIRECTOR_COMPENSATION>
<A NAME="FIS_DIRECTOR_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Director Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On September 23, 2016, our board, after
	receiving the recommendation of the compensation committee, approved the following policy for compensating non-employee members
	of the board:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Each non-employee director receives annual cash compensation of $30,000. In addition, the chairperson of the audit committee,
	compensation committee and nominating and governance committee receives an annual payment of $15,000, $10,000 and $7,500, respectively,
	and the other members of such committees shall receive an annual payment of $7,500, $5,000 and $3,750, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Upon the initial appointment (or election) of non-employee directors to the board, the director will be issued a 10-year option
	to purchase 20,000 shares of our common stock, under the Company's 2015 Stock Plan, with 3-year annual vesting and an exercise
	price equal the closing price of our common stock on the date of the appointment (or election). All non-employee directors serving
	as of September 23, 2016, the date of the initial adoption of the policy, received the foregoing initial stock option grant as
	of such date.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Annually, on the date of our annual meeting, each non-employee director will be issued a 10-year option to purchase 15,000
	shares of our common stock, under the Company's 2015 Stock Plan, with 3-year annual vesting and an exercise price equal the closing
	price of our common stock on the date of the annual meeting.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth the total
	compensation earned by our non-employee directors in 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fees earned or paid in cash ($)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Option awards ($) (1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total ($)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 47%; TEXT-ALIGN: LEFT">
	Michael D. Cannon
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	27,116
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	72,714
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	99,830
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Robert E. George
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,712
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	72,714
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,426
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Jacqueline Northcut
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	72,714
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
	the full grant date fair value of the 20,000 share option award our board approved and granted to each non-employee director on
	September 23, 2016, calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual
	value that may be realized by the director. For a summary of the assumptions made in the valuation of the awards made in 2016,
	please see Note 4 to our financial statements as of and for the period ended September 30, 2016 included elsewhere in this prospectus.
	As of December 31, 2016, the foregoing ten-year option to purchase 20,000 shares at an exercise price of $5.71 per share represented
	the sole option or stock award outstanding for each the non-employee directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Scientific Advisory Board
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our executive team is supported by our
	scientific advisory board, the members of which include scientists experienced in the fields in which we pursue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Dr. Waldemar Priebe,
	Ph.D, Chair of Scientific Advisory Board (SAB)
</I>
	. Waldemar Priebe is a founder of and one of the founding scientists at Moleculin,
	LLC and serves as Chairman of our Scientific Advisory Board. Dr. Priebe is also a Professor of Medicinal Chemistry at the Department
	of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Priebe led the discovery of the molecules
	that form the basis for our lead drug candidates. As a founder or founding scientist at a number of successful biotechnology firms
	such as Aronex Pharmaceuticals, Houston Pharmaceuticals, Reata Pharmaceuticals, and IntertechBio, Dr. Priebe has been integral
	in advancing several drugs through the pipeline, three of which are currently in clinical development. He has also developed several
	new small molecule compounds that have been licensed as potential drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Dr. Madeleine, Duvic, M.D., SAB Member
</I>
	.
	Dr. Duvic is Professor of Internal Medicine and Dermatology and Deputy Chairman of the Department of Dermatology at MD Anderson,
	a former board member of the American Academy of Dermatology and recent Vice President of the Society for Investigative Dermatology.
	Elected to the ADA, Dr. Duvic is also a Founder and board member of the United States Consortium for Cutaneous Lymphomas, performs
	translational research in CTCL, and has been engaged in the design and conduct of clinical trials that resulted in new therapies
	for CTCL. Dr. Duvic also serves on Medical and Scientific Boards of the National Alopecia Areata Foundation and Cutaneous Lymphoma
	Foundation. She is the Principal Investigator of the NAAF funded Alopecia Areata Registry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Dr. John Paul Waymack,
	M.D., ScD, SAB Member.
</I>
	Dr. Waymack has served as CMO of Kitov Pharmaceuticals since July 2013. Dr. Waymack brings over 20 years'
	experience in the biopharma field. A former academic transplant surgeon and FDA medical officer, he has over 20&nbsp;years' experience
	as a drug development consultant for major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle.
	During his 10-year academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and
	immunology. In addition, he was commissioned and served as a Major in the US Army Medical Corps in the position of Chief of Surgical
	Research at the Institute for Surgical Research. Dr. Waymack was also an Associate Professor of Surgery at the University of Texas
	Medical Branch and at the University of Medicine and Dentistry of New Jersey.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Dr. Sandra Silberman,
	M.D., Ph.D
</I>
	. Dr. Silberman&rsquo;s career in clinical development began at Pfizer, Inc., where she oversaw the initiation of
	Tarceva (TM)&nbsp;clinical trials. Dr. Silberman then led the global development of Gleevec&nbsp;(TM) at Novartis.&nbsp;Dr. Silberman
	was a Vice President and Global Therapeutic Area Head in Oncology at Eisai. Subsequently, she served as a senior advisor to a
	number of biopharmaceutical companies, and numerous biotech companies as an independent industry consultant. &nbsp;She joined
	Quintiles in 2009 as the Vice President of Oncology and Global Head of Translational Medicine in the newly formed Innovation division,
	overseeing drug development and novel technologies for new partnerships with the pharmaceutical and biotechnology industries.&nbsp;Dr.
	Silberman earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health
	and School of Medicine, respectively.&nbsp; Her major focus of investigation and doctoral thesis was in the burgeoning area of
	tumor immunology. &nbsp;Dr. Silberman received her M.D. from Cornell University Medical College, completing a postdoctoral training
	and her fellowship in hematology/oncology at the Brigham &amp; Women's and the Dana Farber Cancer Institute in Boston.&nbsp; Dr.
	Silberman is currently an attending physician in the Hematology/Oncology clinic at the Duke VA in Durham, NC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	We intend to compensate
	the members of our Scientific Advisory Board, or SAB, based on our utilization of their time. As of the date hereof, we have entered
	into compensatory agreements with Drs. Waymack and Silberman pursuant to which we (i) agreed to pay the scientific advisors $4,000
	per month, and (ii) made a one-time grant of a 10-year option to purchase 10,000 shares of our common stock, under the Company's
	2015 Stock Plan, with 3-year annual vesting and an exercise price equal the closing price of our common stock on the date of the
	grant, which was $2.31 per share. We currently do not have any compensatory arrangements with Drs. Priebe or Duvic.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Other Executive Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On August 21, 2016, we accepted the resignation
	of Mr. Louis Ploth from his position as our Chief Financial Officer effective immediately. On October 7, 2016, we entered into
	a separation agreement with Mr. Ploth, pursuant to which, among other items, Mr. Ploth generally released us from any claims he
	may have against us or our affiliates, and we agreed to pay Mr. Ploth a severance payment of $100,000 over a 12-month period and
	to pay Mr. Ploth&rsquo;s medical insurance premiums until August 31, 2017. Pursuant to the separation agreement, Mr. Ploth will
	be permitted to exercise 25% of the options to purchase common stock granted to Mr. Ploth in December 2015, or 50,000 shares, until
	May 2020.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_STOCK_PLANS>
<A NAME="FIS_STOCK_PLANS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	2015 Stock Plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have adopted a 2015 Stock Plan (the &ldquo;Plan&rdquo;).
	The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit
	awards to key employees and non-employee directors. The purpose of the Plan is to recognize contributions made to our company and
	its subsidiaries by key employees and non-employee directors and to provide them with additional incentive to achieve the objectives
	of our company. The following is a summary of the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Administration
</I>
	.
</B>
	&nbsp;The Plan
	will be administered by our Compensation Committee of the board of directors (we refer to body administering the Plan as the &ldquo;Committee&rdquo;).
	The Committee will have full authority to select the individuals who will receive awards under the Plan, determine the form and
	amount of each of the awards to be granted and establish the terms and conditions of awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Number of Shares of Common Stock.
</I>
</B>
	&nbsp;The
	number of shares of the common stock that may be issued under the Plan is 2,500,000. Shares issuable under the Plan may be authorized
	but unissued shares or treasury shares. If there is a lapse, forfeiture, expiration, termination or cancellation of any award made
	under the Plan for any reason, the shares subject to the award will again be available for issuance. Any shares subject to an award
	that are delivered to us by a participant, or withheld by us on behalf of a participant, as payment for an award or payment of
	withholding taxes due in connection with an award will not again be available for issuance, and all such shares will count toward
	the number of shares issued under the Plan. The number of shares of common stock issuable under the Plan is subject to adjustment,
	in the event of any reorganization, recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off,
	combination, subdivision, consolidation or exchange of shares, any change in the capital structure of the company or any similar
	corporate transaction. In each case, the Committee has the discretion to make adjustments it deems necessary to preserve the intended
	benefits under the Plan. No award granted under the Plan may be transferred, except by will, the laws of descent and distribution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Eligibility
</I>
	.
</B>
	&nbsp;All employees
	designated as key employees for purposes of the Plan and all non-employee directors are eligible to receive awards under the Plan.
	On November 1, 2015, six employees and all non-employee directors were eligible to participate in the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Awards to Participants
</I>
	.
</B>
	&nbsp;The
	Plan provides for discretionary awards of stock options, stock awards and stock unit awards to participants. Each award made under
	the Plan will be evidenced by a written award agreement specifying the terms and conditions of the award as determined by the Committee
	in its sole discretion, consistent with the terms of the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Stock Options
</I>
	.&nbsp;
</B>
	The Committee
	has the discretion to grant non-qualified stock options or incentive stock options to participants and to set the terms and conditions
	applicable to the options, including the type of option, the number of shares subject to the option and the vesting schedule; provided
	that the exercise price of each stock option will be the closing price of the common stock on the date on which the option is granted
	(&ldquo;fair market value&rdquo;), each option will expire ten years from the date of grant and no dividend equivalents may be
	paid with respect to stock options. It is intended that stock options qualify as &ldquo;performance-based compensation&rdquo; under
	Section 162(m) of the Code and thus be fully deductible by us for federal income tax purposes, to the extent permitted by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, an incentive stock option granted
	to a key employee is subject to the following rules: (i) the aggregate fair market value (determined at the time the option is
	granted) of the shares of common stock with respect to which incentive stock options are exercisable for the first time by a key
	employee during any calendar year (under all incentive stock option plans of the company and its subsidiaries) cannot exceed $100,000,
	and if this limitation is exceeded, that portion of the incentive stock option that does not exceed the applicable dollar limit
	will be an incentive stock option and the remainder will be a non-qualified stock option; (ii) if an incentive stock option is
	granted to a key employee who owns stock possessing more than 10% of the total combined voting power of all class of stock of the
	company, the exercise price of the incentive stock option will be 110% of the closing price of the common stock on the date of
	grant and the incentive stock option will expire no later than five years from the date of grant; and (iii) no incentive stock
	option can be granted after ten years from the date the Plan was adopted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Stock Awards
</I>
	.
</B>
	&nbsp;The Committee
	has the discretion to grant stock awards to participants. Stock awards will consist of shares of common stock granted without any
	consideration from the participant or shares sold to the participant for appropriate consideration as determined by the Board.
	The number of shares awarded to each participant, and the restrictions, terms and conditions of the award, will be at the discretion
	of the Committee. Subject to the restrictions, a participant will be a shareholder with respect to the shares awarded to him or
	her and will have the rights of a shareholder with respect to the shares, including the right to vote the shares and receive dividends
	on the shares; provided that dividends otherwise payable on any performance-based stock award will be held by us and will be paid
	to the holder of the stock award only to the extent the restrictions on such stock award lapse, and the Committee in its discretion
	can accumulate and hold such amounts payable on any other stock awards until the restrictions on the stock award lapse.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Stock Units.
</I>
</B>
	&nbsp;The Committee
	has the discretion to grant stock unit awards to participants. Each stock unit entitles the participant to receive, on a specified
	date or event set forth in the award agreement, one share of common stock or cash equal to the fair market value of one share on
	such date or event, as provided in the award agreement. The number of stock units awarded to each participant, and the terms and
	conditions of the award, will be at the discretion of the Committee. Unless otherwise specified in the award agreement, a participant
	will not be a shareholder with respect to the stock units awarded to him prior to the date they are settled in shares of common
	stock. The award agreement may provide that until the restrictions on the stock units lapse, the participant will be paid an amount
	equal to the dividends that would have been paid had the stock units been actual shares; provided that dividend equivalents otherwise
	payable on any performance-based stock units will be held by us and paid only to the extent the restrictions lapse, and the Committee
	in its discretion can accumulate and hold such amounts payable on any other stock units until the restrictions on the stock units
	lapse.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Performance-Based Awards.
</I>
</B>
	&nbsp;The
	Committee has the discretion to establish restrictions on the stock awards that qualify the awards as &ldquo;performance-based
	compensation&rdquo; under Section 162(m) of the Code so that they are fully deductible by us for federal income tax purposes. In
	such case, the Committee may establish performance goals for certain performance periods and targets for achievement of the performance
	goals, and the restrictions on the stock subject to the award will lapse if the performance goals and targets are achieved for
	the designated performance period. The performance goals will be based on one or more of the following criteria: (i) net earnings
	or net income (before or after taxes); (ii) earnings per share; (iii) net sales or revenue growth; (iv) net operating profit or
	income (including as a percentage of sales); (v) return measures (including, but not limited to, return on assets, capital, invested
	capital, equity, sales, or revenue); (vi) cash flow (including, but not limited to, operating cash flow, free cash flow, cash flow
	return on equity, and cash flow return on investment); (vii) earnings before or after taxes, interest, depreciation, and/or amortization;
	(viii) gross or operating margins; and (ix) share price (including, but not limited to, growth measures and total shareholder return).
	Performance goals may be absolute in their terms or measured against or in relationship to the performance of other companies or
	indices selected by the Committee. The performance goals may be particular to one or more lines of business or subsidiaries or
	may be based on our performance as a whole. The performance goals may be identical for all participants for a given performance
	period or, at the discretion of the Committee, may differ among participants. In addition, performance goals may be adjusted for
	any events or occurrences (including acquisition expenses, extraordinary charges, losses from discontinued operations, restatements
	and accounting charges and restructuring expenses), as may be determined by the Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Payment for Stock Options and Withholding
	Taxes
</I>
	.
</B>
	&nbsp;The Committee may make one or more of the following methods available for payment of any award, including the
	exercise price of a stock option, and for payment of the minimum required tax obligation associated with an award: (i) cash; (ii)
	cash received from a broker-dealer to whom the holder has submitted an exercise notice together with irrevocable instructions to
	deliver promptly to us the amount of sales proceeds from the sale of the shares subject to the award to pay the exercise price
	or withholding tax; (iii) by directing us to withhold shares of common stock otherwise issuable in connection with the award having
	a fair market value equal to the amount required to be withheld; and (iv) by delivery of previously acquired shares of common stock
	that are acceptable to the Committee and that have an aggregate fair market value on the date of exercise equal to the exercise
	price or withholding tax, or certification of ownership by attestation of such previously acquired shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Provisions Relating to a &ldquo;Change
	in Control&rdquo; of the Company
</I>
	.
</B>
	&nbsp;Notwithstanding any other provision of the Plan or any award agreement, in the event
	of a &ldquo;Change in Control&rdquo; of the company, the Committee has the discretion to provide that all outstanding awards will
	become fully exercisable, all restrictions applicable to all awards will terminate or lapse, and performance goals applicable to
	any stock awards will be deemed satisfied at the highest target level. In addition, upon such Change in Control, the Committee
	has sole discretion to provide for the purchase of any outstanding stock option for cash equal to the difference between the exercise
	price and the then fair market value of the common stock subject to the option had the option been currently exercisable, make
	such adjustment to any award then outstanding as the Committee deems appropriate to reflect such Change in Control and cause any
	such award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	Amendment of Award Agreements; Amendment
	and Termination of the Plan; Term of the Plan
</I>
	.
</B>
	&nbsp;The Committee may amend any award agreement at any time, provided that
	no amendment may adversely affect the right of any participant under any agreement in any material way without the written consent
	of the participant, unless such amendment is required by applicable law, regulation or stock exchange rule.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Board may terminate, suspend or amend
	the Plan, in whole or in part, from time to time, without the approval of the shareholders, unless such approval is required by
	applicable law, regulation or stock exchange rule, and provided that no amendment may adversely affect the right of any participant
	under any outstanding award in any material way without the written consent of the participant, unless such amendment is required
	by applicable law, regulation or rule of any stock exchange on which the shares are listed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Notwithstanding the foregoing, neither the
	Plan nor any outstanding award agreement can be amended in a way that results in the repricing of a stock option. Repricing is
	broadly defined to include reducing the exercise price of a stock option or cancelling a stock option in exchange for cash, other
	stock options with a lower exercise price or other stock awards. (This prohibition on repricing without shareholder approval does
	not apply in case of an equitable adjustment to the awards to reflect changes in the capital structure of the company or similar
	events.)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	No awards may be granted under the Plan
	on or after the tenth anniversary of the effective date of the Plan.
</P>
</EFX_STOCK_PLANS>
</EFX_DIRECTOR_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTAIN_TRANSACTIONS>
<A NAME="FIS_CERTAIN_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_028" TITLE="RELATIONSHIPS AND RELATED PARTY TRANSACTIONS">
</A>
	RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We were incorporated in July 2015. In August
	2015, in exchange for the issuance of 630,000 shares of common stock, we acquired the rights to the license agreement with MD Anderson
	covering our WP1122 Portfolio held by IntertechBio Corporation. Waldemar Priebe, chairman of our Scientific Advisory Board, and
	Don Picker, our president and chief operating officer, are shareholders of IntertechBio and control the voting and dispositive
	power over the shares held by IntertechBio.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August 2015, in exchange for the issuance
	of 1,431,000 shares of common stock, we acquired the rights to the Annamycin data related to the original Annamycin IND and the
	development of Annamycin held by AnnaMed, Inc., a company controlled by Walter Klemp, our Chairman and chief executive officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Prior to our IPO, in exchange for the issuance
	of 629,000 shares of common stock, we, on Moleculin, LLC&rsquo;s behalf, entered into an agreement with HPI whereby HPI agreed
	to terminate its option to sublicense certain rights to the WP1066 Portfolio and to enter into a co-development agreement with
	us, allowing us to benefit from HPI&rsquo;s grant-funded development efforts currently under way. Waldemar Priebe and Don Picker
	are shareholders of HPI, and Dr. Priebe have the voting and dispositive power over the shares held by HPI. For a detailed discussion
	of the HPI co-development agreement, see &ldquo;Business &ndash; Our License Agreements.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Prior to our IPO, we merged with Moleculin,
	LLC. Moleculin, LLC was the holder of the license agreement with MD Anderson covering our WP 1066 Portfolio. As a result of the
	merger, we issued the equity interests holders of Moleculin, LLC an aggregate of 999,931 shares of our common stock. Waldemar
	Priebe, Walter Klemp and Don Picker were members of Moleculin, LLC and received 6,046 shares, 22,795 shares and 6,046 shares,
	respectively, of our common stock as a result of the merger. In addition, Walter Klemp and Don Picker were members of the board
	of Moleculin, LLC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In July and August 2015, in Messrs. Klemp,
	Picker and Priebe purchased 1,100,000 shares, 500,000 shares and 3,000,000 shares of our common stock, respectively, at a purchase
	price of $0.001 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On July 1, 2013, Moleculin, LLC agreed to
	reimburse HPI for laboratory space used by Moleculin, LLC from January 2010 through December 2013 in the amount of $31,764. Moleculin,
	LLC stopped using the space in 2014. On September&nbsp;1, 2013, Moleculin, LLC agreed to reimburse HPI for laboratory equipment
	used by Moleculin, LLC for the period from January 2009 through December 2013 in the amount of $35,000. Moleculin, LLC stopped
	using the equipment in 2014. During the year ended December 31, 2013, Moleculin, LLC paid $100,000 for laboratory services provided
	by HPI for the five years prior to August 1, 2013. We do not intend to utilize HPI for such services in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We currently employ Lindsey Picker,
	the daughter of Don Picker, our president and chief operating officer, as a clinical research assistant on an at-will basis with
	an annual salary is $75,000.
</P>
</EFX_CERTAIN_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTAIN_TRANSACTIONS>
<A NAME="FIS_CERTAIN_TRANSACTIONS_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Policies and Procedures for Related Party Transactions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our audit committee charter provides that
	our audit committee is responsible for reviewing and approving in advance any related party transaction. This will cover, with
	certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship,
	or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount
	involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including, without limitation,
	purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness,
	guarantees of indebtedness and employment by us of a related person. All of the transactions described in this section occurred
	prior to the creation of our audit committee and the adoption of this policy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_CERTAIN_TRANSACTIONS>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_STOCKHOLDERS>
<A NAME="FIS_STOCKHOLDERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_029" TITLE="SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT">
</A>
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	SECURITY
	OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth information,
	as of January 17, 2017, regarding beneficial ownership of our common stock by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each of our directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each of our executive officers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	all directors and executive officers as a group; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common
	stock.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Beneficial ownership is determined according to the rules of
	the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared voting or
	investment power of that security, and includes options that are currently exercisable or exercisable within 60 days. Each director
	or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated,
	we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have
	sole investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise
	noted below, the address for each person or entity listed in the table is c/o Moleculin Biotech, Inc., 2575 West Bellfort, Suite
	333, Houston, Texas 77054.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares&nbsp;beneficially
<BR>
	owned&nbsp;prior&nbsp;to
<BR>
	Offering
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Percentage
<BR>
	beneficially
<BR>
	owned&nbsp;prior&nbsp;to
<BR>
	Offering&nbsp;(1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Percentage&nbsp;beneficially
<BR>
	owned
<BR>
	after&nbsp;Offering
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Name and Address of Beneficial Owner
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Walter V. Klemp
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2,480,724
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	20.4
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	16.9
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Donald Picker
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,098,635
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Jonathan Foster
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Louis Ploth
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Robert Shepard
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Robert George
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Michael Cannon
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Jacqueline Northcut
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Directors and Named Executive Officers as a Group (7&nbsp;persons)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,579,359
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(6)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	5% or greater shareholders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Waldemar Priebe
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,140,573
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(3)(5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	AnnaMed, Inc.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,425,000
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	9.7
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	IntertechBio Corp.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	630,000
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Houston Pharmaceuticals, Inc.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	629,000
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	(5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less than 1%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on 12,164,851 shares of common stock outstanding as of January 17, 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 1,425,000 shares held by AnnaMed, Inc. have been
	included in the amount for Mr. Klemp. Mr. Klemp has voting and dispositive power over the shares held by AnnaMed, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 630,000 shares held by IntertechBio Corp. have been
	included in the amounts for Drs. Picker and Priebe. Drs. Picker and Priebe have voting and dispositive power over the shares held
	by IntertechBio Corp.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists of shares underlying options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 629,000 shares held by Houston Pharmaceuticals, Inc.
	have been included in the amount for Dr. Priebe. Dr. Priebe has voting and dispositive power over the shares held by Houston Pharmaceuticals,
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Does
	not include shares underlying options held by Mr. Ploth who resigned from the company in August 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_STOCKHOLDERS>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_030" TITLE="DESCRIPTION OF CAPITAL STOCK">
</A>
	DESCRIPTION OF CAPITAL STOCK
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	The following summary is a description
	of the material terms of our capital stock and is not complete. You should also refer to the Moleculin Biotech, Inc. certificate
	of incorporation and bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part,
	and the applicable provisions of the Delaware General Corporation Law.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our amended and restated certificate
	of incorporation authorizes us to issue up to 75,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares
	of preferred stock, $0.001 par value per share. As of January 17, 2017, we have 12,164,851 shares of common stock outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Shares of our common stock have the following
	rights, preferences and privileges:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.5PT; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Voting
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Each holder of common stock is entitled
	to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Any action at a meeting at
	which a quorum is present will be decided by a majority of the voting power present in person or represented by proxy, except in
	the case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative voting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.5PT; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Dividends
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Holders of our common stock are entitled
	to receive dividends when, as and if declared by the our board of directors out of funds legally available for payment, subject
	to the rights of holders, if any, of any class of stock having preference over the common stock. Any decision to pay dividends
	on our common stock will be at the discretion of our board of directors. Our board of directors may or may not determine to declare
	dividends in the future. See &ldquo;Dividend Policy.&rdquo; The board&rsquo;s determination to issue dividends will depend upon
	our profitability and financial condition any contractual restrictions, restrictions imposed by applicable law and the SEC, and
	other factors that our board of directors deems relevant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.5PT; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Liquidation Rights
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In the event of a voluntary or involuntary
	liquidation, dissolution or winding up of the company, the holders of our common stock will be entitled to share ratably on the
	basis of the number of shares held in any of the assets available for distribution after we have paid in full, or provided for
	payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference over the common
	stock, if any, have received their liquidation preferences in full.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Other
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our issued and outstanding shares of common
	stock are fully paid and nonassessable. Holders of shares of our common stock are not entitled to preemptive rights. Shares of
	our common stock are not convertible into shares of any other class of capital&nbsp;stock, nor are they subject to any redemption
	or sinking fund provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Preferred Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are authorized to issue up to 5,000,000&nbsp;shares
	of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine
	the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications,
	limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the
	number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares
	constituting the series. Our board of directors could, without stockholder approval, issue preferred stock with voting and other
	rights that could adversely affect the voting power and other rights of the holders of common stock and which could have the effect
	of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority
	of our outstanding voting stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Convertible Notes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On various dates from August 31, 2015 through
	January 19, 2016, each as amended on March 10, 2016, we entered into unsecured promissory notes with third party investors. Each
	note bears interest at 8.0% per annum and was to mature on the earlier of June 30, 2016 or the completion of an IPO of our securities.
	Since the completion of the IPO occurred prior to June 30, 2016, these notes were to be automatically converted according to their
	terms into shares of our common stock at their applicable conversion prices upon the IPO to the extent and provided that no holder
	of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially
	own in excess of 4.99% of our common stock after such conversion. Due to this 4.99% limitation, a portion of these notes was not
	converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes will
	remain outstanding and will be converted into shares of our common stock at such time as the 4.99% limitation continues to be met.
	Until such time as the notes are converted into shares of common stock, the maturity date of the notes will automatically be extended
	and we will not be required to repay the notes or the accrued interest relating to the notes in cash. The IPO was completed on
	May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the 4.99% beneficially
	owned condition limitation, discussed above, we issued 1,166,503 shares of common stock in total, reducing the convertible debt
	principal by $183,356 and accrued interest by $17,699. During the three months ended September 30, 2016, an additional 800,057
	shares of common stock were issued due to the number of shares outstanding allowing for conversion of additional shares under the
	4.99% beneficially owned condition limitation. This reduced the convertible debt principal by $133,988 and accrued interest by
	$6,742. The remaining convertible debt without consideration of accrued interest as of September 30, 2016, if converted on September
	30, 2016, would result in an additional 1,928,899 common shares to be issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The holders of our convertible notes have
	agreed to the following lock-up of the common stock issuable upon conversion of the notes:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO,
	(a) a holder of our convertible notes will be able to sell 1% of the number of shares of common stock into which such note is converted
	at the closing of the offering on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b)
	if our common stock price is over $7.00 per share for five consecutive trading days then the holder can sell up to 3% of the number
	of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily
	volume; (c) if our common stock price is over $10.00 per share for five consecutive trading days then the holder can sell up to
	an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any
	trading day of 7% of the daily volume; and (d) if our common stock price is over $14.00 per share then the holder is not restricted
	from making any sales until such time as our common stock price falls back below $14.00 per share; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	thereafter, until the two-year anniversary of the initial closing of our IPO, the holder can sell on any trading day 10%
	of the
	daily volume;
	provided that if our common stock price is over $10.00 per share then the holder is not restricted from making
	any sales until such time as the common stock falls back below $10.00 per share.&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The foregoing lock-up restrictions relate
	to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer
	of the shares agrees to comply with the above restrictions with respect to any public sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Certificate of Incorporation and Bylaw Provisions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our certificate of incorporation and bylaws
	include a number of anti-takeover provisions that may have the effect of encouraging persons considering unsolicited tender offers
	or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts.
	These provisions include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	Advance Notice Requirements.
</I>
</B>
	&nbsp;Our
	bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
	as directors or new business to be brought before meetings of stockholders. These procedures provide that notice of stockholder
	proposals must be timely and given in writing to our corporate Secretary. Generally, to be timely, notice must be received at our
	principal executive offices not fewer than 120&nbsp;calendar days prior to the first anniversary date on which our notice of meeting
	and related proxy statement were mailed to stockholders in connection with the previous year&rsquo;s annual meeting of stockholders.
	The notice must contain the information required by the bylaws, including information regarding the proposal and the proponent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	Special Meetings of Stockholders.
</I>
</B>
	&nbsp;Our
	bylaws provides that special meetings of stockholders may be called at any time by only the Chairman of the Board, the Chief Executive
	Officer, the President or the board of directors, or in their absence or disability, by any vice president.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	No Written Consent of
	Stockholders.
</I>
</B>
	&nbsp;Our certificate of incorporation and bylaws provide that any action required or permitted to be taken
	by stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent
	in writing by such stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	Exclusive Forum Provision.
</I>
</B>
	Our certificate of incorporation provides that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum
	for (i)&nbsp;any derivative action or proceeding brought our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary
	duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising
	pursuant to any provision of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;), or our certificate of incorporation
	or the bylaws, and (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. This choice of
	forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
	with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers
	and employees. Alternatively, a court could find these provisions of our certificate of incorporation to be inapplicable or unenforceable
	in respect of one or more of the specified types of actions or proceedings, which may require us to incur additional costs associated
	with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	Amendment of Bylaws.
</I>
</B>
	&nbsp;Our
	stockholders may amend any provisions of our bylaws by obtaining the affirmative vote of the holders of a majority of each class
	of issued and outstanding shares of our voting securities, at a meeting called for the purpose of amending and/or restating our
	bylaws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
<B>
<I>
	Preferred Stock
</I>
</B>
<I>
	.
</I>
	Our certificate of incorporation authorizes our board of directors to create and issue rights entitling our stockholders to purchase
	shares of our stock or other securities. The ability of our board to establish the rights and issue substantial amounts of preferred
	stock without the need for stockholder approval may delay or deter a change in control of us. See &ldquo;Preferred Stock&rdquo;
	above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Delaware Takeover Statute
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We are subject to Section&nbsp;203 of the
	DGCL which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any &ldquo;business combination&rdquo;
	(as defined below) with any interested stockholder for a period of three years following the date that such stockholder became
	an interested stockholder, unless: (1)&nbsp;prior to such date, the board of directors of the corporation approved either the business
	combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2)&nbsp;on consummation of
	the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least
	85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining
	the voting stock outstanding those shares owned (x)&nbsp;by persons who are directors and also officers and (y)&nbsp;by employee
	stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to this
	plan will be tendered in a tender or exchange offer; or (3)&nbsp;on or subsequent to such date, the business combination is approved
	by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative
	vote of at least 66
<SUP>
	&nbsp;2
</SUP>
	&frasl;
<SUB>
	3
</SUB>
	% of the outstanding voting stock that is not owned by the interested stockholder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Section 203 of the DGCL defines generally
	&ldquo;business combination&rdquo; to include: (1)&nbsp;any merger or consolidation involving the corporation and the interested
	stockholder; (2)&nbsp;any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving
	the interested stockholder; (3)&nbsp;subject to certain exceptions, any transaction that results in the issuance or transfer by
	the corporation of any stock of the corporation to the interested stockholder; (4)&nbsp;any transaction involving the corporation
	that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned
	by the interested stockholder; or (5)&nbsp;the receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
	pledges or other financial benefits provided by or through the corporation. In general, Section&nbsp;203 defines an &ldquo;interested
	stockholder&rdquo; as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and
	any entity or person affiliated with or controlling or controlled by such entity or person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Limitations on Liability and Indemnification of Officers
	and Directors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our certificate of incorporation and bylaws
	limit the liability of our officers and directors and provide that we will indemnify our officers and directors, in each case,
	to the fullest extent permitted by the Delaware General Corporation Law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Listing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our common stock is listed on the Nasdaq
	Capital Market under the symbol &ldquo;MBRX&rdquo;.
</P>
</EFX_SECURITIES_DESCRIPTION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_TRANSFER_AGENT>
<A NAME="FIS_TRANSFER_AGENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Transfer Agent
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The transfer agent for our common stock
	is VStock Transfer, LLC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_TRANSFER_AGENT>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_031" TITLE="DESCRIPTION OF UNITS">
</A>
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	DESCRIPTION
	OF UNITS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In this offering, we are offering for
	sale&nbsp;2,500,000 units, with each unit consisting of: (i) one share of our common stock, (ii) a Series A warrant to purchase
	0.50 of a share of our common stock (and the 1,250,000 shares of our common stock issuable from time to time upon exercise of
	the Series A warrants), (iii) a Series B warrant to purchase one share of our common stock (and the 2,500,000 shares of our common
	stock issuable from time to time upon exercise of the Series B warrants), and (iv) a Series C warrant to purchase 0.50 of a share
	of our common stock (and the 1,250,000 shares of our common stock issuable from time to time upon exercise of the Series C warrants).
	The Series C warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants exercising
	its corresponding Series B warrants included in the unit. The purchase price for each unit is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	. Each warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (100%
	of the unit purchase price). The Series A and C warrants will expire five years from the closing date of this offering. The Series
	B warrants will expire 90 days from the closing date of this offering. The units will not be issued or certificated. The shares
	of common stock and the warrants included in the units will be issued separately but can only be purchased together in the units
	in this offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The material terms and provisions of our
	common stock and each other class of our securities which qualifies or limits our common stock are described under the caption
	&ldquo;Description of Capital Stock&rdquo; in this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Warrants included in the Units
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	The following summary of certain
	terms and provisions of warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety
	by, the provisions of the warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus
	forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description
	of the terms and conditions of the warrants.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Duration and Exercise Price
</I>
	.
	Each warrant offered hereby will have an initial exercise price per share equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	(100% of the unit purchase price). The Series A and C warrants will be immediately exercisable and will expire on the fifth anniversary
	of the closing date of this offering. The Series B warrants will be immediately exercisable and will expire 90 days after the
	closing date of this offering. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate
	adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the
	exercise price. The warrants will be issued separately from the common stock, and may be transferred separately immediately thereafter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Exercisability
</I>
	. The Series C
	warrants in a unit may only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its corresponding
	Series B warrants included in the unit. The warrants will be exercisable, at the option of each holder, in whole or in part, by
	delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased
	upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may
	not exercise any portion of the warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder,
	9.99%) of the outstanding common stock immediately after exercise, provided that the holder may increase the limitation on amount
	of ownership of outstanding stock after exercising the holder&rsquo;s warrants up to 9.99% of the number of shares of our common
	stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with
	the terms of the warrants, provided further that any increase in such limitation shall not be effective until 61 days following
	notice from the holder to us. No fractional shares of common stock will be issued in connection with the exercise of a warrant.
	In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the
	exercise price or round up to the next whole share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Cashless Exercise
</I>
	. If, at the
	time a holder exercises its warrant, a registration statement registering the issuance of the shares of common stock underlying
	the warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated
	to be made to us upon such exercise in payment of the aggregate exercise price, if the holder chooses to exercise the warrants
	it must elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined
	according to a formula set forth in the warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Fundamental Transactions.
</I>
	If
	a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every
	right and power that we may exercise and will assume all of our obligations under the warrants with the same effect as if such
	successor entity had been named in the warrant itself. If holders of our common stock are given a choice as to the securities,
	cash or property to be received in a fundamental transaction, then the holder shall be given the same choice as to the consideration
	it receives upon any exercise of the warrant following such fundamental transaction. In addition, in the event of a fundamental
	transaction, at the request of the holder, we or the successor entity shall purchase the unexercised portion of the warrant from
	the holder by paying to the holder cash in an amount equal to the Black-Scholes value (as defined in the warrants) of the remaining
	unexercised portion of the warrant on the date of such fundamental transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Exchange Listing
</I>
	. We do not intend
	to list the warrants on any securities exchange or nationally recognized trading system.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<I>
	Right as a Stockholder
</I>
	. Except as
	otherwise provided in the warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of
	the warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise
	their warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SECURITIES_DESCRIPTION>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_UNDERWRITING>
<A NAME="FIS_UNDERWRITING"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<A NAME="V458551_S1A_HTM_A_032" TITLE="UNDERWRITING">
</A>
<B>
	UNDERWRITING
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have entered into an underwriting agreement
	with the several underwriters listed in the table below. Roth Capital Partners, LLC is the representative of the underwriters.
	We refer to the several underwriters listed in the table below as the &ldquo;underwriters.&rdquo; Subject to the terms and conditions
	of the underwriting agreement, we have agreed to sell to the underwriters, and the underwriters have agreed to purchase from us,
	units. Our common stock trades on the NASDAQ Capital Market under the symbol &ldquo;MBRX.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the terms and subject to the
	conditions contained in the underwriting agreement, we have agreed to sell to the underwriters named below, and each underwriter
	severally has agreed to purchase from us, the respective number of units set forth opposite its name below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	Underwriter
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of Units
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Roth Capital Partners,&nbsp;LLC
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	National Securities Corporation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;2,500,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The underwriting agreement provides that
	the obligation of the underwriters to purchase the units offered by this prospectus is subject to certain conditions. The underwriters
	are obligated to purchase all of the units offered hereby if any of the units are purchased.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have granted the underwriters an
	option to buy up to an additional 375,000 shares of common stock and/or an additional 375,000 warrant combinations (comprised
	of 187,500 Series A warrants, 375,000 Series B Warrants and 187,500 Series C warrants) at the public offering price per share
	and public offering price per warrant combination, respectively, less the underwriting discounts and commissions, in any combination
	thereof from us, to cover over-allotments, if any. The underwriters may exercise this option at any time, in whole or in part,
	during the 45-day period after the date of this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Discounts, Commissions and Expenses
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The underwriters propose to offer
	the units purchased pursuant to the underwriting agreement to the public at the public offering price set forth on the cover
	page of this prospectus and to certain dealers at that price less a concession not in excess of
	$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per unit. After this offering, the public
	offering price and concession may be changed by the underwriters. No such change shall change the amount of proceeds to be
	received by us as set forth on the cover page of this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the sale of the units
	to be purchased by the underwriters, the underwriters will be deemed to have received compensation in the form of underwriting
	commissions and discounts. The underwriters' commissions and discounts will be &nbsp;&nbsp;&nbsp;&nbsp;% of the gross proceeds of this offering, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
	unit, based on the public offering price per unit set forth on the cover page of this prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have also agreed
	to reimburse the representative at closing for expenses incurred by it in connection with the offering up to a maximum of $75,000.
	In addition, we have agreed to issue to the representative warrants to purchase up to 7% of the aggregate number of shares of
	common stock sold in this offering. The representative warrants will have a term of no greater than 5&nbsp;years from the effective
	date of this registration statement and an exercise price per share equal to the public offering price per share sold in this
	offering&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	and is registered on the registration
	statement of which this prospectus forms a part
</FONT>
	. Pursuant to FINRA Rule 5110(g), the representative warrants and any shares
	issued upon exercise of the representative&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warrants
	shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
	put or call transaction that would result in the effective economic disposition of the securities by any person for a period of
	180 days immediately following the date of effectiveness or commencement of sales of this offering, except the transfer of any
	security:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	by operation of law or by reason of our
	reorganization;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to any FINRA member firm participating
	in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction
	set forth above for the remainder of the time period;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	if the aggregate amount of our securities
	held by the placement agent or related persons do not exceed 1% of the securities being offered;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	that is beneficially owned on a pro-rata
	basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments
	by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the exercise or conversion of any security,
	if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Subject
	to the consummation of this offering, we have also agreed to give the representative a twelve-month right of first refusal to act
	as our lead underwriter or placement agent for any further capital raising transactions undertaken by us. We have also granted
	the representative a six-month tail fee equal to the cash and warrant compensation in this offering, if any investor with which
	we have had substantive discussions with respect to this offering, provides us with further capital during such six-month period
	following termination of our engagement of the representative.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table shows the underwriting
	discounts and commissions payable to the underwriters by us in connection with this offering (assuming both the exercise and non-exercise
	of the over-allotment option to purchase additional shares and/or warrant combinations we have granted to the underwriters):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Per Unit
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Without
<BR>
	Over-
<BR>
	allotment
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	With
<BR>
	Over-
<BR>
	allotment
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Without
<BR>
	Over-
<BR>
	allotment
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	With
<BR>
	Over-
<BR>
	allotment
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Public offering price (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Underwriting discounts and commissions paid by us
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The public
	offering price and underwriting discount correspond to an assumed public offering price
	per share of common stock of $____ and an assumed public offering price per warrant combination
	of $____.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_INDEMNIFICATION>
<A NAME="FIS_INDEMNIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Indemnification
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the underwriting agreement,
	we have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to
	contribute to payments that the underwriters or such other indemnified parties may be required to make in respect of those liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Lock-Up Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the underwriting agreement,
	we have agreed not to (i)&nbsp;offer, pledge, issue, sell, contract to sell, purchase, contract to purchase, lend or otherwise
	transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable
	or exchangeable for our common stock; or (ii)&nbsp;file any registration statement with the SEC relating to the offering of any
	shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, without
	the prior written consent the representative for a period of 90&nbsp;days following the date of this prospectus (the &quot;Lock-up
	Period&quot;). This consent may be given at any time without public notice. These restrictions on future issuances are subject
	to exceptions for (i)&nbsp;the issuance of shares of our common stock sold in this offering, (ii)&nbsp;the issuance of shares
	of our common stock upon the exercise of outstanding options or warrants and the vesting of restricted stock awards or units,
	(iii)&nbsp;the issuance of employee stock options not exercisable during the Lock-up Period and the grant, redemption or forfeiture
	of restricted stock awards or restricted stock units pursuant to our equity incentive plans or as new employee inducement grants
	and (iv)&nbsp;the issuance of common stock or warrants to purchase common stock in connection with mergers or acquisitions of
	securities, businesses, property or other assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, each of our directors and
	executive officers and certain stockholders has entered into a lock-up agreement with the underwriters. Under the lock-up agreements,
	the directors and executive officers and certain stockholders may not, directly or indirectly, sell, offer to sell, contract to
	sell, or grant any option for the sale (including any short sale), grant any security interest in, pledge, hypothecate, hedge,
	establish an open &quot;put equivalent position&quot; (within the meaning of Rule&nbsp;16a-1(h) under the Securities Exchange
	Act of 1934, as amended, or the Exchange Act), or otherwise dispose of, or enter into any transaction which is designed to or
	could be expected to result in the disposition of, any shares of our common stock or securities convertible into or exchangeable
	for shares of our common stock, or publicly announce any intention to do any of the foregoing, without the prior written consent
	of Roth Capital Partners, for a period of 90&nbsp;days from the closing date of this offering, subject to an 18-day extension
	under certain circumstances. This consent may be given at any time without public notice. These restrictions on future dispositions
	by our directors and executive officers are subject to exceptions for (i)&nbsp;one or more bona fide gift transfers of securities
	to immediate family members who agree to be bound by these restrictions and (ii)&nbsp;transfers of securities to one or more trusts
	for bona fide estate planning purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Electronic Distribution
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This prospectus may be made available in
	electronic format on websites or through other online services maintained by the underwriters or by their affiliates. In those
	cases, prospective investors may view offering terms online and prospective investors may be allowed to place orders online. Other
	than this prospectus in electronic format, the information on the underwriters' websites or our website and any information contained
	in any other websites maintained by the underwriters or by us is not part of this prospectus or the registration statement of which
	this prospectus forms&nbsp;a part, has not been approved and/or endorsed by us or the underwriter in its capacity as underwriter,
	and should not be relied upon by investors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Price Stabilization, Short Positions and Penalty Bids
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the offering the underwriters
	may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance
	with Regulation&nbsp;M under the Exchange Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stabilizing transactions permit bids to purchase
	the underlying security so long as the stabilizing bids do not exceed a specified maximum.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Over-allotment involves sales by the underwriters
	of shares in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position.
	The short position may be either a covered short position or a naked short position. In a covered short position, the number of
	shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment
	option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option.
	The underwriters may close out any covered short position by either exercising their over-allotment option and/or purchasing shares
	in the open market.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Syndicate covering transactions involve purchases
	of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In
	determining the source of shares to close out the short position, the underwriters will consider, among other things, the price
	of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment
	option. A naked short position occurs if the underwriters sell more shares than could be covered by the over-allotment option.
	This position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if
	the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing
	that could adversely affect investors who purchase in the offering.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Penalty bids permit the underwriters to reclaim a
	selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing
	or syndicate covering transaction to cover syndicate short positions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	These stabilizing transactions, syndicate
	covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing
	or retarding a decline in the market price of the common stock. As a result, the price of our common stock may be higher than the
	price that might otherwise exist in the open market. These transactions may be discontinued at any time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Neither we nor the underwriters make any
	representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the
	price of our shares of common stock. In addition, neither we nor the underwriters make any representation that the underwriter
	will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Selling Restrictions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	European Economic Area
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.75IN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	prospectus does not constitute an approved prospectus under Directive 2003/71/EC and no such prospectus is intended to be prepared
	and approved in connection with this offering. Accordingly, in relation to each Member State of the European Economic Area which
	has implemented Directive 2003/71/EC (each, a &quot;Relevant Member State&quot;) an offer to the public of any shares of common
	stock which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except
	that an offer to the public in that Relevant Member State of any shares of common stock may be made at any time under the following
	exemptions under the Prospectus Directive, if and to the extent that they have been implemented in that Relevant Member State:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;to
	any legal entity which is a qualified investor as defined in the Prospectus Directive;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;to
	fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150,
	natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior
	consent of the representatives of the underwriter for any such offer; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;in
	any other circumstances which do not require any person to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	For the purposes of this provision, the
	expression an &quot;offer to the public&quot; in relation to any shares of common stock in any Relevant Member State means the
	communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to
	be offered so as to enable an investor to decide to purchase any shares of common stock, as the expression may be varied in that
	Member State by any measure implementing the Prospectus Directive in that Member State and the expression &quot;Prospectus Directive&quot;
	means Directive 2003/71/EC (and any amendments thereto including the 2010 PD Amending Directive to the extent implemented in each
	Relevant Member State) and includes any relevant implementing measure in each Relevant Member State and the expression &quot;2010
	PD Amending Directive&quot; means Directive 2010/73/EU.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	United Kingdom
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	This prospectus is not an approved prospectus
	for purposes of the UK Prospectus Rules, as implemented under the EU Prospectus Directive (2003/71/EC), and has not been approved
	under section&nbsp;21 of the Financial Services and Markets Act 2000 (as amended) (the &quot;FSMA&quot;) by a person authorized
	under FSMA. The financial promotions contained in this prospectus are directed at, and this prospectus is only being distributed
	to, (1)&nbsp;persons who receive this prospectus outside of the United Kingdom, and (2)&nbsp;persons in the United Kingdom who
	fall within the exemptions under articles&nbsp;19 (investment professionals) and 49(2)(a) to (d)&nbsp;(high net worth companies,
	unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons
	together being referred to as &quot;Relevant Persons&quot;). This prospectus must not be acted upon or relied upon by any person
	who is not a Relevant Person. Any investment or investment activity to which this prospectus relates is available only to Relevant
	Persons and will be engaged in only with Relevant Persons. This prospectus and its contents are confidential and should not be
	distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person that is not a Relevant
	Person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The underwriter has represented, warranted
	and agreed that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;it
	has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement
	to engage in investment activity (within the meaning of section&nbsp;21 of the FSMA in connection with the issue or sale of any
	of the shares of common stock in circumstances in which section&nbsp;21(1) of the FSMA does not apply to the issuer; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;it has complied
	with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares
	of common stock in, from or otherwise involving the United Kingdom.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_INDEMNIFICATION>
</EFX_UNDERWRITING>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_VALIDITY>
<A NAME="FIS_VALIDITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<A NAME="V458551_S1A_HTM_A_033" TITLE="VALIDITY OF SECURITIES">
</A>
<B>
	VALIDITY
	OF SECURITIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	The validity of the securities offered
	hereby will be passed upon for us by Schiff Hardin LLP, Washington, DC. Ellenoff Grossman &amp; Schole LLP is acting as counsel
	to the underwriters in connection with this offering.
</P>
</EFX_VALIDITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_EXPERTS>
<A NAME="FIS_EXPERTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
<A NAME="V458551_S1A_HTM_A_034" TITLE="EXPERTS">
</A>
	EXPERTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	The financial statements of Moleculin Biotech,
	Inc. as of December 31, 2015 and for the period from July 28, 2015 (inception) to December 31, 2015 and the financial statements
	of Moleculin, LLC as of and for the years ended December&nbsp;31, 2015 and 2014 included in this prospectus have been audited by
	GBH CPAs, PC, an independent registered public accounting firm, as stated in their reports appearing herein. Such financial statements
	have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
</P>
</EFX_EXPERTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_MORE_INFORMATION>
<A NAME="FIS_MORE_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
<A NAME="V458551_S1A_HTM_A_035" TITLE="WHERE YOU CAN FIND MORE INFORMATION">
</A>
	WHERE
	YOU CAN FIND MORE INFORMATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	We have filed with the SEC a registration
	statement on Form S-1 under the Securities Act for the securities being offered by this prospectus. This prospectus, which is part
	of the registration statement, does not contain all of the information included in the registration statement and the exhibits.
	For further information about us and the securities offered by this prospectus, you should refer to the registration statement
	and its exhibits. References in this prospectus to any of our contracts or other documents are not necessarily complete, and you
	should refer to the exhibits attached to the registration statement for copies of the actual contract or document. You may read
	and copy any document that we file at the SEC&rsquo;s public reference room located at 100&nbsp;F&nbsp;Street,&nbsp;NE, Washington,
	D.C.&nbsp;20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. SEC filings are also
	available to the public at the SEC&rsquo;s website at
<I>
	www.sec.gov
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	We are subject to the reporting and information
	requirements of the Exchange Act and, as a result, will file periodic and current reports, proxy statements and other information
	with the SEC. We expect to make our periodic reports and other information filed with or furnished to the SEC, available, free
	of charge, through our website as soon as reasonably practicable after those reports and other information are filed with or furnished
	to the SEC. Additionally, these periodic reports, proxy statements and other information will be available for inspection and copying
	at the public reference room and website of the SEC referred to above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_MORE_INFORMATION>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	INDEX TO FINANCIAL STATEMENTS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 89%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	Page
</B>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<B>
	Financial Statements for the Quarter Ended September 30, 2016
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_001">
	Balance Sheets as of September 30, 2016 and December 31, 2015 (unaudited)
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-2
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_002">
	Statements of Operations for the Three and Nine Months Ended September 30,
	2016 and the Period from July 28, 2015 (Inception) to September 30, 2015 (unaudited)
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-3
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_003">
	Statements of Cash Flows for the Nine Months Ended September 30, 2016 and
	the Period from July 28, 2015 (Inception) to September 30, 2015 (unaudited)
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-4
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<A HREF="#V458551_S1A_HTM_A_004">
	Notes to Financial Statements (unaudited)
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-5
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<B>
	Audited Financial Statements for the Year Ended December 31, 2015
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_016">
	Report of Independent Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-15
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_005">
	Balance Sheet as of December 31, 2015
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-16
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_006">
	Statement of Operations for the Period from July 28, 2015 (Inception) to December 31, 2015
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-17
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_007">
	Statement of Changes in Stockholders&rsquo; Deficit for the Period from July 28, 2015 (Inception) to December 31, 2015
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-18
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_008">
	Statement of Cash Flows for the Period from July 28, 2015 (Inception) to December 31, 2015
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-19
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_009">
	Notes to Financial Statements
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-20
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<B>
	Moleculin, LLC
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<B>
	Audited Financial Statements for the Years Ended December 31, 2015 and 2014
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_010">
	Report of Independent Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-24
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_011">
	Statements of Financial Position as of December 31, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-25
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_012">
	Statements of Operations for the Years Ended December 31, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-26
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_013">
	Statements of Changes in Members&rsquo; Deficit for the Years Ended December 31, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-27
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_014">
	Statements of Cash Flows for the Years Ended December 31, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-28
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#V458551_S1A_HTM_A_015">
	Notes to Financial Statements
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	F-29
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_001">
</A>
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Balance Sheets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30,
<BR>
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	(Unaudited)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	Assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,183,783
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	244,869
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,428,652
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Long-Term Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Furniture and equipment, net of accumulated depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,346
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Intangible assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,128,790
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total Assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	17,573,788
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	Liabilities and Stockholders' Equity (Deficit)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Accounts payable and accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	944,997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	322,790
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Accounts payable and accrued expenses-related party
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Convertible notes payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	297,656
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,280,153
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	772,790
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Long-term payable-related party
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total Liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,330,153
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	772,790
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commitment and contingencies
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stockholders' Equity (Deficit):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Common stock, $0.001 par value; 75,000,000 authorized, 12,054,813 and 6,661,000 shares issued and outstanding, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,055
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,661
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Subscription receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,485,987
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,251,407
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Total Stockholders' Equity (Deficit)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,243,635
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(744,699
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total Liabilities and Stockholders' Equity (Deficit)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	17,573,788
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the unaudited financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_002">
</A>
<B>
	Moleculin Biotech, Inc.
</B>
<BR>
<B>
	Statements of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	(Unaudited)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Three
<BR>
	Months
<BR>
	Ended
<BR>
	September
<BR>
	30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	From July&nbsp;28, 2015
<BR>
	(Inception)&nbsp;Through
<BR>
	September&nbsp;30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Nine&nbsp;Months&nbsp;Ended
<BR>
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	From
<BR>
	July&nbsp;28,
<BR>
	2015
<BR>
	(Inception)
<BR>
	Through
<BR>
	September
<BR>
	30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 38%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	496,659
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	38,409
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	616,498
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	38,409
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	924,041
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,344
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,847,613
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,344
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	977
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,629
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Total operating expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,421,677
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	222,753
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,465,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	222,753
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,421,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(222,753
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,465,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(222,753
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other expense:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,402
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,562
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(37,307
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,562
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,432,079
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,503,047
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss per common share - basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Weighted average common shares outstanding - basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	11,579,239
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,320,015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	9,066,804
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,320,015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the unaudited financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_003">
</A>
<B>
	Moleculin Biotech, Inc.
</B>
<BR>
<B>
	Statements of Cash Flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Unaudited)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	Nine Months
<BR>
	Ended
<BR>
	September&nbsp;30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	From July&nbsp;28,
<BR>
	2015
<BR>
	(Inception)
<BR>
	Through
<BR>
	September&nbsp;30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows from Operating Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,503,047
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(224,315
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,629
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	208,939
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Shares issued for licenses used for research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,061
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(244,869
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(23,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Accounts payable and accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(146,799
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	63,010
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Accounts payable and accrued expenses &ndash; related parties
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	87,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,584
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Net Cash Used in Operating Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,596,647
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(162,660
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows from Investing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Cash paid for purchase of fixed assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Cash paid for acquisition of Moleculin, LLC, net with cash acquired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(99,638
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net Cash Used in Investing Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(109,793
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows from Financing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Proceeds from notes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	165,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	250,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Payments on notes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(469,939
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Proceeds from sale of common stock, net of direct offering costs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,167,071
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net Cash Provided by Financing Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,862,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	250,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net change in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,155,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	87,340
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents, at beginning of period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents, at end of period
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6,183,783
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	87,340
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Supplemental disclosures of cash flow information:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash paid for interest
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	47,950
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash paid for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Supplemental disclosure of non-cash investing and financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common stock issued to acquire Moleculin, LLC
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,773,586
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Common stock issued for conversion of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	341,785
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Shares subscribed
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the unaudited financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_004">
</A>
<B>
	Moleculin Biotech, Inc.&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Notes to Financial Statements
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Unaudited)
</B>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 1 &ndash; Description of Business and Summary of Significant
	Accounting Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Nature of Business &ndash;
</B>
	The terms
	&ldquo;MBI&rdquo; or &ldquo;the Company&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo; and &ldquo;us&rdquo; are used herein to refer
	to Moleculin Biotech, Inc. MBI is a preclinical-stage pharmaceutical company organized as a Delaware corporation in
	July 2015 to focus on the development of anti-cancer drug candidates, some of which are based on license agreements with The University
	of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our lead drug candidate is liposomal Annamycin,
	which we refer to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia, or
	AML. In August 2015, the Company entered into a rights transfer agreement with AnnaMed, Inc. (&ldquo;AnnaMed&rdquo;), a company
	affiliated with certain members of the Company&rsquo;s management and board of directors, pursuant to which, in exchange for 1,431,000
	shares of the Company&rsquo;s common stock, AnnaMed agreed to transfer any and all data it had regarding the development of Annamycin
	and the Annamycin IND, including all trade secrets, know-how, confidential information and other intellectual property rights held
	by AnnaMed. Annamycin has been in clinical trials pursuant to an investigational new drug application, or IND, that had been filed
	with the U.S. Food and Drug Administration, or FDA. This IND was terminated due to a lack of activity by a prior drug developer.
	The Company intends to apply for a new IND based on the same data that supported the original IND, updated for subsequent clinical
	data, and to commence clinical trials for Annamycin funded with the proceeds from our initial public offering which was completed
	on May 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Annamycin drug substance is no longer covered
	by any existing patent protection. We intend to submit patent applications for formulation, synthetic process and reconstitution
	related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent
	protection. Independently from potential patent protection, we believe Annamycin will qualify for Orphan Drug status, which could
	entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (&ldquo;NDA&rdquo;)
	and Marketing Authorization (&ldquo;MA&rdquo;), in the US and the European Union (&ldquo;EU&rdquo;), respectively. However, there
	can be no assurance that such status will be granted. Separately, the FDA may also grant market exclusivity of up to five years
	for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity
	will be granted or, if granted, for how long.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We have two other drug development projects
	in progress, one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation
	of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting
	the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular. We
	have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to our WP1066 Portfolio
	and WP1122 Portfolio drug technologies, as these patent rights are owned by MD Anderson.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 11, 2015, the Company entered into
	a rights transfer agreement for WP1122 with IntertechBio Corporation (&ldquo;IntertechBio&rdquo;), a company affiliated with certain
	members of our management, whereby IntertechBio agreed to assign its license or sublicense its license to certain metabolic inhibitor
	technology owned by MD Anderson. In consideration, the Company issued 630,000 common shares to IntertechBio. IntertechBio agreed
	to make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments
	and minimum annual royalty payments for sales of products developed under the license agreement. The Company has assumed the rights
	and obligations of IntertechBio under the license agreement with MD Anderson. All out-of-pocket expenses incurred by MD Anderson
	in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company filed a registration statement
	on Form S-1 (which was declared effective on May 2, 2016) with respect to the Company&rsquo;s initial public offering of shares
	of its common stock (&ldquo;IPO&rdquo;) to fund the development of its technologies. Prior to the declaration of effectiveness
	of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI, which survived the merger.
	Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio,
	which is focused on the modulation of key oncogenic transcription factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Presentation - Unaudited Interim
	Financial Information &ndash;
</B>
	The accompanying unaudited interim financial statements and related notes have been prepared
	in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) for interim
	financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
	(the &ldquo;SEC&rdquo;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the
	information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished
	reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary&nbsp;for
	a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results
	for the full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements
	of the Company as of December 31, 2015 and for the period from July&nbsp;28, 2015 (inception) to December 31, 2015 and notes thereto
	contained in the Registration Statement on Form S-1 filed with the SEC on April&nbsp;27, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Use of Estimates in Financial Statement
	Presentation -
</B>
	The preparation of these financial statements in conformity with accounting principles generally accepted in
	the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
	liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition &ndash;
</B>
	We acquired Moleculin,
	LLC (&ldquo;Moleculin&rdquo;) on May 2, 2016, and, going forward our financial statements include the operations of Moleculin,
	LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most
	assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair
	value of acquired in-process research and development (&ldquo;IPR&amp;D&rdquo;) be recorded on the balance sheet. Transaction costs
	are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will
	be recorded as goodwill. The estimated fair values of assets acquired and liabilities assumed were determined based on management&rsquo;s
	best estimates. Preliminary estimated fair values are subject to measurement period adjustments which represent updates made to
	the preliminary purchase price allocation based on revisions to valuation estimates in the interim period subsequent to the acquisition
	and initial accounting date up until the purchase price allocation is finalized which cannot be any later than one year from the
	acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Going Concern -
</B>
	These financial statements
	have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities
	in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial
	support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, and the
	attainment of profitable operations. As of September 30, 2016, the Company has incurred an accumulated deficit of $3,251,407 since
	inception, and had not yet generated any revenue from operations. These factors raise substantial doubt regarding the Company&rsquo;s
	ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification
	of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as
	a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government
	or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances
	and licensing arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Cash and Cash Equivalents -
</B>
	The Company
	considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At September 30,
	2016, all of the Company&rsquo;s cash was deposited in two banks and at December 31, 2015, all of the Company&rsquo;s cash was
	deposited in one bank.&nbsp;Periodically, the Company may carry cash balances at financial institutions in excess of the federally
	insured limit of $250,000. The amount in excess of the FDIC insurance at September 30, 2016 was $5,693,442. On October 13, 2016,
	the Company consolidated all of its cash into one bank with $2 million and $3 million deposited into Certificate of Deposit Account
	Registry Service or CDARS accounts, which are all 100% federally insured, for 4-week and 13-week terms, respectively. The remaining
	cash is deposited into a checking and money market account.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Intangible assets -
</B>
	Intangible assets
	with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is
	identified as an in-process research &amp; development asset then no amortization will occur until the development is complete.
	If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record
	a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets
	will be amortized over their estimated useful lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We evaluate the recoverability of intangible
	assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate
	that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented.
	Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment
	exist, using a fair-value-based approach.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Beneficial Conversion Feature
</B>
	- From
	time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion
	feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value
	of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the
	note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments,
	if any related equity instruments were granted with the debt. Prior to the Company&rsquo;s IPO, the Company estimates the fair
	value of its common stock using the most recent selling price available. The intrinsic value of the beneficial conversion feature
	is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest
	expense over the life of the note using the effective interest method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes -
</B>
	The Company uses the
	asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined
	based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured
	using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then
	assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more
	likely than not that some portion or all of a deferred tax asset will not be realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Stock-based Compensation -
</B>
	Stock-based
	compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity
	awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as
	expense over the applicable vesting period of the stock award using the straight-line method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Earnings (Loss) Per Common Share
</B>
	- Basic
	net earnings (loss) per common share are computed by dividing net earnings (loss) available to common shareholders by the weighted-average
	number of common shares outstanding during the period. Diluted net earnings (loss) per common share is determined using the weighted-average
	number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods
	when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their
	inclusion would have been anti-dilutive. As of September 30, 2016, the Company&rsquo;s potentially dilutive shares included notes
	convertible to 1,928,899 common shares, options to purchase 510,000 common shares and warrants to purchase 107,802 common shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Research and Development Costs -
</B>
	Research
	and development costs are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent Events -
</B>
	The Company&rsquo;s
	management reviewed all material events through the date these financial statements were issued for subsequent event disclosure
	consideration.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recent Accounting Pronouncements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In May 2014, the FASB issued Accounting Standard
	Update (&quot;ASU&quot;) 2014-09, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in
	U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing
	revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict
	the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects
	to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date
	of the guidance until annual and interim reporting periods beginning after December 15, 2017. The Company is currently evaluating
	the impact that this standard will have on its financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In August 2014, the FASB issued ASU 2014-15,
	Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability
	to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&rsquo;s ability to continue
	as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective
	for annual periods beginning after December 15, 2016, and for annual and interim periods thereafter; early adoption is permitted.
	The Company is currently evaluating the impact that this standard will have on its financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In January 2016, the FASB issued ASU No. 2016-01,
	Financial Instruments &ndash; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&ldquo;ASU 2016-01&rdquo;).&nbsp;ASU
	2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and
	disclosure requirements of financial instruments.&nbsp;ASU 2016-01 is effective for fiscal years beginning after December 15, 2017,
	including interim periods within those fiscal years.&nbsp;The Company is currently evaluating the impact that this standard will
	have on its financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In February 2016, the FASB issued ASU No. 2016-02,
	Leases (Topic 842) (&ldquo;ASU 2016-02&rdquo;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets
	and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&nbsp;ASU 2016-02 offers specific
	accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative
	and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing
	and uncertainty of cash flows arising from leases.&nbsp;For public companies, ASU 2016-02 is effective for annual reporting periods
	beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective
	adoption, with early adoption permitted.&nbsp;The Company is currently evaluating the impact that this standard will have on its
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In March 2016, the FASB issued ASU 2016-09,
	Compensation-Stock Compensation (Topic 718). The new guidance changes the accounting and simplifies various aspects of the accounting
	for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based
	on an estimated number of awards that are expected to vest. ASU 2016-09 is effective for annual periods beginning after December
	15, 2016, with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company does not believe that any other
	recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect
	on the accompanying financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 2 &ndash; Intangible Assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	The Acquisition of Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On May 2, 2016, Moleculin, LLC, a Texas limited
	liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin
	equity interests an aggregate of 999,931 shares of the Company&rsquo;s common stock valued at $5,999,586 based on the estimated
	acquisition-date fair value of our common stock of $6.00 per share, equal to the IPO price announced in our prospectus filed on
	that date. These shares contain certain trading restrictions. Prior to the Company&rsquo;s acquisition of Moleculin, the Company
	had loaned $57,822 to Moleculin which was treated as part of the consideration paid to acquire Moleculin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	As additional consideration payable to the
	Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed
	by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive
	a 2.5% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or
	royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &ldquo;Existing IP Assets&rdquo;
	to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the
	intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio
	Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated June 21, 2010,
	as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to
	receive the contingent royalty payments described herein is limited to&nbsp;drugs developed only for dermatology indications, and
	does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any
	drugs for dermatology indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our acquisition of Moleculin, LLC, occurring
	prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering
	the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&ldquo;HPI&rdquo;), a related
	party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio in all
	non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis,
	however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range
	of tumors, Moleculin, LLC focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive
	sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition
	to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development
	for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin,
	LLC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In connection with the acquisition of Moleculin,
	LLC, we also negotiated on behalf of Moleculin, LLC two agreements with HPI. Under the first agreement, the HPI&rsquo;s option
	to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of $100,000 and the issuance of 629,000
	shares of our common stock. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology
	rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment
	of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling $750,000 over a three-year
	period commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting
	from the research and development conducted by HPI which will be expensed, as incurred, as research and development expense. Notwithstanding
	our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research
	or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the effective date
	to buy-out from HPI all rights granted to HPI under the agreement for a payment of $1.0 million. Upon our exercise of the buy-out
	we will no longer be obligated to make any payments to HPI remaining from the $750,000 obligation discussed above. If we do not
	exercise the foregoing buy-out right within three years, the license granted to HPI shall convert into an exclusive license. As
	such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the
	WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend
	to set aside and designate cash and cash equivalents in the amount of $1.0 million to make the buy-out payment. If we ultimately
	decide to exercise the buy-out right from HPI all rights granted the HPI under the agreement, we will need to raise additional
	funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at
	all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The agreements with HPI were executed on May
	2, 2016, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&rsquo;s
	ability to complete the IPO by June 30, 2016. They became effective on May 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The termination of the HPI option was completed
	on behalf of Moleculin, LLC, was required to enable the sale of Moleculin, LLC by materializing the value of its most significant
	asset, and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the
	acquisition on May 2, 2016 as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily
	for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby
	increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The HPI option termination price amounted to
	$3,874,000, consisting of 629,000 shares of our common stock valued at the IPO price of $6.00 per share, and $100,000 paid in cash
	in July 2016, and was included in acquisition-date liabilities assumed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Purchase Price Allocation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The acquisition price was allocated on a preliminary
	basis, which is subject to change, to the assets acquired and liabilities assumed based upon their estimated fair values and the
	information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities
	assumed as of the acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%">
	Cash
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	362
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,820
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Intangibles
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,128,790
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets acquired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,136,972
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Liability assumed (HPI)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,874,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Liabilities assumed
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,205,564
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net assets acquired/total consideration transferred
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,057,408
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company is in the process of obtaining
	input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value
	of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC; thus the provisional measurements
	of current assets, property and equipment, intangibles, and liabilities assumed are subject to change, which could be significant.
	We will finalize the amounts recognized as we obtain the information necessary to complete our analysis. As of this date, management
	believes all or most of the intangible assets are IPR&amp;D related to the WP1066 Portfolio, and, as such, no amortization has
	been recorded to date. Any changes to the provisional measurements will be recognized in the period in which they are determined.
	We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Intangible assets consisted of the following
	at September 30, 2016 and December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September&nbsp;30,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Intangibles acquired from Moleculin, LLC
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	11,128,790
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Unaudited Pro Forma Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The following comparative table presents the
	unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred
	as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. This information
	has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have
	been achieved had the transaction already occurred or that may be achieved in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the
<BR>
	Three
<BR>
	Months
<BR>
	Ended
<BR>
	September
<BR>
	30,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma
<BR>
	For the Nine
<BR>
	Months
<BR>
	Ended
<BR>
	September
<BR>
	30,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma
<BR>
	For the
<BR>
	Three
<BR>
	Months
<BR>
	Ended
<BR>
	September
<BR>
	30,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pro Forma
<BR>
	For the Nine
<BR>
	Months
<BR>
	Ended
<BR>
	September
<BR>
	30,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Total operating expenses
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(1,421,677
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(2,561,908
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(295,422
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(769,549
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,432,079
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,539,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(297,129
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(779,779
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss per common share &ndash; basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.07
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted average outstanding common shares &ndash; basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,579,239
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,513,660
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,052,116
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,028,506
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The nine months ended September 30, 2016 are
	adjusted on a pro forma basis to exclude $145,078 in net interest expense related to the amortization of deferred financing costs
	and debt discount amortization for Moleculin, LLC&rsquo;s convertible notes. The holders of the convertible notes were issued the
	Company&rsquo;s common shares upon the Company&rsquo;s acquisition of Moleculin, LLC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The three months ended September 30, 2015 are
	adjusted on a pro forma basis to exclude $112,846 in net interest expense related to the interest expense, the amortization of
	deferred financing costs and debt discount amortization for Moleculin, LLC&rsquo;s convertible notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The nine months ended September 30, 2015 are
	adjusted on a pro forma basis to exclude $322,547 in net interest expense related to the interest expense, the amortization of
	deferred financing costs and debt discount amortization for Moleculin, LLC&rsquo;s convertible notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 3 &ndash; Convertible Notes Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On various dates from August 31, 2015 through
	January 19, 2016, each as amended on March 10, 2016, the Company entered into seven unsecured promissory notes with three separate
	third party investors. Each note bears interest at 8.0% per annum and was to mature on the earlier of June 30, 2016 or the completion
	of an IPO of the Company&rsquo;s securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Since the completion of the IPO occurred prior
	to June 30, 2016, these notes were to be automatically converted according to their terms into shares of the Company&rsquo;s common
	stock at applicable conversion price upon the Company&rsquo;s IPO to the extent and provided that no holder of these notes was
	or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess
	of 4.99% of our common stock after such conversion. Due to this 4.99% limitation, a portion of these notes was not converted at
	the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes will remain outstanding
	and will be converted into shares of our common stock at such time as the 4.99% limitation continues to be met. Until such time
	as the notes are converted into shares of common stock, the maturity date of the notes will automatically be extended and we will
	not be required to repay the notes or the accrued interest relating to the notes in cash.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The IPO was completed on May 31, 2016. On May
	31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the 4.99% beneficially owned condition
	limitation, discussed above, the Company issued 1,166,503 common shares in total, reducing convertible debt principal by $183,356
	and accrued interest by $17,699. During the three months ended September 30, 2016, an additional 800,057 common shares were issued
	due to the number of common shares outstanding allowing for conversion of additional shares under the 4.99% beneficially owned
	condition limitation. This reduced the convertible debt principal by $133,988 and accrued interest by $6,742. The remaining convertible
	debt without consideration of accrued interest as of September 30, 2016, if converted on September 30, 2016, would result in an
	additional 1,928,899 common shares to be issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The convertible notes were analyzed for a beneficial
	conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The table below represents the shares that
	are convertible at September 30, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares
	that are convertible relating to the associated accrued interest:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Issuance Date
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September&nbsp;30,
<BR>
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Conversion Rate
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
<BR>
	Convertible at
<BR>
	September&nbsp;30,
<BR>
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%">
	August 31, 2015 (a)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	38,299
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	125,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.1299
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	294,832
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	September 3, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	125,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	125,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.1299
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	962,279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	October 4, 2015(a)(c)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	147,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	151,402
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	October 4, 2015(b)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	October 28, 2015(b)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	January 14, 2016(c)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,577
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	107,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	January 19, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	82,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	412,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.25IN">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	297,656
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,928,899
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Debt partially converted on May 31, 2016 and on August 19, 2016.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Debt fully converted to common shares on May 31, 2016.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Debt partially converted on September 1, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The common shares relating to the above mentioned
	convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO
	and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number
	of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily
	volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can
	sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any
	trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days
	then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly
	basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00
	per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back
	below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note
	can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the
	holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share.
	The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted
	by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public
	sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 105; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 4 &ndash; Equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On May 2, 2016, the Company amended and restated
	its certificate of incorporation to increase the number of shares authorized to 80,000,000 of which 5,000,000 shares of preferred
	stock are authorized and 75,000,000 shares of common stock are authorized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Preferred Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We are authorized to issue up to 5,000,000
	shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to
	determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications,
	limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the
	number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares
	constituting the series. As of September 30, 2016, there was no designated preferred stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On May 31, 2016, the Company completed its
	IPO and sold 1,540,026 shares of the Company&rsquo;s common stock. The IPO price per share was $6.00. The Company received net
	proceeds of $8,464,183 after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant
	to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase 107,802 shares
	of common stock exercisable for a period of 5 years from date of issuance at an exercise price of $7.50 per share. The relative
	fair value of these warrants was $374,763 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
	option-pricing model include: (1) discount rate of 1.39% (2) expected life of 5 years, (3) expected volatility of 80.61%, and (4)
	zero expected dividends.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In August 2015, the Company agreed to issue
	4,600,000 shares of common stock to its director, officers and founders for subscriptions of $4,600 cash to be received. As of
	September 30, 2016, the Company had not collected the proceeds for $3,000 of the subscriptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	During the period from January 1, 2016 through
	May 2, 2016, the Company sold 234,296 common shares for $702,888. These shares are subject to the following lock-up agreement,
	from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until
	the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to
	a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per
	share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject
	to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over
	$12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price
	falls back below $12.00 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On June 20, 2016, the Company agreed to issue
	24,000 shares of common stock to PCG Advisory Group, the Company&rsquo;s investor relations firm, for services provided. The fair
	value of these shares was $157,688 based on the market price on the grant date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Adoption of 2015 Stock Plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On December 5, 2015, the Board of Directors
	of the Company approved the Company&rsquo;s 2015 Stock Plan, which was amended on April&nbsp;22,&nbsp;2016. The expiration date
	of the plan is December 5, 2025 and the total number of underlying shares of the Company&rsquo;s common stock available for grant
	to employees, directors and consultants under the plan is 2,500,000 shares. The awards under the 2015 Stock Plan can be in the
	form of stock options, stock awards or stock unit awards. The following is a summary of option activities for the nine months ended
	September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Shares
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Remaining
<BR>
	Contractual
<BR>
	Term
<BR>
	(in years)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%">
	Outstanding, December 31, 2015
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	460,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.83
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Cancelled
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(150,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Outstanding, September 30, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	510,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	5.28
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	9.29
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	275,500
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Exercisable, September 30, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	0.20
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	3.67
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	275,500
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	During the nine months ended September 30,
	2016, the Company granted an employee and its board of directors options, in the aggregate, to purchase 460,000 shares of the Company&rsquo;s
	common stock with an exercise price ranging from $5.71 per share to $5.85 per share, a term of 10 years, and a vesting period of
	3 to 4 years.&nbsp;The exercise price was based upon the closing price of the stock on the day of the grant. The options have an
	aggregated fair value of $1,725,052 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
	option-pricing model include: (1) discount of 1.30% (2) expected lives of 6 to 6.25 years, (3) expected volatility of 70.18% to
	70.44%, and (4) zero expected dividends. During the nine months ended September 30, 2016, the Company recorded $51,251 in stock-based
	compensation in relation to these options
<B>
	.
</B>
	The Company entered into a separation agreement with its former Chief Financial
	Officer in October 2016 and as part of the agreement, options to purchase 150,000 shares of common stock issued to the former Chief
	Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase 50,000 shares of common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 106; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 5 &ndash; Income Taxes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	As of September 30, 2016, the Company had an
	operating loss carry forward of approximately $3,343,000 which expires commencing in 2035. The value of these carryforwards depends
	on the Company&rsquo;s ability to generate taxable income. A change in ownership, as defined by federal income tax regulations,
	could significantly limit the Company&rsquo;s ability to utilize our net operating loss carryforwards. Additionally, because federal
	tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails
	to generate taxable income prior to the expiration dates the Company may not be able to fully utilize the net operating loss carryforwards
	to reduce future income taxes. The Company has cumulative losses and there is no assurance of future taxable income, therefore,
	valuation allowances have been recorded to fully offset the deferred tax asset at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 6 &ndash; Commitments and Contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	MD Anderson &ndash; IntertechBio Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 11, 2015, the Company acquired the
	rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio and MD Anderson dated
	April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license to intellectual
	property including patent rights related to the Company&rsquo;s drug product candidate, WP1122. Under the agreement, IntertechBio
	agreed to pay annual maintenance fee in the amount of $10,000 on the first anniversary of the effective date of the agreement,
	$20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary of the effective date
	of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement, $80,000 on the fifth anniversary of
	the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of the agreement, except that such
	payments will no longer be due upon the first sale of a licensed product. Under the agreement, IntertechBio also agreed to make
	a minimum annual royalty payment in the amount of $200,000 for the first anniversary following the first sale of a licensed product,
	$400,000 for the second anniversary following the first sale of a licensed product, and $600,000 for the third year following the
	first sale of a licensed product. IntertechBio also agreed to make certain milestone payments. Pursuant to an amendment on October
	19, 2015, the Company will pay milestone payments as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Phase
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT">
	Commencement of Phase II Study for a licensed product
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commencement of Phase III Study for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	250,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Filing of a New Drug Application for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Receipt of market approval for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Per the October 2015 amendment to the agreement,
	MD Anderson has the right to terminate the license agreement if (i) a preclinical toxicology program for a licensed product is
	not initiated within one year of the effective date of the amendment (which has occurred), (ii) an investigational new drug application
	is not filed with the Food and Drug Administration for a Phase I study for a licensed product within three years of the effective
	date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within five years of the effective date
	of the amendment. The agreement will expire upon the expiration of the licensed intellectual property. The rights obtained by the
	Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that the technology covered
	by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All
	out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall
	continue to be assumed by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 8, 2015, IntertechBio Corporation
	entered into a letter agreement with MD Anderson wherein MD Anderson agreed to receive past due maintenance fees and patent expenses
	of $98,108 owed by IntertechBio Corporation in four installments. The past due amount is related to certain metabolic inhibitor
	technology license that was assigned to the Company by IntertechBio Corporation and was owed by IntertechBio Corporation prior
	to the Company&rsquo;s acquisition of the license. Pursuant to the letter, IntertechBio Corporation also agreed to pay $65,504
	in patent fees to a law firm. In order to have the license in good standing, the Company agreed to pay MD Anderson the $98,108
	and the $65,504 in patent fees to a patent law firm on behalf of IntertechBio Corporation. As of December 31, 2015, $45,000 of
	the past due amount to MD Anderson and $42,504 in patent fees to a patent law firm were still outstanding and were included in
	accounts payable and accrued liabilities. On April 15, 2016, the Company entered into a letter agreement with MD Anderson where
	MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of a) May 31, 2016 or b) four days after
	the Company&rsquo;s completion of the IPO. These amounts were paid prior to or on May 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	MD Anderson &ndash; Patent &amp; Technology
	License Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Upon the Company&rsquo;s acquisition of Moleculin,
	LLC on May 2, 2016, we obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent
	rights related to our WP1066 drug product candidate from MD Anderson through a Patent and Technology License Agreement Moleculin,
	LLC entered with MD Anderson on June&nbsp;21, 2010 (the &ldquo;Moleculin License Agreement&rdquo;). Under the Moleculin License
	Agreement, Moleculin, LLC obtained the right to manufacture, have manufactured, use, import, offer to sell or sell products worldwide
	for any indication under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed
	to make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales
	of products developed under the license agreement. Specifically, under the Moleculin License Agreement, Moleculin, LLC agreed to
	pay a nonrefundable upfront documentation fee and an annual maintenance fee in the amount of $20,000 on June 21, 2011, which has
	and shall increase in $10,000 increments on an annual basis thereafter up to a maximum of $100,000, except that such payments will
	no longer be due upon marketing approval in any country of a licensed product. Under the Moleculin License Agreement, Moleculin,
	LLC also agreed to make a minimum annual royalty payment to MD Anderson in the amount of $200,000 after the first sale of a licensed
	product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 107; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Upon completion of our acquisition of Moleculin,
	LLC, we assumed the rights and obligations of Moleculin, LLC. However, the rights we have obtained pursuant to the assignment of
	the Moleculin License Agreement are made subject to the rights of the U.S. government to the extent that the technology covered
	by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All
	out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall
	continue to be assumed by us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 8, 2015, Moleculin, LLC entered
	into a letter agreement with MD Anderson for Moleculin, LLC&rsquo;s past due fees to MD Anderson in the amount of $691,186 of which
	$300,000 had been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining
	past due fee in three installments: a) $125,000 on October 31, 2015; b) $175,000 on January 31, 2016; and c) $91,186 on April 30,
	2016. Moleculin, LLC paid $125,000 to MD Anderson on November 2, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 19, 2015, the agreement was amended
	for the milestone payments. The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed
	drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States
	- $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States $600,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 28, 2016, the Company and Moleculin,
	LLC entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or
	before the earlier of April 30, 2016 or four days after our IPO. This date was amended and per the amended agreement, the Company
	paid the outstanding Moleculin, LLC fees on May 31, 2016 in the amount of $306,186.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	Bonwick Capital Partners LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 22, 2016, as amended on February
	15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (&ldquo;Bonwick&rdquo;) to engage Bonwick
	as an exclusive financial advisor of the Company. Pursuant to the agreement, the Company agreed to: a) pay success fees equal to
	7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Company&rsquo;s equity
	securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Company&rsquo;s common stock
	paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses
	incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.
	Upon completion of the Company&rsquo;s IPO, the Company paid Bonwick a $50,000 advisory fee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Bonwick is also entitled to a success fee as
	set forth above if the Company completes a financing with parties introduced by Bonwick prior to the termination agreement or during
	the 6-month period following the termination of the agreement, which occurred on August 2, 2016. In connection with the Company&rsquo;s
	IPO, Bonwick received a success fee of $646,872, warrants to purchase 107,802 shares of common stock at an exercise price of $7.50
	per share, and $6,266 for reimbursement of expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Houston Pharmaceuticals, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our acquisition of Moleculin, LLC, occurring
	prior to our IPO offering, provided us with the rights of the license agreement that Moleculin, LLC had with MD Anderson covering
	the WP1066 Portfolio. As discussed in Note 2, we are obligated to make payments to HPI totaling $750,000 over a three-year period
	commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the
	research and development conducted by HPI. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of
	the date we enter into the agreement to buy-out from HPI all rights granted to HPI under the agreement for a payment of $1.0 million.
	Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the $750,000 obligation
	discussed above. We will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding
	will be available on satisfactory terms, or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Employment Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 13, 2016, the Company and its Chief
	Executive Officer entered into an employment agreement, pursuant to which, during the period commencing June 1, 2016 and ending
	June 1, 2017, $12,500 per month of the compensation is deferred. The deferred compensation shall be payable in a lump sum on the
	earlier of the termination of the employment agreement or June 1, 2019. As of September 30, 2016, deferred compensation of $50,000
	was included in long-term payable-related party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 7 &ndash; Subsequent Events
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In December 2016, the Company
	issued 110,038 shares of its common stock for conversion of convertible notes previously issued and agreed to issue
	79,167 shares of its common stock to a third-party in settlement of $237,500 in past due amounts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 108; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_016">
</A>
	REPORT OF INDEPENDENT REGISTERED
	PUBLIC ACCOUNTING FIRM
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	To the Board of Directors and Stockholders of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Moleculin Biotech, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Houston, Texas
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying balance sheet
	of Moleculin Biotech, Inc. as of December 31, 2015 and the related statements of operations, changes in stockholders&rsquo; deficit,
	and cash flows for the period from July 28, 2015 (Inception) to December 31, 2015. Moleculin Biotech, Inc.&rsquo;s management is
	responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on
	our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audit in accordance with the
	standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the
	audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not
	required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included
	consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
	circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over
	financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
	the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made
	by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable
	basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the financial statements referred
	to above present fairly, in all material respects, the financial position of Moleculin Biotech, Inc. as of December 31, 2015 and
	the results of its operations and cash flows for the period from July 28, 2015 (Inception) to December 31, 2015 in conformity with
	accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The accompanying financial statements have
	been prepared assuming that Moleculin Biotech, Inc. will continue as a going concern. As discussed in Note 1 to the financial statements,
	Moleculin Biotech, Inc. incurred an accumulated loss and has not yet generated any revenue from operations that raise substantial
	doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described
	in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	/s/ GBH CPAs, PC
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	GBH CPAs, PC
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-DECORATION: UNDERLINE">
<U>
	www.gbhcpas.com
</U>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Houston, Texas
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	March 21, 2016
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 109; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_005">
</A>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Balance Sheet
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,&nbsp;&nbsp;
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
<A NAME="FIS_BALANCE_SHEET_3"></A>
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.25IN; TEXT-INDENT: 0IN">
	Total Assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Accounts payable and accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	322,790
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Notes payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Total Liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	772,790
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commitments and contingencies
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stockholders&rsquo; Deficit:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0; PADDING-LEFT: 0.125IN">
	Common stock, $0.001 par value; 20,000,000 shares authorized, 6,661,000 shares issued and outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,661
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Subscription receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Total Stockholders&rsquo; Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(744,699
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.25IN">
	Total Liabilities and Stockholders&rsquo; Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 110; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_006">
</A>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Statement of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	From July 28,
<BR>
	2015
<BR>
	(Inception) to
<BR>
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	260,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	477,810
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	738,228
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Loss from operations
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(738,228
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other expense:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN">
	Total other expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.25IN">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss per common share - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted average number of common shares outstanding - basic and diluted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,691,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 111; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_007">
</A>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Statement of Changes in Stockholders&rsquo;
	Deficit
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Common Stock
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Subscription
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Receivable
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Deficit
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0IN">
	Balance at July 28, 2015 (Inception)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; PADDING-LEFT: 0.125IN">
	Issuance of shares for cash
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,600,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,600
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,600
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 16.55PT">
	Shares issued for licenses used for research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,061,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,061
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,061
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6,661,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6,661
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(3,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(744,699
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 112; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_008">
</A>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Statement of Cash Flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the period
<BR>
	from July 28,
<BR>
	2015 (Inception)
<BR>
	to December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows From Operating Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(748,360
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Shares issued for licenses used for research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,061
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN; PADDING-LEFT: 0IN">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	322,790
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.375IN">
	Net Cash Used In Operating Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(423,509
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows From Financing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Proceeds from stock issuance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
	Proceeds from notes payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.375IN">
	Net Cash Provided By Financing Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	451,600
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net change in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalent at beginning of period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalent at end of period
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,091
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Supplemental cash flows disclosures:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Cash paid for interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Cash paid for income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-cash investing and financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	Shares subscribed
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 113; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_009">
</A>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Notes to Financial Statements
</B>
</P>
</EFX_AUDITORS_OPINION>
</EFX_SECURITIES_DESCRIPTION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 1 - Description of Business and Summary of Significant Accounting
	Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Nature of Business &ndash;
</B>
	Moleculin
	Biotech, Inc. (&ldquo;MBI&rdquo;, the &ldquo;Company&rdquo;) is a preclinical-stage pharmaceutical company organized
	as a Delaware corporation in July 2015 to focus on the development of anti-cancer drug candidates. The Company has two in-licensed
	drug development technologies.The lead drug candidate is Lipsosomal Annamycin, which is referred to as Annamycin, an anthracyline
	that targets the treatment of relapsed or refractory acute myeloid leukemia, or AML. In August 2015, the Company entered into a
	rights transfer agreement with AnnaMed, Inc. (&ldquo;AnnaMed&rdquo;), a company affiliated with certain members of our management
	and board of directors, pursuant to which, in exchange for 1,431,000 shares of our common stock, AnnaMed agreed to transfer any
	and all data it had regarding the development of Annamycin and the Annamycin IND, including all trade secrets, know-how, confidential
	information and other intellectual property rights held by AnnaMed. Annamycin has been in clinical trials pursuant to an investigational
	new drug application, or IND, that had been filed with the U.S. Food and Drug Administration, or FDA. This IND was terminated due
	to a lack of activity by a prior drug developer who was developing the drug for a different indication. We intend to apply for
	a new IND based on the same data that supported the original IND, updated for subsequent clinical data, and to commence a Phase
	II clinical trial for Annamycin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company also has a second drug development
	technology, WP1122, a molecule targeting the treatment of glioblastoma through metabolic inhibition, which was developed at The
	University of Texas M.D. Anderson Cancer Center (&ldquo;MD Anderson&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 11, 2015, the Company entered into
	a rights transfer agreement with IntertechBio Corporation (&ldquo;IntertechBio&rdquo;), a company affiliated with certain members
	of our management and board of directors, whereby IntertechBio agreed to assign its license or sublicense its license to certain
	metabolic inhibitor technology owned by MD Anderson. In consideration, the Company issued 630,000 common shares to Intertech Bio.
	IntertechBio agreed to make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance
	fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. The Company
	has assumed the rights and obligations of IntertechBio under the license agreement with MD Anderson. All out-of-pocket expenses
	incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed
	by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company intends to file a registration
	statement on Form S-1 with respect to the Company&rsquo;s initial public offering of shares of its common stock (&ldquo;IPO&rdquo;)
	to fund the development of its technologies and also intends to acquire Moleculin, LLC, a Texas limited liability company. Moleculin,
	LLC is the holder of a license agreement with MD Anderson covering technology referred to as WP1066 Portfolio, which is focused
	on the modulation of key oncogenic transcription factors. Immediately prior to the declaration of effectiveness of the registration
	statement on Form S-1, Moleculin, LLC will be merged with and into MBI, which will survive the merger.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Use of Estimates in Financial Statement
	Presentation -
</B>
	The preparation of these financial statements in conformity with accounting principles generally accepted in
	the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
	liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Going Concern -
</B>
	These financial statements
	have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities
	in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial
	support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, and the
	attainment of profitable operations. As of December 31, 2015, the Company has incurred an accumulated loss of $748,360 since inception,
	had a working capital deficit of $744,699, and had not yet generated any revenue from operations. These factors raise substantial
	doubt regarding the Company&rsquo;s ability to continue as a going concern. These financial statements do not include any adjustments
	to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should
	the Company be unable to continue as a going concern. The Company intends to fund its future operations through equity offerings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Cash and Cash Equivalents -
</B>
	The Company
	considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At December 31, 2015,
	all of the Company&rsquo;s cash was deposited in one bank.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Beneficial Conversion Feature
</B>
	- From
	time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion
	feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value
	of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the
	note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments,
	if any related equity instruments were granted with the debt. The Company estimates the fair value of its common stock using the
	most recent selling price available. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with
	a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note
	using the effective interest method.&nbsp; &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes -
</B>
	The Company uses the
	asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined
	based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured
	using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then
	assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more
	likely than not that some portion or all of a deferred tax asset will not be realized.
</P>
<!-- FIELD: PAGE; SEQUENCE: 114; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Stock-based Compensation -
</B>
	Stock-based
	compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity
	awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as
	expense over the applicable vesting period of the stock award using the straight-line method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Earnings Per Share
</B>
	- Basic net earnings
	(loss) per common share are computed by dividing net earnings (loss) available to common shareholders by the weighted-average number
	of common shares outstanding during the period. Diluted net earnings (loss) per common share is determined using the weighted-average
	number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods
	when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their
	inclusion would be anti-dilutive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Research and Development Costs -
</B>
	Research
	and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company
	as a reduction of research and development costs.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent Events -
</B>
	The Company&rsquo;s
	management reviewed all material events through the date these financial statements were issued for subsequent event disclosure
	consideration.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recent Accounting Pronouncements -
</B>
	The
	Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if
	adopted, would have a material effect on the accompanying financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 2 - Notes Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 31 and September 3, 2015, as amended
	on March 10, 2016, the Company entered into two unsecured convertible promissory notes with a third party, in the amount totaling
	$250,000. These notes bear interest at 8.0% per annum and mature on the earlier of June 30, 2016 or the completion of an IPO of
	the Company&rsquo;s securities. However, if the completion of the IPO occurs prior to June 30, 2016, these notes shall be automatically
	converted according to its terms into shares of the Company&rsquo;s common stock at a conversion price of $0.1299 per share upon
	the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 6, 2015, as amended on March 10,
	2016, the Company entered into an unsecured promissory note with a third party in the amount of $150,000. The note bears interest
	at 8.0% per annum and matures on the earlier of June 30, 2016 or the completion of an IPO of the Company&rsquo;s securities. However,
	if the completion of the IPO occurs prior to June 30, 2016, the note shall be automatically converted according to its terms into
	shares of the Company common stock at a conversion price equal to $0.20 per share upon the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 28, 2015, as amended on March 10,
	2016, the Company entered into an unsecured promissory note with a third party in the amount of $50,000. The note bears interest
	at 8.0% per annum and matures on the earlier of June 30, 2016 or the completion of an IPO of the Company&rsquo;s securities. However,
	if the completion of the IPO occurs prior to June 30, 2016, the note shall be automatically converted according to its terms into
	shares of the Company common stock at a conversion price equal to $0.20 per share upon the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Pursuant to the note agreements dated October
	6, 2015 and October 28, 2015, the Company agreed, during the term of the notes, not to have greater than 8,171,000 shares of its
	common stock outstanding, excluding any shares underlying convertible notes that will convert into 3,750,000 shares of the Company&rsquo;s
	common stock, and excluding options to purchase up to 300,000 shares of the Company&rsquo;s common stock at an exercise price of
	no less than $0.75 per share that may be issued. The Company is currently in compliance with this covenant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The convertible notes were analyzed for a beneficial
	conversion feature at which time it was concluded that a beneficial conversion feature did not exist.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 3 - Equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In August 2015, the Company entered into an
	agreement to issue 4,600,000 shares of common stock to its director and officers for subscriptions of $4,600 cash to be received.
	As of December 31, 2015, the Company had not collected the proceeds for $3,000 of the subscriptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 11, 2015, the Company was granted
	an assignment of a license agreement between MD Anderson and IntertechBio in exchange for 630,000 shares of the Company&rsquo;s
	common stock. The sublicense gives the Company rights to access certain metabolic inhibitor technology owned by MD Anderson that
	had been licensed to IntertechBio. The shares were valued at a total of $630 and the related expense included in research and development
	costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 21, 2015, the Company acquired the
	right to the intellectual property of AnnaMed in exchange for 1,431,000 shares of the Company&rsquo;s common stock. The license
	gives the Company full ownership rights to the data package supporting the FDA IND Number 46869, allowing the Company to resubmit
	a request for IND to the FDA to begin development work on Annamycin. The shares were valued at a total of $1,431 and the related
	expense included in research and development costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Adoption of 2015 Stock Plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On December 5, 2015, the Board of Directors
	of the Company approved the Company&rsquo;s 2015 Stock Plan. The expiration date of the plan is December 5, 2025 and the total
	number of underlying shares of the Company&rsquo;s common stock available for grant to employees, directors and consultants under
	the plan is 1,500,000 shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Stock Options
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On December 10, 2015, the Board of Directors
	of the Company granted it Chief Financial Officer, Louis Ploth, options to purchase 200,000 shares of the Company&rsquo;s common
	stock with exercise price of $0.20 per share and a term of 10 years. These options vest in four years. The grant date fair value
	of $27,390 was calculated using the Black-Scholes model. Variables used in the Black-Scholes model include: (1) discount rate of
	2.24% (2) expected life of 6.25 years, (3) expected volatility of 74.2%, and (4) zero expected dividends. As of December 31, 2015,
	no option is exercisable.
</P>
<!-- FIELD: PAGE; SEQUENCE: 115; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 4 - Income Taxes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company is subject to the United States
	federal income taxes at an approximate rate of 35%. The reconciliation of the provision for income taxes at the United States federal
	statutory rate compared to the Company&rsquo;s income tax expense as reported is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	From July 28,
<BR>
	2015
<BR>
	(Inception) to
<BR>
	December&nbsp;31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	Income tax benefit computed at the statutory rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	261,926
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(261,926
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Provision for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Significant components of the Company&rsquo;s
	deferred tax assets after applying enacted corporate income tax rates are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	As of
<BR>
	December&nbsp;31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred income tax assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Net operating losses
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	261,926
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Less: valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(261,926
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net deferred income tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The Company has an operating loss carry forward
	of approximately $748,000, which expires commencing in 2035.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 5 &ndash; Commitments and contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Burnham Securities Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 5, 2015, the Company entered into
	a letter agreement with Burnham Securities Inc. (&ldquo;Burnham&rdquo;) to engage Burnham as an exclusive financial advisor of
	the Company for 12 months. Pursuant to the agreement, the Company agreed to: a) pay success fees equal to 7% of the gross proceeds
	from any form of financing; b) issue warrants to purchase 7% of the Company&rsquo;s equity securities sold with a cashless exercise
	provision, exercisable at a price per share of the equity securities paid by investors in the transaction. In addition, the Company
	agreed to reimburse Burnham for all of its reasonable out-of-pocket expenses. Upon execution of this agreement, the Company also
	paid Burnham a $50,000 advisory fee and agreed to pay an additional advisory fee of $50,000 upon completion of the Company&rsquo;s
	IPO. For the period from inception to December 31, 2015, the Company incurred $31,500 success fees related to the notes issued
	to in August, September and October 2015. See Note 3. This agreement was terminated by mutual consent on January 22, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	MD Anderson &ndash; IntertechBio Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 11, 2015, the Company acquired the
	rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio and MD Anderson dated
	April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license to intellectual
	property including patent rights related to the Company&rsquo;s drug product candidate, WP1122. Under the agreement, IntertechBio
	agreed to pay annual maintenance fee in the amount of $10,000 on the first anniversary of the effective date of the agreement,
	$20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary of the effective date
	of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement (this payment was not made and the parties
	expect to enter into an amendment to defer this payment until the earlier of May 31, 2016 or four days after the IPO), $80,000
	on the fifth anniversary of the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of
	the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the agreement,
	IntertechBio also agreed to make a minimum annual royalty in the amount of $200,000 for the first anniversary following the first
	sale of a licensed product, $400,000 for the second anniversary following the first sale of a licensed product, and $600,000 for
	the third year following the first sale of a licensed product. IntertechBio also agreed to make certain milestone payments. On
	October 19, 2015, pursuant to an amendment, the Company will pay milestone payments as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Phase
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: LEFT">
	Commencement of Phase II Study for a licensed product
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commencement of Phase III Study for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	250,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Filing of a New Drug Application for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Receipt of market approval for a licensed product
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 116; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	MD Anderson has the right to terminate the
	agreement upon advanced notice in the event of a default by IntertechBio. The agreement will also be terminated immediately upon
	IntertechBio&rsquo;s insolvency. Additionally, per the October 2015 amendment to the agreement, MD Anderson has the right to terminate
	the license agreement if (i) a preclinical toxicology program for a licensed product is not initiated within one year of the effective
	date of the amendment, (ii) an investigational new drug application is not filed with the Food and Drug Administration for a Phase
	I study for a licensed product within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed
	product is not commenced within five years of the effective date of the amendment. The agreement will expire upon the expiration
	of the licensed intellectual property. The rights obtained by the Company pursuant to the agreement are made subject to the rights
	of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding
	agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting
	and maintaining the licensed patents have been and shall continue to be assumed by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 8, 2015, IntertechBio Corporation
	entered into a letter agreement with MD Anderson where MD Anderson agreed to receive past due maintenance fees and patent expenses
	of $98,108 owed by IntertechBio Corporation in four installments. The past due amount is related to certain metabolic inhibitor
	technology license that was assigned to the Company by IntertechBio Corporation and was owed by IntertechBio Corporation prior
	to the Company&rsquo;s acquisition of the license. Pursuant to the letter, IntertechBio Corporation also agreed to pay $65,504
	in patent fees to a law firm. In order to have the license in good standing, the Company agreed to pay MD Anderson the $98,108
	and the $65,504 in patent fees to a patent law firm on behalf of IntertechBio Corporation. As of December 31, 2015, $45,000 of
	the past due amount to MD Anderson and $42,504 in patent fees to a patent law firm were still outstanding and were included in
	accounts payable and accrued liabilities. On January 28, 2016, the Company entered into a letter agreement with MD Anderson where
	MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of a) April 30, 2016 or b) four days after
	the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	MD Anderson &ndash; Option Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 15, 2015, the Company entered into
	an exclusive option agreement with MD Anderson granting the Company a period of time to evaluate the potential of acquiring and
	to negotiate the purchase of an exclusive license in the field of cancer therapeutics. The option period extends from October 15,
	2015 through May 11, 2016. MD Anderson shall not offer the license to any other third party during the option period. In consideration
	of the option granted, the Company paid $5,000 to MD Anderson.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 6 - Subsequent Events
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 14, 2016, as amended March 10, 2016,
	the Company entered into an unsecured convertible promissory note with a third party in the amount of $82,500. The note bears interest
	at 8.0% per annum and matures on the earlier of June 30, 2016 or the completion of an IPO of the Company&rsquo;s securities. However,
	if the completion of the IPO occurs prior to June 30, 2016, the note shall be converted according to its terms into shares of the
	Company common stock at a conversion price equal to $0.20 per share upon the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 19, 2016, as amended March 10, 2016,
	the Company entered into an unsecured convertible promissory note with a third party in the amount of $82,500. The note bears interest
	at 8.0% per annum and matures on the earlier of June 30, 2016 or the completion of an IPO of the Company&rsquo;s securities. However,
	if the completion of the IPO occurs prior to June 30, 2016, the note shall be converted according to its terms into shares of the
	Company common stock at a conversion price equal to $0.20 per share upon the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 22, 2016, as amended on February
	15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (&ldquo;Bonwick&rdquo;) to engage Bonwick
	as an exclusive financial advisor of the Company. Pursuant to the agreement, the Company agreed to: a) pay success fees equal to
	7% of the gross proceeds from any form of financing; b) issue warrants to purchase 7% of the Company&rsquo;s equity securities
	sold with a cashless exercise provision, exercisable at 125% of the price per share of the Company&rsquo;s common stock paid by
	investors in the transaction. The warrants should have a term of 5 years. In addition, the Company agreed to reimburse Burnham
	for all of its out-of-pocket expenses incurred in connection with this offering, which shall not exceed $25,000, and fees and expenses
	of their counsel not to exceed $100,000. Upon completion of the Company&rsquo;s IPO, the Company shall pay Bonwick a $50,000 advisory
	fee. The agreement will expire on the earlier of August 6, 2016 or the mutual written agreement of the Company and Bonwick. Bonwick
	shall be entitled to a success fee as set forth above if the Company complete a financing with parties introduced by Bonwick prior
	to the termination agreement during the 6 months period following the termination of the agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 8, 2016, Moleculin, LLC issued a
	revolving line of credit promissory note to the Company where the Company agreed to loan up to $50,000 to Moleculin LLC. The note
	bears annual interest rate at 8% and has a late charge of 5% for amount overdue. Interest is payable monthly to the Company commencing
	on July 8, 2016 and all outstanding balance is payable on January 8, 2017. The Company has funded $25,000 to Moleculin, LLC subsequent
	to January 8, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Subsequent to December 31, 2015 through March
	21, 2016, the Company sold 128,833 common shares for $386,499.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 7 - Additional Subsequent Events (Unaudited)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	During April 2016, the Company sold a total
	of 97,130 common shares for $291,390 to several investors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 117; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="V458551_S1A_HTM_A_010">
</A>
	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
	FIRM
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	To the Board of Directors and Stockholders of
<BR>
	Moleculin, LLC
<BR>
	Houston, Texas
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying statements
	of financial position of Moleculin, LLC as of December 31, 2015 and 2014 and the related statements of operations, changes in members&rsquo;
	deficit, and cash flows for the years then ended. Moleculin, LLC&rsquo;s management is responsible for these financial statements.
	Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance with
	the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company
	is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included
	consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
	circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over
	financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
	the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made
	by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
	basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the financial statements referred
	to above present fairly, in all material respects, the financial position of Moleculin, LLC as of December 31, 2015 and 2014 and
	the results of its operations and cash flows for the years then ended in conformity with accounting principles generally accepted
	in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The accompanying financial statements have
	been prepared assuming that Moleculin, LLC will continue as a going concern. As discussed in Note 1 to the financial statements,
	Moleculin, LLC has suffered recurring losses from operations and has insufficient working capital that raise substantial doubt
	about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note
	1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	/s/ GBH CPAs, PC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	GBH CPAs, PC
<BR>
<U>
	www.gbhcpas.com
</U>
<BR>
	Houston, Texas
<BR>
	March 21, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 118; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_011">
</A>
	Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Statements of Financial Position
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	As of December 31, 2015 and 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	December 31,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	31,867
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	524,477
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 13.2PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,354
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,076
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 13.8PT; PADDING-LEFT: 13.2PT">
	Total Current Assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	526,553
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	232,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Property and equipment, net of accumulated depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,259
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,595
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 27PT">
	Total Assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	45,480
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	781,448
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	LIABILITIES AND MEMBERS&rsquo; DEFICIT
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current Liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Accounts payable and accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	838,072
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,047,455
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Accounts payable and accrued liabilities - related parties
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,871
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,744
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Common units payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	548,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Current portion of long-term note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	414,165
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 13.2PT">
	Convertible notes payable, net of $79,076 discount and $35,787 deferred financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,020,064
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 13.2PT">
	Convertible notes payable- related parties, net of $30,215 discount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	483,864
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 13.8PT; PADDING-LEFT: 13.2PT">
	Total Current Liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,878,810
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,621,829
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Long-term note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	414,165
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Convertible notes payable, net of $237,664 discount and $107,558 deferred financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	789,705
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Convertible notes payable - related parties, net of $90,811 discount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	423,268
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 27PT">
	Total Liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,878,810
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,248,967
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commitments and contingencies
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Members&rsquo; Deficit:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -15.75PT; PADDING-LEFT: 29.25PT">
	Preferred units, 16,321,558 units authorized, 13,515,820 units issued and outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,620,186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,620,186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 13.5PT">
	Common units, 4,727,074 authorized, 4,178,444 units issued and outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 13.5PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(14,203,516
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,837,705
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 13.8PT; PADDING-LEFT: 13.2PT">
	Total Members&rsquo; Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,833,330
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,467,519
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: 27PT">
	Total Liabilities and Members&rsquo; Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	45,480
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	781,448
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 119; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_012">
</A>
	Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Statements of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	For the Years Ended December 31, 2015 and
	2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Revenue
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	125,442
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	798,785
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	328,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	839,556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: 9PT">
	Depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,336
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,005
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	465,348
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,649,346
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	Loss from operations
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(465,348
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,649,346
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Gain on extinguishment of liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	548,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Other income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 9PT">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(449,643
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(160,540
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	Total other income (expense)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	99,537
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(159,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 120; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_013">
</A>
	Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Statements of Changes in Members&rsquo; Deficit
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	For the Years Ended December 31, 2015 and
	2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Preferred Units
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Common Units
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Units
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Units
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 22%">
	Balance at December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	13,515,820
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	10,207,934
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,178,444
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	750,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(12,028,619
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(1,070,685
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	Beneficial conversion feature of convertible notes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	412,252
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	412,252
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0.15PT">
	Balance at December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,515,820
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,620,186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,178,444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,837,705
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,467,519
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0.15PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.15PT; PADDING-LEFT: 9PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,515,820
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,620,186
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,178,444
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	750,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(14,203,516
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,833,330
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 121; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_014">
</A>
	Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Statements of Cash Flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	For the Years Ended December 31, 2015 and
	2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows From Operating Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(365,811
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(1,809,086
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	Depreciation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,005
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	Amortization of debt discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	219,184
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	83,777
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	Amortization of deferred financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71,771
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,192
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	Gain on extinguishment of liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(548,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 27PT">
	Prepaid expenses and other current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,386
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 27PT">
	Accounts payable and accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(153,609
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	317,673
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 27PT">
	Accounts payable and accrued liabilities - related parties
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	41,127
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,908
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.5IN">
	Net Cash Used In Operating Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(724,910
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,354,145
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows From Investing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 9PT">
	Collection from other receivables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	232,300
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.5IN">
	Net Cash Provided By Investing Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	232,300
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash Flows From Financing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Proceeds from issuances of convertible notes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,011,177
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 9PT">
	Proceeds from issuances of convertible notes payable - related parties
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	514,079
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.5IN">
	Net Cash Provided By Financing Activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,525,256
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net change in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(492,610
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	171,111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	524,477
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	353,366
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	31,867
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	524,477
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Supplemental cash flow disclosures:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Cash paid for interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Cash paid for income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-cash investing and financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Long-term note payable issued to settle accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	414,165
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Note payable issued to settle accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 9PT">
	Beneficial conversion feature of convertible notes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	412,252
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	See accompanying notes to the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 122; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V458551_S1A_HTM_A_015">
</A>
	Moleculin, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Notes to Financial Statements
</B>
</P>
</EFX_AUDITORS_OPINION>
</EFX_SECURITIES_DESCRIPTION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION_5"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 1 - Description of Business and Summary
	of Significant Accounting Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Nature of Business -
</B>
	Moleculin, LLC,
	a Texas limited liability company, (the &ldquo;Company&rdquo; or &ldquo;Moleculin&rdquo;) is an early-stage Houston-based pharmaceutical
	company formed in December 2006 to create novel therapies for skin disorders and the development of cancer related technology.
	Although the Company previously focused on the development of treatments for skin disorders, the Company&rsquo;s current focus
	is on the development of drugs for cancer treatment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Moleculin intends to be acquired by Moleculin
	Biotech, Inc. (&ldquo;MBI&rdquo;) by merging into MBI. The intended transaction is scheduled to occur immediately prior to the
	declaration of effectiveness of MBI&rsquo;s registration statement on Form S-1 with respect to MBI&rsquo;s initial public offering
	of its common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Use of Estimates in Financial Statement
	Presentation -
</B>
	The preparation of these financial statements in conformity with accounting principles generally accepted in
	the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
	liabilities at the date of these financial statements and the reported amounts of revenues and expenses during the reporting period.
	Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Going Concern -
</B>
	These financial statements
	have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities
	in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial
	support from its members, the ability of the Company to obtain necessary equity financing to continue operations, and the attainment
	of profitable operations. The Company has suffered recurring losses from operating and has insufficient working capital. As of
	December 31, 2015, the Company has incurred accumulated deficit of $14,203,516 since inception, had a working capital deficit of
	$2,844,589, and has not yet generated any significant revenue from operations. These factors raise substantial doubt regarding
	the Company&rsquo;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability
	and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable
	to continue as a going concern. The Company intends to be acquired by MBI and to fund the operations through MBI&rsquo;s equity
	offerings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Cash and Cash Equivalents -
</B>
	The Company
	considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Balances held by
	the Company are typically in excess of Federal Deposit Insurance Corporation&rsquo;s insured limits ($250,000 per depositor per
	bank). At December&nbsp;31, 2015 and 2014, all of the Company&rsquo;s cash was deposited in one bank.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Property and Equipment -
</B>
	Property and
	equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives. Leasehold improvements are
	recorded at cost and depreciated on a straight-line basis over the shorter of the estimated useful life or the lease term. When
	assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or
	loss is reflected in income (loss) for the period. Expenditures for major additions which extend the useful lives of assets are
	capitalized. Minor replacements, maintenance and repairs, which do not improve or extend the life of such assets are charged to
	expense as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Impairment of Long-Lived Assets -&nbsp;
</B>
	Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
	may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated
	future undiscounted cash flows associated with the asset are compared to the asset&rsquo;s carrying value to determine if an impairment
	of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset
	and its carrying value. For the years ended December 31, 2015 and 2014, there were no impairments recorded.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Fair Value of Financial Instruments -
</B>
	&nbsp;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly
	transaction between market participants. A fair value hierarchy has been established for valuation inputs that give the highest
	priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.
	The fair value hierarchy is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	Level 1 Inputs - Unadjusted quoted
	prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
	date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	Level 2 Inputs - Inputs other than
	quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include
	quoted prices for similar assets or liabilities&nbsp;in&nbsp;active markets, quoted prices for identical or similar assets or liabilities
	in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest
	rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
	data by correlation or other means.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	Level 3 Inputs - Unobservable inputs
	for determining the fair values of assets or liabilities that reflect an entity&rsquo;s own assumptions about the assumptions that
	market participants would use in pricing the assets or liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 123; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes -
</B>
	The Company elected to
	be taxed as a partnership under the Internal Revenue Code. The Company pays no U.S. taxes on its earnings. The Company&rsquo;s
	net earnings/losses are passed through to the Company&rsquo;s members and, as such, reports no income tax expense or liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Revenue Recognition
</B>
	- The Company recognizes
	revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been provided, the purchase
	price is fixed or determinable and collectability is reasonably assured. The Company may receive cost reimbursement-based grants.
	For these grants, revenues are based on costs incurred that are specifically covered under reimbursement arrangements. These revenues
	are recognized as grant-related expenses are incurred by the Company or its subcontractors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Research and Development Costs -
</B>
	Research
	and development costs are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent Events
</B>
	- The Company&rsquo;s
	management reviewed all material events through the date these financial statements were issued for subsequent event disclosure
	consideration.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recent Accounting Pronouncements
</B>
	-
<FONT STYLE="COLOR: #1A1A1A">
	In
	June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements.
	ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the
	elimination of inception-to-date information on the statements of operations, cash flows and stockholders&rsquo; equity. The amendments
	in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods
	within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 as of December&nbsp;31,
	2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; COLOR: #1A1A1A">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; COLOR: #1A1A1A">
	In April&nbsp;2015, the FASB
	issued ASU 2015-03, Interest &ndash; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&nbsp;The
	amended guidance requires that debt issuance costs be presented in the balance sheet as a direct reduction from the carrying amount
	of the recognized debt liability, consistent with the treatment of debt discounts.&nbsp;Amortization of debt issuance costs is
	to be reported as interest expense.&nbsp;The updated guidance is effective for reporting periods beginning after December&nbsp;15,
	2015, and interim periods within those annual periods, however early adoption is permitted.&nbsp;The Company evaluated and adopted
	ASU 2015-13 as of December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; COLOR: #1A1A1A">
	The Company does not believe
	that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have
	a material effect on the accompanying financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; COLOR: #1A1A1A">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 2 &ndash; Other Receivables
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 27, 2010, the Company entered into
	a Patent and Technology Development and License Agreement with Dermin, Sp. Zo. O. (&ldquo;Dermin&rdquo;), a Polish limited liability
	company, to assist in the development and commercialization of certain pharmaceutical products within a described licensed territory
	in exchange for royalty payments. On December 19, 2011, the Company advanced $200,000 to Dermin providing funding assistance to
	Dermin&rsquo;s efforts in developing and commercializing these pharmaceutical products in and around the Poland European region.
	Further, throughout the year 2012, the Company paid $32,300 of expenses on behalf of Dermin. As of December 31, 2014, the Company
	had $232,300 long-term note receivable from Dermin which was collected in August 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 3 - Property and Equipment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Property and equipment consisted of the following
	at December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Lives
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Leasehold improvements
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1 year
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	81,602
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	81,602
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Machinery and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57,327
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57,327
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Furniture and fixtures
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,955
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,955
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Less: accumulated depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(135,625
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(124,289
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Property and equipment, net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	11,259
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	22,595
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Depreciation expense for the years ended December
	31, 2015 and 2014 were $11,336 and $11,005, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 124; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	Note 4 &ndash; Notes Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On September 8, 2015, the Company issued an
	unsecured promissory note to Hilltop Research in the amount of $55,774 to settle an outstanding payable. The note matures on June
	30, 2016 and accrues interest at 6.0% per annum. In the event that the Company or a significant portion of the Company&rsquo;s
	assets are acquired by MBI prior to the maturity date, the loan becomes due and payable upon closing of MBI&rsquo;s initial public
	offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On September 16, 2014, the Company issued a
	promissory note in the amount of $414,165 to Davos Chemical Corporation to settle an outstanding accounts payable balance. The
	note bears interest at an annual rate of 6.0% and matures on the earlier of December 31, 2016 or the completion of one of the following
	prior to December 31, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company (i) is awarded a grant from the Cancer Prevention and Research Institute of Texas (&ldquo;CPRIT&rdquo;) of at least $5,000,000, and (ii) is deemed by CPRIT to have received the 50% matching funds required by the CPRIT grant; or
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company concludes a privately placed sale of the Company&rsquo;s Series A Preferred Units of at least $3,000,000.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015 and 2014, accrued interest
	related these notes were $34,275 and $7,217, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 5 &ndash; Convertible Notes Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	From May to November 2014, the Company issued
	various convertible notes to its creditors. Gross proceeds from third and related parties were $1,134,927 and $514,079, respectively.
	These notes bear interest at 8% per annum and are due on the earlier of June 30, 2016 or the consummation of a liquidation event,
	unless these notes are converted, pursuant to the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Automatic conversion upon CPRIT qualified financing- When the Company is awarded a grant from the CPRIT of at least $3,500,000 and is deemed by CPRIT to have received the 50% matching funds required by the CPRIT grant. The conversion price is $0.80 per unit in the event of a CPRIT qualified financing.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First tier automatic conversion - When the Company concludes a privately placed sale of the Company&rsquo;s Series A Preferred Units of at least $3,000,000 and is at a pre-money valuation of not less than $20,000,000. The conversion price is 80% of the lowest per unit purchase price in the privately placed sale in the event of a first tier automatic conversion.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second tier automatic conversion - When the Company concludes a privately placed sale of the Company&rsquo;s Series A Preferred Units of at least $2,000,000. The conversion price is 70% of the lowest per unit purchase price in the privately placed sale in the event of a second tier automatic conversion.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	d)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Voluntary conversion - At any time after the earlier of June 30, 2016 or a liquidation event, the note holders can elect to convert the notes into the Company&rsquo;s Preferred Units at $0.80 per unit.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	A liquidation event means: a) the acquisition
	of the Company by another entity; b) a sale, exclusive license, lease or other conveyance of all or substantially all of the Company&rsquo;s
	assets; c) any liquidation, dissolution of the Company; d) the acquisition of an aggregate of 50% or more of the Company&rsquo;s
	voting power by a party; e) in a bankruptcy proceeding. Upon a liquidation event, the note holders is entitle to 150% of the then
	outstanding principal and unpaid interest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	These convertible notes were analyzed for a
	beneficial conversion feature at which time it was concluded that a beneficial conversion feature existed.&nbsp;The beneficial
	conversion feature was measured using the commitment-date stock price and was determined to be $283,732 for third party notes and
	$128,520 for related party notes.&nbsp;&nbsp;This amount was recorded as a debt discount and is amortized to interest expense over
	the term of these notes. For the years ended December 31, 2015, amortization of debt discount for third and related parties were
	$158,588 and $60,596, respectively. For the years ended December 31, 2014, amortization of debt discount for third and related
	parties were $46,068 and $37,709, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On September 30, 2014, the Company entered
	into an agreement with Brompton Group NA, LLC (&ldquo;Brompton&rdquo;) for a non-exclusive arrangement to identify investors or
	lenders interested in providing financing for the Company. In exchange for their services, the Company agreed to pay Brompton 15%
	of the proceeds received from any financing provided by the investors introduced by Brompton. Brompton agreed to receive two-thirds
	of the fee, at their option, in either cash or in the form of the same securities offered in the financing being offered to the
	identified investors or lenders. The remaining fee should be paid in the form of the same securities offered in the financing.
	Of the $1,254,874 debt raised from third party investors during the fourth quarter of 2014, $825,000 was raised through investors
	introduced by Brompton. As such, $123,750 of finder&rsquo;s fee was recorded as debt discount and amortized over the life of the
	notes. For the years ended December 31, 2015 and 2014, interest expense associated with the amortization of the finder&rsquo;s
	fee was $71,771 and $16,192, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, accrued interest for
	third party and related party notes were $118,400 and $66,871, respectively. As of December 31, 2014, accrued interest for third
	party and related party notes were $27,605 and $25,744, respectively.
</P>
<!-- FIELD: PAGE; SEQUENCE: 125; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	Note 6 - Commitments
	and Contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	MD Anderson Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On June 21, 2010, the Company entered into
	a patent and technology license agreement with the University of Texas M.D. Anderson Cancer Center (&ldquo;MD Anderson&rdquo;)
	under which the Company is obligated to make upfront and periodic progress payments. The agreement allows the Company to obtain
	from MD Anderson an exclusive, worldwide royalty-bearing license to research, develop, manufacture, have manufactured, use, import,
	offer to sell or sell products comprising or made through the use of certain patent and technology rights owned by MD Anderson.
	In consideration, the Company agreed to pay for all out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining
	patent rights. Pursuant to the agreement, the Company also agreed to pay: a) an annual maintenance fee starting at $20,000 per
	year and increase by $10,000 each year up to a maximum of $100,000; b) royalties equal to 2.5% of net sales for licensed products
	approved for dermatological use; and c) royalties equal to 4.0% of net sales for licensed products approved for all other uses.
	The 2.5% and 4.0% royalties could be further reduced if certain criteria are met. Annual minimum royalties are $200,000 following
	the first sale after marketing approval is obtained from MD Anderson by the Company for any licensed products. In addition, the
	Company will be required to issue 3.5% of the total issued and outstanding common units of the Company on a fully diluted basis
	to MD Anderson at the time the Company commences its first phase II trial of a drug covered by the agreement. The Company is also
	required to pay certain milestone payments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 8, 2015, the Company entered into
	a letter agreement with MD Anderson for the Company&rsquo;s past due fees to MD Anderson in the amount of $691,186 of which $300,000
	has been paid prior to the letter agreement. Pursuant to the letter agreement, MD Anderson agreed to receive the remaining past
	due fee in three installments: a) $125,000 due on October 31, 2015; b) $175,000 due on January 31, 2016; and c) $91,186 due on
	April 30, 2016. The Company paid $125,000 to MD Anderson on November 2, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 19, 2015, the agreement was amended
	for the milestone payments. The amended milestone payments are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Phase
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 87%; TEXT-ALIGN: JUSTIFY">
	Commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	150,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Submission of the first NDA within the United States
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Receipt of first marketing approval for sale of a license product in the United States
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	600,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The amendment also removed the term regarding
	the issuance of 3.5% of the Company outstanding units.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 28, 2016, the Company entered into
	a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier
	of a) April 30, 2016 or b) four days after the Company&rsquo;s IPO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 15, 2015, the Company entered into
	a $5,000 exclusive option agreement with MD Anderson allowing the Company a period of time to evaluate the potential of acquiring
	and to negotiate the purchase of an exclusive license in the field of cancer therapeutics. The option period extends from October
	15, 2015 through August 31, 2016. MD Anderson shall not offer a license to any third party during the option period. The $5,000
	option fee was paid by MBI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Dermin Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On October 27, 2010, the Company entered into
	a Patent and Technology Development and License Agreement with Dermin. The agreement provided Dermin with sub-license rights to
	the Company&rsquo;s technologies for use in limited territories in exchange for Dermin&rsquo;s use of Polish government grant funding
	to pay for development costs the Company would otherwise have been required to fund. Dermin&rsquo;s territories are primarily Poland
	and surrounding countries, but not including any of the major European markets (UK, Germany, France, Spain and Italy).&nbsp;Pursuant
	to the agreement, Dermin has to pay the Company a running royalty on sales of license products. As of December 31, 2015, no sales
	have occurred and no royalty paid to the Company by Dermin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Lease Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On July 31, 2007, the Company entered into
	a rental agreement for office space at 2575 West Belfort, Houston, Texas. The agreement was renewed on July 26, 2010 for one year.
	After July 2011, the lease continues on a month-to-month basis. Therefore, there are no future minimum obligations on the lease.
	Rent expense for the year ended December 31, 2015 and 2014 were $29,765 and $26,600, respectively, and are included in general
	and administrative expenses on the statements of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 126; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 7 - Equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In March 2011, the Company amended its articles
	of incorporation to create two classes of interests referred to as &lsquo;Series A Preferred Membership Interests&rsquo; and &lsquo;Common
	Membership Interests&rsquo;, with each interest issued being measured as Units (Series A Preferred Units and Common Units, respectively).
	The Series A Preferred Units are further broken down into 4 series including Series A-1, Series A-2, Series A-3 and Series A-4.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Pursuant to Moleculin, LLC's Company Agreement,
	the Board shall distribute net cash, as defined in the Company Agreement, to the members at such times and in such amounts as the
	Board may determine in the following order and priority:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First, to the Series A Preferred members in proportion to each such members&rsquo; original capital contribution until such members receive net cash equal to 150% of their original capital contribution.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second, to the members in proportion to their percentage interests until Series A Preferred members have received net cash equal to 300% of their original capital contribution.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third, to the common members in proportion to each common member&rsquo;s common units until the common members have receive aggregate distributions of net cash equal to the then total amount of distributions to all members for all company fiscal years multiplied by the common members&rsquo; aggregate percentage interests; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	d)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Fourth, to the members in accordance with their percentage interests.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015 and 2014, the Preferred
	Units are summarized as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Units Outstanding
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
	Series
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Contribution
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: JUSTIFY">
	Series A-1
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	283,604
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	283,604
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	150,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Series A-2
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,595,552
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,595,552
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	600,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Series A-3
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,942,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,942,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	513,672
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Series A-4
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,694,264
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,694,264
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,356,514
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,515,820
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,515,820
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,620,186
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	During the first quarter of 2013, the Company
	commenced the first Phase II Study of a licensed product in the patent and technology license agreement between the Company and
	MD Anderson. Pursuant to the agreement, the Company was obligated to issue MD Anderson 548,630 common units, representing 3.5%
	of its issued and outstanding equity units. These common units were valued at their estimated fair value of $548,630, which was
	recorded as a research and development expense. In October 2015, MD Anderson agreed to forfeit its right to these units. The Company
	recorded a gain on liability extinguishment of $548,630 upon the forfeiture.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Note 8 - Subsequent Event
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 2, 2016, the Company purchased 189,070
	common units from one of the Company's unit holders for $100.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 8, 2016, the Company issued a revolving
	line of credit promissory note to MBI where MBI agreed to loan up to $50,000 to the Company. The note bears annual interest rate
	at 8% and has a late charge of 5% for amount overdue. Interest is payable monthly commencing on July 8, 2016 and all outstanding
	balance is payable on January 8, 2017. $25,000 under this note has been received subsequent to January 8, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 127; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	2,500,000 Units
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Each Consisting of One Share of Common
	Stock and
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series A Warrant to Purchase 0.50
	Shares of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series B Warrant to Purchase One
	Share of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Series C Warrant to Purchase 0.50
	Shares of Common Stock
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 24PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Moleculin Biotech, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Roth Capital Partners
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	National Securities Corporation
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SECURITIES_DESCRIPTION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 128 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	PART II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INFORMATION NOT REQUIRED IN PROSPECTUS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFERING_EXPENSE>
<A NAME="FIS_OFFERING_EXPENSE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Item&nbsp;13. Other Expenses of Issuance and Distribution.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth the estimated
	costs and expenses to be incurred in connection with the issuance and distribution of the securities of Moleculin Biotech, Inc.
	(the &ldquo;Registrant&rdquo;) which are registered under this Registration Statement on Form S-1 (this &ldquo;Registration Statement&rdquo;),
	other than underwriting discounts and commissions. All amounts are estimates except the Securities and Exchange Commission registration
	fee and the Financial Industry Regulatory Authority, Inc. filing fee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following expenses will be borne solely
	by the Registrant:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Amount&nbsp;to&nbsp;be
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Paid
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 87%; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	SEC Registration fee
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,045.92
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Financial Industry Regulatory Authority,
	Inc. filing fee
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	3,130.00&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Legal fees and expenses
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	150,000.00
</P>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Accounting fees and expenses
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	30,000.00&nbsp;
</P>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Transfer Agent&rsquo;s fees
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	2,000.00&nbsp;
</P>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Miscellaneous fees
	and expenses
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	5,000.00
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 12PT; TEXT-INDENT: -12PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.5IN; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	192,175.92
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_OFFERING_EXPENSE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_INDEMNIFICATION>
<A NAME="FIS_INDEMNIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Item&nbsp;14. Indemnification of Directors and Officers.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to Section&nbsp;145 of the Delaware
	General Corporation Law (the &ldquo;DGCL&rdquo;), a corporation shall have the power to indemnify any person who was or is a party
	or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
	administrative or investigative (other than a derivative action by or in the right of such corporation) by reason of the fact that
	such person is or was a director, officer, employee or agent of such corporation, or serving at the request of such corporation
	in such capacity for another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo;
	fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or
	proceeding, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
	interests of such corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or
	her conduct was unlawful.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The DGCL also permits indemnification by
	a corporation under similar circumstances for expenses (including attorneys&rsquo; fees) actually and reasonably incurred by such
	persons in connection with the defense or settlement of a derivative action or suit, except that no indemnification shall be made
	in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to such corporation unless
	the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that such
	person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	To the extent a present or former director
	or officer is successful in the defense of such an action, suit or proceeding referenced above, or in defense of any claim, issue
	or matter therein, a corporation is required by the DGCL to indemnify such person for actual and reasonable expenses incurred in
	connection therewith. Expenses (including attorneys&rsquo; fees) incurred by such persons in defending any action, suit or proceeding
	may be paid in advance of the final disposition of such action, suit or proceeding upon in the case of a current officer or director,
	receipt of an undertaking by or on behalf of such person to repay such amount if it is ultimately determined that such person is
	not entitled to be so indemnified.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 129; OPTIONS: NEWSECTION; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The DGCL provides that the indemnification
	described above shall not be deemed exclusive of other indemnification that may be granted by a corporation pursuant to its bylaws,
	disinterested directors&rsquo; vote, stockholders&rsquo; vote and agreement or otherwise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Section&nbsp;102(b)(7) of the DGCL enables
	a corporation, in its certificate of incorporation or an amendment thereto, to eliminate or limit the personal liability of a director
	to the corporation or its stockholders for monetary damages for violations of the directors&rsquo; fiduciary duty, except (i)&nbsp;for
	any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not
	in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;pursuant to Section&nbsp;174 of
	the DGCL (providing for liability of directors for unlawful payment of dividends or unlawful stock purchases or redemptions) or
	(iv)&nbsp;for any transaction from which a director derived an improper personal benefit. The Registrant&rsquo;s certificate of
	incorporation provides for such limitations on liability for its directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The DGCL also provides corporations with
	the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of such
	corporation, or is or was serving at the request of such corporation in a similar capacity for another corporation, partnership,
	joint venture, trust or other enterprise, against any liability asserted against him or her in any such capacity or arising out
	of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such liability
	as described above. In connection with this offering, the Registrant will obtain liability insurance for its directors and officers.
	Such insurance would be available to its directors and officers in accordance with its terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Registrant&rsquo;s certificate of incorporation
	in requires the Registrant to indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists
	or may hereafter be amended, any person (a &ldquo;covered person&rdquo;) who was or is made or is threatened to be made a party
	or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
	or investigative (a &ldquo;proceeding&rdquo;) by reason of the fact that he or she is or was a director, officer or member of a
	committee of the Registrant, or, while a director or officer of the Registrant, is or was serving at the request of the Registrant
	as a director or officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise or non-profit
	entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including
	attorneys&rsquo; fees), judgment, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
	with a proceeding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In addition, under the Registrant&rsquo;s
	certificate of incorporation, in certain circumstances, the Registrant shall pay the expenses (including attorneys&rsquo; fees)
	incurred by a covered person in defending a proceeding in advance of the final disposition of such proceeding; provided, however,
	that the Registrant shall not be required to advance any expenses to a person against whom the Registrant directly brings an action,
	suit or proceeding alleging that such person (1)&nbsp;committed an act or omission not in good faith or (2)&nbsp;committed an act
	of intentional misconduct or a knowing violation of law. Additionally, an advancement of expenses incurred by a covered person
	shall be made only upon delivery to the Registrant of an undertaking, by or on behalf of such covered person, to repay all amounts
	so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal or otherwise
	in accordance with Delaware law that such covered person is not entitled to be indemnified for such expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The foregoing statements are subject to
	the detailed provisions of Section&nbsp;145 of the DGCL and the full text of the Registrant&rsquo;s certificate of incorporation,
	which is filed as Exhibit 3.1 hereto. Reference is made to the form of underwriting agreement to be filed as Exhibit 1.1 hereto
	for provisions providing that the underwriters are obligated under certain circumstances, to indemnify our directors, officers
	and controlling persons against certain liabilities under the Securities Act of 1933, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 130; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_INDEMNIFICATION>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SALE_OF_UNREGISTERED_SECURITIES>
<A NAME="FIS_SALE_OF_UNREGISTERED_SECURITIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Item&nbsp;15. Recent Sales of Unregistered Securities.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Except as set forth below, in the three
	years preceding the filing of this Registration Statement, the Registrant has not issued any securities that were not registered
	under the Securities Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August 2015, Messrs. Klemp, Picker and
	Priebe purchased 1,100,000 shares, 500,000 shares and 3,000,000 shares of our common stock, respectively, at a purchase price of
	$0.001 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August 2015, in exchange for the issuance
	of 630,000 shares of common stock, we acquired the rights to the license agreement with MD Anderson covering our WP1122 Portfolio
	held by IntertechBio Corporation, a company affiliated with Messrs. Priebe and Picker. In August 2015, in exchange for the issuance
	of 1,431,000 shares of common stock, we acquired the rights to the Annamycin IND and all data related to the Annamycin IND or the
	development of Annamycin held by AnnaMed, Inc., a company affiliated with Mr. Klemp.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In May 2016, Moleculin, LLC, a Texas limited
	liability company, was merged with and into MBI, which survived the merger. As a result of the merger, we issued the equity interests
	holders of Moleculin, LLC (including the convertible noteholders of Moleculin, LLC) an aggregate of 999,931 shares of our common
	stock. Messrs. Klemp, Picker and Priebe are members of Moleculin, LLC and received shares of our common stock as a result of the
	merger.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In August and September 2015, the Registrant
	issued two 8% convertible notes in an aggregate of $250,000 in principal amount of convertible notes to one investor, which principal
	and accrued interest automatically converted into shares of common stock upon the closing of the Company&rsquo;s initial public
	offering at a conversion rate of $0.1299 per share. In October 2015, the Registrant issued two 8% convertible notes in an aggregate
	of $200,000 in principal amount of convertible notes to two investors, which principal and accrued interest automatically converted
	into shares of common stock upon the closing of the Company&rsquo;s initial public offering at a conversion rate of $0.20 per share.
	At the time of such purchase in October 2015, the convertible note investors and the Registrant agreed that the investors would
	fund the Registrant up to the filing of its initial non-confidential registration statement an additional $165,000 on the same
	terms as in the October financing. Pursuant to such agreement, such amounts were received in January 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Between January and May 2016, the Registrant
	sold 225,963 shares of common stock for a total purchase price of $677,889 to 19 investors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On June 20, 2016, the Registrant agreed
	to issue 24,000 shares of common stock to an investor relations firm for services provided.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In January 2017, the Registrant agreed
	to issue 79,167 shares of common stock to a third-party in settlement of $237,500 in past due amounts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;None of these transactions involved
	a public offering. We believe that each of the above issuances was exempt from registration under the Securities Act in reliance
	on Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering.
</P>
</EFX_SALE_OF_UNREGISTERED_SECURITIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Item&nbsp;16. Exhibits and Financial Statement Schedules.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(a)
<B>
<I>
	Exhibits
</I>
</B>
	: Reference is
	made to the Exhibit Index following the signature pages hereto, which Exhibit Index is hereby incorporated into this Item.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(b)
<B>
<I>
	Financial Statement Schedules
</I>
</B>
	:
	All schedules are omitted because the required information is inapplicable or the information is presented in the financial statements
	and the related notes.
</P>
</EFX_EXHIBITS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNDERTAKINGS>
<A NAME="FIS_UNDERTAKINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Item&nbsp;17. Undertakings
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The undersigned hereby undertakes:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(a) The undersigned Registrant hereby undertakes
	to provide to the underwriter at the closing specified in the underwriting agreement certificates in such denominations and registered
	in such names as required by the underwriter to permit prompt delivery to each purchaser.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 131; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(b) Insofar as indemnification for liabilities
	arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
	to the provisions referenced in Item&nbsp;14 of this Registration Statement, or otherwise, the Registrant has been advised that
	in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act
	and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
	by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful
	defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
	being registered hereunder, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
	precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy
	as expressed in the Act and will be governed by the final adjudication of such issue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(c) The undersigned Registrant hereby undertakes
	that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
	(1) For purposes of determining
	any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this Registration
	Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
	(4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared
	effective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-INDENT: 24.5PT">
	(2) For the purpose of determining
	any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed
	to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time
	shall be deemed to be the initial bona fide offering thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 132; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_UNDERTAKINGS>
</EFX_PART_II>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements of the
	Securities Act, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
	duly authorized, in the city of Houston, Texas, on February 7, 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	MOLECULIN BIOTECH, INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	(Registrant)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 46%; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;/s/ Walter V. Klemp
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Walter V. Klemp
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director and Chief Executive Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Pursuant to the requirements of the Securities
	Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the
	dates indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SIGNATURE
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 41%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TITLE
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 18%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DATE
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Walter V. Klemp
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Walter V. Klemp
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Executive Officer and Sole Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	February 7, 2017
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Executive Officer)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Jonathan P. Foster
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;Jonathan P. Foster
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN: 0PT 0">
	February 7, 2017
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Financial Officer and Principal Accounting Officer)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Donald Picker
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Operating Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	February 7, 2017
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Robert George
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	February 7, 2017
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Michael Cannon
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	February 7, 2017
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Jacqueline Northcut
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	February 7, 2017
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	* By: &nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Walter V. Klemp
</FONT>
</TD>
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Walter V. Klemp
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Attorney-in-Fact
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 133; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 12%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 88%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Underwriting Agreement
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated
	by reference to exhibit 3.1 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Bylaws of Moleculin Biotech, Inc. (incorporated by reference to exhibit
	3.2 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1*
</FONT>
</TD>
<TD>
<P STYLE="MARGIN: 0PT 0">
	Form of Series A/B/C
<FONT STYLE="FONT-SIZE: 10PT">
	Warrant Agreement
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	5*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Opinion of Schiff Hardin LLP as to legality of the securities being registered
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Moleculin Biotech, Inc. 2015 Incentive Plan (incorporated by reference to exhibit 10.1 of
	the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Rights Transfer Agreement between Moleculin Biotech, Inc. and AnnaMed, Inc. (incorporated
	by reference to exhibit 10.2 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent and Technology License Agreement dated June 21, 2010 by and between The Board of
	Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.3 of the Form S-1/A
	filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and
	between The Board of Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.4
	of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent and Technology License Agreement dated April 2, 2012 by and between The Board of
	Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.5 of the Form
	S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and
	between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to
	exhibit 10.6 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent and Technology Development and License Agreement June 28, 2012 by and between Annamed,
	Inc. and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.7 of the Form S-1/A filed April 15, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent and Technology Development and License Agreement dated April 15, 2011 by and between
	IntertechBio Corporation and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.8 of the Form S-1/A filed March 21,
	2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent and Technology Development and License Agreement dated October 27, 2010 by and between
	Moleculin, LLC and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.9 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.10
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Rights Transfer Agreement dated between Moleculin Biotech, Inc. and IntertechBio Corporation
	dated August 11, 2015 (incorporated by reference to exhibit 10.10 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.11
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Agreement and Plan of Merger between Moleculin Biotech, Inc. and Moleculin, LLC (incorporated
	by reference to exhibit 10.11 of the Form S-1/A filed March 21, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.12
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Technology Rights and Development License Agreement to be entered into by Moleculin Biotech,
	Inc. and Houston Pharmaceuticals, Inc. (incorporated by reference to exhibit 10.13 of the Form S-1/A filed April 15, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement between Moleculin Biotech, Inc. and Jonathan P. Foster dated August
	19, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed August 25, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Employment Agreement between Moleculin Biotech, Inc. and Walter Klemp dated October
	13, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed October 13, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.15
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	General Release and Separation Agreement between Moleculin Biotech, Inc. and Louis Ploth
	dated October 7, 2016 (incorporated by reference to Exhibit 10.2 of the Form 8-K filed October 13, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Development Collaboration Agreement between Moleculin Biotech, Inc. and Dermin Sp. Z o.
	o. dated September 30, 2016 (incorporated by reference to Exhibit 10.4 of the Form 10-Q filed November 21, 2016)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 134; VALUE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	21
</FONT>
</TD>
<TD STYLE="WIDTH: 88%">
<FONT STYLE="FONT-SIZE: 10PT">
	Subsidiaries of the Registrant (incorporated by reference to exhibit
	21 of the Form S-1/A filed April 15, 2016)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	23.1*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consent of GBH CPAs, PC
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	23.2*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consent of Schiff Hardin LLP (included in Exhibit 5)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.INS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Instance Document (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.SCH
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Schema Document (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.CAL
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Calculation Linkbase Document (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.DEF
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Definition Linkbase Document (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.LAB
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Label Linkbase Document (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	101.PRE
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Presentation Linkbase Document (1)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be filed by amendment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 135; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_EXHIBIT_INDEX>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage135"></A>
<A NAME="V458551_EX1-1_HTM"></A>
<EFX_EXHIBIT_1>
<A NAME="FIS_EXHIBIT_1"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
<B>
	Exhibit 1.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	____________ SHARES
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE">
	of
	Common Stock,
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	_____________
	SERIES A Warrants,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	_____________
	SERIES b Warrants,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	and
	_____________ SERIES c Warrants of
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	MOLECULIN BIOTECH, INC.
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	UNDERWRITING AGREEMENT
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<BR>
	February __, 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	ROTH CAPITAL PARTNERS, LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As the Representative of the
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Several underwriters, if any, named in
<U>
	Schedule
	I
</U>
	hereto
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	c/o ROTH CAPITAL PARTNERS, LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	888 San Clemente Drive
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Newport Beach, California 92660
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Ladies and Gentlemen:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The undersigned, Moleculin
	Biotech, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including,
	without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Moleculin
	Biotech, Inc., (the &ldquo;
<U>
	Company
</U>
	&rdquo;)), hereby confirms its agreement (this &ldquo;
<U>
	Agreement
</U>
	&rdquo;) with the
	several underwriters (such underwriters, including the Representative (as defined below), the &ldquo;
<U>
	Underwriters
</U>
	&rdquo;
	and each an &ldquo;
<U>
	Underwriter
</U>
	&rdquo;) named in
<U>
	Schedule I
</U>
	hereto for which Roth Capital Partners, LLC is acting
	as representative to the several Underwriters (the &ldquo;
<U>
	Representative
</U>
	&rdquo; and if there are no Underwriters other than
	the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have
	the same meaning as Underwriter) on the terms and conditions set forth herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	It is understood that
	the several Underwriters are to make a public offering of the Public Securities as soon as the Representative deems it advisable
	to do so. The Public Securities are to be initially offered to the public at the initial public offering price set forth in the
	Prospectus. The Representative may from time to time thereafter change the public offering price and other selling terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	It is further understood
	that you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities and, if any, the
	Option Securities in accordance with this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE I.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DEFINITIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Definitions
</U>
	.
	In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
	meanings set forth in this Section 1.1:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Action
</U>
	&rdquo;
	shall have the meaning ascribed to such term in Section 3.1(k).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Affiliate
</U>
	&rdquo;
	means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or
	is controlled by or is under common control with such Person as such terms are used in and construed under Rule 405 under the Securities
	Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Board
	of Directors
</U>
	&rdquo; means the board of directors of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Business
	Day
</U>
	&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
	any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
	close.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
</U>
	&rdquo;
	means the closing of the purchase and sale of the Closing Securities pursuant to Section 2.1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Date
</U>
	&rdquo; means the hour and the date on the Trading Day on which all conditions precedent to (i) the Underwriters&rsquo;
	obligations to pay the Closing Purchase Price and (ii) the Company&rsquo;s obligations to deliver the Closing Securities, in each
	case, have been satisfied or waived, but in no event later than 10:00 a.m. (New York City time) on the third Trading Day following
	the date hereof or at such earlier time as shall be agreed upon by the Representative and the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Purchase Price
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(b), which aggregate purchase price shall
	be net of the underwriting discounts and commissions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Securities
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(ii).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Shares
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(i).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Closing
	Warrants
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(ii).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Combined
	Purchase Price
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Commission
</U>
	&rdquo;
	means the United States Securities and Exchange Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Common
	Stock
</U>
	&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
	such securities may hereafter be reclassified or changed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Common
	Stock Equivalents
</U>
	&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
	acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
	that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
	Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Company
	Auditor
</U>
	&rdquo; means GBH CPAs, PC, with offices located at 6002 Rogerdale Road #500, Houston, Texas 77072.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Company
	Counsel
</U>
	&rdquo; means Schiff Hardin LLP, with offices located at 100 North 18
<SUP>
	th
</SUP>
	, Suite 300, Philadelphia, Pennsylvania
	19103.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Disclosure
	Schedules
</U>
	&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Effective
	Date
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 3.1(f).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	EGS
</U>
	&rdquo;
	means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Exchange
	Act
</U>
	&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Execution
	Date
</U>
	&rdquo; shall mean the date on which the parties execute and enter into this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Exempt
	Issuance
</U>
	&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
	pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors
	or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise
	or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
	into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
	since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or
	conversion price of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a
	majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the equity
	holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
	with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but
	shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
	entity whose primary business is investing in securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	FCPA
</U>
	&rdquo;
	means the Foreign Corrupt Practices Act of 1977, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	FINRA
</U>
	&rdquo;
	means the Financial Industry Regulatory Authority.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	GAAP
</U>
	&rdquo;
	shall have the meaning ascribed to such term in Section 3.1(i).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Indebtedness
</U>
	&rdquo;
	means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
	the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness
	of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
	except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
	of business; and (c) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
	accordance with GAAP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Liens
</U>
	&rdquo;
	means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Lock-Up
	Agreements
</U>
	&rdquo; means the lock-up agreements, in the form of
<U>
	Exhibit E
</U>
	attached hereto, delivered on the date hereof
	by each of the Company&rsquo;s officers and directors and each holder of Common Stock and Common Stock Equivalents holding, on
	a fully diluted basis, more than 5% of the Company&rsquo;s issued and outstanding Common Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Material
	Adverse Effect
</U>
	&rdquo; means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
	(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
	of the Company and the Subsidiaries, taken as a whole or (iii) a material adverse effect on the Company&rsquo;s ability to perform
	in any material respect on a timely basis its obligations under any Transaction Document.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Offering
</U>
	&rdquo;
	shall have the meaning ascribed to such term in Section 2.1(c).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Option
	Closing Date
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2(c).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Option
	Closing Purchase Price
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2(b), which aggregate purchase price
	shall be net of the underwriting discounts and commissions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Option
	Securities
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2(a)(ii).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Option
	Shares
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2(a)(i).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Option
	Warrant Combinations
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2(a).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Over-Allotment
	Option
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.2.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Person
</U>
	&rdquo;
	means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
	company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Preliminary
	Prospectus
</U>
	&rdquo; means, if any, any preliminary prospectus relating to the Securities included in the Registration Statement
	or filed with the Commission pursuant to Rule 424(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Proceeding
</U>
	&rdquo;
	means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
	proceeding, such as a deposition), whether commenced or threatened.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Prospectus
</U>
	&rdquo;
	means the final prospectus filed for the Registration Statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Prospectus
	Supplement
</U>
	&rdquo; means, if any, any supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is
	filed with the Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Public
	Securities
</U>
	&rdquo; means, collectively, the Closing Securities and, if any, the Option Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Registration
	Statement
</U>
	&rdquo; means, collectively, the various parts of the registration statement prepared by the Company on Form S-1 (File
	No. 333-214898) with respect to the Securities, each as amended as of the date hereof, including the Prospectus and Prospectus
	Supplement, if any, the Preliminary Prospectus, if any, and all exhibits filed with or incorporated by reference into such registration
	statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Required
	Approvals
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Rule
	424
</U>
	&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
	from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
	and effect as such Rule.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	SEC
	Reports
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 3.1(i).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Securities
</U>
	&rdquo;
	means the Closing Securities, the Option Securities and the Warrant Shares.
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Securities
	Act
</U>
	&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Series
	A Warrants
</U>
	&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with
	Section 2.2(a) hereof, which Series A Warrants shall be exercisable immediately and have a term of exercise equal to five (5) years,
	in the form of
<U>
	Exhibit D-1
</U>
	attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Series
	B Warrants
</U>
	&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with
	Section 2.2(a) hereof, which Series B Warrants shall be exercisable immediately and have a term of exercise equal to ______, in
	the form of
<U>
	Exhibit D-2
</U>
	attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Series
	C Warrants
</U>
	&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with
	Section 2.2(a) hereof, which Series C Warrants shall be exercisable immediately, subject to vesting as described therein, and have
	a term of exercise equal to five (5) years, in the form of
<U>
	Exhibit D-3
</U>
	attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Share
	Purchase Price
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Shares
</U>
	&rdquo;
	means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section 2.1(a)(i) and Section
	2.2(a).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Subsidiary
</U>
	&rdquo;
	means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
	formed or acquired after the date hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Day
</U>
	&rdquo; means a day on which the principal Trading Market is open for trading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Market
</U>
	&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
	the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the
	New York Stock Exchange (or any successors to any of the foregoing).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Transaction
	Documents
</U>
	&rdquo; means this Agreement, the Warrants, the Lock-Up Agreements, and any other documents or agreements executed
	in connection with the transactions contemplated hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Transfer
	Agent
</U>
	&rdquo; means VStock Transfer, LLC, with offices located at 18 Lafayette Place, Woodmere, New York 11598, and any successor
	transfer agent of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrant
	Combination
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrant
	Combination Purchase Price
</U>
	&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrant
	Shares
</U>
	&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Warrants
</U>
	&rdquo;
	means, collectively, the Series A Warrants, the Series B Warrants and the Series C Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE II.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	PURCHASE AND SALE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Closing
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate ________ shares of Common
	Stock and Warrants, and each Underwriter agrees to purchase, severally and not jointly, at the Closing, the following securities
	of the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	number of shares of Common Stock (the &ldquo;
<U>
	Closing Shares
</U>
	&rdquo;) set forth opposite the name of such Underwriter on
<U>
	Schedule
	I
</U>
	hereof;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series
	A Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on
<U>
	Schedule
	I
</U>
	hereof (the &ldquo;
<U>
	Closing Series A Warrants
</U>
	&rdquo;), which Warrants shall have an exercise price of $____, subject
	to adjustment as provided therein;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series
	B Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on
<U>
	Schedule
	I
</U>
	hereof (the &ldquo;
<U>
	Closing Series B Warrants
</U>
	&rdquo;), which Warrants shall have an exercise price of $____, subject
	to adjustment as provided therein; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series
	C Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on
<U>
	Schedule
	I
</U>
	hereof (the &ldquo;
<U>
	Closing Series C Warrants
</U>
	&rdquo; and, collectively with the Closing Series A Warrants and Closing
	Series B Warrants (the &ldquo;
<U>
	Closing Warrants
</U>
	&rdquo;) and the Closing Shares and the Closing Warrants, collectively, the
	&ldquo;
<U>
	Closing Securities
</U>
	&rdquo;), which Warrants shall have an exercise price of $____, subject to adjustment as provided
	therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter on
<U>
	Schedule
	I
</U>
	hereto (the &ldquo;
<U>
	Closing Purchase Price
</U>
	&rdquo;). The combined purchase price for one Share, a Series A Warrant to
	purchase ___ Warrant Share, a Series B Warrant to purchase ___ Warrant Share and a Series C Warrant to purchase ___ Warrant Share
	shall be $_____ (the &ldquo;
<U>
	Combined Purchase Price
</U>
	&rdquo;) which shall be allocated as $_____ per Share (the &ldquo;
<U>
	Share
	Purchase Price
</U>
	&rdquo;) and $____ per Warrant Combination (the &ldquo;
<U>
	Warrant Combination Purchase Price
</U>
	&rdquo;). For
	purposes herein, &ldquo;
<U>
	Warrant Combination
</U>
	&rdquo; means a Series A Warrant to purchase ___ Warrant Share, a Series B Warrant
	to purchase ___ Warrant Share, and a Series C Warrant to purchase ___ Warrant Share, which warrants shall be issued separately
	by the Company but shall be purchasable as a fixed combination of warrants by the Underwriters hereunder; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	On the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available
	funds equal to such Underwriter&rsquo;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter
	its respective Closing Securities and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at
	the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the
	offices of EGS or such other location as the Company and Representative shall mutually agree. The Public Securities are to be offered
	initially to the public at the offering price set forth on the cover page of the Prospectus (the &ldquo;
<U>
	Offering
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Over-Allotment
	Option
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
	the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative
	is hereby granted an option (the &ldquo;
<U>
	Over-Allotment Option
</U>
	&rdquo;) to purchase, in the aggregate, up to _____ shares
	of Common Stock (the &ldquo;
<U>
	Option Shares
</U>
	&rdquo;) and ____ Warrant Combinations (the &ldquo;
<U>
	Option Warrant Combinations
</U>
	&rdquo;
	and, collectively with the Option Shares, the &ldquo;
<U>
	Option Securities
</U>
	&rdquo;)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	&nbsp;1&nbsp;
</SUP>
</FONT>
	which may be purchased in any combination of Option Shares and/or Option Warrant Combinations at the Share Purchase Price and/or
	Warrant Combination Purchase Price, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	connection with an exercise of the Over-Allotment Option, (a) the purchase price to be paid for the Option Shares is equal to the
	product of the Share Purchase Price multiplied by the number of Option Shares to be purchased and (b) the purchase price to be
	paid for the Option Warrant Combinations is equal to the product of the Warrant Combination Purchase Price multiplied by the number
	of Option Warrant Combinations (the aggregate purchase price to be paid on an Option Closing Date, the &ldquo;
<U>
	Option Closing
	Purchase Price
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Over-Allotment Option granted pursuant to this Section 2.2 may be exercised by the Representative as to all (at any time) or any
	part (from time to time) of the Option Securities within 45 days after the Execution Date. An Underwriter will not be under any
	obligation to purchase any Option Securities prior to the exercise of the Over-Allotment Option by the Representative. The Over-Allotment
	Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed
	in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares and/or Option
	Warrant Combinations to be purchased and the date and time for delivery of and payment for the Option Securities (each, an &ldquo;
<U>
	Option
	Closing Date
</U>
	&rdquo;), which will not be later than three (3) full Business Days after the date of the notice or such other
	time as shall be agreed upon by the Company and the Representative, at the offices of EGS
<B>
</B>
	or at such other place (including
	remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such
	delivery and payment for the Option Securities does not occur on the Closing Date, each Option Closing Date will be as set forth
	in the notice. Upon exercise of the Over-Allotment Option, the Company will become obligated to convey to the Underwriters, and,
	subject to the terms and conditions set forth herein, the Underwriters will become obligated to purchase, the number of Option
	Shares and/or Option Warrant Combinations specified in such notice. The Representative may cancel the Over-Allotment Option at
	any time prior to the expiration of the Over-Allotment Option by written notice to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	&nbsp;1&nbsp;
</SUP>
</FONT>
<SUP>
</SUP>
	15% of the Closing Shares and 15% of the Closing Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Deliveries
</U>
	.
	The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shares shall
	be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, the Closing Series A Warrants and, as to each Option Closing Date, if any, the Series A Warrants in the applicable
	Option Warrant Combinations for the accounts of the several Underwriters in certificated form registered in the name or names and
	in such authorized denominations as the applicable Underwriter may request in writing at least two full Business Days prior to
	the Closing Date and, if any, each Option Closing Date;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, the Closing Series B Warrants and, as to each Option Closing Date, if any, the Series B Warrants in the applicable
	Option Warrant Combinations for the accounts of the several Underwriters in certificated form registered in the name or names and
	in such authorized denominations as the applicable Underwriter may request in writing at least two full Business Days prior to
	the Closing Date and, if any, each Option Closing Date;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, the Closing Series C Warrants and, as to each Option Closing Date, if any, the Series C Warrants in the applicable
	Option Warrant Combinations for the accounts of the several Underwriters in certificated form registered in the name or names and
	in such authorized denominations as the applicable Underwriter may request in writing at least two full Business Days prior to
	the Closing Date and, if any, each Option Closing Date;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, to the Representative only, a Common Stock purchase warrant to purchase up to a number of shares of Common Stock
	equal to 7% of the Closing Shares issued on the Closing Date, for the account of the Representative (or its designees), which
	Common Stock purchase warrant shall have an exercise price of $____
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	&nbsp;2
</SUP>
</FONT>
	,
	subject to adjustment therein, and registered in the name of the Representative, otherwise on substantially the same terms as
	the Series A Warrants;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	2&nbsp;
</SUP>
</FONT>
	Exercise
	price equal to Combined Purchase Price
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance
	letter, substantially in the form of
<U>
	Exhibit A
</U>
	attached hereto and as to each Option Closing Date, if any, a bring-down
	opinion from Company Counsel in form and substance reasonably satisfactory to the Representative, including, without limitation,
	a negative assurance letter, addressed to the Underwriters and in form and substance satisfactory to the Representative;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contemporaneously
	herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all respects to the Representative
	from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down letter dated as of the Closing
	Date and each Option Closing Date, if any;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
	the Closing Date and on each Option Closing Date, the duly executed and delivered Officer&rsquo;s Certificate, substantially in
	the form required by
<U>
	Exhibit B
</U>
	attached hereto;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
	the Closing Date and on each Option Closing Date, the duly executed and delivered Secretary&rsquo;s Certificate, substantially
	in the form required by
<U>
	Exhibit C
</U>
	attached hereto; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contemporaneously
	herewith, the duly executed and delivered Lock-Up Agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Closing
	Conditions
</U>
	. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option Closing
	Date are subject to the following conditions being met:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company
	already qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the
	Company contained herein (unless as of a specific date therein);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
	obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been
	performed;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	delivery by the Company of the items set forth in Section 2.3 of this Agreement;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	Registration Statement shall be effective on the date of this Agreement and at each of the Closing Date and each Option Closing
	Date, if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings
	for that purpose shall have been instituted or shall be pending or contemplated by the Commission and any request on the part of
	the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
	the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation
	allowable or payable to the Underwriters as described in the Registration Statement;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	Closing Shares, the Option Shares and the Warrant Shares have been approved for listing on the Trading Market; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior
	to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have been no material adverse change
	or development involving a prospective material adverse change in the condition or prospects or the business activities, financial
	or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement and Prospectus;
	(ii)&nbsp;no action suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Affiliate
	of the Company before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable
	decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income
	of the Company, except as set forth in the Registration Statement and Prospectus; (iii)&nbsp;no stop order shall have been issued
	under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv)&nbsp;the
	Registration Statement and the Prospectus and any amendments or supplements thereto shall contain all material statements which
	are required to be stated therein in accordance with the Securities Act and the rules and regulations thereunder and shall conform
	in all material respects to the requirements of the Securities Act and the rules and regulations thereunder, and neither the Registration
	Statement nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit
	to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
	under which they were made, not misleading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE III.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPRESENTATIONS AND WARRANTIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Representations
	and Warranties of the Company
</U>
	. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
	a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding
	section of the Disclosure Schedules, the Company represents and warrants to the Underwriters as of the Execution Date, as of the
	Closing Date and as of each Option Closing Date, if any, as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Subsidiaries
</U>
	.
	All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
	all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
	shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
	rights to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries or
	any of them in the Transaction Documents shall be disregarded.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Organization
	and Qualification
</U>
	. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
	existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
	and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
	nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
	bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
	and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
	or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
	the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted
	in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Authorization;
	Enforcement
</U>
	. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
	by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations
	hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
	and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
	on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders
	in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
	Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
	accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
	the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
	reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)
	as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
	insofar as indemnification and contribution provisions may be limited by applicable law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Conflicts
</U>
	. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
	which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
	and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
	or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
	(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
	of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
	or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
	a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
	any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
	with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
	or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
	or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
	and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Filings,
	Consents and Approvals
</U>
	. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
	to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
	Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
	the filing with the Commission of the Prospectus and (ii) such filings as are required to be made under applicable state securities
	laws (collectively, the &ldquo;
<U>
	Required Approvals
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Registration
	Statement
</U>
	. The Company has filed with the Commission the Registration Statement, including any related Prospectus or Prospectuses,
	for the registration of the Securities under the Securities Act, which Registration Statement has been prepared by the Company
	in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the Commission
	under the Securities Act. The Registration Statement has been declared effective by the Commission on the date hereof (the &ldquo;
<U>
	Effective
	Date
</U>
	&rdquo;). The Company has advised the Representative of all further information (financial and other) with respect to the
	Company required to be set forth therein in the Registration Statement and Prospectus. Any reference in this Agreement to the Registration
	Statement, the Prospectus or any Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference
	therein; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
	with respect to the Registration Statement, the Prospectus or any Prospectus Supplement shall be deemed to refer to and include
	the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Prospectus as the
	case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules
	and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo;
	&ldquo;set forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Prospectus (and all other references of like
	import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed
	to be incorporated by reference in the Registration Statement, or the Prospectus, as the case may be. No stop order suspending
	the effectiveness of the Registration Statement or the use of the Prospectus has been issued, and no proceeding for any such purpose
	is pending or has been initiated or, to the Company's knowledge, is threatened by the Commission. For purposes of this Agreement,
	&ldquo;
<U>
	free writing prospectus
</U>
	&rdquo; has the meaning set forth in Rule 405 under the Securities Act. The Company will not,
	without the prior consent of the Representative, prepare, use or refer to, any free writing prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Issuance
	of Securities
</U>
	. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
	Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The
	Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable,
	free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
	number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The holder of the Securities will not be
	subject to personal liability by reason of being such holders. The Securities are not and will not be subject to the preemptive
	rights of any holders of any security of the Company or similar contractual rights granted by the Company. All corporate action
	required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken. The Securities
<B>
</B>
	conform in all material respects to all statements with respect thereto contained in the Registration Statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Capitalization
</U>
	.
	The capitalization of the Company is as set forth in the SEC Reports. Except as set forth in the SEC Reports, the Company has not
	issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
	of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant
	to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
	outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first
	refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
	Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants,
	scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations
	convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of
	Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
	bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not
	obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Underwriters) and will not
	result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of
	such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid
	and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares
	was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. The authorized shares
	of the Company conform in all material respects to all statements relating thereto contained in the Registration Statement and
	the Prospectus. The offers and sales of the Company&rsquo;s securities were at all relevant times either registered under the Securities
	Act and the applicable state securities or Blue Sky laws or, based in part on the representations and warranties of the purchasers,
	exempt from such registration requirements. No further approval or authorization of any stockholder, the Board of Directors or
	others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other
	similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the
	Company, between or among any of the Company&rsquo;s stockholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	SEC
	Reports; Financial Statements
</U>
	. The Company has filed all reports, schedules, forms, statements and other documents required
	to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
	for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
	material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
	the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;
<U>
	SEC Reports
</U>
	&rdquo;) on
	a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
	of any such extension. Except as set forth on
<U>
	Schedule 3.1(i)
</U>
	, as of their respective dates, the SEC Reports complied in
	all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports,
	when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
	or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
	The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
	requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial
	statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
	basis during the periods involved (&ldquo;
<U>
	GAAP
</U>
	&rdquo;), except as may be otherwise specified in such financial statements
	or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
	present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates
	thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
	to normal, immaterial, year-end audit adjustments. The agreements and documents described in the Registration Statement, the Prospectus,
	the Prospectus Supplement and the SEC Reports conform to the descriptions thereof contained therein and there are no agreements
	or other documents required by the Securities Act and the rules and regulations thereunder to be described in the Registration
	Statement, the Prospectus, the Prospectus Supplement or the SEC Reports or to be filed with the Commission as exhibits to the Registration
	Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to
	which the Company is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to in the Registration
	Statement, the Prospectus, the Prospectus Supplement or the SEC Reports, or (ii)&nbsp;is material to the Company&rsquo;s business,
	has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable
	against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as
	such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights
	generally, (y)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal and state
	securities laws, and (z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be
	subject to the equitable defenses and to the discretion of the court before which any proceeding therefore may be brought. None
	of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the best of the Company&rsquo;s
	knowledge, any other party is in default thereunder and, to the best of the Company&rsquo;s knowledge, no event has occurred that,
	with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the best of the Company&rsquo;s
	knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation
	of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign,
	having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to environmental
	laws and regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage150"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Material
	Changes; Undisclosed Events, Liabilities or Developments
</U>
	. Since the date of the latest audited financial statements included
	within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has
	been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
	(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
	incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
	Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not
	altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
	to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v) the
	Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option
	plans and (vi) no officer or director of the Company has resigned from any position with the Company. The Company does not have
	pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities
	contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is
	reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
	properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
	laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to
	the date that this representation is made. Unless otherwise disclosed in an SEC Report filed prior to the date hereof, the Company
	has not: (i)&nbsp;issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared
	or paid any dividend or made any other distribution on or in respect to its capital stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Litigation
</U>
	.
	There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
	threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
	governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;
<U>
	Action
</U>
	&rdquo;)
	which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
	or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except
	as set forth on
<U>
	Schedule 3.1(k)
</U>
	, neither the Company nor any Subsidiary, nor any director or officer thereof, is or has
	been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
	of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any
	investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
	has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
	any Subsidiary under the Exchange Act or the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Labor
	Relations
</U>
	. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
	the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
	employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
	the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
	that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
	any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
	or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
	in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
	its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
	with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
	conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
	reasonably be expected to have a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Compliance
</U>
	.
	Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
	waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
	Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
	loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
	bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
	court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
	of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
	protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
	could not have or reasonably be expected to result in a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Regulatory
	Permits
</U>
	. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
	state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
	except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each,
	a &ldquo;
<U>
	Material Permit
</U>
	&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating
	to the revocation or modification of any Material Permit. The disclosures in the Registration Statement concerning the effects
	of Federal, State, local and all foreign regulation on the Company&rsquo;s business as currently contemplated are correct in all
	material respects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Title
	to Assets
</U>
	. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights
	to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the
	Subsidiaries as the business is described in the SEC Reports, in each case free and clear of all Liens, except for (i) Liens as
	do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of
	such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate
	reserves have been made in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real
	property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable
	leases with which the Company and the Subsidiaries are in compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Intellectual
	Property
</U>
	. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
	applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
	and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
	and which the failure to do so could have a Material Adverse Effect (collectively, the &ldquo;
<U>
	Intellectual Property Rights
</U>
	&rdquo;).
	None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
	Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)
	years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited
	financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
	Property Rights violate or infringe upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property
	Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
	Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of
	their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected
	to have a Material Adverse Effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage153"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Insurance
</U>
	.
	The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
	in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
	but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
	that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
	from similar insurers as may be necessary to continue its business without a significant increase in cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Transactions
	With Affiliates and Employees
</U>
	. Except as set forth in the SEC Reports, none of the officers or directors of the Company or
	any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
	to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
	any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
	personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
	to or from, any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
	or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
	in excess of $100,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
	incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan
	of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Sarbanes-Oxley;
	Internal Accounting Controls
</U>
	. The Company and the Subsidiaries are in compliance with any and all applicable requirements of
	the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
	by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth in the SEC
	Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
	that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
	are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
	(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the
	recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
	with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
	in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures
	to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is
	recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The
	Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and
	the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
	the &ldquo;
<U>
	Evaluation Date
</U>
	&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
	Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
	evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial
	reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is
	reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage154"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Certain
	Fees
</U>
	. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
	by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent,
	investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. To the Company&rsquo;s
	knowledge, there are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any
	of its stockholders that may affect the Underwriters&rsquo; compensation, as determined by FINRA. The Company has not made any
	direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&rsquo;s fee, consulting fee
	or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised
	or provided capital to the Company; (ii)&nbsp; any FINRA member; or (iii)&nbsp;any person or entity that has any direct or indirect
	affiliation or association with any FINRA member, within the twelve months prior to the Execution Date. None of the net proceeds
	of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized
	herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Investment
	Company
</U>
	. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities will not
	be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
	The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
	under the Investment Company Act of 1940, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Registration
	Rights
</U>
	. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
	of any securities of the Company or any Subsidiary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage155"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Listing
	and Maintenance Requirements
</U>
	. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
	has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
	Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
	such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on
	which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or
	maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable
	future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible
	for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
	in payment of the fees of the Depository Trust Company (or such other established clearing corporation) in connection with such
	electronic transfer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Application
	of Takeover Protections
</U>
	. The Company and the Board of Directors have taken all necessary action, if any, in order to render
	inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
	or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
	or the laws of its state of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling
	their obligations or exercising their rights under the Transaction Documents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Disclosure;
	10b-5
</U>
	. The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules
	as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, if any, at the
	time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable rules
	and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain any untrue
	statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
	therein not misleading. The Prospectus and the Prospectus Supplement, each as of its respective date, comply in all material respects
	with the Securities Act and the Exchange Act and the applicable rules and regulations. Each of the Prospectus and the Prospectus
	Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material
	fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which
	they were made, not misleading. Except as set forth on
<U>
	Schedule 3.1(y)
</U>
	, the SEC Reports, when they were filed with the Commission,
	conformed in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, and none of
	such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state
	a material fact necessary to make the statements therein (with respect to the SEC Reports incorporated by reference in the Prospectus
	or Prospectus Supplement), in light of the circumstances under which they were made not misleading; and any further documents so
	filed and incorporated by reference in the Prospectus or Prospectus Supplement, when such documents are filed with the Commission,
	will conform in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable,
	and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
	therein, in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration
	Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental
	change in the information set forth therein is required to be filed with the Commission. There are no documents required to be
	filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant
	to the Securities Act or (y) will not be filed within the requisite time period. There are no contracts or other documents required
	to be described in the Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement,
	which have not been described or filed as required. The press releases disseminated by the Company during the twelve months preceding
	the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material
	fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
	they were made and when made, not misleading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage156"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Integrated Offering
</U>
	. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
	or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would
	cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder
	approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Solvency
</U>
	.
	Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
	Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
	the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
	known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
	on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
	capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
	thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
	all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
	respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
	to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
	The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
	under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports sets forth
	as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company
	or any Subsidiary has commitments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage157"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Tax
	Status
</U>
	. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
	Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
	income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
	(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
	on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
	all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
	taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
	of any Subsidiary know of no basis for any such claim. The provisions for taxes payable, if any, shown on the financial statements
	filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and
	for all periods to and including the dates of such consolidated financial statements. The term &ldquo;taxes&rdquo; mean all federal,
	state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits,
	license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
	windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatsoever, together with any interest
	and any penalties, additions to tax, or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns,
	declarations, reports, statements, and other documents required to be filed in respect to taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Foreign
	Corrupt Practices
</U>
	. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
	or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
	contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
	unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
	from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
	acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
	provision of FCPA. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient
	to cause the Company to comply in all material respects with the FCPA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Accountants
</U>
	.
	To the knowledge and belief of the Company, the Company Auditor (i) is an independent registered public accounting firm as required
	by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
	Annual Report for the fiscal year ending December 31, 2016. The Company Auditor has not, during the periods covered by the financial
	statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of
	the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage158"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	FDA
</U>
	.
	As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;
<U>
	FDA
</U>
	&rdquo;) under the Federal
	Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;
<U>
	FDCA
</U>
	&rdquo;) that is manufactured, packaged,
	labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;
<U>
	Pharmaceutical
	Product
</U>
	&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
	by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
	investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
	good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
	failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
	threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
	or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
	any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket
	clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
	of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
	suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any
	Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
	(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
	decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
	rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
	a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
	respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the
	FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
	produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product
	being developed or proposed to be developed by the Company.
<U>
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Office
	of Foreign Assets Control
</U>
	. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
	employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
	Foreign Assets Control of the U.S. Treasury Department.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	U.S.
	Real Property Holding Corporation
</U>
	. The Company is not and has never been a U.S. real property holding corporation within the
	meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Representative&rsquo;s
	request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Bank
	Holding Company Act
</U>
	. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
	of 1956, as amended (the &ldquo;
<U>
	BHCA
</U>
	&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
	&ldquo;
<U>
	Federal Reserve
</U>
	&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
	or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%)
	or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
	the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
	or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage159"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Money
	Laundering
</U>
	. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
	applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
	as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;
<U>
	Money
	Laundering Laws
</U>
	&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body
	or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
	of the Company or any Subsidiary, threatened.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	D&amp;O
	Questionnaires
</U>
	. To the Company&rsquo;s knowledge, all information contained in the questionnaires completed by each of the
	Company&rsquo;s directors and officers prior to the Offering as well as in the Lock-Up Agreement provided to the Underwriters is
	true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed
	in such questionnaires become inaccurate and incorrect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	FINRA
	Affiliation
</U>
	. No officer, director or any beneficial owner of 5% or more of the Company&rsquo;s unregistered securities has
	any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules and regulations
	of FINRA) that is participating in the Offering. The Company will advise the Representative and EGS
<B>
</B>
	if it learns that any
	officer, director or owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock or Common Stock Equivalents
	is or becomes an affiliate or associated person of a FINRA member firm.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Officers&rsquo;
	Certificate
</U>
	. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative or EGS
	shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Board
	of Directors
</U>
	. The Board of Directors is comprised of the persons set forth under the heading of the Prospectus captioned &ldquo;Management.&rdquo;
	The qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the
	Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of the Trading Market.
	At least one member of the Board of Directors qualifies as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley
	Act of 2002 and the rules promulgated thereunder and the rules of the Trading Market. In addition, at least a majority of the persons
	serving on the Board of Directors qualify as &ldquo;independent&rdquo; as defined under the rules of the Trading Market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage160"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE IV.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	OTHER AGREEMENTS OF THE PARTIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Amendments
	to Registration Statement
</U>
	. The Company has delivered, or will as promptly as practicable deliver, to the Underwriters complete
	conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof,
	and conformed copies of the Registration Statement (without exhibits), the Prospectus and the Prospectus Supplement, as amended
	or supplemented, in such quantities and at such places as an Underwriter reasonably requests. Neither the Company nor any of its
	directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material in connection
	with the offering and sale of the Securities other than the Prospectus, the Prospectus Supplement, the Registration Statement,
	and copies of the documents incorporated by reference therein. The Company shall not file any such amendment or supplement to which
	the Representative shall reasonably object in writing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Federal
	Securities Laws
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Compliance
</U>
	.
	During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its best efforts to
	comply with all requirements imposed upon it by the Securities Act and the rules and regulations thereunder and the Exchange Act
	and the rules and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales
	of or dealings in the Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus
	relating to the Securities is required to be delivered under the Securities Act, any event shall have occurred as a result of which,
	in the opinion of counsel for the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes
	an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the
	statements therein, in light of the circumstances under which they were made, not misleading, or if it is necessary at any time
	to amend the Prospectus to comply with the Securities Act, the Company will notify the Underwriters promptly and prepare and file
	with the Commission, subject to Section 4.1 hereof, an appropriate amendment or supplement in accordance with Section 10 of the
	Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exchange
	Act Registration
</U>
	. For a period of three years from the Execution Date, the Company will use its best efforts to maintain the
	registration of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock under the Exchange Act
	without the prior written consent of the Representative.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Free
	Writing Prospectuses
</U>
	. The Company represents and agrees that it has not made and will not make any offer relating to the Securities
	that would constitute an issuer free writing prospectus, as defined in Rule 433 of the rules and regulations under the Securities
	Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative
	is hereinafter referred to as a
<B>
	&ldquo;
</B>
<U>
	Permitted Free Writing Prospectus
</U>
	.&rdquo; The Company represents that it will
	treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus&rdquo; as defined in rule and regulations
	under the Securities Act, and has complied and will comply with the applicable requirements of Rule 433 of the Securities Act,
	including timely Commission filing where required, legending and record keeping.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage161"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Delivery
	to the Underwriters of Prospectuses
</U>
	. The Company will deliver to the Underwriters, without charge, from time to time during
	the period when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies of
	each Prospectus as the Underwriters may reasonably request and, as soon as the Registration Statement or any amendment or supplement
	thereto becomes effective, deliver to you two original executed Registration Statements, including exhibits, and all post-effective
	amendments thereto and copies of all exhibits filed therewith or incorporated therein by reference and all original executed consents
	of certified experts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Effectiveness
	and Events Requiring Notice to the Underwriters
</U>
	. The Company will use its best efforts to cause the Registration Statement
	to remain effective with a current prospectus until the later of nine (9) months from the Execution Date and the date on which
	the Warrants are no longer outstanding, and will notify the Underwriters and holders of the Warrants immediately and confirm the
	notice in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of the issuance
	by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&nbsp;of
	the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Securities for
	offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv)&nbsp;of
	the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus;
	(v)&nbsp;of the receipt of any comments or request for any additional information from the Commission; and (vi)&nbsp;of the happening
	of any event during the period described in this Section 4.4 that, in the judgment of the Company, makes any statement of a material
	fact made in the Registration Statement or the Prospectus untrue or that requires the making of any changes in the Registration
	Statement or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made,
	not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at
	any time, the Company will make every reasonable effort to obtain promptly the lifting of such order.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Expenses
	of the Offering
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage162"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company hereby agrees to pay on each of the Closing Date and each Option Closing Date, if any, to the extent not paid at the Closing
	Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited
	to: (a) all filing fees and communication expenses relating to the registration of the Securities to be sold in the Offering (including
	the Option Securities) with the Commission; (b) all FINRA Public Offering Filing System fees associated with the review of the
	Offering by FINRA; all fees and expenses relating to the listing of such Closing Shares, Option Shares and Warrant Shares on the
	Trading Market and such other stock exchanges as the Company and the Representative together determine; (c) all fees, expenses
	and disbursements relating to the registration or qualification of such Securities under the &ldquo;blue sky&rdquo; securities
	laws of such states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation,
	all filing and registration fees, and the fees and expenses of Blue Sky counsel); (d) the costs of all mailing and printing of
	the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate,
	any Agreement Among Underwriters, Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney),
	Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses
	as the Representative may reasonably deem necessary; (e) the costs and expenses of the public relations firm; (f) the costs of
	preparing, printing and delivering the Securities; (g) fees and expenses of the Transfer Agent for the Securities (including, without
	limitation, any fees required for same-day processing of any instruction letter delivered by the Company); (h) stock transfer and/or
	stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (i) the fees and expenses of
	the Company&rsquo;s accountants; (j) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives;
	(k) the Underwriters&rsquo; costs of mailing prospectuses to prospective investors; (l) the costs associated with advertising the
	Offering in the national editions of the Wall Street Journal and New York Times after the Closing Date; (m)
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
<U STYLE="TEXT-DECORATION: NONE; VERTICAL-ALIGN: BASELINE">
	the
	Underwriters&rsquo; use of i-Deal&rsquo;s book-building, prospectus tracking and compliance software (or other similar software)
	for the Offering; and (n) the Underwriters&rsquo; actual &ldquo;road show&rdquo; expenses for the Offering
</U>
</FONT>
<U>
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE; COLOR: BLUE">
<B>
	.
</B>
</FONT>
</U>
	The Underwriters may also deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or each Option
	Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Expenses
	of the Representative
</U>
	. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.5(a), on
	the Closing Date, the Company will reimburse the Representative for its out-of-pocket expenses related to the Offering, including
	fees and expenses of counsel, up to an aggregate of $75,000, which shall be paid by deduction from the proceeds of the Offering
	contemplated herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Application
	of Net Proceeds
</U>
	. The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application
	described under the caption &ldquo;Use Of Proceeds&rdquo; in the Prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Delivery
	of Earnings Statements to Security Holders
</U>
	. The Company will make generally available to its security holders as soon as practicable,
	but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement (which
	need not be certified by independent public or independent certified public accountants unless required by the Securities Act or
	the Rules and Regulations under the Securities Act, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of
	the Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Stabilization
</U>
	.
	Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
	has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected
	to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the
	Company to facilitate the sale or resale of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage163"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Internal
	Controls
</U>
	. The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
	(i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii)&nbsp;transactions
	are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
	for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
	and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
	is taken with respect to any differences.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Accountants
</U>
	.
	The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period of at least
	three years after the Execution Date. The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	FINRA
</U>
	.
	The Company shall advise the Underwriters (who shall make an appropriate filing with FINRA) if it is aware that any 5% or greater
	shareholder of the Company becomes an affiliate or associated person of an Underwriter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Fiduciary Duties
</U>
	. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
	contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates
	or any selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company
	or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding
	anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the
	success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the
	Company by the Underwriters for the shares and the Underwriters have no obligation to disclose, or account to the Company for,
	any of such additional financial interests. The Company hereby waives and releases, to the fullest extent permitted by law, any
	claims that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Warrant
	Shares
</U>
	. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover
	the issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise at a time when such Warrant Shares would
	be eligible for resale under Rule 144 by a non-affiliate of the Company, the Warrant Shares issued pursuant to any such exercise
	shall be issued free of all restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent
	registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for
	the sale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration
	statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective
	again and available for the sale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability
	of the Company to issue, or any holder thereof to sell, any of the Warrant Shares in compliance with applicable federal and state
	securities laws).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage164"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Board
	Composition and Board Designations
</U>
	. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as board
	members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated
	thereunder and with the listing requirements of the Trading Market and (ii)&nbsp;if applicable, at least one member of the Board
	of Directors qualifies as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley Act of 2002 and the
	rules promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Securities
	Laws Disclosure; Publicity
</U>
	. At the request of the Representative, by 9:00 a.m. (New York City time) on the date hereof, the
	Company shall issue a press release disclosing the material terms of the Offering. The Company and the Representative shall consult
	with each other in issuing any other press releases with respect to the Offering, and neither the Company nor any Underwriter shall
	issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
	to any press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of
	the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which
	case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. The
	Company will not issue press releases or engage in any other publicity, without the Representative&rsquo;s prior written consent,
	for a period ending at 5:00 p.m. (New York City time) on the first business day following the 40th day following the Closing Date,
	other than normal and customary releases issued in the ordinary course of the Company&rsquo;s business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Shareholder
	Rights Plan
</U>
	. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
	Underwriter of the Securities is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination, poison
	pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
	adopted by the Company, or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement,
	by virtue of receiving Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Reservation
	of Common Stock
</U>
	. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
	at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
	to issue Option Shares pursuant to the Over-Allotment Option and Warrant Shares pursuant to any exercise of the Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Listing
	of Common Stock
</U>
	. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on
	the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote
	all of the Closing Shares, Option Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the
	Closing Shares, Option Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to
	have the Common Stock traded on any other Trading Market, it will then include in such application all of the Closing Shares, Option
	Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Closing Shares, Option Shares and
	Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
	reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
	with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage165"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Right
	of First Refusal
</U>
	. The Company agrees that if the Securities are sold in accordance with the terms of this Agreement, the Representative
	shall have an irrevocable preferential right for a period of twelve (12) months from the date the Offering is completed to purchase
	for its account or to sell for the account of the Company, or any subsidiary of or successor to the Company any securities (whether
	debt or equity or any combination thereof) of the Company or any such subsidiary or successor which the Company or any such subsidiary
	or successor may seek to sell whether with or without or through an underwriter, placement agent or broker-dealer and whether pursuant
	to registration under the Securities Act or otherwise. The Company and any such subsidiary or successor will consult the Representative
	with regard to any such proposed financing and will offer the Representative the opportunity to purchase or sell any such securities
	on terms not more favorable to the Company or any such subsidiary or successor, as the case may be, than it or they can secure
	elsewhere. If the Representative fails to accept such offer within 10 business days after the mailing of a notice containing the
	material terms of the proposed financing proposal by registered mail or overnight courier service addressed to the Representative,
	then the Representative shall have no further claim or right with respect to the financing proposal contained in such notice. If,
	however, the terms of such financing proposal are subsequently modified in any material respect, the preferential right referred
	to herein shall apply to such modified proposal as if the original proposal had not been made. The Representative&rsquo;s failure
	to exercise its preferential right with respect to any particular proposal shall not affect its preferential rights relative to
	future proposals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Subsequent
	Equity Sales
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
	the date hereof until ninety (90) days following the Closing Date, neither the Company nor any Subsidiary shall issue, enter into
	any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
	the date hereof until ______, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance
	by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving
	a Variable Rate Transaction. &ldquo;
<U>
	Variable Rate Transaction
</U>
	&rdquo; means a transaction in which the Company (i) issues
	or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive,
	additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
	upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance
	of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future
	date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
	or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
	under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future
	determined price. Any Underwriter shall be entitled to obtain injunctive relief against the Company to preclude any such issuance,
	which remedy shall be in addition to any right to collect damages.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage166"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
	the foregoing, this Section 4.20 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
	be an Exempt Issuance.
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	4.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Research
	Independence
</U>
	. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments, if any, are
	required to be independent from their respective investment banking divisions and are subject to certain regulations and internal
	policies, and that such Underwriter&rsquo;s research analysts may hold and make statements or investment recommendations and/or
	publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers.
	The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such
	Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent
	research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company
	by such Underwriter&rsquo;s investment banking divisions. The Company acknowledges that the Representative is a full service securities
	firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account
	of its customers and hold long or short position in debt or equity securities of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	ARTICLE V.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	DEFAULT
	BY UNDERWRITERS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	If
	on the Closing Date or any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the Closing
	Securities or Option Securities, as the case may be, which such Underwriter has agreed to purchase and pay for on such date (otherwise
	than by reason of any default on the part of the Company), the Representative, or if the Representative is the defaulting Underwriter,
	the non-defaulting Underwriters, shall use their reasonable efforts to procure within 36 hours thereafter one or more of the other
	Underwriters, or any others, to purchase from the Company such amounts as may be agreed upon and upon the terms set forth herein,
	the Closing Securities or Option Securities , as the case may be, which the defaulting Underwriter or Underwriters failed to purchase.
	If during such 36 hours the Representative shall not have procured such other Underwriters, or any others, to purchase the Closing
	Securities or Option Securities, as the case may be, agreed to be purchased by the defaulting Underwriter or Underwriters, then
	(a) if the aggregate number of Closing Securities or Option Securities, as the case may be, with respect to which such default
	shall occur does not exceed 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the other Underwriters
	shall be obligated, severally, in proportion to the respective numbers of Closing Securities or Option Securities, as the case
	may be, which they are obligated to purchase hereunder, to purchase the Closing Securities or Option Securities, as the case may
	be, which such defaulting Underwriter or Underwriters failed to purchase, or (b) if the aggregate number of Closing Securities
	or Option Securities, as the case may be, with respect to which such default shall occur exceeds 10% of the Closing Securities
	or Option Securities, as the case may be, covered hereby, the Company or the Representative will have the right to terminate this
	Agreement without liability on the part of the non-defaulting Underwriters or of the Company except to the extent provided in Article
	VI hereof. In the event of a default by any Underwriter or Underwriters, as set forth in this Article V, the applicable Closing
	Date may be postponed for such period, not exceeding seven days, as the Representative, or if the Representative is the defaulting
	Underwriter, the non-defaulting Underwriters, may determine in order that the required changes in the Prospectus or in any other
	documents or arrangements may be effected. The term &ldquo;Underwriter&rdquo; includes any person substituted for a defaulting
	Underwriter. Any action taken under this Section shall not relieve any defaulting Underwriter from liability in respect of any
	default of such Underwriter under this Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage167"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE VI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INDEMNIFICATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Indemnification
	of the Underwriters
</U>
	. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Underwriters,
	and each dealer selected by each Underwriter that participates in the offer and sale of the Securities (each a &ldquo;
<U>
	Selected
	Dealer
</U>
	&rdquo;) and each of their respective directors, officers and employees and each Person, if any, who controls such Underwriter
	or any Selected Dealer (&ldquo;
<U>
	Controlling Person
</U>
	&rdquo;) within the meaning of Section 15 of the Securities Act or Section
	20 of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to
	any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced
	or threatened, or any claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such
	Underwriter and any third party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange
	Act or any other statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any
	untrue statement or alleged untrue statement of a material fact contained in (i) any Preliminary Prospectus, if any, the Registration
	Statement or the Prospectus (as from time to time each may be amended and supplemented); (ii) any materials or information provided
	to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities, including
	any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically); or
	(iii) any application or other document or written communication (in this Article VI, collectively called &ldquo;
<U>
	application
</U>
	&rdquo;)
	executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the
	Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, Trading Market
	or any securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
	to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement
	or omission was made in reliance upon and in conformity with written information furnished to the Company with respect to the applicable
	Underwriter by or on behalf of such Underwriter expressly for use in any Preliminary Prospectus, if any, the Registration Statement
	or Prospectus, or any amendment or supplement thereto, or in any application, as the case may be. With respect to any untrue statement
	or omission or alleged untrue statement or omission made in the Preliminary Prospectus, if any, the indemnity agreement contained
	in this Section 6.1 shall not inure to the benefit of an Underwriter to the extent that any loss, liability, claim, damage or expense
	of such Underwriter results from the fact that a copy of the Prospectus was not given or sent to the Person asserting any such
	loss, liability, claim or damage at or prior to the written confirmation of sale of the Securities to such Person as required by
	the Securities Act and the rules and regulations thereunder, and if the untrue statement or omission has been corrected in the
	Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under
	this Agreement. The Company agrees promptly to notify each Underwriter of the commencement of any litigation or proceedings against
	the Company or any of its officers, directors or Controlling Persons in connection with the issue and sale of the Public Securities
	or in connection with the Registration Statement or Prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage168"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Procedure
</U>
	.
	If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity may be
	sought against the Company pursuant to Section 6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case may
	be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of
	such action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter or such Selected
	Dealer, as the case may be) and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall
	have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense
	of such Underwriter, such Selected Dealer or Controlling Person unless (i) the employment of such counsel at the expense of the
	Company shall have been authorized in writing by the Company in connection with the defense of such action, or (ii) the Company
	shall not have employed counsel to have charge of the defense of such action, or (iii) such indemnified party or parties shall
	have reasonably concluded that there may be defenses available to it or them which are different from or additional to those available
	to the Company (in which case the Company shall not have the right to direct the defense of such action on behalf of the indemnified
	party or parties), in any of which events the reasonable fees and expenses of not more than one additional firm of attorneys selected
	by such Underwriter (in addition to local counsel), Selected Dealer and/or Controlling Person shall be borne by the Company. Notwithstanding
	anything to the contrary contained herein, if any Underwriter, Selected Dealer or Controlling Person shall assume the defense of
	such action as provided above, the Company shall have the right to approve the terms of any settlement of such action which approval
	shall not be unreasonably withheld.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Indemnification
	of the Company
</U>
	. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, its directors,
	officers and employees and agents who control the Company within the meaning of Section 15 of the Securities Act or Section 20
	of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the
	Company to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements
	or omissions made in any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement
	thereto or in any application, in reliance upon, and in strict conformity with, written information furnished to the Company with
	respect to such Underwriter by or on behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the Registration
	Statement or Prospectus or any amendment or supplement thereto or in any such application. In case any action shall be brought
	against the Company or any other Person so indemnified based on any Preliminary Prospectus, if any, the Registration Statement
	or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against
	such Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other Person
	so indemnified shall have the rights and duties given to such Underwriter by the provisions of this Article VI. Notwithstanding
	the provisions of this Section 6.3, no Underwriter shall be required to indemnify the Company for any amount in excess of the underwriting
	discounts and commissions applicable to the Securities purchased by such Underwriter. The Underwriters' obligations in this Section
	6.3 to indemnify the Company are several in proportion to their respective underwriting obligations and not joint.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage169"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Contribution
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Contribution
	Rights
</U>
	. In order to provide for just and equitable contribution under the Securities Act in any case in which (i) any Person
	entitled to indemnification under this Article VI makes a claim for indemnification pursuant hereto but it is judicially determined
	(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial
	of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article
	VI provides for indemnification in such case, or (ii) contribution under the Securities Act, the Exchange Act or otherwise may
	be required on the part of any such Person in circumstances for which indemnification is provided under this Article VI, then,
	and in each such case, the Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities,
	claims, damages and expenses of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter,
	as incurred, in such proportions that such Underwriter is responsible for that portion represented by the percentage that the underwriting
	discount appearing on the cover page of the Prospectus bears to the initial offering price appearing thereon and the Company is
	responsible for the balance; provided, that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section
	11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.
	For purposes of this Section, each director, officer and employee of such Underwriter or the Company, as applicable, and each Person,
	if any, who controls such Underwriter or the Company, as applicable, within the meaning of Section 15 of the Securities Act shall
	have the same rights to contribution as such Underwriter or the Company, as applicable. Notwithstanding the provisions of this
	Section 6.4, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions
	applicable to the Securities purchased by such Underwriter. The Underwriters' obligations in this Section 6.4 to contribute are
	several in proportion to their respective underwriting obligations and not joint.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage170"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Contribution
	Procedure
</U>
	. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the commencement
	of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another
	party (&ldquo;
<U>
	contributing party
</U>
	&rdquo;), notify the contributing party of the commencement thereof, but the failure to
	so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
	hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party
	or its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to
	participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall
	not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such
	party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this
	Section 6.4 are intended to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the
	Exchange Act or otherwise available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	ARTICLE VII.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	MISCELLANEOUS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Termination
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Termination
	Right
</U>
	. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)&nbsp;if
	any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the immediate future
	materially disrupt, general securities markets in the United States; or (ii)&nbsp;if trading on any Trading Market shall have been
	suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for
	securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction,
	or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities, or (iv)&nbsp;if
	a banking moratorium has been declared by a New York State or federal authority, or (v)&nbsp;if a moratorium on foreign exchange
	trading has been declared which materially adversely impacts the United States securities markets, or (vi)&nbsp;if the Company
	shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious
	act which, whether or not such loss shall have been insured, will, in the Representative&rsquo;s opinion, make it inadvisable to
	proceed with the delivery of the Securities, or (vii)&nbsp;if the Company is in material breach of any of its representations,
	warranties or covenants hereunder, or (viii)&nbsp;if the Representative shall have become aware after the date hereof of such a
	material adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions
	as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the
	Securities or to enforce contracts made by the Underwriters for the sale of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Expenses
</U>
	.
	In the event this Agreement shall be terminated pursuant to Section 7.1(a), within the time specified herein or any extensions
	thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable out
	of pocket expenses related to the transactions contemplated herein then due and payable, including the fees and disbursements of
	EGS up to $25,000 (
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that such expense
	cap in no way limits or impairs the indemnification and contribution provisions of this Agreement
</FONT>
	).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage171"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Indemnification
</U>
	.
	Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement,
	and whether or not this Agreement is otherwise carried out, the provisions of Article VI shall not be in any way effected by such
	election or termination or failure to carry out the terms of this Agreement or any part hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Entire
	Agreement
</U>
	. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
	contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
	and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
	exhibits and schedules. Notwithstanding anything herein to the contrary, the Engagement Agreement, dated October 26, 2016 and amended
	on February 1, 2017 (&ldquo;
<U>
	Engagement Agreement
</U>
	&rdquo;), between the Company and the Representative, shall continue to
	be effective and the terms therein, including, without limitation, Section 7 with respect to any future offerings, shall continue
	to survive and be enforceable by the Representative in accordance with its terms, provided that, in the event of a conflict between
	the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notices
</U>
	.
	Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
	shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
	via facsimile or e-mail attachment at the facsimile number or email address set forth on the signature pages attached hereto at
	or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice
	or communication is delivered via facsimile or e-mail attachment at the facsimile number or email address as set forth on the signature
	pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the
	second (2
<SUP>
	nd
</SUP>
	) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
	or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
	shall be as set forth on the signature pages attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Amendments;
	Waivers
</U>
	. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
	in the case of an amendment, by the Company and the Representative. No waiver of any default with respect to any provision, condition
	or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
	or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any
	right hereunder in any manner impair the exercise of any such right.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage172"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Headings
</U>
	.
	The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
	any of the provisions hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Successors
	and Assigns
</U>
	. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
	assigns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Governing
	Law
</U>
	. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
	be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
	principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
	and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
	hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
	exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
	jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
	dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
	to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any action,
	suit or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
	proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of
	process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or
	certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
	this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
	contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
	party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
	of the Company under Article VI, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party
	for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
	of such action or proceeding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Survival
</U>
	.
	The representations and warranties contained herein shall survive the Closing and the Option Closing, if any, and the delivery
	of the Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Execution
</U>
	.
	This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
	agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
	understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
	or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
	party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
	signature page were an original thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage173"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Severability
</U>
	.
	If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
	void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
	force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
	reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
	by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
	they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
	hereafter declared invalid, illegal, void or unenforceable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Remedies
</U>
	.
	In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Underwriters
	and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages
	may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
	and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy
	at law would be adequate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Saturdays,
	Sundays, Holidays, etc
</U>
	.
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	If the last or appointed day for the taking
	of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken
	or such right may be exercised on the next succeeding Business Day.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Construction
</U>
	.
	The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
	Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
	party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
	every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
	and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
	the date of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	7.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>
<U>
	WAIVER
	OF JURY TRIAL
</U>
	. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING
	OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO
	THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY
	RIGHT TO TRIAL BY JURY.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<I>
	(Signature Pages Follow)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage174"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If the foregoing correctly
	sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that
	purpose, whereupon this letter shall constitute a binding agreement among the Company and the several Underwriters in accordance
	with its terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	Very truly yours,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	MOLECULIN BIOTECH, INC.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-DECORATION: NONE; VERTICAL-ALIGN: BASELINE">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Address for Notice:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Copy to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Accepted on the date first above written.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	ROTH CAPITAL PARTNERS, LLC
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As the Representative of the several
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Underwriters listed on
<U>
	Schedule I
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	By: Roth Capital Partners, LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; TEXT-DECORATION: NONE; VERTICAL-ALIGN: BASELINE">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<BR>
	Address for Notice:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	888 San Clemente Drive
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Newport Beach, California
	92660
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Email: RothECM@roth.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Attention: Roth Equity
	Capital Markets
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Copy to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Ellenoff Grossman &amp;
	Schole LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1345 Avenue of the Americas
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	New York, New York 10105
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Facsimile: (212) 401-4741
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Attention: Robert F.
	Charron
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage175"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	SCHEDULE I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Schedule
	of Underwriters
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Underwriters
</U>
	&#9;
<U>
	Closing Shares
</U>
	&#9;
<U>
	Closing Series A Warrants
</U>
	&#9;
<U>
	Closing Series B Warrants
</U>
<U>
	Closing Series C Warrants Closing Purchase Price
</U>
	&#9;&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN">
	Total
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
</EFX_EXHIBIT_1>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage176"></A>
<A NAME="V458551_EX4-1_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	Exhibit 4.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	[FORM OF SERIES
	A/B/C
<U STYLE="TEXT-DECORATION: NONE; VERTICAL-ALIGN: BASELINE">
	WARRANT]
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	SERIES
	[A/B/C] COMMON STOCK PURCHASE WARRANT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	moleculin
	biOtech, inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; PADDING-LEFT: 0.375IN">
<P STYLE="MARGIN: 0PT 0">
	Series [A/B/C] Warrant No.: A-__
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; PADDING-LEFT: 0.375IN">
	Warrant Shares: _______
</TD>
<TD STYLE="WIDTH: 60%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; FONT-SIZE: 10PT">
	Initial Exercise Date: _______, 2017
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	THIS COMMON STOCK PURCHASE
	WARRANT (the &ldquo;
<U>
	Warrant
</U>
	&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;
<U>
	Holder
</U>
	&rdquo;)
	is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
	or after the date hereof (the &ldquo;
<U>
	Initial Exercise Date
</U>
	&rdquo;) and on or prior to the close of business on the _____
<SUP>
	1
</SUP>
	anniversary of the Initial Exercise Date (the &ldquo;
<U>
	Termination Date
</U>
	&rdquo;) but not thereafter, to subscribe
	for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the &ldquo;
<U>
	Company
</U>
	&rdquo;), up to ______ shares (as
	subject to adjustment hereunder, the &ldquo;
<U>
	Warrant Shares
</U>
	&rdquo;) of Common Stock[;provided, however, the exercisability
	of this Series C Warrant shall vest ratably from time to time in proportion to the Holder&rsquo;s (or its permitted assigns) exercise
	of the Series B Common Stock Purchase Warrant as compared with all Series B Common Stock Purchase Warrants issued to the Holder
	on the Initial Exercise Date (&ldquo;Vesting Schedule&rdquo;). By way of an example, if the Holder exercises all of its Series
	B Common Stock Purchase Warrants, all Warrant Shares hereunder may be exercised by the Holder, if the Holder exercises half of
	the Series B Common Stock Purchase Warrant, only half of the Warrant Shares hereunder may be exercised by the Holder until such
	time that the Holder exercises additional Series B Common Stock Purchase Warrants.]
<SUP>
	&nbsp;2
</SUP>
	The purchase price of one
	share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<U>
	Section 1
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Definitions
</U>
	.
	In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section
	1:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Affiliate
</U>
	&rdquo;
	means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
	control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Business
	Day
</U>
	&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
	any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
	to close.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Commission
</U>
	&rdquo;
	means the United States Securities and Exchange Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Common
	Stock Equivalents
</U>
	&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
	acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
	that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
	Common Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Exchange
	Act
</U>
	&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Person
</U>
	&rdquo;
	means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
	company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Securities
	Act
</U>
	&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Day
</U>
	&rdquo; means a day on which the Common Stock is traded on a Trading Market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Trading
	Market
</U>
	&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
	the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the
	New York Stock Exchange (or any successors to any of the foregoing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<SUP>
	1&nbsp;
</SUP>
	&#9;Series A Warrant: 5 year; Series B Warrant:
	90 day; Series C Warrant: 5 year
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<SUP>
	2 &nbsp;
</SUP>
	Series C Warrant only.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage177"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Transfer
	Agent
</U>
	&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette
	Place, Woodmere, New York 11598 and a facsimile number of (646) 536-3179, and any successor transfer agent of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<U>
	Section 2
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&#9;[Subject
	to the Vesting Schedule,]
<SUP>
	&nbsp;3&nbsp;
</SUP>
	Exercise of the purchase rights represented by this Warrant may be made, in whole
	or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the
	Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the
	address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice
	of Exercise in the form annexed hereto. Within the earlier of (i) three (3) Trading Days and (ii) the number of Trading Days comprising
	the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall
	deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
	check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
	applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
	type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
	the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the
	Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
	to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company.
	Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder
	shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
	number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
	and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of
	receipt of such notice.
<B>
	The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
	the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
	available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Exercise
	Price
</U>
	. The exercise price per share of the Common Stock under this Warrant shall be
<B>
	$
</B>
	_____, subject to adjustment hereunder
	(the &ldquo;
<U>
	Exercise Price
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Cashless
	Exercise
</U>
	. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
	therein is not available for the issuance of the Warrant Shares to the Holder, then, upon exercise of this Warrant by the Holder,
	this Warrant may only be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the
	Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	3&nbsp;
</SUP>
</FONT>
	Series C Warrant only.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage178"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
	(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
	Notice of Exercise if such Exercise Notice is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is
	not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular
	trading hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading
	Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the
	Holder&rsquo;s execution of the applicable Exercise Notice if such Exercise Notice of Exercise is executed during &ldquo;regular
	trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section 2(a) hereof or (iii)
	the VWAP on the date of the applicable Exercise Notice if the date of such Notice of Exercise is a Trading Day and such Notice
	of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of &ldquo;regular trading hours&rdquo;
	on such Trading Day;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	(B) = the
	Exercise Price of this Warrant, as adjusted hereunder; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 103.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -31.5PT">
	(X)
	= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
	if such exercise were by means of a cash exercise rather than a cashless exercise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 103.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -31.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	If
	Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
	of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The
	Company agrees not to take any position contrary to this Section 2(c).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	Bid Price
</U>
	&rdquo; means, for any date, the price determined by the first of the following
	clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for
	the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
	reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;
	if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
	preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX
	and if prices for the Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or
	a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
	Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent
	appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably
	acceptable to the Company, the fees and expenses of which shall be paid by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<U>
	VWAP
</U>
	&rdquo;
	means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
	listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
	preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
	on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
	Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
	OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
	Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization
	or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
	or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
	in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
	the fees and expenses of which shall be paid by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Mechanics
	of Exercise
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Delivery
	of Warrant Shares Upon Exercise
</U>
	. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
	Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
	Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;
<U>
	DWAC
</U>
	&rdquo;) if the Company is then a participant
	in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
	resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical
	delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the
	number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
	Notice of Exercise by the date that is the earlier of
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	(i) the earlier of (A) three
	(3) Trading Days after the delivery to the Company of the Notice of Exercise and (B) one (1) Trading Day after delivery of the
	aggregate Exercise Price and (ii) the number of Trading Days comprising the Standard Settlement Period
</FONT>
	(such date, the
	&ldquo;
<U>
	Warrant Share Delivery Date
</U>
	&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all
	corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
	irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
	in the case of a cashless exercise) is received within the earlier of (i) three Trading Days and (ii) the number of Trading Days
	comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to
	deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall
	pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
	(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
	per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant
	Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
	transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
	herein, &ldquo;
<U>
	Standard Settlement Period
</U>
	&rdquo; means the standard settlement period, expressed in a number of Trading
	Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the
	Notice of Exercise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage179"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Delivery
	of New Warrants Upon Exercise
</U>
	. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
	and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
	evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
	in all other respects be identical with this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Rescission
	Rights
</U>
	. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
	2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Compensation
	for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise
</U>
	. In addition to any other rights available to the Holder,
	if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
	of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
	is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
	purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
	receiving upon such exercise (a &ldquo;
<U>
	Buy-In
</U>
	&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
	if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
	Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
	to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
	purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
	number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
	to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
	and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
	to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to
	such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
	the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
	of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
	right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
	performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
	exercise of the Warrant as required pursuant to the terms hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage180"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Fractional Shares or Scrip
</U>
	. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
	of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
	Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
	multiplied by the Exercise Price or round up to the next whole share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Charges,
	Taxes and Expenses
</U>
	. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
	other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
	Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the
	Holder;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that in the event that Warrant Shares are to be issued in a name other than the name
	of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
	by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
	tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise
	and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required
	for same-day electronic delivery of the Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Closing
	of Books
</U>
	. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
	this Warrant, pursuant to the terms hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Holder&rsquo;s
	Exercise Limitations
</U>
	. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not effect any exercise of this Warrant, and a Holder
	shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after
	giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the
	Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
	(such Persons, &ldquo;
<U>
	Attribution Parties
</U>
	&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation
	(as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the
	Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of
	this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
	would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or
	any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any
	other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
	conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates
	or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
	shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
	it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
	with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
	therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant
	is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and
	of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
	of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other
	securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
	in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the
	accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined
	in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this
	Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
	shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission,
	as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or
	the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a
	Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock
	then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect
	to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
	Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;
<U>
	Beneficial Ownership
	Limitation
</U>
	&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
	the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase
	or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
	in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
	of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue
	to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61
<SUP>
	st
</SUP>
	day after such notice
	is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
	strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
	or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
	or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
	holder of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage181"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<U>
	Section 3
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Certain
	Adjustments
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Stock
	Dividends and Splits
</U>
	. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
	makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
	in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
	exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
	by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
	of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
	by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
	immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
	after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
	the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
	effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
	and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Subsequent
	Rights Offerings
</U>
	. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
	or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
	holders of any class of shares of Common Stock (the &ldquo;
<U>
	Purchase Rights
</U>
	&rdquo;), then the Holder will be entitled to
	acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
	if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
	to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
	date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
	as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
	(provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the
	Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right
	to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and
	such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would
	not result in the Holder exceeding the Beneficial Ownership Limitation).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage182"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<U>
	Pro
	Rata Distributions
</U>
	. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
	other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
	or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
	a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;
<U>
	Distribution
</U>
	&rdquo;),
	at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
	to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
	acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
	the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
	record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
	in such Distribution (
<U>
	provided
</U>
	,
<U>
	however
</U>
	, to the extent that the Holder's right to participate in any such Distribution
	would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
	in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
	to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time,
	if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	To
	the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of
	the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Fundamental
	Transaction
</U>
	. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more
	related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
	directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
	substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
	tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
	Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
	the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related
	transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
	exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
	property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
	purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
	or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
	of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
	making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
	agreement or other business combination) (each a &ldquo;
<U>
	Fundamental Transaction
</U>
	&rdquo;), then, upon any
	subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
	issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
	(without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of
	the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
	consideration (the &ldquo;
<U>
	Alternate Consideration
</U>
	&rdquo;) receivable as a result of such Fundamental Transaction by a
	holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
	Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such
	exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
	based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
	Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner
	reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
	given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
	given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
	such Fundamental Transaction. Notwithstanding anything to the contrary, the Company or any Successor Entity (as defined
	below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the
	consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the Holder an amount of cash
	equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such
	Fundamental Transaction. &ldquo;
<U>
	Black Scholes Value
</U>
	&rdquo; means the value of this Warrant based on the Black and
	Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;
<U>
	Bloomberg
</U>
	&rdquo;)
	determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a
	risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
	announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the
	greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately
	following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such
	calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash
	consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time
	between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment
	of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the
	Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any
	successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;
<U>
	Successor
	Entity
</U>
	&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the
	provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to and approved
	by a majority of the Holders of Warrants (without unreasonable delay) prior to such Fundamental Transaction and shall, at the
	option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
	written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
	number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock
	acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant)
	prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
	of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
	Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price
	being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
	Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
	be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may
	exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with
	the same effect as if such Successor Entity had been named as the Company herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage183"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Calculations
</U>
	.
	All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
	For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
	be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notice
	to Holder
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Adjustment
	to Exercise Price
</U>
	. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
	promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
	adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notice
	to Allow Exercise by Holder
</U>
	. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
	Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
	Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
	of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
	with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
	of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
	into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
	or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email
	to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
	20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
	a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not
	to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
	rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
	or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common
	Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
	upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such
	notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
	in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
	regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
	to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
	date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage184"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<U>
	Section 4
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Transfer
	of Warrant
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Transferability
</U>
	.
	This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
	part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
	of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
	to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
	shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
	or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
	of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	Notwithstanding
	anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the
	Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)
	Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full.
</FONT>
	The Warrant,
	if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having
	a new Warrant issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	New
	Warrants
</U>
	. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
	the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
	by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
	division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
	to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
	issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
	thereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Warrant
	Register
</U>
	. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;
<U>
	Warrant
	Register
</U>
	&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
	Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
	and for all other purposes, absent actual notice to the contrary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<U>
	Section 5
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Miscellaneous
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	No
	Rights as Stockholder Until Exercise
</U>
	. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
	as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
	Section 3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Loss,
	Theft, Destruction or Mutilation of Warrant
</U>
	. The Company covenants that upon receipt by the Company of evidence reasonably
	satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
	Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
	of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
	if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
	in lieu of such Warrant or stock certificate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage185"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Saturdays,
	Sundays, Holidays, etc
</U>
	. If the last or appointed day for the taking of any action or the expiration of any right required
	or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
	Business Day.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Authorized
	Shares
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company
	covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
	sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this
	Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
	charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The
	Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
	herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
	Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
	represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
	Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
	and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
	with such issue).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Except and
	to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
	its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
	or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
	of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
	actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
	limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
	payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
	or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
	of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
	public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
	this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Before taking
	any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
	Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
	from any public regulatory body or bodies having jurisdiction thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Jurisdiction
</U>
	.
	This Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving
	effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising
	out of, or relating in any way to this Warrant shall be brought and enforced in the New York Supreme Court, County of New York,
	or in the United States District Court for the Southern District of New York located in the Borough of Manhattan in the City of
	New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection
	to such exclusive jurisdiction and that such courts represent an inconvenient forum.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage186"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Restrictions
</U>
	.
	The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder
	does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Nonwaiver
	and Expenses
</U>
	. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
	as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
	of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
	material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
	expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
	the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Notices
</U>
	.
	Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
	in accordance with the address set forth in the Warrant Register.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Limitation
	of Liability
</U>
	. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
	Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
	for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
	or by creditors of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Remedies
</U>
	.
	The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
	to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
	for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
	the defense in any action for specific performance that a remedy at law would be adequate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Successors
	and Assigns
</U>
	. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
	to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
	of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
	shall be enforceable by the Holder or holder of Warrant Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Amendment
</U>
	.
	This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Severability
</U>
	.
	Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
	law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
	to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
	of this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Headings
</U>
	.
	The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
	this Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	********************
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<I>
	(Signature Page
	Follows)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage187"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 10.5PT; TEXT-ALIGN: JUSTIFY">
	IN WITNESS WHEREOF, the Company
	has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE">
<B>
	moleculin
	biotech, inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	By:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Name:
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Title:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage188"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	NOTICE OF EXERCISE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	To:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	moleculin
	biotech, inc.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
	The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached
	Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
	transfer taxes, if any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)&nbsp;
</FONT>
	Payment
	shall take the form of (check applicable box):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	in lawful money of the United States; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	[if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth
	in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
	cashless exercise procedure set forth in subsection 2(c).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
	Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;_______________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Warrant Shares
	shall be delivered to the following DWAC Account Number:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;_______________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;_______________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;_______________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	[SIGNATURE
	OF HOLDER]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Name of Investing
	Entity: ________________________________________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Signature of Authorized
	Signatory of Investing Entity
</I>
	: _________________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Name of Authorized
	Signatory: ___________________________________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Title of Authorized
	Signatory: ____________________________________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Date: ________________________________________________________________________________________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage189"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
<B>
	EXHIBIT B
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	ASSIGNMENT
	FORM
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 10.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 10.5PT">
<I>
	(To assign the
	foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 10.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 10.5PT">
	FOR VALUE RECEIVED,
	the foregoing Warrant and all rights evidenced thereby are hereby assigned to
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 10.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Name:
</TD>
<TD STYLE="WIDTH: 51%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	(Please Print)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Address:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	(Please Print)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	Phone Number:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	Email Address:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Dated: _______________ __, ______
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Holder&rsquo;s Signature: _________________________
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	Holder&rsquo;s Address: __________________________
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage190"></A>
<A NAME="V458551_EX5_HTM"></A>
<EFX_EXHIBIT_5>
<A NAME="FIS_EXHIBIT_5"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 5
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	February 7, 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Board of Directors
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Moleculin Biotech, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	2575 West Bellfort, Suite 333
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Houston, Texas 77054
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration
	Statement on Form S-1 (File No. 333-214898)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Ladies and Gentlemen:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	We have acted as counsel to Moleculin Biotech,
	Inc., a Delaware corporation (the &ldquo;
<U>
	Company
</U>
	&rdquo;), in connection with the filing of a registration statement (No.
	333-214898) on Form S-1 (as amended, the &ldquo;
<U>
	Registration Statement
</U>
	&rdquo;) with the Securities and Exchange Commission,
	including a related prospectus (the &ldquo;
<U>
	Prospectus
</U>
	&rdquo;), covering an underwritten public offering of (i) up to 2,500,000
	units (the &ldquo;Units&rdquo;), each consisting of one share of the Company&rsquo;s common stock, par value $0.001 per share (the
	&ldquo;Common Stock&rdquo;), a Series A warrant to purchase 0.50 of a share of Common Stock, a Series B warrant to purchase one
	share of Common Stock, and a Series C warrant to purchase 0.50 of a share of Common Stock, (ii) up to 1,250,000 Series A warrants,
	2,500,000 Series B warrants and 1,250,000 Series C warrants (collectively, the &ldquo;
<U>
	Warrants
</U>
	&rdquo;) included in the Units,
	and (iii) up to 5,000,000 shares of Common Stock issuable pursuant to the Warrants (the &ldquo;
<U>
	Warrant Shares
</U>
	&rdquo;). In
	addition, the Registration Statement covers (i) a warrant issuable to the underwriters in the offering referred to above (the &ldquo;
<U>
	Underwriters&rsquo;
	Warrant
</U>
	&rdquo;) to purchase up to 201,250 shares of Common Stock (the &ldquo;
<U>
	Underwriters&rsquo; Warrant Shares
</U>
	&rdquo;)
	and (ii) the Underwriters&rsquo; Warrant Shares. The Units, the Shares, the Warrants and the Warrant Shares are to be sold by the
	Company as described in the Registration Statement and Prospectus. The Units, the Shares, the Warrants, the Underwriters&rsquo;
	Warrant and the Underwriters&rsquo; Warrant Shares are collectively referred to as the &ldquo;
<U>
	Securities
</U>
	&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In connection with
	this opinion, we have examined the Registration Statement, including the exhibits thereto, the form of Warrant and form of Underwriters&rsquo;
	Warrant, the Underwriting Agreement filed as an exhibit to the Registration Statement and such other documents, corporate records
	and instruments, and have examined such laws and regulations, as we have deemed necessary for purposes of the opinion set forth
	herein. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us
	as originals, the conformity to the originals of all documents submitted to us as copies and the legal capacity of all natural
	persons.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Based on the foregoing,
	and subject to the qualifications set forth below, we are of the opinion that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(i) The Shares have
	been duly authorized and, when issued and delivered as part of the Units against payment therefor in accordance with the Registration
	Statement and the Prospectus, will be validly issued, fully paid and nonassessable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(ii) The Warrants and
	Underwriters&rsquo; Warrants have been duly authorized by the Board of Directors of the Company and, when executed on behalf of
	the Company and issued and delivered, in the case of the Warrants as part of the Units against payment therefor, in accordance
	with the Registration Statement and the Prospectus, will be valid and binding obligations of the Company in accordance with their
	respective terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(iii) The Warrant Shares
	and the Underwriters&rsquo; Warrant Shares, when issued and delivered upon exercise of the Warrants and Underwriters&rsquo; Warrant,
	respectively, in accordance with the terms thereof will be duly authorized, validly issued, fully paid and nonassessable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The opinions set forth
	above are subject to the following qualifications:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage191"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	opinions expressed herein with respect to the legality, validity, binding nature and enforceability of the Warrants and Underwriters&rsquo;
	Warrants are subject to (i) applicable laws relating to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer
	or other similar laws affecting creditors&rsquo; rights generally, whether now or hereafter in effect, and (ii) general principles
	of equity, including, without limitation, concepts of materiality, laches, reasonableness, good faith and fair dealing and the
	principles regarding when injunctive or other equitable remedies will be available (regardless of whether considered in a proceeding
	at law or in equity).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	foregoing opinions are limited to the laws of the State of New York and the General Corporation Law of Delaware, and we express
	no opinion as to the laws of any other jurisdiction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The opinions expressed
	in this opinion letter are as of the date of this opinion letter only and as to laws covered hereby only as they are in effect
	on that date, and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may come
	to our attention after that date or any changes in law that may occur or become effective after that date. The opinions herein
	are limited to the matters expressly set forth in this opinion letter, and no opinion or representation is given or may be inferred
	beyond the opinions expressly set forth in this opinion letter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We hereby consent to
	the filing of this opinion as an exhibit to the Registration Statement and to the reference made to this firm in the Prospectus
	under the heading &ldquo;Validity of Securities.&rdquo; In giving such consent, we do not admit that we are within the category
	of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange
	Commission issued thereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Very truly yours,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SCHIFF HARDIN LLP
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; TEXT-DECORATION: NONE; VERTICAL-ALIGN: BASELINE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ Cavas Pavri
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Cavas Pavri
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_5>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage192"></A>
<A NAME="V458551_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We hereby consent to the inclusion in this Registration Statement
	on Form S-1 (Amendment No. 2) of our report dated March 21, 2016 relating to Moleculin Biotech, Inc.&rsquo;s financial statements
	as of December 31, 2015 and for the period from July 28, 2015 (Inception) to December 31, 2015 and our report dated March&nbsp;21,
	2016 relating to Moleculin, LLC&rsquo;s financial statements as of December 31, 2015 and 2014 and for the years then ended. We
	also consent to the reference to our firm under the heading
<I>
	&quot;Experts&quot;
</I>
	appearing therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ GBH CPAs, PC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	GBH CPAs, PC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: BLUE">
	www.gbhcpas.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Houston, Texas
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	February 6, 2017
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</EFX_EXHIBIT_23>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
